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One of the objectives of the Health Research 
Board Stategy 2016-2020 is to promote and 
support evidence synthesis and knowledge 
translation activities to help policy-makers, 
service planners and providers make evidence-
based decisions. In order to inform the 
deliberations of the steering committee working 
on the new National Drugs Strategy and to support 
the development of a strategy based on evidence 
the HRB, on behalf of the Drugs Policy Unit in 
the Department of Health, commissioned the 
Public Health Institute at Liverpool John Moores 
University to undertake this review
The aim of this review is to provide a synthesis 
of the best international research on responses 
to problem drug use. The approach taken by 
the HRB when commissioning this study was to 
identify evidence through a ‘review of reviews’. 
This provides an overview of the most recent high 
quality evidence in the treatment, recovery, harm 
reduction and prevention areas. 
Incorporating evidence into policy has been a 
concern of several countries developing drugs 
strategies in recent years. Part of this process 
is identifying responses which have been shown 
to work but, just as importantly, also identifying 
what evidence is relevant to the national 
situation, where the gaps in evidence are and 
what interventions are shown not be effective or 
produce harmful results. 
Ensuring that a strategy is evidence-based requires 
an acknowledgement that evidence is constantly 
improving and knowledge on effective responses 
will develop during the term of the strategy. A 
dynamic strategy supports this development and 
recognises the value of the evidence produced 
by the evaluative process built into responses. 
This review will not answer all the questions that 
will arise when policy makers and practitioners 
face difficult decisions with regard to selecting, 
implementing and evaluating responses, but it will 
serve as valuable guide to seeking the evidence 
to support decisions and identifying those areas 
where the evidence base needs to be built.
The Health Research Board is pleased to make 
this contribution to policy development in this 
important area of public health and to provide a 
resource that will be of great interest to policy 
makers, practitioners, researchers and the general 
public both in Ireland and internationally.
 
Dr Mairead O’Driscoll  
Interim Chief Executive
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This review examines the evidence on the 
effectiveness of interventions in the areas of 
prevention, harm reduction, treatment and long-
term recovery related to illicit drug misuse and 
dependence. The primary research questions for 
this review were:
» Which interventions are effective in reducing 
the initiation, or continued use, of illicit drugs 
and related harmful behaviours among children 
and young people aged up to 25 years?
» Which interventions are effective in reducing 
harmful behaviours related to illicit drug use?
» Which interventions are effective in treating 
drug misuse among people who misuse or who 
are dependent on illicit drugs?
» What interventions are effective in supporting 
people who misuse illicit drugs to fully recover 
from their illicit drug misuse and become better 
reintegrated into the community following/
alongside treatment?
Evidence was identified through a ‘review of 
reviews’ approach. High-quality systematic 
reviews published since 2010 were identified 
through a comprehensive search of relevant 
electronic databases, and screened for relevance 
against pre-defined inclusion and exclusion criteria. 
The quality of relevant reviews was determined 
using the quality check tool in the Joanna Briggs 
Institute Reviewers’ Manual for undertaking 
umbrella reviews (Joanna Briggs Institute, 2014). 
Lower-quality reviews and reviews published prior 
to 2010 were included where evidence was missing 
on key interventions.
In total, 97 review articles were identified to 
answer the primary research questions and were 
divided across three reviews under the headings 
‘prevention’ (13 reviews), ‘harm reduction’ (24 
reviews) and ‘treatment and recovery’ (62 reviews), 
with two reviews covering both harm reduction 
and treatment interventions. Outcomes relating to 
the review research questions were summarised 
in outcomes tables of evidence. The quality of the 
evidence was determined using a GRADE approach 
and rated ‘low’, ‘medium’ or ‘high’ depending on 
the quality and extent of primary studies and the 
consistency of the direction of findings.
1.1 Key findings
Key findings from the evidence for interventions 
on prevention, harm reduction, treatment and 
recovery are presented here. These are based 
on the direction of evidence relating to the 
intervention approaches considered in this review, 
and the quality of the available evidence. These 
statements of evidence should be considered 
alongside evidence discussed in the main body 
of the report and presented in outcomes tables 
(linked under each evidence statement here).
1.1.1 Prevention
School‑based programmes
Low-moderate quality review-level evidence 
suggests that some structured, comprehensive 
school-based programmes that combine the 
teaching of skills such as refusal, decision-making 
and coping, raise awareness of social influences on 
drug use, provide information about drug use, and 
may be effective in preventing drug use. However, 
this evidence is inconsistent and inconclusive, and 
can be applied predominantly to cannabis use 
(any use or frequency of use) only. Low-quality 
1
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review-level evidence suggests that school-based 
programmes that focus mainly on increasing 
knowledge of the risks of drug use alone appear 
ineffective in preventing drug use.
Low-quality review-level evidence also suggests 
that drug use and sexual health prevention 
interventions may be more effective if 
interventions focus on multiple domains rather 
than school-based only programmes, although 
impact on drug use appears limited.
See Section 5.2 Universal school-based 
prevention programmes
Family‑based interventions
Moderate-quality review-level evidence suggests 
that universal family interventions that include 
both parents and children may be effective in 
preventing cannabis use, but evidence on other 
drug use is inconclusive. Programmes may be 
most effective when targeting multiple domains 
(e.g. school alongside family, mentoring or media 
settings). There was low-quality and mixed review-
level evidence on the effectiveness of prevention 
targeted at families of at-risk young people, and 
therefore no conclusions could be made about 
these approaches.
See Section 5.3 Family-based prevention 
interventions; Section 5.4 Additional cannabis 
prevention interventions
Brief and/or motivational interventions
Moderate-quality review-level evidence suggests 
that brief interventions set within schools 
appear to be generally ineffective in preventing 
drug use. Similarly, low-quality review-level 
evidence suggests that brief interventions set 
within healthcare settings appear to be generally 
ineffective in preventing drug use. Interventions 
that are based on motivational interview 
may have some benefits when delivered in 
emergency department or primary care settings, 
but this evidence was low quality and findings 
were inconclusive.
See Section 5.5 Brief and/or motivational 
interventions
Mass media interventions
Low-quality review-level evidence suggests 
that mass-media campaigns delivered alone to 
prevent drug use are unlikely to be effective, with 
mixed and inconsistent drug use outcomes from 
campaigns. Low-quality review-level evidence 
suggests that interventions delivered through 
computers and the Internet may have positive 
effects on cannabis use.
See Section 5.6 Media interventions
Mentoring interventions
Low-quality review-level evidence suggests that 
mentoring interventions may be ineffective in 
preventing drug use among high-risk young people. 
However, this is based on very few primary studies 
and findings are therefore inconclusive.
See Section 5.7 Mentoring interventions
1.1.2 Harm reduction
Needle and syringe programmes
The review-level evidence is low quality and 
inconclusive regarding the impact of needle and 
syringe programmes in community and prison 
settings, although the evidence suggests they 
may be associated with reductions in harms, 
including transmission of blood-borne viruses and 
sharing of injecting equipment. Needle and syringe 
programmes appear to have a greater impact when 
delivered in combination with opioid substitution 
therapy, and this is associated with reduced 
harms for people who inject drugs, including 
risk of blood-borne virus infection and risky 
injection behaviours.
See Section 6.3 Provision of needles and other 
injecting equipment; Section 6.12 Individuals in 
contact with the criminal justice system who 
use drugs
Psychosocial and behavioural interventions
Evidence on the effectiveness of psychosocial 
and behavioural interventions for reducing 
harms related to drug use is mixed. There is 
insufficient evidence to assess the effectiveness of 
individual psychosocial interventions on reducing 
harms. There is low-moderate quality review-
level evidence that multisession psychosocial 
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interventions and peer education training may be 
associated with some reductions in harms among 
people who inject drugs. Low-quality review-level 
evidence suggests that peer-based interventions 
targeting people who inject drugs and intranasal 
heroin users may also be effective in reducing 
initiation of injecting, although this evidence is 
based on a small number of primary studies.
See Section 6.5 Psychosocial and behavioural 
interventions
Overdose prevention (including naloxone 
distribution)
The provision of opioid overdose prevention 
training with take-home naloxone is supported only 
by low-quality review-level evidence. It may be 
associated with reduced overdose mortality among 
people who inject drugs, and improved response to 
overdose.
See Section 6.6 Overdose prevention
Drug consumption rooms
A combination of low- and moderate-quality 
evidence indicates that drug consumption rooms 
appear likely to be acceptable to people who 
inject drugs. They may be associated with reduced 
sharing and reuse of syringes and reduced drug-
related litter, and not associated with increases in 
injecting drug use.
See Section 6.7 Drug consumption rooms
Blood‑borne virus treatments for people who 
inject drugs
Low-quality review-level evidence suggests that 
effective treatment options for people with HIV 
and hepatitis C are suitable for people who inject 
drugs. This includes highly active antiretroviral 
therapy and direct antiretroviral therapy for people 
with HIV and combination treatment with ribavirin 
plus recombinant, or pegylated interferon-α, for 
chronic hepatitis C.
See Section 6.11 Individuals with BBVs who use 
illict drugs
Drugs other than opioids
There is insufficient evidence to draw conclusions 
on the effectiveness of harm reduction 
interventions targeting populations other than 
people who inject drugs. For example, there is a 
need for high-quality research on the impact of 
harm reduction delivered in recreational, festival 
or nightlife settings such as analytical chemistry 
approaches (‘drug checking’) or harm reduction 
information provision.
See Section 6.10 Additional harm reduction 
approaches
1.1.3 Treatment
Pharmacological treatments for opiate use
High-quality review-level evidence supports 
the use of methadone and buprenorphine for 
reducing use of illicit opioids, and as agents 
supporting abstinence through detoxification. 
Evidence suggests that better treatment 
retention may be achieved with methadone and 
that for individuals who have not responded to 
maintenance treatment, there is moderate-quality 
evidence to support the use of injectable heroin 
prescription in combination with flexible-dose 
oral methadone. High-quality evidence suggests 
that detoxification treatments are enhanced 
when delivered in combination with structured 
psychosocial interventions. Review-level evidence 
on relapse prevention treatment with naltrexone 
was low in quality, but indicates that naltrexone 
implants (but not oral naltrexone) may be effective 
in supporting continued abstinence among those 
highly motivated to remain abstinent.
See Section 7.3.1 Pharmacological treatments - 
Opioids
Pharmacological treatments for stimulants 
and cannabis use
Primarily low-moderate quality review-
level evidence consistently suggests that 
pharmacological treatments alone or delivered 
alongside psychosocial interventions may not 
be effective in treatment for dependence on 
stimulants, including cocaine and amphetamines, 
or cannabis. Evidence on cannabis abuse or 
dependence is limited by the low number 
of studies included in reviews examining the 
effectiveness of these treatments.
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See Section 7.3.2 Pharmacological treatments 
– Stimulants; Section 7.3.3 Pharmacological 
treatments – cannabis
Psychosocial treatments
Moderate-quality review-level evidence 
consistently supports the use of multidimensional 
family therapy (MDFT) for the treatment of 
young people’s drug use over other psychosocial 
intervention types. This evidence supports the 
application of MDFT in treatment for cannabis use 
only however.
For adults, moderate-quality review-level 
evidence supports treatment with couples-based 
interventions over cognitive behavioural therapy 
(CBT) among people with cocaine dependence and 
a non-drug dependent partner. Further moderate-
quality review-level evidence supports the use of 
contingency management for people with cocaine 
or opioid dependence, although the long-term 
impact of contingency management on abstinence 
is unclear. Additionally, moderate-quality review-
level evidence indicates that drug use treatments 
based on CBT or motivational interview may be 
effective in comparison to no treatment, but are 
no more or less effective than other psychosocial 
treatment approaches. The review-level evidence 
on mindfulness-based treatments is limited and 
of low quality, but suggests that mindfulness 
interventions may achieve reduced drug use.
See Section 7.4 Psychosocial and 
motivational treatments
Residential rehabilitation treatments
Review-level evidence on the effectiveness of 
residential programmes is limited and of low 
quality. There is no consistent evidence on the 
effectiveness of different therapeutic community 
models or 12-step group participation in residential 
settings, and it is difficult to draw conclusions, due 
to the limitations of the evidence base.
See Section 7.5 Residential rehabilitation 
treatment programmes
1.1.4 Treatments focusing on 
long‑term recovery and 
reintegration
Review-level evidence on the effectiveness 
of interventions to support recovery and 
reintegration was limited. Evidence on peer-
supported interventions was limited and was 
based on small numbers of primary studies with 
methodological issues, but low-quality review-level 
evidence indicates that peer coaching, recovery 
housing and mutual aid approaches may have 
benefits for drug use outcomes.
Review-level evidence on the effectiveness of 
continuing care programmes is mixed, and is 
based on a small number of primary studies. 
Low-quality review-level evidence suggests that 
case management approaches for people in drug 
treatment/recovery may have beneficial outcomes.
See Section 7.6 Interventions focusing on recovery 
and reintegration
1.1.5 Other treatment approaches
Supportive practice
Evidence was identified on two further approaches 
for treating illicit drug use – treatments based 
on acupuncture and physical activity. Moderate-
quality review-level evidence suggests that physical 
activity interventions as part of drug treatment 
may support abstinence from drug use, although 
this was based on a small number of primary 
studies. Additionally, low-quality review-level 
evidence suggests that acupuncture may enhance 
the effectiveness of pharmacological treatments 
for opioid craving, but is not effective when 
delivered alone.
See Section 7.7 Other treatment approaches
Treatments for individuals in contact with the 
criminal justice system
Moderate-quality review-level evidence supports 
the use of opioid substitution therapy (OST) in 
prison and community settings to reduce drug use 
among people with opioid dependency who are 
in contact with the criminal justice system. There 
is low-quality review-level evidence suggesting 
that high-dose methadone may be more effective 
than low-dose methadone maintenance treatment 
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(MMT), and that buprenorphine maintenance 
may be as effective as MMT. There is insufficient 
evidence to draw conclusions regarding 
detoxification and relapse prevention in criminal 
justice system settings.
There is moderate-quality review-level evidence 
to support treatment through prison-based 
therapeutic communities to reduce drug relapse 
and criminal activity among prisoners. Benefits 
were identified for therapeutic communities alone 
and with aftercare provision. Evidence on other 
treatment types for this population, including drug 
courts, boot camps and psychosocial interventions, 
is inconclusive and is based on small numbers 
of studies.
See Section 7.8 Individuals in contact with the 
criminal justice system
Treatments for individuals with co‑occurring drug 
use and mental illness
Moderate-quality review-level evidence indicates 
that individuals with co-occurring drug use and 
trauma are likely to benefit from treatments that 
include CBT interventions focusing on drug use 
and post-traumatic stress disorder (PTSD). For 
people with severe mental illnesses and drug 
misuse, there is insufficient evidence to draw 
conclusions on the effectiveness of psychosocial 
interventions. For individuals – in particular, women 
with borderline personality disorders and drug use 
disorders – moderate-quality evidence suggests 
that there may be benefits from treatments based 
on dialectical behaviour therapy and dynamic 
deconstructive psychotherapy.
See Section 7.9 Individuals with drug use problems 
and co-occurring mental illness
Treatments for pregnant and parenting women
Evidence on the effectiveness of pharmacological 
treatments for pregnant women with opiate use 
is limited, but low-quality review-level evidence 
suggests that slow-release morphine may be 
more beneficial than methadone for heroin 
use, and buprenorphine may be as beneficial as 
methadone on drug use outcomes. Moderate-
quality review-level evidence indicates that home 
visit programmes are no more effective than no 
treatment, and low-moderate quality review-level 
evidence on integrated treatment programmes is 
inconclusive. Low-moderate quality review-level 
evidence based on a small number of studies did 
not support the use of psychosocial interventions 
in place of comprehensive usual care for the 
treatment of drug use in this population.
See Section 7.10. Pregnant and parenting women
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2Background
Recent analysis of drug use in the EU reveals 
that while historical patterns of use have been 
maintained, new behaviours are emerging, with an 
accompanying shift in treatment and intervention 
responses (EMCDDA, 2015a). In Ireland, between 
2006 and 2014 treatment demand for problematic 
drug use (primarily opiates) increased (Bates et al., 
2016), and although general population surveys 
have shown a decrease in all forms of drug use 
by children (Hibbell et al., 2011), there have been 
recent increases in past year cannabis and ecstasy 
use (National Advisory Committee on Drugs and 
Alcohol, 2016).
The Irish National Drugs Strategy (interim) 2009–
2016 (NDS) implements priority actions in supply 
and drug demand reduction, as well as steering 
policy ambition towards rehabilitation and recovery 
from problematic drug use. The Department 
of Health 2013 progress report (Department 
of Health, 2014) identified work taken towards 
achieving key NDS priorities, and these will be 
taken forward in the Strategy that will begin in 
2017. They include the prioritisation of universal 
and selective prevention activities (including social 
and personal health education; drug awareness; 
outreach; family and early years interventions) 
as well as the long-term development of an 
integrated national treatment and rehabilitation 
service (including the prevention and treatment of 
blood-borne viruses).
This review was commissioned by the Health 
Research Board (HRB) and is designed to explore 
the evidence on responses to problem drug use to 
support the development of the new Irish National 
Drugs Strategy. It examines evidence on effective 
delivery of interventions in the areas of prevention, 
harm reduction, treatment and recovery relating 
to illicit drug use, with the overarching aim of 
reducing the use of illicit drugs and related 
harms, and increasing successful recovery and 
rehabilitation following drug misuse.
Primary research questions
1. Which interventions are effective in reducing 
the initiation, or continued use, of illicit 
drugs and related harmful behaviours among 
children and young people aged up to 
25 years?
2. Which interventions are effective in reducing 
the harms related to drug use?
3. Which interventions are effective in 
treating drug misuse among people who 
misuse drugs?
4. What interventions are effective in 
supporting people who use drugs to 
recover following/alongside drug treatment 
and become better reintegrated into 
the community?
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The review was carried out in accordance with 
the pre-defined project scope and methodology, 
as outlined in the review protocol (Appendix 1, 
Section 11.1).
3.1 Search strategy
The search approach taken for the review was 
comprehensive and aimed to identify all potentially 
relevant reviews. Searches were conducted 
in a range of topic and methodology-specific 
databases, supplemented by a search of key 
websites, to identify high-quality systematic 
reviews relevant to the different intervention 
areas for this review: prevention, harm reduction, 
treatment and recovery.
Search terms
An initial search strategy was developed using 
a combination of topic-relevant and method-
relevant key search terms and MeSH headings 
to identify relevant articles within MEDLINE. 
This strategy was adapted for searching within 
the other electronic databases used. A sample 
search strategy used is presented in Appendix 2 
(Section 11.2).
Electronic sources
The following major health and health economics 
databases were searched in August 2015:
Databases searched Studies 
retrieved
Cochrane Library of Systematic Reviews 1,288
DARE 275
Joanna Briggs Institute Database 
of Systematic Reviews
22
Campbell Collaboration Library 179
EPPI Centre Library 3
PsycINFO 1,899
Health Technology Assessment database 77
Total identified 3,743
Duplicates removed 94
TOTAL 3,649
3.2 Inclusion and exclusion 
criteria
Inclusion in the review was limited to English 
language studies and search limits were applied 
so that only studies published since 2010 were 
retrieved for screening. References from the 
database searches were downloaded into EndNote, 
deduplicated and screened on title and abstract 
against pre-defined inclusion and exclusion criteria. 
All references judged to be potentially relevant for 
the review were included and the full-text article 
was retrieved and screened again against the same 
criteria. At both title and abstract and full-text 
screening stages, references were screened by two 
reviewers independently, with any disagreements 
3
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on inclusion and exclusion resolved through 
discussion between reviewers and consultation 
with a third reviewer if necessary. Articles that 
were identified as being relevant were categorised 
under the four review headings.
Types of studies
High-quality systematic reviews of quantitative 
data including meta-analyses and narrative 
synthesis only were included in this review. It was 
decided to include high-quality reviews for two 
reasons: i) to limit the inclusion of poor-quality 
evidence and ii) in consideration of the large 
amount of evidence available relating to this topic. 
However, it was decided that where any gaps in the 
included evidence were identified, then reviews of 
lower quality would be considered. Additionally, 
high-quality systematic reviews published prior 
to 2010 that included evidence not covered by 
reviews published after that date were considered 
for inclusion. Systematic reviews of qualitative 
evidence were not included in this review.
Types of interventions
Prevention
Interventions, activities or programmes with an 
aim of preventing or reducing illicit drug use among 
young people (aged 25 and under) were eligible 
for inclusion. For example, the review sought to 
identify evidence on school-based programmes, 
family-based programmes, brief interventions and 
mass media campaigns, but any intervention that 
aimed to prevent initiation of or reduce drug use 
among young people was considered. Interventions 
were compared with other interventions, normal 
conditions and no intervention. Reviews of 
interventions with the primary aim of treating drug 
use disorders or reducing problematic drug use 
were excluded from this strand of the review, and 
considered under ‘Treatment and recovery’.
Harm reduction
Interventions, activities or programmes with 
an aim of reducing the harms and risks that 
individuals are exposed to relating to drug use 
were eligible for inclusion. For example, the review 
sought to identify evidence on needle and syringe 
programmes, supervised drug consumption 
facilities and blood-borne virus treatment and 
testing, but any intervention that aimed to reduce 
drug-related harms among current drug users 
was considered. Interventions were compared 
with other interventions, normal conditions (for 
example, harm reduction practice as normal in 
the case of studies into new innovations) and 
no intervention.
Treatment and recovery
Interventions that aim to bring about cessation 
or reduction of drug use, or continued recovery 
from drug use, were eligible for inclusion. This 
included treatments such as substitute prescribing, 
psychosocial interventions (for example, brief 
interventions and contingency management 
interventions), residential treatment programmes, 
recovery communities and mutual aid interventions 
(for example, peer support networks, 12-step 
programmes). All illicit drugs were considered 
relevant for this review.
Reviews that examined interventions for alcohol, 
tobacco or other legal drugs only were excluded 
from all strands of this review.
Types of populations
Harm reduction or treatment interventions aimed 
at any population who use illicit drugs, or are in 
recovery from drug use, were eligible for inclusion. 
However, reviews of prevention interventions were 
only included if they encompassed studies that 
focused on children and young people aged 25 
years and younger but, where review participants 
included both young people and older adults, they 
were eligible for inclusion. In particular, the review 
sought to highlight evidence on interventions for 
‘high-risk’ groups including, but not limited to, 
prisoners and people in contact with the criminal 
justice system, homeless populations, sex workers, 
Travellers, pregnant and parenting women, people 
with mental health problems and lesbian, gay, 
bisexual and transgender (LGBT) populations.
Types of outcomes
Reviews that included drug use or treatment 
outcomes or outcomes relating to harmful 
behaviours were eligible for this review. Primary 
outcomes of interest were:
» Prevalence of drug use (according to the 
reviewed study, but including length of time of 
drug abstention, amount of drugs used per day, 
money spent per day, craving)
» Frequency of drug use
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» Cessation of drug use
» Drug dependence
» Drug-related morbidity and mortality
» Prevalence and transmission of blood-borne 
viruses including hepatitis B, hepatitis C and HIV
» Uptake of testing and treatment for blood-
borne viruses, and uptake of hepatitis 
B vaccination
» Prevalence of high-risk behaviours associated 
with drug use; injection equipment sharing and 
risky injection behaviours, drug-driving
» Injecting-related injuries
» Overdose
» Use of needle and syringe programmes (NSPs) 
and uptake of drug treatment and use of 
health services
» Disposal of used needles and equipment
» Risky sexual behaviours
» Treatment outcomes (such as time participants 
spend in treatment, retention rate at a given 
time, drop out, adverse treatment effects)
Secondary outcomes of interest were:
» Criminal activity (such as recidivism, 
incarceration, arrest)
» Mental health symptoms (depression, anxiety, 
post-traumatic stress disorder)
» Social functioning and reintegration (e.g. 
housing status, employment status and quality 
of employment, education status (including 
statutory and vocational qualifications)
» Alcohol use
Reviews that only included outcomes such as 
knowledge and attitudes towards drug use, or 
intentions towards future drug use were excluded.
3.3 Assessment of 
quality of reviews
All reviews identified as being relevant for inclusion 
after full-text screening were assessed using the 
Joanna Briggs Institute tool for assessing the quality 
of systematic reviews (Joanna Briggs Institute, 
2014). Two reviewers independently assessed the 
quality of all studies. Any disagreements were 
resolved through discussion between the review 
team. A score out of 10 was assigned to each study 
based on the quality assessment. Reviews were 
categorised as being ‘high quality’ if: i) they scored 
8 or more and ii) the authors adequately evidenced 
the quality assessment process undertaken. 
Reviews scoring 5–7 were rated ‘medium’ quality 
and reviews scoring 4 or lower were rated ‘low’ 
quality. Details of the scoring system used to 
assess review quality are provided in Appendix 3 
(Section 11.3).
3.4 Data extraction
Data from each article included in this review 
were extracted into a predesigned table in 
Access, and were independently checked for 
accuracy by a second reviewer. A range of data 
were collected, including review methodology, 
intervention types, participants and outcomes. 
Verified outcomes (e.g. those measured through 
blood or urine analysis, police records, treatment 
records) were prioritised, but self-reported 
outcomes were included where verified outcomes 
were not available or to supplement these. Unless 
otherwise stated, outcomes are for the longest 
follow-up time reported. Where meta-analysis 
data were available for three or more primary 
studies on a given outcome combined, these data 
were extracted and are included in the evidence 
tables provided.
Summary tables of the reviews identified were 
developed and are presented here for each 
intervention type. Evidence tables for each 
outcome identified were created for each 
treatment comparison and were coded using 
a traffic light system to indicate the direction 
of effect (Joanna Briggs Institute, 2014). The 
evidence table number matches the ‘evidence 
table reference’ given next to each outcome in the 
summary tables presented under each intervention 
type in this review.
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3.5 Categorisation of 
review‑level evidence
The quality of the evidence available for each 
outcome examined was determined according 
to GRADE criteria, with evidence rated ‘high’, 
‘medium’ or ‘low’ strength:
» High‑quality review‑level evidence – one or 
more up-to-date systematic reviews rated high 
quality using the JBI tool that are based on 
at least two high-quality primary studies with 
consistent results.
» Moderate‑quality review‑level evidence – one 
or more up-to-date systematic reviews of high 
or moderate quality as determined by JBI tool; 
based on at least one high-quality primary study 
or based on at least two primary studies of 
moderate quality with consistent results.
» Low‑quality review‑level evidence – one or 
more systematic reviews of variable quality as 
assessed using the JBI tool; based on primary 
studies of moderate or low quality (or where 
the quality of primary studies was unknown) or 
based on inconsistent results in the reviews.
Up-to-date systematic reviews were those reviews 
published since 2010. Quality of primary studies 
was based on the assessment of quality undertaken 
in the reviews identified. Quality of review-level 
evidence was calculated and reported in the 
summary tables and text in this review.
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4.1 Study selection process
The 3,649 articles identified through the literature 
search were assessed against review inclusion and 
exclusion criteria. Following a rigorous screening 
process (Figure 1), 97 articles were identified that 
were eligible for inclusion in this review. The 97 
articles were categorised according to the area 
of interventions that each review article focused 
on, including treatment/recovery (n=62), harm 
reduction (n=24) and prevention (n=13). Two 
reviews were included in both the treatment/
recovery and harm reduction reviews. Articles 
that were excluded from the review at the full-text 
screening stage or later are provided in section 
10.3 – References to excluded articles.
4.2 Articles included in 
this review
In total, 97 systematic reviews were included 
across the three reviews. A summation of 
the evidence identified is provided in Table 1 
(prevention), Table 8 (harm reduction) and Table 
18 (treatment and recovery). The identified reviews 
included seven articles published before 2010 
and 90 articles published between 2010 and 2015. 
Reviews published before 2010 were only included 
where they filled an important gap in the evidence; 
for example, no high-quality reviews published 
after 2010 were available on the effectiveness of 
methadone maintenance treatment. Of the 97 
included articles, 85 were rated high quality, 10 
were rated medium quality and one was rated low 
quality.1 Reviews rated medium or low quality were 
only included where they filled an important gap in 
the evidence.
4.2.1 Areas of intervention 
identified
Findings are presented under the three major 
intervention areas of prevention, harm reduction 
and treatment and recovery. Within each 
major heading, the evidence that was identified 
was grouped into the following main types 
of interventions:
Prevention
» Universal school-based programmes
» Universal and targeted 
family-based programmes
» Brief interventions in primary care, emergency 
department and school settings
» Mentoring interventions
» Media interventions, including media campaigns 
and computer/Internet-based interventions
» Interventions targeting young people with 
mental health disorders.
Harm reduction
» Provision of needles and injecting equipment
» Pharmacological interventions
» Psychosocial and behavioural interventions
» Opioid overdose prevention programmes with 
distribution of naloxone
1 Additionally, one article was a pooled analysis of evidence 
rather than a systematic review and therefore was not 
assigned a quality rating.
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» Drug consumption rooms
» Interventions to prevent initiation of injecting
» Interventions to increase uptake of blood-borne 
virus testing
» Interventions to reduce harm in 
recreational settings
» Interventions to increase uptake and adherence 
to blood-borne virus treatment
» Interventions targeting individuals in contact 
with the criminal justice system
» Interventions targeting individuals who are 
sex workers.
Treatment and recovery
» Pharmacological treatments for opiate use
» Pharmacological treatments for stimulant use
» Pharmacological treatments for cannabis use
» Psychosocial interventions
» Residential rehabilitation
» Treatments focusing on long-term recovery 
and reintegration
» Treatment interventions for individuals in 
contact with the criminal justice system
» Treatment interventions for individuals with co-
occurring drug use and mental illness
» Treatment interventions for pregnant and 
parenting women.
Additionally, evidence was identified on physical 
activity and acupuncture-based interventions 
and these are discussed under ‘other 
treatment approaches’.
4.2.2 Study selection diagram
Eligible for title and 
abstract screening
n=3,649
Excluded
n=3,374
Excluded
n=189
Primary exclusion reason:
Review quality: n=76
Methodology*: n=55
Review scope: n=50
Foreign language review: n=3
Review withdrawn: n=2
Date of review search: n=2
Updated review available: n=1
Eligible for full
text screening
n=277
Eligible for inclusion
n=96
Harm reduction
n=24
Treatment/recovery
n=42
Prevention
n=13
Identiﬁed from 
additional searches:
(reference list,
key websites)
n=9
* articles excluded based on methodology were those that were not a systematic review, were a 
protocol for a systematic review only, were systematic reviews of qualitative evidence, or were 
systematic reviews of reviews.
Figure 1: Study selection diagram
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5Prevention
In total, 13 systematic reviews were included 
in this review. A summation of the evidence 
identified is provided in Table 1. The evidence that 
was identified was grouped by intervention type 
including:
» Universal school-based programmes
» Universal and targeted family-based 
programmes
» Brief interventions in primary care, emergency 
department and school settings
» Mentoring interventions
» Media interventions including media campaigns 
and computer/Internet-based interventions.
Additional evidence was identified relating 
to cannabis prevention interventions and 
interventions targeting young people with mental 
health disorders.
5.1 Quality of included 
prevention reviews
Initially, only reviews that scored 8 or higher 
on the JBI tool, and included assessment of 
primary-level evidence quality, were included 
in this review. For the prevention strand of the 
review, 11 reviews published since 2010 met 
these criteria. Additionally, two studies published 
since 2010 and rated ‘medium’ quality on the JBI 
quality assessment tool were included to cover 
intervention gaps not covered by the high-quality 
evidence. Review scores on the JBI assessment 
are provided in the summary of reviews identified 
(Table 1) and full details of quality assessment 
for each review are provided in Appendix 4 
(Section 11.4).
5.2 Universal school‑based 
prevention programmes
Typically, school-based programmes aim to inform 
young people about the risks and effects of drug 
use, and to modify young people’s social skills 
and personality traits such as drug refusal skills, 
self-esteem and self-efficacy. Multicomponent 
school-based programmes addressing young 
people’s social influences and social skills are 
considered best practice for reducing drug use, 
and specifically cannabis use (EMCDDA, 2015b). 
In Ireland, there has been a drive to develop drug 
use education through schools in the context 
of Social, Personal and Health Education (SPHE) 
(Department of Health, 2015). This is one of the 
most frequently used prevention approaches 
for drug use, due to the ease of access to young 
people and an educational platform (Stockings et 
al., 2016). However, young people who are most 
at risk of drug use may be less likely to attend 
school and so access to this group may be limited 
through school-based programmes (Degenhardt et 
al., 2016).
Two reviews were identified that looked at 
universal school-based programmes (Table 2).2One 
review (Faggiano et al., 2014) looked at drug use 
programmes and one review (Jackson et al., 2012) 
looked at programmes aiming to reduce both 
drug use and sexual risk behaviours. Only one 
primary study featured in both reviews. The review 
by Jackson and colleagues included predominantly 
school-based programmes, and family-based 
programmes are considered in section 5.3 of 
this review.
2 Targeted brief interventions delivered in school settings are 
examined in section 7.4 Brief interventions.
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Table 1: Summary of prevention reviews identified
Citation Prevention intervention 
details
Target population 
details
Number of 
relevant 
studies 
included
Location JBI score 
for review 
quality 
(/10)
Carney et al., 
2014
Brief interventions delivered 
in school settings
Schoolchildren who 
had prior experience 
of drug use
6 USA n=4; UK n=2 10
Faggiano et 
al., 2014
Universal school-based 
programmes
Schoolchildren 51 USA n=42; Australia 
n=2; UK n=2; China n=1; 
Czech Republic n=1; 
Hong Kong n=1; South 
Africa n=1; Europe n=1
10
Ferri et al., 
2013
Media campaigns Young people 16 USA n=14; Australia n=1; 
Canada and USA n=1
10
Jackson et al., 
2012
Interventions to reduce 
drug use and risky sexual 
behaviour in school and 
family settings
Predominantly 
schoolchildren
18 USA n=12; South Africa 
n=2; Australia n=1; 
Canada n=1; Namibia 
n=1; UK n=1
9
Newton et al., 
2013
Motivational interview within 
emergency departments
Young people with a 
history of cannabis 
use or associated 
high-risk behaviours.
2 USA n=2 10
Norberg et al., 
2013
Cannabis prevention 
programmes
Children and young 
people
25 USA n=21; Australia n=1; 
UK n=1; Europe n=1
10
Patnode et 
al., 2014
Brief interventions set within 
primary care and computer-
based interventions
Children and young 
people
6 USA n=5; USA and Czech 
Republic n=1
10
Salvo et al., 
2012
Range of interventions Children and young 
people with mental 
disorders
3 NR 9
Tait et al., 
2013
Computer-based 
interventions in a range of 
settings
Young people 10 USA n=5; Germany n=2; 
Australia n=2; USA and 
Canada n=1
10
Thomas et al., 
2013
Mentoring interventions Children and young 
people aged 6 –18 
years
6 USA n=5; Sweden n=1 7
VanBuskirk et 
al,. 2014
Motivational interview within 
primary care
Young people 2 USA n=2 8
Vermeulen-
Smit et al., 
2015
Family-based interventions Young people and 
their parents
22 USA n=22 7
Wood et al., 
2014
Universal and targeted 
computer-based 
interventions in a range of 
settings
Young people 10 USA n=6; USA and 
Canada n=1; Australia 
n=2; Germany n=1
9
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Findings from one review (Faggiano et al., 2014) 
that included over 50 primary studies of universal 
school-based drug prevention programmes suggest 
that generally this intervention approach is not 
effective in reducing use of illicit drugs. However, 
some specific ‘manualised’ programmes (i.e. 
those that are structured and specify programme 
activities, usually in the form of a curriculum) that 
combine the teaching of skills such as refusal, 
decision-making and coping with awareness raising 
regarding the social influences on drug use and 
information provision were found to be effective. 
The review examined different school-based 
interventions based on an adaptation of Thomas’ 
(2006) classification of school-based smoking 
prevention interventions:
» Programmes based on a social competence 
approach: include principles of affective 
education and assumes that risk of drug use is 
increased among those with poor personal and 
social skills. Interventions are often based on 
social learning theory which assumes that drug-
related behaviours are influenced by modelling 
and imitating the behaviour of others, and this 
reinforces pro-drug decisions. These types of 
programmes aim to teach cognitive-behavioural 
and general skills around decision-making, 
coping, goal setting, and resistance.
» Programmes based on a social norms approach: 
assume that drug use arises from inaccurate 
estimates of drug use among peers, and 
how this might lead to a desire for social 
acceptability or normalisation through drug 
use. Interventions focus on education, and aim 
to correct misestimates by providing accurate 
information on the true extent of use.
» Knowledge-focused programmes: assume that 
drug use is influenced by information deficits, 
i.e. poor knowledge about associated risks 
and dangers. Participants are provided with 
information regarding prevalence, and the 
health, social and legal risks associated with 
drug use.
Low-quality review-level evidence suggests that 
knowledge-based programmes are not likely to be 
effective in preventing use of cannabis or other 
drugs. Across outcomes, including cannabis use, 
hard drug use and other drug use at different 
follow-up times, the review indicates that there 
were no consistent effects for interventions 
based on social competence or social influence 
approaches, although programmes based on 
a social competence approach were better 
supported. Prevention programmes that were 
based on a combination of social competence and 
Table 2: Universal school‑based prevention programmes ‑ summary
Population Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference citations Outcome
Outcome table reference
Children and 
young people
Universal programmes 1 (H 1) Faggiano et al., 2014 Cannabis use
Outcome table 1
Hard drug use
Outcome table 2
Other drug use 
Outcome table 3
Any drug use
Outcome table 4
Curriculum interventions to 
prevent sexual health risk 
behaviours and drug use
1 (H 1) Jackson et al., 2012 Drug use and sexual health
Outcome table 5
Curriculum interventions 
with additional components 
to prevent sexual health risk 
behaviours and drug use
1 (H 1) Jackson et al., 2012 Drug use and sexual health
Outcome table 5
Whole school programmes 1 (H 1) Jackson et al., 2012 Drug use and sexual health
Outcome table 5
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influence approaches had more promising results 
and there was some evidence to suggest that these 
interventions may lead to reduced short-term drug 
use, and reduced long-term use of cannabis and 
hard drugs. However, the evidence on combined 
programmes was inconsistent and inconclusive. The 
authors of an earlier review looking at cannabis and 
alcohol prevention programmes in school settings3 
concluded that comprehensive programmes, which 
combine information with training in refusal skills, 
self-management skills and social skills, are most 
likely to be effective (Lemstra et al., 2010).
Across all intervention approaches included in the 
review by Faggiano and colleagues, the strongest 
evidence was regarding cannabis use, as only small 
numbers of primary studies included in the review 
looked at other outcomes. It is important to note 
that where there were mixed results, outcomes 
sometimes favoured the intervention groups and 
sometimes favoured controls, suggesting that some 
programmes may be harmful.
One review was identified that examined school-
based programmes (and programmes in other 
settings) that addressed both drug use and sexual 
risk behaviours (Jackson et al., 2012). For each type 
of school-based programme, including curriculum 
interventions (with or without additional 
components) and whole school or multicomponent 
programmes, interventions appeared generally 
not to be effective in drug use outcomes. 
Evidence suggests that programmes that address 
sexual health and drug use outcomes in school 
programmes may be more effective for sexual risk 
behaviours and alcohol use, although this evidence 
is inconclusive (Jackson et al., 2012). The authors 
concluded that the most effective interventions 
are those that focus on multiple domains rather 
than school-based only programmes, although 
impact on drug use appears to remain limited.
3 This systematic review (Lemstra et al., 2014) was excluded 
from our review, as all drug-related primary studies 
included in the review were included in the more up-to-date 
systematic review included here (Faggiano et al., 2014).
5.3 Family‑based interventions
Family-based programmes are one of the most 
commonly used approaches internationally to 
prevent drug misuse in young people (Stockings 
et al., 2016). These interventions can be aimed at 
all individuals (the parents and young people) or 
parents only in a range of settings. Information 
around the harms of drug use and sessions on 
effective parenting, communication and discipline 
typically feature on these programmes (ALICE 
RAP, 2014). Currently, in Europe interventions 
involving the whole family are more likely to be 
recommended than those that train parents 
only (EMCDDA, 2015b). In Ireland, family-based 
programmes are recognised as having an important 
role in developing parenting skills and breaking the 
cycle of drug use among children who live currently 
with a parent who misuses drugs (Department of 
Health, 2015).
Two reviews rated high quality using the JBI tool 
included family-based interventions (Jackson et al., 
2012; Patnode et al., 2014). Additionally, one review 
rated medium quality (Vermeulen-Smit et al., 2015) 
specifically reviewed the effectiveness of family-
based interventions on drug use among young 
people and was included, as the review covered 
intervention areas not covered in the high-quality 
review (Table 3).
The review by Vermeulen-Smit and colleagues 
(2015) included universal interventions as well 
as interventions targeting high-risk groups and 
individuals already using drugs on a recreational 
basis. High-risk groups included a range of 
populations such as delinquents, those at risk of 
drug use, juvenile offenders, children of drug-
using parents, those in high-risk neighbourhoods, 
homeless youth, children of parents with HIV and 
children of divorced parents. Interventions aiming 
to reduce drug use in recreational users included 
i) a brief family intervention and ii) a coping skills 
training intervention delivered to parents only. The 
review by Jackson and colleagues (2012) included 
a small number of studies not set in schools that 
were based around parent or family interventions; 
the remaining review included multiple evaluations 
of a mother-daughter targeted computer-based 
intervention (Patnode et al., 2014). Across the three 
reviews, the interventions were delivered in a range 
of settings and comprised a variety of components.
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5.3.1 Universal family‑based 
interventions
Low-quality review-level evidence suggests that 
universal family-based interventions may reduce 
initiation and use of cannabis among adolescents 
(Jackson et al., 2012; Patnode et al., 2014; 
Vermeulen-Smit et al., 2015), but may not be 
effective on initiation of drugs other than cannabis 
(Jackson et al., 2012; Vermeulen-Smit et al., 2015). 
Findings suggest that a combined parent and child 
intervention approach may be more effective 
in reducing cannabis initiation and use than 
interventions that target parents alone.
5.3.2 Targeted family‑based 
interventions
The evidence on the effectiveness of family 
interventions that target ‘high-risk’ adolescents 
is inconclusive. Low-quality review-level evidence 
suggests that targeted family interventions have 
no impact on prevention of illicit drug use, but 
their impact on reducing frequency of hard drug 
and cannabis use and later drug dependency 
varied across different studies, with some positive 
and negative intervention effects (Vermeulen-
Smit et al., 2015). Evidence is scarce on family 
interventions targeted at children of drug-using 
parents, but low-quality review-level evidence 
suggests that targeted family interventions may be 
effective in reducing the frequency of illicit drug 
and cannabis use.
In addition, one article that was excluded from 
this review based on methodological quality 
was identified that looked at the provision of 
interventions to prevent drug use among children 
from drug-affected families (Broning et al., 2012). 
The article contained little evidence of relevance to 
this review, but the authors concluded that there 
is preliminary evidence to support programmes 
delivered over a substantial period of time with 
components including skills training for children, 
parents and families to reduce drug use. However, 
the evidence relating to illicit drug use was scarce 
and inconclusive.
5.4 Additional cannabis 
prevention interventions
One review rated high quality was identified that 
looked specifically at the impact of prevention 
programmes on cannabis use (Norberg et al., 2013). 
The review included evidence from a range of 
interventions, including universal school and family 
programmes, and interventions targeting groups 
Table 3: Family‑based interventions – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Reference 
citations
Outcome
Outcome table 
reference
Children and 
adolescents
Range Universal family-
based interventions
3 (1M, 2H) Jackson et al., 
2012; Patnode 
et al., 2014; 
Vermeulen-Smit 
et al., 2015
Frequency of drug use
Outcome table 6
Adolescents 
using illicit 
drugs 
recreationally
Community Targeted family-
based interventions
1 (M) Vermeulen-Smit 
et al., 2015
Frequency of drug use
Outcome table 7
High-risk 
adolescents
Community Targeted family-
based interventions
1 (M) Vermeulen-Smit 
et al., 2015
Frequency of drug use
Outcome table 8
Vermeulen-Smit 
et al., 2015
Drug disorders
Outcome table 9
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such as females, athletes and at-risk populations. 
Of the 25 studies included in the review by Norberg 
and colleagues, 14 are included within the evidence 
presented in previous sections of this review.
The authors compared cannabis outcome-
related effect sizes across studies considering 
different approaches including uni- and multi-
modal universal and targeted interventions. It was 
identified that universal programmes that target 
multiple domains (for example, school programme 
alongside parent/family, mentoring or media 
components) may be more effective in preventing 
cannabis use than universal interventions set in 
one domain or targeted interventions. Similarly, an 
earlier review (Jones et al., 2006) indicated that 
comprehensive community-based programmes are 
more effective than school or community only-
based interventions in preventing both licit and 
illicit drug use.
5.5 Brief and/or motivational 
interventions
Brief and motivational interventions are applied 
across the domains of harm reduction, prevention 
and treatment to motivate and change behaviour.4 
Brief interventions can take place in a number 
of settings including schools, work, university, 
primary care and emergency departments and 
hospitals (Stockings et al., 2015). They are often 
delivered opportunistically to encourage or 
motivate individuals, including those deemed 
at risk of becoming drug users, to change their 
behaviour. For individuals who are already misusing 
drugs a brief intervention may not be appropriate 
or sufficient to change an established behaviour, 
but brief interventions are applied to recreational 
users or individuals at risk of misusing drugs. While 
evidence on effectiveness in drug prevention is 
scarce, there is substantial evidence to suggest 
that brief interventions may be effective in 
alcohol prevention (Tanner-Smith et al., 2015). 
In the UK, brief interventions are recommended 
for engaging with individuals who are unlikely to 
have contact with drug services (NICE, 2007). 
Similarly, motivational interventions (primarily 
delivered as motivational interviewing) seek to 
4 Interventions that target people who are misusing 
or dependent on drugs that fall within the field of 
brief or motivational interventions are covered in the 
treatment strand of this review. Within this prevention 
strand, interventions may include people who use drugs 
recreationally or are not currently using drugs.
strengthen an individual’s motivation to change 
behaviour or reduce ambivalence regarding drug 
use. Motivational interviewing may form part of a 
brief intervention or a more substantial programme 
or series of sessions to support an individual to 
recognise a need to change behaviour or attitude 
towards drug use.
Four reviews were identified that examined brief 
and/or motivational interventions across a range 
of settings (Table 4). The review of school-based 
brief interventions (Carney et al., 2014) included six 
interventions based on a combination of screening, 
motivational interview, information provision 
and brochures that were targeted at current 
drug users. The reviews of interventions based in 
primary care (Newton et al., 2013) and emergency 
departments (VanBuskirk and Wetherell, 2014) 
included studies that utilised motivational interview 
interventions. The non-school-based reviews 
(Newton et al., 2013; VanBuskirk and Wetherell, 
2014) included a range of studies, with the majority 
focusing on legal drugs and primarily alcohol, 
with just two studies included in each review that 
focused on illicit drugs, which are reported here.
5.5.1 School‑based interventions
One review looked at brief interventions targeted 
at current drug users in school settings (Carney 
et al., 2014). Primarily moderate-quality review-
level evidence suggests that brief interventions 
delivered in schools to children already using 
drugs are neither more nor less effective than 
information provision at reducing use of any drug, 
cannabis or alcohol, or at reducing cannabis-
related dependence or behavioural outcomes. 
However, brief interventions may be more effective 
in comparison to assessment only conditions for 
reducing cannabis use (Carney et al., 2014).
5.5.2 Primary care‑based 
interventions
Two reviews were identified that looked at brief 
and/or motivational drug prevention interventions 
in primary care settings (Patnode et al., 2014; 
VanBuskirk and Wetherell, 2014). The review 
by Patnode and colleagues (2014) covers three 
brief interventions, including one computer-
led screening and brief advice intervention, 
one counselling session and one study including 
a therapist-led and computer-led brief 
interventions. Findings relating to use of cannabis 
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and other drugs were mixed and inconclusive, with 
only one arm of the computer-led intervention 
indicating consistent significant intervention 
effects. Additionally, one review examined 
motivational interviews delivered in primary care 
settings to young people at risk of drug misuse 
(VanBuskirk and Wetherell, 2014). There is low-
quality review-level evidence to indicate that 
motivational interviewing may be effective for 
drug prevention when delivered in primary care 
settings; however, drug use findings were limited 
greatly by low numbers of participants and studies. 
The review authors examined the effectiveness of 
motivational interview delivered in primary care 
on other health behaviours and concluded that 
this approach may be effective, which adds to 
previous evidence suggesting that alcohol brief 
interventions delivered in primary care may have 
positive impacts (O’Donnell et al., 2013).
Table 4: Brief and motivational interventions – summary
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
Children and 
young people
Emergency 
department
Motivational 
interview
1 (H) Newton et al., 
2013
Cannabis abstinence
Outcome table 10
Cannabis use
Outcome table 10
Alcohol use
Outcome table 11
Primary care Motivational 
interview
1 (H) VanBuskirk 
and Wetherell, 
2014
Cannabis use
Outcome table 12
Drug use
Outcome table 12
Trouble due to alcohol use
Outcome table 13
Brief 
interventions
1 (H) Patnode et al., 
2014
Cannabis use
Outcome table 14
Cannabis cessation
Outcome table 14
Cannabis initiation
Outcome table 14
Drug use
Outcome table 14
Adolescents 
already using 
drugs
School Brief 
interventions
1 (H) Carney et al., 
2014
Drug use
Outcome table 15
Cannabis quantity
Outcome table 15
Cannabis frequency
Outcome table 15
Cannabis dependence
Outcome table 15
Alcohol frequency
Outcome table 16
Alcohol quantity
Outcome table 16
Behavioural outcomes
Outcome table 17
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5.5.3 Emergency department‑
based interventions
One review was identified that looked at the 
effectiveness of a motivational interview delivered 
to young people with a history of cannabis use or 
associated behaviours who visited an emergency 
department. Low-quality review-level evidence 
indicates that in comparison to handout-only 
control groups, motivational interviewing delivered 
in an emergency department may be effective in 
increasing abstinence from cannabis use among 
young people with a history of cannabis use. 
However, there was no evidence of effectiveness 
on other drug-related outcomes such as days 
of use, injury or risk sex (Newton et al., 2013). 
Findings were limited by the low number of studies 
included in the review that focused on illicit drugs 
and it is not possible to draw conclusions on the 
effectiveness of brief interventions in this setting 
on that basis. A review by the EMCDDA (2016a) 
of brief interventions in emergency department 
settings identified that there are potential benefits 
to this approach, but the current evidence base is 
largely focused on alcohol prevention.
5.6 Media interventions
Interventions in the form of mass media campaigns 
can target illicit drug use as well as prevent 
use of drugs such as alcohol or tobacco. The 
EMCDDA (2013) describes two types of mass media 
campaigns relating to drug use: i) information 
campaigns that may warn the population about 
risks and harms and provide information about 
support services and interventions; and ii) social 
marketing campaigns that provide information on 
prevalence of drug use, look at social and legal 
norms and promote positive behaviours. In general, 
such campaigns are implemented and disseminated 
using television commercials, radio broadcasts, 
newspaper or magazine advertisements, 
brochures, posters in public spaces, as well as 
Internet-based campaigns. While media campaigns 
have the potential to reach a wide audience, 
potential disadvantages include their passive 
nature, with no guarantee that they will obtain 
significant exposure, be consciously noticed by 
the target audience, or have the direct effect of 
altering attitudes and subsequent health-related 
behaviours (Slater et al., 2006). Additionally, 
there are concerns about unintentional harmful 
effects from media campaigns that may raise 
interest or awareness of particular drugs (EMCDDA, 
2013). With these potential flaws in mind, media 
campaigns tend to be part of a wider campaign 
that involves multiple rather than standalone 
intervention strategies (Wakefield et al., 2010).
Media campaigns have been demonstrated to 
have positive effects in areas such as smoking 
prevention and road safety (Wakefield et al., 
2010). While there are many examples of media 
campaigns to prevent or reduce drug use, there is 
a lack of evidence on their effectiveness (EMCDDA, 
2013), which might reflect potential difficulties 
in evaluating widespread campaigns. Examples of 
media campaigns in Ireland include the ‘What’s 
in the pill?’ and the new ‘What’s in the powder?’ 
campaigns on university campuses. These media 
campaigns provide facts and information through 
multiple formats including posters, factsheets and 
social media. The focus of these campaigns is more 
on harm reduction than on preventing drug use, 
however.
In addition to interventions that are delivered 
through mass media, technological developments 
have increased the potential for Internet- and 
computer-based prevention programmes. These 
are often undertaken independently by the young 
person, meaning that programmes can be tailored 
to their needs and personalised feedback can be 
provided (Dennhardt and Murphy, 2013). Further 
appealing characteristics of computer programmes 
include their ability to allow the user to manage 
their own pace, privacy, low associated costs 
and suitability for engagement with young people 
through multimedia (Stockings et al., 2016). Best 
practice in Europe supports computer-based 
programmes for reducing drug use in the medium 
term. This includes both universal programmes 
and those targeted at recreational drug users 
(EMCDDA, 2015b).
Three reviews were identified that looked at the 
effectiveness of media-based interventions to 
prevent drug use (Table 5). One review examined 
media campaigns on drug use among children and 
adolescents (Ferri et al., 2013) and two reviews 
looked at computer-based and Internet-based 
interventions (Tait et al., 2013; Wood et al., 2014). 
There was substantial overlap between these 
two reviews with regard to the primary studies 
included. The review by Ferri and colleagues 
included standalone TV and radio advertisements 
and Internet interventions, and multicomponent 
campaigns including a combination of TV, radio, 
printed media and Internet modules.
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Table 5: Media interventions – summary
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table 
reference
Children and 
young people
Community Multicomponent 
media campaign
1 (H) Ferri et al., 
2013
Any drug use
Outcome table 18
Cannabis use
Outcome table 18
Methamphetamine use
Outcome table 18
TV/radio 
advertisement
1 (H) Ferri et al., 
2013
Any drug use
Outcome table 19
School/ 
community
Universal computer 
and Internet-based 
interventions
3 (H) Ferri et al., 
2013; Tait 
et al., 2013; 
Wood et al., 
2014
Cannabis use
Outcome table 20
1 (H) Wood et al., 
2014
Polydrug use
Outcome table 20
Any drug use
Outcome table 20
College Targeted computer 
and Internet-based 
interventions
1 (H) Ferri et al., 
2013; Wood et 
al., 2014
Any drug use
Outcome table 21
5.6.1 Media campaigns
One review looked at the effectiveness of a range 
of media campaigns on drug use among children 
and adolescents (Ferri et al,. 2013). The review 
looked at drug use among participants following 
exposure to TV public service announcements and 
multicomponent interventions, including television, 
radio and printed media alone or in combination 
with a school-wide campus intervention or 
curriculum-based intervention.
There was little evidence to support the 
application of media campaigns to reduce drug 
use among young people and the authors note 
that interventions and outcomes were not easily 
comparable. There was low-quality review-level 
evidence to suggest that standalone television 
commercials may reduce cannabis use, but findings 
are limited by the design of the one study that 
looked at this effect. Evidence on the effectiveness 
of multicomponent media campaigns (those 
incorporating a combination of television, radio 
and printed media), including those delivered 
alongside a school-based intervention, was mixed 
and inconclusive. It is important to note that some 
interventions appeared to have adverse effects 
where participants were more likely to use drugs 
following exposure to media campaigns.
5.6.2 Computer‑based and 
Internet‑based interventions
Three reviews rated high quality using the JBI tool 
examined the effects of computer-based and 
Internet-based interventions to prevent drug use 
among young people5 (Ferri et al., 2013; Tait et al., 
2013; Wood et al., 2014). Universal programmes 
consisted typically of 10–15 sessions and were 
delivered in school or online to children of a 
range of ages. Programmes were knowledge-
based and skill-based, with skills for drug refusal 
or dealing with peer pressure featuring on all 
programmes. Primarily low-quality review-level 
evidence suggests that universal computer-based 
programmes for young people appear largely 
ineffective in reducing drug use immediately 
following the intervention; however, evidence 
suggests that there may be benefits in the 
medium term. The evidence is most substantial 
for cannabis use, with high-quality review-level 
evidence suggesting a positive overall intervention 
effect (Tait et al., 2013). Findings from studies 
on the mother-daughter computer intervention 
5 Additionally, the review by Woods and colleagues (2014) 
examined interventions delivered to older adults, but these 
interventions are not included here.
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covered within the family interventions section 
of this review (Section 5.3, Patnode et al., 2014) 
add to this evidence, suggesting that computer-
based interventions may have positive effects on 
cannabis use among young people.
Additionally, the reviews reported findings from 
two programmes that targeted recreational drug 
users in college, including one study that provided 
personalised computer feedback based on 
motivational interview and one online counselling 
programme. Low-quality review-level evidence 
suggests that an online counselling programme may 
be effective in reducing short-term cannabis use, 
but there were no intervention effects reported 
for the personalised Internet-based feedback 
intervention (Ferri et al., 2013; Woods et al., 2014).
5.7 Mentoring interventions
Peer mentoring is a system of giving and receiving 
support that is founded on the key principles 
of respect, shared responsibility and mutual 
agreement on what is helpful. In this sense, peer 
support has been regarded as a holistic approach 
that can be utilised as a powerful strategy for 
preventing drug and alcohol use (MacArthur et 
al., 2015). For example, there is a growing body of 
evidence supporting how peer mentoring can act 
as an effective approach to engage individuals in 
skill-building activities as well as provide social 
support and reinforcement of behaviours that 
support prevention of drug use (Petosa and Smith, 
2014). For example, a previous meta-analysis 
indicates that mentoring may be an effective 
approach to prevent alcohol use (Thomas et 
al., 2011).
While encouraging health-promoting behaviours 
does not simply involve telling individuals what they 
should or should not do, through the mechanism 
of social influence there are instances when a 
person’s behaviour is significantly influenced by 
that of another. More specifically, individuals are 
more likely to copy or take on board the advice of 
their peers, i.e. those they are familiar with and/
or have a sense of shared identity with. In other 
words, health-related behaviour, such as drug and 
alcohol use, can be influenced by the behaviour 
and advice of individuals perceived as sharing a 
similar lifestyle, cultural background, linguistic and 
socioeconomic circumstance (Huang et al., 2012; 
Salvy et al., 2012). In relation to the prevention of 
drug use, peers can be more effectively used as 
mentors, whereby individuals are used to actively 
encourage abstinence from such behaviours.
For young people in particular, mentoring can offer 
a useful method of engagement, as this allows 
mutual respect and a conversation to take place in 
a shared cultural language as well as a more equal 
power balance that enables individuals to speak 
confidently and openly while providing support. 
Mentoring by adults, such as a teacher trying to 
encourage a young person not to consume drugs, 
may be less effective as the young person is likely 
to feel as though they are being subjected to 
authority and do not have a choice in the matter.
In Ireland, there are several examples of 
longstanding mentoring projects that have been 
shown to provide opportunities to help young 
people lead healthy and happy lives free from 
harmful behaviours such as drug and alcohol 
misuse (UNESCO Child and Family Research Centre, 
2012). For example, The Big Brothers Big Sisters 
Youth Mentoring Programme was established 
in Ireland in 2001, and has two key strands – a 
community-based programme that facilitates 
friendship between a young person and an older 
adult in the community, as well as a school-
based programme that ‘matches’ young people 
to a slightly older student from the same school. 
Through the scheme, it is expected that mentees 
will be able to develop supportive friendships with 
their peer mentors in a safe environment, which 
can enable them to increase their confidence and 
self-esteem, and welcome a positive role model 
into their lives (UNESCO Child and Family Research 
Centre, 2012).
One review rated medium quality was identified 
that examined the effectiveness of mentoring 
interventions to reduce or prevent drug use 
(Thomas et al., 2013; Table 6). These were delivered 
to children and adolescents who were generally 
perceived as being at high risk, although it was 
not clear in all included studies how this was 
determined. Mentors varied, but included older 
adults, trained adults and peers, and members of 
a ‘Big Brothers’ or ‘Big Sisters’ programme. In one 
study included in this review, participants were 
homeless adolescents who received a mentoring 
intervention alongside drug use treatment.
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Review findings indicate that mentoring 
interventions may have little effect on drug 
and alcohol use when delivered to high-risk 
adolescents (Thomas et al., 2013). Low-quality 
review-level evidence suggests that a mentoring 
intervention including older adults as mentors 
may reduce cannabis use in high-risk adolescents. 
For all other outcomes reported, including illicit 
drug use, any drug use, drug use initiation, alcohol 
use and alcohol use initiation, there were no 
statistically significant benefits for participants 
who received any of the range of mentoring 
interventions included in the review. Similarly, 
low-quality review-level evidence suggests no 
benefit to homeless adolescents from a mentoring 
intervention delivered in combination with drug 
use treatment, although findings were based 
on a very small sample who were followed up in 
the study.
Findings throughout were limited by the small 
number of studies and heterogeneity between 
populations and intervention approaches. 
Additionally, the review authors stated that 
there was a lack of rigorous evaluation across 
studies. Consequently, while the evidence 
indicates that mentoring interventions appear 
ineffective in preventing or reducing drug use in 
high-risk children and adolescents, it is difficult 
to draw firm conclusions based on the limited 
evidence available.
5.8 Interventions for children 
and adolescents with 
mental health disorders
The risks of smoking, abusing alcohol and other 
drugs are higher among individuals with severe 
and mild mental illness than among the general 
population (Hartz et al., 2014). Adolescents with 
a mental disorder have been shown to have high 
rates of both alcohol and illicit drug abuse, as have 
adolescents with anxiety disorders (Abram, 2016). 
Additionally, drug use is linked with increased poor 
mental well-being (Lai et al., 2015) and, among 
heavier cannabis users, psychoses (Volkow et 
al., 2014).
It is suggested that high rates of comorbidity with 
drug misuse and mental disorders may be due to 
overlapping genetic vulnerabilities (Kendler et al., 
2003) and overlapping environmental triggers such 
as stress, exposure to drugs and trauma (Alado et 
al., 2010; Brady and Sinha, 2005). Experiencing 
mental health problems, as a result of negative 
experiences in childhood, can be an independent 
predictor of experiencing addiction to drugs (Anda 
et al., 2006), such as if drugs are used to help cope 
with or alleviate symptoms. There is a clear overlap 
between drug misuse and mental illness, and the 
social and economic costs of treating both issues 
are likely to have greater costs than each on their 
Table 6: Mentoring‑based interventions – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
Adolescents 
including 
predominantly 
those at high risk
Community Mentoring-based 
interventions
1 (M) Thomas et al., 
2013
Drug use
Outcome table 22
Thomas et al., 
2013
Drug use initiation
Outcome table 22
Thomas et al., 
2013
Alcohol use
Outcome table 23
Thomas et al., 
2013
Alcohol initiation
Outcome table 23
Homeless 
adolescents
Community Mentoring-based 
intervention
1 (M) Thomas et al., 
2013
Drug use
Outcome table 24
Thomas et al., 
2013
Alcohol use
Outcome table 25
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own (Whiteford, 2013). It is important, therefore, 
that individuals with a mental illness are considered 
as key populations to target when planning and 
delivering drug prevention programmes.
One review rated high quality examined drug 
prevention among children and young people with 
mental health disorders (Salvo et al., 2012; Table 7).
A limited amount of evidence, however, was 
included in the review (Salvo et al., 2012) on three 
disorders:6 individuals with a disruptive behavioural 
disorder or ADHD, or those at high risk of early 
psychosis. For each disorder, low-quality review-
level evidence was based on individual studies 
and small samples and, therefore, while findings 
included some promising results, the evidence on 
drug prevention interventions targeting children 
with mental health disorders is inconclusive.
6 The review also included evidence on high-risk populations, 
but there was a lack of information about the nature of 
interventions to include the evidence in this review.
Table 7: Interventions for people with mental health disorders – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
Children with a 
DBD
Psychiatric 
clinics and MH 
centres
Multicomponent: 
CBT, parent 
intervention 
and behavioural 
and social skills 
programme
1 (H) Salvo et al., 2012 Cannabis use
Outcome table 26
Adolescents with 
ADHD
Psychiatric 
clinics and 
community
ADHD medication 1 (H) Salvo et al., 2012 Drug use
Outcome table 27
Drug disorder
Outcome table 27
Adolescents and 
young adults 
at high risk of 
early psychosis, 
including 
cannabis users
Not reported MI and CBT 1 (H) Salvo et al., 2012 Drug use
Outcome table 28
DBD – disruptive behavioural disorder. MH – mental health. MI – motivational interview. CBT – cognitive behavioural therapy. 
ADHD – attention deficit hyperactivity disorder
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5.9 Prevention interventions – 
key messages
School‑based programmes
Low-moderate quality review-level evidence 
suggests that comprehensive school-based 
programmes that combine the teaching of skills 
such as refusal, decision-making and coping, 
raise awareness of social influences on drug use, 
and provide information about drug use may be 
effective in preventing drug use. However, this 
evidence is inconsistent and inconclusive, and can 
be applied predominantly to cannabis use (any use 
or frequency of use) only. Low-quality review-level 
evidence suggests that school-based programmes 
that focus mainly on increasing knowledge of 
the risks of drug use alone appear ineffective in 
preventing drug use.
Low-quality review-level evidence also suggests 
that drug use and sexual health prevention 
interventions may be more effective if 
interventions focus on multiple domains rather 
than school-based only programmes, although 
impact on drug use appears limited.
Family‑based interventions
Moderate-quality review-level evidence suggests 
that universal family interventions which include 
both parents and children may be effective in 
preventing cannabis use, but evidence on other 
drug use is inconclusive. Programmes may be 
most effective when targeting multiple domains 
(e.g. school alongside family, mentoring or media 
settings). There was low-quality and mixed review-
level evidence on the effectiveness of prevention 
targeted at families of at-risk young people and 
therefore no conclusions could be made about 
these approaches.
Brief and/or motivational interventions
Moderate-quality review-level evidence suggests 
that brief interventions set within schools 
appear to be generally ineffective in preventing 
drug use. Similarly, low-quality review-level 
evidence suggests that brief interventions set 
within healthcare settings appear to be generally 
ineffective in preventing drug use. Interventions 
that are based on motivational interview may 
have some benefits when delivered in emergency 
department or primary care settings, but this 
evidence was low quality and findings were 
inconclusive.
Mass media interventions
Low-quality review-level evidence suggests 
that mass media campaigns delivered alone to 
prevent drug use are unlikely to be effective, with 
mixed and inconsistent drug use outcomes from 
campaigns. Low-quality review-level evidence 
suggests that interventions delivered through 
computers and the Internet may have positive 
effects on cannabis use.
Mentoring interventions
Low-quality review-level evidence suggests that 
mentoring interventions may be ineffective in 
preventing drug use among high-risk young people. 
However, this is based on very few primary studies 
and findings are therefore inconclusive.
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6Harm reduction
In this section, evidence is presented on the 
effectiveness of a range of harm reduction 
interventions for people who use illicit drugs. 
This is categorised according to intervention type.
6.1 Review articles included 
in this review
In total, 23 systematic reviews and one paper that 
pooled evidence from UK studies were included 
in the harm reduction strand of this review. A 
summation of the evidence identified is provided 
in Table 8. The evidence that was identified was 
grouped by population, including:
» Interventions for people who use illicit drugs
» Interventions for vulnerable groups within the 
drug-using population including people living 
with a blood-borne virus (BBV), people in 
contact with the criminal justice system and 
sex workers.
The following types of interventions were identified:
» Provision of needles and injecting equipment
» Pharmacological interventions
» Psychosocial and behavioural interventions
» Drug consumption rooms
» Opioid overdose prevention programmes with 
distribution of naloxone
» Interventions to prevent initiation of injecting
» Interventions to increase uptake of BBV testing
» Interventions to reduce harm in recreational 
settings
» Interventions to increase uptake and adherence 
to BBV treatment
» Interventions targeting people in contact with 
the criminal justice system
» Interventions targeting people who are 
sex workers
6.2 Quality of included reviews
Initially, only reviews that scored 8 or higher, 
and included assessment of primary-level 
evidence quality, were included in this review. 
For the harm reduction strand of the review, 17 
reviews published since 2010 met these criteria. 
Additionally, five studies rated ‘medium’ quality 
on the JBI quality assessment tool and one 
‘high-quality’ review published before 2010 
were included where missing or scarce evidence 
was identified on relevant intervention types. 
Furthermore, one non-systematic review that 
pooled evidence from the UK only was included, 
as this review was considered highly relevant to 
Irish policy. Review scores on the JBI assessment 
are provided in the summary of reviews identified 
(Table 1) and full details of quality assessment are 
provided in Appendix 4 (Section 11.4).
6.3 Provision of needles and 
other injecting equipment
Needle and syringe programmes (NSPs) are a 
fundamental component of harm reduction 
services and provide access to sterile injection 
equipment for people who inject drugs (PWID). 
Through this provision of equipment, NSPs aim to 
prevent BBVs, bacterial infections and overdoses, 
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and frequently provide a setting for a range of 
health interventions (Hunt, 2003). The impact 
of NSPs on BBV infection may be greater where 
clients engage in other health interventions in 
addition to needle exchange, or are provided with 
additional paraphernalia: for example, NSPs in the 
Netherlands have observed a significant reduction 
in HIV and overdoses after increasing foil provision 
for smoking (Kools, 2009).
Effective disposal systems for used equipment 
are vital for improving the safety of communities 
and tackling negative attitudes towards needle 
exchange programmes (World Health Organization, 
2004). For example, in the UK, the provision of 
sharps boxes and public sharps bins at NSPs 
is encouraged to ensure safe disposal of used 
needles and equipment (NICE, 2014). Conversely, 
some NSPs operate a returns policy where clients 
are required to swap used needles and syringes for 
new ones, although this is not considered to be 
good practice. NSPs can be integrated within other 
services (e.g. a pharmacy) or they can operate 
on their own as a static specialist service or 
outreach programme.
For NSPs to be effective, they must reach as 
many injecting individuals as possible. The Irish 
National Drug Strategy 2009–2016 included an 
objective to ‘expand the availability of, and access 
to needle exchange services (where required)’. 
The partnership initiative between the Elton John 
AIDS Foundation, the Irish Pharmacy Union and 
the Health Service Executive Pharmacy Needle 
Exchange Programme has been expanding the 
provision of NSPs across Ireland since 2011 
(Bingham et al., 2015). As of 2013, there were 
24 fixed-site needle exchanges and a total of 71 
exchanges based within pharmacies in Ireland, 
with an estimated 9,200 clients served annually 
and more than 350,000 syringes distributed 
(EMCDDA, 2015c).
Evidence on the effectiveness of NSPs was 
identified in six systematic reviews, including five 
which were rated high quality and one which was 
rated medium quality (Table 9). Additionally, one 
review article which pooled analyses from evidence 
from the UK was identified (Turner et al., 2011).
Table 8: Needle and other injecting equipment provision interventions – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Reference citations Outcome
Outcome table reference
People who 
inject drugs
Community NSP 4 (H 3, M 1) Aspinall et al., 2013; 
Abdul Quader et al., 
2013; Gillies et al., 
2010; Hagan et al., 
2011
BBV infection
Outcome table 29
2 (H 2) Gillies et al 2010; 
Jones et al., 2011
Injection risk behaviours
Outcome table 30
NSP plus OST 2 (H 1, NA1 1) Turner et al., 2011;
Jones et al., 2010
BBV infection
Outcome table 31
1 (NA1) Turner et al., 2011 Injection risk behaviours
Outcome table 32
1 This article was not a systematic review. Therefore, it was not scored using the JBI tool.
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Table 9: Summary of reviews identified – Harm reduction
Citation Harm reduction 
intervention details
Target population details Number 
of studies 
included
Location JBI score 
for review 
quality 
(/10)
Abad et al., 
2015
HIV and STI behaviour 
change interventions
Female sex workers who 
use drugs
18 USA n=18 8
Abdul-Quader 
et al., 2013
Needle and syringe 
programmes
People who inject drugs 15 USA n=5; UK n=3; Canada 
n=2; Australia n=1; China 
n=1; Ireland n=1; Vietnam 
n=1; France and Spain n=1.
9
Akbar et al., 
2011
Strategies to reduce 
harm in recreational 
settings associated with 
polydrug use
People in recreational 
settings including people 
who use drugs
5 Sweden n=3; UK n=2 7
Aspinall et al., 
2013
Needle and syringe 
programmes
People who inject drugs 12 Canada n=5; USA n=5; 
Europe n=2
9
Bolier et al., 
2011
Strategies to reduce 
drug use and harm in 
recreational settings
People in recreational 
settings including people 
who use drugs
2 Netherlands n=1; Sweden 
n=1
7
Camp Binford 
et al., 2012
Antiretroviral adherence 
interventions
People who inject drugs 
living with HIV
45 Not reported 8
Clark et al., 
2014
Opioid overdose 
prevention/naloxone 
distribution
People who use opiates 19 USA n=13; UK n=4; 
Canada n=1; Germany 
and UK n=1
7
Gillies et al., 
2010
Provision of injecting 
paraphernalia
People who inject drugs 13 USA n=11; Canada n=2 8
Gowing et al., 
2011
Opioid substitution 
therapy
People who inject drugs 38 USA n=26; Australia 
n=3; UK n=3; Italy n=1; 
Germany n=1; Canada 
n=1; Malaysia n=1; 
Ukraine n=1
8
Hagan et al., 
2011
Range of harm reduction 
interventions to prevent 
HCV
People who inject drugs 26 USA n=11; Australia n=6; 
Canada n=5; UK n=2; 
Ireland n=1; Netherlands 
n=1; Italy n=1; France n=1
9
Jones et al., 
2008
Needle and syringe 
programmes
People who inject drugs 
who are in contact with 
the criminal justice 
system
19 USA n=16; Canada n=3; 
France n=1; Germany 
n=1; Netherlands n=1; 
Russia n=1; Switzerland 
n=1
10
Jones et al., 
2010
Needle and syringe 
programmes
People who inject drugs 16 USA n=11; France n=1; 
Canada n=2; Russia n=1; 
The Netherlands n=1
10
Jones et al., 
2013
Interventions to increase 
uptake of BBV testing
High-risk groups 
including current and 
former people who 
inject drugs
8 UK n=3; France n=2; 
Ireland n=1; Netherlands 
n=1; USA n=1
10
MacArthur et 
al., 2012
Opioid substitution 
therapy
People who inject drugs 15 USA n=5; Canada n=1; 
UK n=1; Netherlands n=1; 
Austria n=1; Italy n=1; 
Thailand n=2; Puerto 
Rico n=1; China n=1
8
Malta et al., 
2010
Adherence to 
antiretroviral therapy
People who use drugs 
who are living with HIV
38 Not reported 7
Meader et al., 
2010
Multisession 
psychosocial 
interventions
People who inject drugs 35 Not reported 9
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Table 9 (continued): Summary of reviews identified – Harm reduction
Citation Harm reduction 
intervention details
Target population details Number 
of studies 
included
Location JBI score 
for review 
quality 
(/10)
Meader et al., 
2013
Multisession 
psychosocial 
interventions
People who inject drugs 51 USA n=44; Australia n=2; 
Thailand, Russia, China, 
Kazakhstan, USA and 
Thailand together n=1
9
Potier et al., 
2014
Drug consumption rooms People who inject drugs 75 Canada n=51; Australia 
n=17; Europe n=2; Not 
reported n=9
6
Sacks-Davis et 
al., 2012
Behavioural interventions People who inject drugs 6 Not reported 9
Turner et al., 
2011
Needle and syringe 
programmes and opioid 
substitution therapy on 
hepatitis C incidence
People who inject drugs 6 UK n=6 Not 
applicable
Underhill et 
al., 2014
HIV risk reduction 
interventions
People who inject drugs 
who are in contact with 
the criminal justice 
system
37 USA n=34; Australia, 
China and Iran n=1
9
Wang et al., 
2013
Interventions to reduce 
the number of sexual 
partners and drug and 
alcohol abuse
People who use drugs 
who are living with HIV
3 USA n=3 8
Werb et al., 
2013
Range of interventions 
to prevent initiation of 
injection
People who use drugs 8 North America n=5; 
Europe n=1; Australia 
n=1; Central Asia n=1
9
Zanini et al., 
2010
Combination treatment 
with ribavirin plus 
recombinant, or 
pegylated interferon-α, 
for chronic hepatitis C
People who use drugs 
who are living with 
hepatitis C
19 Not reported 8
6.3.1 Needle and syringe 
programmes alone
Four reviews, all rated high quality, looked at the 
impact of NSPs on BBV outcomes (Abdul-Quader 
et al., 2013; Aspinall et al., 2013; Gillies et al., 
2010; Hagan et al., 2011). Evidence on the impact 
of NSPs on HCV prevalence and incidence was 
inconclusive and of low quality (Gillies et al., 2010; 
Hagan et al., 2011). Moderate-quality review-level 
evidence suggests, however, that NSP exposure is 
associated with reduced HIV transmission among 
PWID (Aspinall et al., 2013). Furthermore, low-
quality review-level evidence from one review 
(Abdul-Quader et al., 2013) suggests an association 
between structural-level interventions that allow 
the expansion of NSPs on a large scale and a 
significant decrease in HIV and HCV incidence, 
and HIV prevalence. Additionally, low-quality 
review-level evidence suggests that provision of 
non-needle/syringe injecting paraphernalia is 
associated with reduced sharing of paraphernalia 
(Gillies et al., 2010) and one review identified 
mixed findings among studies looking at the impact 
of NSPs on injection risk behaviour (Jones et 
al., 2010).
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6.3.2 Needle and syringe 
programmes combined 
with OST
Two reviews looked at the effectiveness of providing 
full harm reduction (opioid substitution therapy 
[OST] delivered with NSP coverage) in comparison 
with reduced or minimal harm reduction (Jones et 
al.,2010; Turner et al., 2011). The review by Jones and 
colleagues was rated high quality, and the article 
by Turner and colleagues was a pooled analysis of 
UK evidence rather than a systematic review article 
and was not rated using the JBI tool. The evidence 
suggests that OST delivered in combination with NSP 
is associated with reduced incidence of HIV and HCV 
(Jones et al., 2010; Turner et al., 2011) and reduced 
injection risk behaviours (Turner et al., 2011).
6.4 Opioid substitution therapy
Opioid substitution therapy (OST) enables PWID to 
consume drugs in a regulated and safer manner. 
OST is provided in drug treatment settings, and 
outcomes around achieving abstinence from illicit 
drugs are considered in the drug treatment strand 
of this review. OST is a well-supported treatment 
approach for people who use opioids and is linked 
with positive treatment outcomes. However, OST 
is also an important harm reduction intervention 
for people who use drugs, including those who 
are not ready to achieve abstinence. For example, 
outcomes of OST may include reducing risky injection 
practices, reducing illicit drug use and increasing 
access to other interventions. In Ireland, OST is 
provided in various settings, including community 
treatment services, specialised general practices 
and prison drug services. The number of individuals 
in Ireland receiving OST has increased since 2005. 
Buprenorphine has been available as an alternative 
pharmacological agent in Ireland since 2002, 
although the vast majority of individuals receive MMT 
(EMCDDA, 2015d).
Two reviews rated high quality were identified that 
examined the impact of OST on relevant outcomes 
(Gowing et al., 2011; MacArthur et al., 2012). Findings 
from these reviews are reported in full in the 
treatment strand of this review, alongside other 
outcomes for pharmacological treatments for 
individuals with opioid dependency (see Section 
7.3.1). Briefly, findings indicate that OST was 
associated with significant reductions in injecting, 
sharing of equipment, risk of HIV infection and HCV 
infection, and opioid use among people with a recent 
history of injecting opioids.
6.5 Psychosocial and 
behavioural interventions
In the UK, NICE recommends that all people who 
misuse drugs are provided with information and 
advice about reducing exposure to BBVs (NICE clinical 
guideline 51). Four reviews rated high quality using 
the JBI tool were identified; these reviews looked 
at the effectiveness of psychosocial or behavioural 
harm reduction interventions delivered to people 
who inject drugs (Table 10). Two reviews looked 
at the effectiveness of multisession psychosocial 
interventions on injection risk behaviours (Meader et 
al., 2010) and sexual risk behaviours (Meader et al., 
2013) and two reviews looked at a range of behavioural 
interventions on blood-borne virus prevalence and 
injection risk behaviours (Hagan et al.,2011; Sacks-Davis 
et al., 2012).
Table 10: Psychosocial and behavioural interventions – summary
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
People who 
inject drugs
Community Behavioural 
interventions
2 (H 2) Hagan et al., 2011; 
Sacks-Davis et al., 
2012
Blood-borne virus 
prevalence
Outcome table 33
1 (H 1) Sacks-Davis et al., 
2012
Injection risk behaviours
Outcome table 34
Injecting frequency
Outcome table 34
Multisession 
psychosocial 
intervention
2 (H 2) Meader et al., 
2010; Meader et 
al., 2013
Injection risk behaviours
Outcome table 34
Sexual risk behaviours
Outcome table 35
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Moderate-quality review-level evidence was 
identified; this evidence suggests that multisession 
psychosocial interventions aimed at people who 
inject drugs may have beneficial impacts on sexual 
risk behaviours (Meader et al., 2013), but not on 
injection risk behaviours (Meader et al., 2010). 
Evidence regarding behavioural interventions was 
limited and was based on small numbers of primary 
studies: Low-quality evidence suggests that the 
impact of behavioural interventions is mixed, with 
the provision of peer education training associated 
with reduced injecting frequency and injection risk 
behaviours (Sacks-Davis et al., 2012), but not with 
changes in prevalence of HCV infection (Hagan 
et al., 2011; Sacks-Davis et al., 2012). Low-quality 
review-level evidence indicates that counselling 
interventions (Sacks-Davis et al., 2012) are not 
effective in changing injection behaviours and 
neither counselling interventions (Sacks-Davis et 
al., 2012) nor motivational interview appear to have 
an impact on HCV incidence (Hagan et al., 2011).
6.6 Overdose prevention
This section focuses on interventions aiming to 
reduce the risk from overdose among current drug 
users, rather than reducing risk through universal 
drug prevention interventions or increasing access 
or uptake of drug treatment. Evidence suggests 
that up to half of all deaths among drug users may 
be caused by overdose, with individuals who use 
opioids and those who participate in polydrug 
identified as being particularly at risk (EMCDDA, 
2015e). Almost 70,000 people a year are estimated 
to die following an opioid overdose (World 
Health Organization, 2014). In Ireland in 2013, 219 
individuals were reported to have died following an 
opioid overdose (Health Research Board, 2016a).
Currently in Ireland, response to prevent overdose 
throughout specific training and programmes is 
limited. Naloxone7 is an opioid antagonist that 
quickly reverses opioid intoxication, without 
significant adverse effects (Boyer, 2012). In the 
UK, naloxone can be provided to anyone, or to 
individuals such as family members and friends of 
drug users, although in practice provision varies 
between legislative adminsitrations. The provision 
of naloxone and training in overdose management 
to individuals who may encounter overdose (such 
as families and friends of injecting opiate users) is 
recommended by the World Health Organization, 
alongside other interventions to reduce risk and 
drug use, such as access to OST and detoxification 
(World Health Organization, 2014).
No high-quality reviews were identified that looked 
at overdose prevention. One review rated medium 
quality (Clark et al., 2014) was identified that 
examined opioid overdose prevention programmes 
and naloxone administration and was included in 
the absence of high-quality reviews on this topic 
(Table 11).
7 Further information on naloxone and its role in the 
management of opioid overdose is available from the 
EMCDDA: Strang J and McDonald R (2016) Preventing 
opioid overdose deaths with take-home naloxone. 
European Monitoring Centre for Drugs and Drug Addiction. 
Luxembourg: Publications Office of the European Union. 
Available at www.drugsandalcohol.ie/25045/1/Naloxone.pdf
Table 11: Overdose prevention – summary
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
People who 
inject drugs
Community OOPP with 
naloxone 
distribution
1 (M 1) Clark et al., 2014 Overdose mortality
Outcome table 36
Response to overdose
Outcome table 36
Naloxone administration
Outcome table 36
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Low-quality review-level evidence suggests that 
provision of overdose prevention training leads 
to effective administration of naloxone and 
appropriate responses to overdose (Clark et al., 
2014). Low-quality review-level evidence also 
suggests that increased provision of overdose 
prevention training including naloxone distribution 
is associated with lower opioid-related mortality 
(Clark et al., 2014). A review published by the 
EMCDDA (EMCDDA, 2015e) was carried out 
based largely on the same evidence base as the 
review by Clark and colleagues. The EMCDDA 
review corroborates findings presented here 
and concludes that the provision of overdose 
prevention training with take-home naloxone 
appears to be associated with decreasing 
overdose-related deaths, and improved response 
to overdose.
6.7 Drug consumption rooms
Drug consumption rooms, also known as 
supervised drug consumption/injection facilities, 
are sites where individuals can use illicit drugs 
under supervision from medical or trained staff. 
The provision of these facilities aims to ensure the 
safety of PWID, reduce risk of overdose and BBV 
transmission and put PWID in contact with health 
professionals (EMCDDA, 2015f). Such facilities 
give health professionals the opportunity to 
provide PWID with materials and advice such as 
sterile needles and injecting equipment, condoms 
and referrals to other health services (Kerr and 
Palepu, 2001).
As of June 2015, there were 74 drug consumption 
facilities in Europe, with the majority in the 
Netherlands, Germany, Switzerland and Spain, 
and examples further afield in Australia and 
Canada (EMCDDA, 2015f). In Ireland, there are 
currently no drug consumption rooms available, 
but there has been debate recently around future 
provision of these services. Qualitative research 
undertaken with PWID and experts in the field 
has suggested that PWID would be likely to use 
drug consumption rooms in Ireland (O’Shea, 
2007) and drug consumption rooms are included 
in the 2016 Misuse of Drugs Act Amendment Bill. 
As with interventions that provide needles and 
other injecting equipment, however, evaluating 
the impact of these facilities on outcomes such as 
BBV prevalence may be challenging. For example, 
when examining outcomes, attributing causality 
to consumption facilities rather than other 
interventions may be difficult (EMCDDA, 2015f).
No high-quality reviews were identified that looked 
at any other type of drug consumption facilities. 
Consequently, one review rated medium quality 
was included. It examined the impact of ‘safer 
injecting facilities’ on a range of outcomes relating 
to injection and sexual risks and BBVs (Potier et al., 
2014; Table 12).
Table 12: Supervised injection facilities – summary
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
People who 
inject drugs
Community Drug 
consumption 
room 
availability
1 (M 1) Potier et al., 2014 Overdose
Outcome table 37
Injection risk behaviours
Outcome table 38
Drug-related litter
Outcome table 39
Injection drug use
Outcome table 38
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Findings from one review that looked at the 
provision of drug consumption rooms (Potier 
et al., 2014) were generally positive, but were 
inconclusive due to the quality of evidence 
available. Low-quality review-level evidence 
suggests that drug consumption rooms are 
associated with reduced cases of overdose, 
improved injection risk behaviours and reductions 
in drug-related litter. No association between drug 
consumption room access and injecting drug use 
was reported. Additionally, low-quality evidence 
suggests that drug consumption rooms are likely to 
be acceptable to PWID (Potier et al., 2014).
6.8 Route transition 
interventions
Although use of drugs through any method of 
administration may be associated with a wide 
range of harms, injecting drugs is associated with 
increased risk to health and, in particular, is a 
significant risk factor for acquisition of BBVs. The 
risk of premature death is significantly greater 
among individuals who inject drugs than among the 
general population (Mathers et al., 2013) and new 
injectors may be particularly at risk (Carneiro et 
al., 2000). Effective harm reduction interventions 
that aim to prevent initiation of injecting drug use 
are therefore desirable. While this may overlap 
with prevention programmes designed to reduce 
initiation of drug use, the focus of this review is on 
harm reduction among current drug users.
One review rated high quality using the JBI tool 
that examined the effectiveness of interventions 
aiming to prevent initiation of injecting drug use 
was included (Werb et al., 2013; Table 13). The 
review looked at a range of interventions and 
phenomena, including two interventions relevant 
for this review: peer-based behaviour modification 
and law enforcement to prevent the initiation of 
injecting drug use.
Low-quality review-level evidence suggests that 
peer-based behaviour modification interventions 
(including ‘Break the Cycle’ which targeted 
current PWID, and an AIDS education and injecting 
prevention intervention, which targeted intranasal 
heroin users) may have positive impacts on 
injecting initiation. This included current PWIDs 
injecting in front of non-injectors, willingness to 
initiate a non-injector and initiation of injection. 
Low-quality evidence indicates that there is no 
association between increased police deterrence 
and initiation of injecting drug use (Werb et 
al., 2013).
6.9 Interventions to increase 
uptake of BBV testing
People who inject drugs are at risk of acquiring and 
transmitting BBVs through the sharing of needles 
and other injecting equipment, and through risky 
sexual practices. Frequently, however, large 
proportions of PWID are unaware of their BBV 
status and, due to poor engagement with health 
services, may not have access to testing. In 
Ireland, numbers of PWID with HIV have decreased 
in recent years (Health Protection Surveillance 
Centre, 2014). Data for 2015, however, suggest that 
the rate of new cases of HIV may be increasing as 
a result of an outbreak among PWID in the Dublin 
area (Health Protection Surveillance Centre, 2015). 
Numbers of PWID in Ireland with hepatitis C are not 
available, but in the general population prevalence 
has decreased since 2011. Among the majority 
(79%) of individuals with hepatitis C, however, the 
likely risk factor was considered to be injecting 
drug use (Health Protection Surveillance Centre, 
2013). In Ireland, hepatitis C testing and a hepatitis 
B immunisation programme are widely available in 
the community.
Table 13: Route transition interventions
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
People who 
inject drugs
Community Injection 
initiation 
prevention
1 (H 1) Werb et al., 2013 Injection drug use
Outcome table 40
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Table 14: Blood‑borne virus testing – summary
Population Setting Intervention Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
People who 
inject drugs
Community Targeted case 
finding in 
primary care
1 (H 1) Jones et al., 2013 BBV testing uptake
Outcome table 41
People who 
inject drugs
Community, 
prison
DBST 
provision
1 (H 1) Jones et al., 2013 BBV testing uptake
Outcome table 41
People who 
formerly 
injected drugs
Community Targeted case 
finding in 
primary care
1 (H 1) Jones et al., 2013 BBV testing uptake
Outcome table 41
One review was identified that looked at 
approaches to increasing awareness and uptake 
of hepatitis C testing (Jones et al., 2013). The 
review looked at interventions for ‘high-risk’ 
groups including PWID and other groups such 
as migrant populations and people with mental 
illness (Table 14). Evidence on PWID was available in 
interventions which included targeted case finding 
in primary care, and provision of dried blood spot 
testing (DBST).
Low-quality review-level evidence suggests that 
targeted case finding in primary care is associated 
with increased offering and accepting of testing 
for hepatitis C among current and former PWID. 
However, the review authors report that both 
studies of targeted case findings reported high 
rates of failure to attend and drop out from HCV 
treatment services following referral (Jones et 
al., 2013). Low-quality review-level evidence 
suggests that offering DBST in drug services and 
prisons is associated with an increased rate of 
testing uptake in comparison with services offering 
venepuncture only, although the review authors 
note that the intervention effect varied greatly 
across sites (Jones et al., 2013). Findings in this 
review were limited by the small number of primary 
studies available.
6.10 Additional harm reduction 
approaches
The majority of harm reduction interventions focus 
on reducing or tackling the risks from injecting drug 
use, particularly relating to opioid use. However, 
use of a wide range of other drugs is associated 
with a variety of acute and long-term harms and it 
is important therefore to identify and implement 
harm reduction interventions to reduce these risks.
6.10.1 Harm reduction in 
recreational settings
Recreational settings such as nightclubs and 
festivals are associated with use of drugs including 
ecstasy, amphetamines and new psychoactive 
drugs, with high proportions of patrons reporting 
lifetime and recent drug use (Fletcher et al., 2010). 
Use of these drugs is associated with a range of 
harms, and in recreational settings risk may be 
increased through use in combination with other 
drugs, particularly alcohol. It has been identified 
that a variety of strategies are involved with 
effective harm reduction in recreational settings; 
these include staff training, law enforcement, 
user/patron prevention and harm reduction 
interventions (van Hasselt et al., 2012).
Examples of interventions to tackle the harms 
from illicit drug use in recreational settings include 
the introduction of guidelines to increase safety 
in nightlife settings, with objectives such as the 
provision of free water, outreach education 
and on-site pill testing (Fletcher et al., 2010). 
For example, in the Netherlands, pill testing was 
introduced in 1992 as part of the Drug Information 
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and Monitoring System (DIMS) project, with the 
primary aim of reducing the risk of contaminated 
drugs being used. The provision of pill testing 
kits in recreational settings such as nightclubs 
and festivals allows people who use drugs to gain 
feedback regarding the content and potency 
of what they are consuming. This approach has 
been criticised for potentially informing people 
who use drugs that what they are consuming is 
‘safe’ (van Hasselt et al., 2012), and there remain 
doubts regarding the accuracy and consistency 
of commonly used testing equipment (Fletcher et 
al., 2010).
Two reviews rated medium quality were identified 
that looked at harm reduction interventions 
in nightclubs and other licensed premises, but 
did not provide conclusive evidence regarding 
the effectiveness of interventions (Akbar et al., 
2011; Bolier et al., 2011). The reviews included 
interventions based around staff training 
to increase understanding, response to and 
management of drug use and the effects of 
drug use among patrons. One review included 
evidence on the effectiveness of an educational 
intervention involving the distribution of leaflets 
and infocards containing information regarding 
drug risks and harm reduction strategies (Bolier 
et al., 2011). The review by Akbar and colleagues 
assessed the types of interventions that have 
been applied in these settings to reduce polydrug 
use rather than intervention effectiveness. The 
review authors reported that interventions were 
too heterogeneous to allow useful comparisons 
between the different approaches. The review 
by Bolier and colleagues included two primary 
studies that looked at illicit drug use, with the 
remaining studies focusing on alcohol use. Low-
quality review-level evidence suggests that there 
are no positive or negative impacts resulting from 
the provision of educational materials in nightlife 
settings and that an intervention by nightclub 
doormen may lead to increased refusal of entrance 
to drug-impaired individuals (Bolier et al., 2014).
No evidence was identified on pill testing kits or 
similar interventions for inclusion in this review, 
reflecting the lack of evidence available (at primary 
or review level) on this approach.
6.10.2 Other interventions 
and drugs
No reviews were identified that looked at harm 
reduction interventions aimed at groups such 
as people who use cannabis or cocaine, or 
other harm reduction approaches such as mass 
media campaigns or educational programmes. 
Additionally, it is noted that no evidence was 
identified specifically relating to the provision of 
information through approaches such as leaflets, 
web-based materials or videos designed to reduce 
harm among drug users, although this may have 
formed part of other interventions examined, such 
as needle and syringe programmes.
6.11 Individuals with BBVs who 
use illicit drugs
A review in 2011 of the prevalence of BBVs among 
PWID worldwide suggested that in Ireland, around 
three-quarters (74.6%) of PWID may have hepatitis 
C and a minority (17.5%) have hepatitis B (Nelson 
et al., 2011). However, data from Ireland included 
in this review were from 2001 and 2003. In the UK, 
current data indicate that approximately half of 
PWID in Scotland, England and Wales have been 
infected with hepatitis C and around two out of 
five PWID are currently living with the virus (Public 
Health England, 2015). Lower proportions of PWID 
in the UK are infected with HIV (1%) and hepatitis B 
(less than 1%).
In Ireland, there has been a decrease in the 
number of new cases of HIV among PWID since 
2006. Since 2012, however, numbers have 
increased (Health Protection Surveillance Centre, 
2014) and data from 2015 suggest concerns about 
an HIV outbreak among PWID in Dublin (Health 
Protection Surveillance Centre, 2015). Similarly, 
numbers of PWID diagnosed with hepatitis B and 
hepatitis C have decreased since 2006 in the 
general population in Ireland (Health Protection 
Surveillance Centre, 2013). However, among 
those diagnosed with hepatitis C, the majority 
of cases were identified as injecting drug users 
for whom this was the most likely risk factor for 
their diagnosis. There is a high risk of BBVs among 
vulnerable groups within the drug-using population 
in Ireland, such as people who are homeless, are in 
prison or are involved in sex work.
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It is therefore important to identify evidence 
on interventions to reduce harms among PWID 
who are living with a BBV, and four reviews were 
identified in this category (Table 15). This included 
one review rated high-quality using the JBI tool 
that looked at interventions to increase treatment 
uptake and adherence for hepatitis C among PWID 
(Zanini et al., 2010) and three reviews that looked 
at interventions for people with HIV (Camp Binford 
et al., 2012; Malta et al., 2010; Wang et al., 2013). 
Two reviews rated high quality (Camp Binford et al., 
2012; Wang et al., 2013) examined the effectiveness 
of risk reduction interventions for this population 
(Wang et al., 2013) and HIV treatment (Camp 
Binford et al., 2012) and one review rated medium 
quality was identified that examined an alternative 
HIV treatment intervention (Malta et al., 2010). 
The review by Camp Binford and colleagues 
looked at interventions to improve adherence 
to HIV combination treatment including direct 
active antiretroviral therapy (DAART), contingency 
management and nurse-delivered interventions. 
The review by Malta and colleagues (2010) looked 
at the use of highly active antiretroviral therapy 
(HAART) among the drug-using population.
Table 15: Interventions to increase uptake and adherence to BBV treatment – summary
Population Setting Intervention/ 
treatment
Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
People living 
with HIV who 
inject drugs
Community Direct active 
antiretroviral 
therapy
1 (H 1) Camp Binford et 
al., 2012
HIV treatment outcomes
Outcome table 42
Contingency 
management
1 (H 1) Camp Binford et 
al., 2012
HIV treatment outcomes
Outcome table 42
Nurse-
delivered 
interventions
1 (H 1) Camp Binford et 
al., 2012
HIV treatment outcomes
Outcome table 42
Highly active 
antiretroviral 
therapy 
(HAART)
1 (M 1) Malta et al., 2010 HIV treatment outcomes
Outcome table 42
‘Risk 
reduction’ 
interventions
1 (H 1) Wang et al., 2013 Needle sharing
Outcome table 43
Wang et al., 2013 Drug use
Outcome table 43
People living 
with hepatitis 
C who inject 
drugs
Community Combination 
treatment 
with 
ribavirin plus 
recombinant, 
or pegylated 
interferon-α, 
for chronic 
hepatitis C
1 (H 1) Zanini et al., 2010 HCV treatment outcomes
Outcome table 44
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6.11.1 People living with HIV
Three reviews were identified that looked at harm 
reduction approaches for PWID who are living 
with HIV. One review looked at the effectiveness 
of ‘risk reduction’ interventions including case 
management, guided harm reduction programmes 
and peer mentoring on drug use outcomes among 
PWID (Wang et al., 2013). Low-quality review-level 
evidence suggests that risk reduction interventions 
for PWID with HIV can be beneficial by reducing 
drug use (Wang et al., 2013). Findings are limited by 
a low number of studies and limited outcomes, and 
heterogeneity in terms of intervention approach.
Two reviews examined the effectiveness and 
suitability of HIV treatments among PWID (Camp 
Binford et al., 2012; Malta et al., 2010). Findings 
were generally positive towards the use of 
HAART and DAART as appropriate HIV treatment 
approaches. Low-quality review-level evidence 
suggests that adherence to HAART among PWID 
is comparable with adherence among the general 
population and when delivered in combination 
with OST leads to greater adherence to treatment 
than if HAART is used alone (Malta et al., 2010). 
Low-quality review-level evidence suggests that 
DAART is associated with improved HIV treatment 
outcomes among PWID. Evidence is inconsistent on 
the effectiveness of contingency management and 
nurse-delivered interventions aimed at increasing 
treatment adherence (Camp Binford et al., 2012).
6.11.2 People living with  
Hepatitis C
One review rated high quality using the JBI tool 
was identified that looked at the effectiveness 
of combination treatment with ribavirin plus 
recombinant, or pegylated interferon-α, for 
chronic hepatitis C among PWID (Zanini et al., 
2010). It is suggested that combination treatment 
for hepatitis C is appropriate for this population, 
as evidence in this review indicates no significant 
differences in sustained virological response and 
treatment drop out among PWID in comparison to 
people who do not use drugs.
6.12 Individuals in contact with 
the criminal justice system 
who use drugs
A range of interventions is available to PWID in 
prisons in Ireland, including OST and psychosocial 
interventions, predominantly counselling and 
motivational interventions. Evidence suggests that 
among prisoners in Ireland the most commonly 
used drug is cannabis (past year use 69%), with 
almost one-third reporting past year use of heroin 
and cocaine (Drummond et al., 2014). Lifetime 
injecting drug use prevalence has been estimated 
at 26%, with 1% of the prison population believed 
to be current injecting drug users (Drummond et 
al., 2014). The same study identified that among 
those who injected drugs, around half had ever 
shared needles or syringes.
Two reviews were identified that looked at harm 
reduction interventions delivered in criminal 
justice settings (Table 16). One review rated high 
quality looked at a range of HIV risk reduction 
interventions for people in contact with the 
criminal justice system in different settings 
(Underhill et al., 2014). In the majority of primary 
studies included in this review, study populations 
included, and in many cases actively recruited, 
people who used drugs. HIV risk reduction 
interventions included increasing accessibility to 
HIV testing, a range of psychosocial interventions 
and OST. Additionally, one review also rated high 
quality (Jones et al., 2008) was identified that 
examined the effectiveness of needle and syringe 
programmes in prisons, and was included as no 
reviews published after 2010 examined needle and 
syringe programme delivery in this setting.
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Table 16: Interventions for people in contact with the criminal justice system who use drugs – summary
Population Setting Intervention/ 
treatment
Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
Prisoners 
with opioid 
dependency
Prison Needle 
and syringe 
programmes
1 (H 1) Jones et al., 2008 Blood-borne viruses
Outcome table 45
People in 
contact with 
the criminal 
justice system 
who use 
drugs
Prison, 
community
HIV risk 
reduction 
interventions
1 (H 1) Underhill et al., 
2014
Blood-borne viruses
Outcome table 46
Underhill et al., 
2014
Injection risk behaviours
Outcome table 47
Underhill et al., 
2014
Sexual risk behaviours
Outcome table 48
BBV test 
intervention
1 (H 1) Underhill et al., 
2014
Blood-borne virus testing
Outcome table 49
6.12.1 HIV risk reduction
Moderate-quality review-level evidence indicates 
that improving accessibility to HIV testing through 
offering on-site testing in probation and immediate 
next day testing in prison is associated with 
increased uptake of HIV testing (Underhill et al., 
2014). A range of HIV risk reduction interventions 
were examined for effectiveness on drug and 
sexual risk behaviours, and evidence suggests that 
for the majority of interventions, findings were 
either inconclusive or suggest no intervention 
effect on a range of outcomes (Underhill et al., 
2014). The provision of OST was included in the 
review and was associated with positive outcomes: 
this is explored further in the treatment strand of 
this review of reviews.
6.12.2 Needle and syringe 
programmes
Low-quality review-level evidence indicates that 
prison-based distribution of injecting equipment 
through needle and syringe programmes may have 
benefits on BBV incidence (Jones et al., 2010). 
However, the evidence was from two uncontrolled 
studies and, as a result, it is difficult to draw any 
conclusions about effectiveness.
6.13 Sex workers who use drugs
When compared with sex workers who do not 
inject drugs, sex workers who also inject drugs 
appear to be at risk of poor health outcomes, 
including HIV and participation in risky injecting and 
sexual behaviours (Ditmore, 2013). Furthermore, 
many individuals may enter sex work as a means to 
fund their drug use (Jeal and Salisbury, 2004). In 
Ireland, research on drug use among sex workers 
is limited, but suggests high levels of drug use, 
injection drug use and BBVs among this population 
(Cox and Whitaker, 2009; Nelson et al., 2010). The 
potential benefits of harm reduction services for 
reducing both risky sexual and drug use behaviours 
among sex workers are clear, but it is suggested 
that accessing services and interventions can be 
particularly difficult for this population due to the 
stigma and laws regarding both drug use and sex 
work (Ditmore, 2013).
One review rated high quality using the JBI tool was 
identified (Abad et al., 2015) and examined harm 
reduction interventions for sex workers (Table 17).
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Table 17: Interventions for sex workers who use drugs – summary
Population Setting Intervention/ 
treatment
Number of 
systematic reviews 
(high, medium, low 
quality)
Reference 
citations
Outcome
Outcome table reference
Female sex 
workers who 
use drugs
Community Harm 
reduction 
interventions
1 (H 1) Abad et al., 2015 Sexual risk behaviours
Outcome table 50
Abad et al., 2015 Drug risk behaviours
Outcome table 50
One review rated high quality using the JBI tool 
was identified that looked at a range of harm 
reduction interventions, which were typically 
based on HIV or sexually transmitted infection (STI) 
and drug use prevention education that targeted 
sex workers who use drugs. Low-quality review-
level evidence was mixed and inconclusive on 
the effectiveness of these interventions on risk 
behaviours relating to sex and drug use among 
sex workers (Abad et al., 2015). Evidence in the 
review was limited by the lack of high-quality, 
robust studies within this population and it is not 
possible to draw conclusions on the effectiveness 
of these interventions. Additionally, evidence from 
one article not included in this review (Jones et al., 
2014) identified one study that examined a peer-
led mobile outreach programme among female 
sex workers who use drugs. The authors reported 
that use of the programme was associated 
with use of addiction treatment services and 
a drug and alcohol counsellor. It suggests that 
outreach services may be an effective approach 
for increasing access to treatment among this 
population, although further evidence is required 
before conclusions can be drawn.
6.14 Key messages – Harm 
reduction interventions
Needle and syringe programmes
The review-level evidence is low quality and 
inconclusive regarding the impact of needle and 
syringe programmes in community and prison 
settings, although the evidence suggests that 
they may be associated with reductions in harms, 
including transmission of blood-borne viruses and 
sharing of injecting equipment. Needle and syringe 
programmes appear to have a greater impact when 
delivered in combination with opioid substitution 
therapy, and this is associated with reduced 
harms for people who inject drugs, including 
risk of blood-borne virus infection and risky 
injection behaviours.
Psychosocial and behavioural interventions
Evidence on the effectiveness of psychosocial 
and behavioural interventions for reducing 
harms related to drug use is mixed. There is 
insufficient evidence to assess the effectiveness of 
individual psychosocial interventions on reducing 
harms. There is low-moderate quality review 
level-evidence that multisession psychosocial 
interventions and peer education training may be 
associated with some reductions in harms among 
people who inject drugs. Low-quality review-level 
evidence suggests that peer-based interventions 
targeting people who inject drugs and intranasal 
heroin users may also be effective in reducing 
initiation of injecting, although this evidence is 
based on a small number of primary studies.
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Overdose prevention (including 
naloxone distribution)
The provision of opioid overdose prevention 
training with take-home naloxone is supported only 
by low-quality review-level evidence. It may be 
associated with reduced overdose mortality among 
people who inject drugs and improved response 
to overdose.
Drug consumption rooms
A combination of low- and moderate-quality 
evidence indicates that drug consumption rooms 
appear likely to be acceptable to people who 
inject drugs. They may be associated with reduced 
sharing and reuse of syringes and reduced drug-
related litter, and not associated with increases in 
injecting drug use.
Blood‑borne virus treatments for people who 
inject drugs
Low-quality review-level evidence suggests that 
effective treatment options for people with HIV 
and hepatitis C are suitable for people who inject 
drugs. This includes highly active antiretroviral 
therapy and direct antiretroviral therapy for people 
with HIV and combination treatment with ribavirin 
plus recombinant, or pegylated interferon-α, for 
chronic hepatitis C.
Drugs other than opioids
There is insufficient evidence to draw conclusions 
on the effectiveness of harm reduction 
interventions targeting populations other than 
people who inject drugs. For example, there is a 
need for high-quality research on the impact of 
harm reduction delivered in recreational, festival 
or nightlife settings such as analytical chemistry 
approaches (‘drug checking’) or harm reduction 
information provision.
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7Treatment and recovery
In this section, evidence is presented on the 
effectiveness of treatments for drug misuse and 
dependence. Findings on evidence of interventions 
to support recovery and reintegration are also 
included in this section. However, as noted 
in Section 7.6, we found no suitable review-
level evidence for inclusion in this type of 
intervention approach.
7.1 Review articles included 
in this review
In total, 62 systematic reviews were included in the 
treatment and recovery strand of this review. A 
summation of the evidence identified is provided in 
Table 18. This included six reviews published before 
2010 and 56 published between 2010 and 2015. 
Reviews published before 2010 were only included 
where they filled an important gap in the evidence; 
for example, no high-quality reviews published 
after 2010 were available on the effectiveness of 
methadone maintenance.
The evidence that was identified was grouped 
into the following main types of treatment or 
recovery interventions:
» Pharmacological treatments for opiate use
» Pharmacological treatments for stimulant use
» Pharmacological treatments for cannabis use
» Psychosocial interventions
» Residential rehabilitation
» Treatments focusing on recovery and 
re-integration
» Treatment interventions delivered within the 
criminal justice system
» Treatment interventions for people with drug 
use problems and co-occurring mental illness
» Treatment interventions for pregnant and 
parenting women
Additionally, evidence was identified on physical 
activity and acupuncture-based interventions 
and these are discussed under ‘other 
treatment approaches’.
7.2 Quality of included reviews
Initially, only reviews that scored 8 or higher, and 
included assessment of primary-level evidence 
quality, were included in this review. For the 
treatment strand of the review, 52 reviews 
published since 2010 and six published before 
2010 met these criteria. Additionally, three 
studies published after 2010 and rated ‘medium’ 
quality, and one review rated ‘low’ quality on 
the JBI quality assessment tool were included 
where missing or scarce evidence was identified 
on relevant intervention types. Review scores on 
the JBI assessment are provided in the summary 
of reviews identified (Table 18) and full details of 
quality assessment for each review are presented 
in Appendix 4 (Section 11.4).
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Table 18: Summary of reviews identified
Citation Treatment intervention 
details
Population details Number 
of studies 
included
Location JBI score for 
review quality
Alvarez et al., 
2013
Pharmacological treatment 
using antipsychotics
Cocaine dependents 12 USA n=12 10
Amato et al., 2013 Tapered methadone for 
managing opioid withdrawal
Opiate dependents 23 USA = 6; UK = 7; 
Spain = 4;
China n=2; Iran 
n=2; Germany 
n=2; Austria n=1; 
Italy n=1
10
Amato et al., 
2011b
Psychosocial treatment 
plus agonist maintenance 
treatment for relapse 
prevention
Opiate dependents 35 UK n=31; Germany 
n=1; Malaysia 
n=1; China n=1; 
Scotland n=1
9
Amato et al., 
2011a
Psychosocial plus 
pharmacological treatment 
for opioid detoxification
Opiate dependents 11 USA n=10; UK n=11 9
Bender et al., 
2011
Range of psychosocial 
interventions
Adolescent cannabis 
users
15 Not reported 9
Benishek et al., 
2014
Contingency management Drug dependents 18 USA n=17; China 
n=1
10
Blodgett et al., 
2014
Continuing care People in recovery 33 Not reported 7
Boyuan et al., 
2014
Acupuncture Opiate dependents 16 Not reported 8
Castells et al., 
2010
Pharmacological treatment 
using psychostimulants
Cocaine dependents 16 USA n=15; 
Australia n=1
10
Chiesa and 
Serretti, 2014
Mindfulness-based 
interventions
People with drug 
misuse
24 Not reported 9
Cooper et al., 
2015
Range of psychosocial 
interventions
Adult cannabis users 33 USA n=13; 
Australia n=7;
Germany n=3; 
Brazil n=2; 
Canada n=2; 
Switzerland n=2; 
multi-country 
n=2; Denmark 
and Ireland=1
10
Ferri et al., 2011 Heroin maintenance Opiate dependents 
with previous 
treatment failures
8 Netherlands n=2; 
UK n=2; Canada 
n=1; Germany 
n=1; Spain n=1; 
Switzerland n=1
10
Ferri et al., 2013 Slow-release oral morphine 
maintenance
Opiate dependents 3 Austria n=2; 
Australia n=1
10
Filges 2015a Multidimensional family 
therapy
Adolescent drug 
users
5 USA n=4; Belgium 
n=1; France n=1; 
Germany n=1; 
Switzerland n=2
9
Filges 2015b Cognitive behavioural 
therapy
Adolescent drug 
users
7 USA n=6; 
Netherlands n=1
10
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Table 18 (continued): Summary of reviews identified
Citation Treatment intervention 
details
Population details Number 
of studies 
included
Location JBI score for 
review quality
Gowing et al., 
2009a
Opioid detoxification – 
buprenorphine
Opiate dependents 22 USA n=12; 
Germany n=3; 
UK n=1; Australia 
n=1; India n=1; 
Iran n=1; Israel 
n=1; Italy n=1; 
Switzerland n=1
10
Gowing et al., 
2009b
Opioid detoxification – 
opioid antagonists
Opiate dependents 9 USA n=3; UK 
n=3; Italy n=2; 
Australia n=1
10
Gowing et al., 
2011
Pharmacological – 
maintenance
Opiate dependents 38 USA n=26; 
Australia n=3; 
UK n=3; Italy 
n=1; Germany 
n=1; Canada n=1; 
Malaysia n=1; 
Ukraine n=1
10
Gowing et al., 
2014
Alpha-adrenergic agonists 
for management of the 
acute phase of opioid 
withdrawal
Opiate withdrawers 25 USA n=5; Spain 
n=5; UK n=4; 
Italy n=3; China 
n=2; Australia 
n=1; India n=1; 
Switzerland 
n=1; Taiwan n=1; 
Germany n=1; 
Hungary n=1
9
Hayhurst et al., 
2015
Diversion interventions Drug-dependent 
prisoners
16 USA n=11; UK 
n=4; Canada n=1; 
Australia n=1
10
Hedrich et al., 
2012
Opioid substitution therapy Opiate-dependent 
prisoners (pre- and 
post- release)
21 North America 
n=10; Australia 
n=5; France n=2; 
Spain n=2; Iran 
n=2
8
Hunt et al., 2013 Psychosocial interventions Individuals with 
severe mental illness 
and co-occurring 
drug use
32 USA n=19; 
Australia n=6; UK 
n=3; Denmark 
n=1; Germany 
n=1; Ireland n=1; 
Switzerland n=1
9
Jegu et al., 2011 Slow-release oral morphine 
maintenance
Opiate dependents 13 Austria n=7; 
Australia n=3; 
Bulgaria n=1; India 
n=1; Slovenia n=1
9
Larney et al., 
2010
Opioid substitution 
treatment in prison in 
reducing HIV risk behaviours
Opiate-dependent 
prisoners
5 Iran n=1; Australia 
n=1; Canada n=1; 
Puerto Rico n=1
8
Larney et al., 2014 Pharmacological – 
naltrexone
Opiate dependents 9 Not reported 9
Lee et al., 2015 Psychosocial interventions Adults with 
borderline 
personality disorder 
and co-occurring 
drug use disorder
10 Not reported 9
Lindstrom et al., 
2015
Family behaviour therapy Adolescent cannabis 
users
2 USA n=2 10
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Table 18 (continued): Summary of reviews identified
Citation Treatment intervention 
details
Population details Number 
of studies 
included
Location JBI score for 
review quality
MacArthur et al., 
2012
Opioid substitution therapy Opiate injectors 14 USA n=10; 
Australia n=3; 
Israel n=1
8
Malivert et al., 
2012
Residential therapeutic 
communities
Drug misusers 12 USA n=7; Canada 
n=2; Australia 
n=2; Peru n=1; 
Spain n=1
4
Marshall et al., 
2014
Pharmacotherapy for 
cannabis use
Cannabis dependents 14 USA n=10; 
Australia n=3; 
Israel n=1
9
Mattick et al., 
2009
Pharmacological – 
maintenance treatments
Opiate dependents 11 USA n=7; Sweden 
n=1; Australia n=1; 
Hong Kong n=1; 
Thailand n=1
10
Mattick et al., 
2014
Pharmacological – 
buprenorphine maintenance
Opiate dependents 31 North America 
n=15; Europe n=9; 
Middle East n=4; 
Australia n=2; 
Asia n=2
10
Milligan et al., 
2011
Integrated treatment 
programmes
Pregnant or parenting 
women
9 Not reported 9
Milligan et al., 
2010
Integrated treatment 
programmes
Pregnant or parenting 
women
21 Not reported 9
Minozzi et al., 
2011
Pharmacological treatment 
using naltrexone
Opiate dependents 13 USA n=4; Israel 
n=2; Russia n=2; 
Germany n=1; 
Italy n=1; Spain 
n=1; Malaysia n=1; 
China n=1
10
Minozzi et al., 
2013
Pharmacological – 
methadone maintenance
Opiate-dependent 
pregnant women
4 Australia n=2; 
USA n=1; multi-
country n=1
9
Minozzi et al., 
2014
Detoxification treatment 
alone or in combination with 
a psychosocial intervention
Opiate dependents 2 USA n=2 10
Minozzi et al., 
2015a
Pharmacological treatment 
using dopamine agonists
Cocaine dependents 24 USA n=22; Spain 
n=1; Brazil n=1
10
Minozzi et al., 
2015b
Pharmacological treatment 
using anticonvulsants
Cocaine dependents 20 USA n=18; Mexico 
n=1; Netherlands 
n=1
10
Mitchell et al., 
2012
Range of interventions Drug-using offenders 74 USA n=65; 
Canada n=4; 
Australia n=3; UK 
n=1; Taiwan n=1
10
National 
Collaborating 
Centre For Mental 
Health, 2008
Range of interventions Drug misusers Not 
reported
Not reported 9
Pani et al., 2010 Pharmacological treatment 
using disulfiram
Cocaine dependents 7 USA n=7 10
Pani et al.,2011 Pharmacological treatment 
using antidepressants
Cocaine dependents 37 USA n=37 10
www.hrb.ie52
Table 18 (continued): Summary of reviews identified
Citation Treatment intervention 
details
Population details Number 
of studies 
included
Location JBI score for 
review quality
Perez-Mana et al., 
2011
Pharmacological treatment 
using indirect dopamine 
agonists
Psychostimulant 
dependents
11 USA n=7; Australia 
n=2; Sweden n=1; 
Finland n=1
10
Perez-Mana et al., 
2013
Pharmacological treatment 
using psychostimulants
Psychostimulant 
dependents
29 USA n=26; 
Australia n=2; 
Finland n=1
10
Perry et al., 2009 Therapeutic communities in 
prison
Drug-using offenders 24 USA n=23; 
Australia n=1
8
Perry et al., 2015a Range of interventions Drug-using offenders 
with co-occuring 
mental illness
9 USA n=9 10
Perry et al., 
2015b
Range of psychosocial 
interventions
Female offenders 9 USA n=8; Spain 
n=1
10
Perry et al., 2015c Pharmacological treatment 
– opioid substitution therapy
Opiate-dependent 
offenders
14 USA n=9; 
England n=2; 
Iran, Australia, 
Germany, Norway 
n=1
10
Rapp et al., 2014 Case management People with drug 
dependency
31 Not reported 10
Reif et al., 2014a Peer recovery coaching People in recovery 11 Not reported 9
Reif et al., 2014b Recovery housing People in recovery 10 All USA 7
Roberts et al., 
2015
Range of psychosocial 
interventions
People with trauma 
and co-occurring 
drug misuse
14 USA n=12; 
Australia n=2
9
Shonin et al., 
2013
Mindfulness interventions Prisoners 8 USA n=7; Taiwan 
n=1
9
Smedslund et al., 
2011
Motivational interview Drug misusers 59 USA n=44; 
Australia n=5; 
Netherlands n=3; 
UK n=3; Canada 
n=2; Germany 
n=1; New Zealand 
n=1
10
Terplan et al., 
2015
Contingency management 
and motivational 
interviewing
Pregnant and 
parenting women
14 USA n=13; 
Australia n=1
9
Torchalla et al., 
2012
Integrated treatment 
programmes
People with trauma 
and co-occurring 
drug misuse
17 Not reported 
(primarily USA)
8
Turnbull and 
Osborn, 2012
Home visits Pregnant and 
parenting women
7 Not reported 9
Vanderplasschen 
et al., 2013
Residential therapeutic 
communities
People in recovery 30 USA n=30 7
Wang et al., 2014 Physical activity Opiate dependents 22 Not reported 8
Watson et al., 
2013
Brief interventions in 
outpatient settings
Drug misusers 2 USA n=2 10
Zgierska et al., 
2009
Mindfulness-based 
interventions
Drug misusers 25 Not reported 9
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7.3.1 Opioids
The most recent study of its kind estimated that 
there are 20,790 opioid users in Ireland (Kelly et 
al., 2006) and heroin is the most common primary 
drug of clients entering drug treatment, with 
around 4,000 cases in Ireland in 2013 (Health 
Research Board, 2016b). Three pharmacological 
treatment types for opioids were identified 
in this review: opioid maintenance, opioid 
detoxification and relapse prevention. In addition, 
evidence was identified on the delivery of opioid 
maintenance and opioid detoxification alongside 
psychosocial interventions.
Opioid maintenance
Opioid maintenance treatments aim to minimise 
the harms related to opioid use and to reduce 
illicit drug use through the replacement of 
an illegal opioid with a prescribed alternative 
medicine. The opioid agonist methadone has 
been the primary substitute treatment provided 
in Ireland since 1992 and is the recommended 
treatment, although buprenorphine is an available 
alternative and suggested for use in the 2009–2016 
Drugs Strategy. In the UK, both methadone and 
buprenorphine, using flexible dosing regimens, 
are recommended by NICE as options for OST. In 
Ireland, around 10,000 individuals received OST in 
2014, the number having increased substantially 
through the preceding decade (EMCDDA, 2015d). 
In almost all cases, methadone has been the 
substitute treatment provided, although in 
recent years a small proportion of cases have 
received buprenorphine.
Detoxification
Detoxification is the process through which 
individuals who wish to become drug-free 
eliminate opioids from their body while minimising 
the risk of unpleasant withdrawal symptoms. 
Different pharmacological agents are used as 
detoxification agents to ameliorate symptoms 
associated with withdrawal. For example, in the UK, 
methadone and buprenorphine are recommended 
for use as detoxification agents by NICE. In Ireland, 
opioid detoxification is provided in a range of 
both inpatient and outpatient settings including 
detoxification units, residential treatments and 
general practitioners (EMCDDA, 2016b).
Relapse prevention
Many individuals who attempt to abstain from 
using drugs may relapse during or following drug 
treatment. Relapse prevention interventions are 
designed to prevent this process. For example, 
in the UK, NICE recommends naltrexone as a 
treatment option in detoxified, formerly opioid-
dependent people who are highly motivated to 
remain in an abstinence programme.
Evidence was identified in 12 reviews on these 
intervention types and the various pharmacological 
agents are summarised in Table 19.
7.3 Pharmacological treatments
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Table 19: Pharmacological treatments for opiate use – summary
Population Setting Intervention/ 
treatment
Pharmacological 
agent
Number of 
systematic 
reviews 
(high, 
medium, 
low 
quality)
Reference 
citations
Outcome
Outcome table 
reference
People 
with opioid 
dependence
Community OST Methadone 1 (H 1) Mattick et al., 
2009
Retention in 
treatment
Outcome table 51
1 (H 1) Mattick et al., 
2009
Illicit opioid use
Outcome table 52
1 (H 1) Mattick et al., 
2009
Criminal activity 
Outcome table 54
1 (H 1) Mattick et al., 
2009
Mortality
Outcome table 55
Buprenorphine 1 (H 1) Mattick et al., 
2014
Retention in 
treatment
Outcome table 51
1 (H 1) Mattick et al., 
2014
Illicit opioid use
Outcome table 52
1 (H 1) Mattick et al., 
2014
Illicit drug use (non-
opioid)
Outcome table 53
1 (H 1) Mattick et al., 
2014
Criminal activity
Outcome table 54
Supervised 
injectable heroin 
and methadone
1 (H 1) Ferri et al., 
2011
Retention in 
treatment
Outcome table 51
1 (H 1) Ferri et al., 
2011
Illicit opioid use
Outcome table 52
1 (H 1) Ferri et al., 
2011
Mortality
Outcome table 55
1 (H 1) Ferri et al., 
2011
Adverse events
Outcome table 56
1 (H 1) Ferri et al., 
2011
Criminal activity
Outcome table 54
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Table 19 (continued): Pharmacological treatments for opiate use – summary
Population Setting Intervention/ 
treatment
Pharmacological 
agent
Number of 
systematic 
reviews 
(high, 
medium, 
low 
quality)
Reference 
citations
Outcome
Outcome table 
reference
People 
with opioid 
dependence
Community OST in 
combination 
with 
psychosocial 
interventions
Agonist treatment 1 (H 1) Amato et al., 
2011b
Retention in 
treatment
Outcome table 57
1 (H 1) Amato et al., 
2011b
Abstinence
Outcome table 58
Opioid 
detoxification
Methadone 1 (H 1) Amato et al., 
2013
Completion of 
treatment
Outcome table 59
1 (H 1) Amato et al., 
2013
Abstinence
Outcome table 60
Buprenorphine 1 (H 1) Gowing et al., 
2009a
Completion of 
treatment
Outcome table 59
Alpha2 adrenergic 
agonist
1 (H 1) Gowing et al., 
2014
Completion of 
treatment
Outcome table 59
1 (H 1) Gowing et al., 
2014
Withdrawal severity
Outcome table 61
Opioid 
antagonists
1 (H 1) Gowing et al., 
2009b
Completion of 
treatment
Outcome table 59
1 (H 1) Gowing et al., 
2009b
Withdrawal severity
Outcome table 61
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Table 19 (continued): Pharmacological treatments for opiate use – summary
Population Setting Intervention/ 
treatment
Pharmacological 
agent
Number of 
systematic 
reviews 
(high, 
medium, 
low 
quality)
Reference 
citations
Outcome
Outcome table 
reference
People 
with opioid 
dependence
Community Opioid 
detoxification 
in 
combination 
with 
psychosocial 
interventions
Not specified 1 (H 1) Amato et al., 
2011a
Dropout of treatment
Outcome table 62
1 (H 1) Amato et al., 
2011a
Illicit opioid use
Outcome table 63
Relapse 
prevention
Oral naltrexone 1 (H 1) Minozzi et al., 
2011
Retention in 
treatment
Outcome table 64
1 (H 1) Minozzi et al., 
2011
Abstinence
Outcome table 65
1 (H 1) Minozzi et al., 
2011
Reincarceration
Outcome table 67
Naltrexone 
implants
1 (H 1) Larney et al., 
2014
Retention in 
treatment
Outcome table 64
1 (H 1) Larney et al., 
2014
Abstinence
Outcome table 65
1 (H 1) Larney et al., 
2014
Illicit opioid use
Outcome table 66
People 
with opioid 
dependence 
and a recent 
history of IDU
Community Opioid 
maintenance
Not specified 1 (H 1) Gowing et al., 
2011
Illicit opioid use
Outcome table 68
1 (H 1) Gowing et al., 
2011
Injecting drug use
Outcome table 69
1 (H 1) Gowing et al., 
2011
Injecting risk 
behaviours
Outcome table 69
1 (H 1) MacArthur et 
al., 2012
HIV incidence
Outcome table 70
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Opioid maintenance
Six systematic reviews rated high quality using 
the JBI tool examined the effects of OST (Ferri et 
al., 2011; Mattick et al., 2009; Mattick et al., 2014; 
Gowing et al., 2011; MacArthur et al., 2012). No 
high-quality evidence was initially identified that 
examined the effects of methadone maintenance 
treatment, and therefore one high-quality review 
from 2009 was included as a result (Mattick et 
al., 2009).
High-quality review-level evidence from 
randomised controlled trials (RCTs) supports 
the use of methadone rather than non-
pharmacological treatments for reducing use of 
illicit opioids and for treatment retention, but not 
for other outcomes, including reducing crime or 
mortality (Mattick et al., 2014). Non-RCT evidence 
shows positive effects of OST on mortality, 
however. Moderate-quality review-level evidence 
suggests that buprenorphine is as effective as 
methadone in reducing use of opioids, but less 
effective for treatment retention (Mattick et al., 
2014). Additionally, moderate-quality review-level 
evidence suggests that among recent injectors 
use of either methadone and buprenorphine is 
effective in reducing opioid use and injecting 
risk behaviours (Gowing et al., 2011). One review 
looked at risk of HIV infection and moderate-
quality review-level evidence suggests that both 
methadone and buprenorphine are effective in 
reducing the risk of HIV infection (MacArthur et 
al., 2012).
Moderate-quality review-level evidence suggests 
that prescribing injectable heroin alongside oral 
methadone may have benefits for increasing 
treatment retention and for reducing illicit heroin 
use and mortality, but may lead to increased risk 
of experiencing adverse treatment events (Ferri et 
al., 2011). Review authors conclude that injectable 
heroin prescription should be considered for 
those individuals who have not responded to 
maintenance treatment. Two reviews examined the 
use of slow-release oral morphine for OST (Ferri et 
al., 2013; Jegu et al., 2011). In both reviews, authors 
concluded that due to the lack of controlled 
trials using slow-release oral morphine it was 
not possible to assess its effectiveness for OST 
although treatment retention appeared similar to 
other maintenance therapies.
Additionally, one review was identified 
that examined OST (including methadone, 
buprenorphine and Levo-α-acetylmethadol 
(LAAM) delivered in combination with psychosocial 
interventions (Amato et al., 2011b). High-
quality review-level evidence indicates that no 
benefits derive from combining more structured 
psychosocial or behavioural interventions and OST, 
as opposed to using OST delivered with standard 
psychosocial support on outcomes including 
abstinence and treatment retention.
Opioid detoxification
Four systematic reviews rated high quality using 
the JBI tool examined the effects of opioid 
detoxification (Amato et al., 2013; Gowing et 
al., 2009a; Gowing et al., 2009b; Gowing et al., 
2014). The two reviews published before 2010 
were included to take account of evidence on 
buprenorphine (Gowing et al., 2009b) and opioid 
antagonists (Gowing et al., 2009a).
High-quality review-level evidence suggests 
that there is no difference between methadone 
and other pharmacological agents, including 
buprenorphine, in terms of detoxification 
completion or achieving abstinence (Amato et 
al., 2013; Gowing et al., 2009a). When compared 
with placebo treatment, detoxification with 
methadone is associated with reduced treatment 
drop outs and withdrawal (Amato et al., 2013). 
Moderate-quality review-level evidence suggests 
that alpha2-adrenergic agonists are less effective 
than reducing doses of methadone in reducing 
symptoms of withdrawal (Gowing et al., 2014). 
Low-quality review-level evidence limits any 
conclusions that can be reached about the overall 
effectiveness of opioid antagonists combined with 
alpha2-adrenergic agonists in opioid detoxification 
(Gowing et al., 2009b).
One review rated high quality was identified that 
examined the delivery of detoxification treatments 
combined with psychosocial interventions on 
opiate use and treatment outcomes (Amato et al., 
2011a). The evidence suggests that detoxification 
and psychosocial treatments combined are 
more effective than pharmacological treatments 
delivered alone for opiate use, opiate abstinence 
and treatment completion.
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Relapse prevention
Two systematic reviews examined the effects 
of naltrexone (Larney et al., 2014; Minozzi et al., 
2011). Low- quality review-level evidence suggests 
that abstinence is more likely to be maintained 
with naltrexone implants than either placebo 
implants or treatment with oral naltrexone (Larney 
et al., 2014). Low-quality review-level evidence 
suggests that oral naltrexone is no more effective 
in maintaining abstinence than treatment with 
placebo or no pharmacological treatment (Minozzi 
et al., 2011).
7.3.2 Stimulants
In Ireland, there are around 600 cases of treatment 
for cocaine use annually and numbers have 
remained steady overall since 2005 (EMCDDA, 
2015d). Cocaine is the second most prevalent 
drug after cannabis, with 1.5% of the population 
reporting use in the past year and 0.5% within the 
past month (National Advisory Committee on Drugs 
and Alcohol, 2012). Stimulants other than cocaine, 
such as amphetamines and methamphetamine, 
are used by a small proportion of the population 
and only a small number of treatment cases have 
been recorded. For example, in 2013, there were 
130 cases of stimulant treatment (EMCDDA, 2015d). 
Although the use of OST and other pharmacological 
treatments for opiate use is well supported, 
pharmacological agents are less prominent in 
the treatment of other illicit drugs. There is a 
growing evidence base on the effectiveness 
of pharmacological agents for the treatment 
of stimulants.
Eight high-quality reviews were identified for 
inclusion in this review. These examined the 
effectiveness of a range of pharmacological agents, 
including those delivered alongside psychosocial 
interventions, in the treatment of stimulant use 
(Table 20). They included six reviews that looked at 
cocaine dependence and two reviews that looked 
at amphetamine dependence. There was some 
overlap between the types of pharmacological 
agent examined in the eight reviews identified and, 
as a result, there was overlap in terms of primary 
studies that provided the evidence in the included 
reviews. Out of 164 articles reporting findings from 
primary studies included across the reviews, there 
were 124 unique articles.
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Table 20: Pharmacological treatments for stimulants – summary
Population Setting Intervention/ 
treatment
Pharmacological 
agent
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table 
reference
People with 
cocaine 
dependence
Community/ 
outpatient
Pharmacological 
treatments alone
Dopamine 
agonists
1 (H 1) Minozzi et 
al., 2015a
Cocaine 
abstinence
Outcome table 71
Minozzi et 
al., 2015a
Cocaine craving
Outcome table 73
Minozzi et 
al., 2015a
Drop out during 
treatment
Outcome table 75
Minozzi et 
al., 2015a
Adverse events 
during treatment
Outcome table 78
People with 
cocaine 
dependence
Community/ 
outpatient
Pharmacological 
treatments alone
Anticonvulsants 1 (H 1) Minozzi et 
al., 2015b
Cocaine use
Outcome table 72
Minozzi et 
al., 2015b
Cocaine craving
Outcome table 73
Minozzzi et 
al., 2015b
Drop out during 
treatment
Outcome table 75
Minozzi et 
al., 2015b
Treatment 
compliance
Outcome table 77
Minozzi et 
al., 2015b
Adverse events 
during treatment
Outcome table 78
Minozzi et 
al., 2015b
Anxiety
Outcome table 79
Minozzi et 
al., 2015b
Depression
Outcome table 80
People with 
cocaine 
dependence
Community/ 
outpatient
Pharmacological 
treatments alone
Pyschostimulants 1 (H 1) Castells et 
al., 2010
Cocaine use
Outcome table 72
Castells et 
al., 2010
Cocaine 
abstinence
Outcome table 71
Castells et 
al., 2010
Cocaine craving
Outcome table 73
Castells et 
al., 2010
Treatment 
completion
Outcome table 76
Castells et 
al., 2010
Drop out during 
treatment
Outcome table 75
Castells et 
al., 2010
Depression
Outcome table 80
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Table 20 (continued): Pharmacological treatments for stimulants – summary
Population Setting Intervention/ 
treatment
Pharmacological 
agent
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table 
reference
People with 
cocaine 
dependence
Community/ 
outpatient
Pharmacological 
treatments alone
Antipsychotics 1 (H 1) Alvarez et 
al., 2013
Cocaine use
Outcome table 72
Alvarez et 
al., 2013
Cocaine craving
Outcome table 73
Alvarez et 
al., 2013
Drop out during 
treatment
Outcome table 75
Disulfiram 1 (H 1) Pani et al., 
2010
Cocaine use
Outcome table 72
Pani et al., 
2010
Cocaine 
abstinence
Outcome table 71
Pani et al., 
2010
Drop out during 
treatment
Outcome table 75
People with 
cocaine 
dependence
Community/ 
outpatient
Pharamcological 
treatment 
alone or with 
psychosocial 
intervention
Antidepressants 1 (H 1) Pani, 2011 Cocaine 
abstinence
Outcome table 71
Pani, 2011 Cocaine use
Outcome table 72
Pani, 2011 Cocaine craving
Outcome table 73
Pani, 2011 Treatment 
retention
Outcome table 74
Pani, 2011 Drop out during 
treatment
Outcome table 75
Pani, 2011 Depression
Outcome table 80
People with 
cocaine 
dependence
Community/ 
outpatient
Pharmacological 
treatment plus 
psychostimulant
Indirect dopamine 
agonists
1 (H 1) Perez-
Mana et al., 
2011
Cocaine 
abstinence
Outcome table 71
Perez-
Mana et al., 
2011
Treatment 
retention
Outcome table 74
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Table 20 (continued): Pharmacological treatments for stimulants – summary
Population Setting Intervention/ 
treatment
Pharmacological 
agent
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table 
reference
People with 
amphetamine 
dependence
Community Psychostimulants 
plus psychosocial 
intervention
Psychostimulants 1 (H 1) Perez-
Mana et al., 
2013
Amphetamine use
Outcome table 82
Perez-
Mana et al., 
2013
Psychostimulant 
abstinence
Outcome table 81
Perez-
Mana et al., 
2013
Amphetamine 
craving
Outcome table 83
Perez-
Mana et al., 
2013
Drop outs during 
treatment
Outcome table 84
Pharmacological 
treatment plus 
psychostimulant
Indirect dopamine 
agonists
1 (H 1) Perez-
Mana et al., 
2011
Psychostimulant 
abstinence
Outcome table 81
Perez-
Mana et al., 
2011
Treatment 
retention
Outcome table 85
Cocaine
There were seven reviews identified and rated 
high quality using the JBI tool that examined 
the effectiveness of treatments for cocaine 
dependence. Six reviews looked at the impact 
of treatments using a range of overlapping 
pharmacological agents including dopamine 
agonists (Minozzi et al., 2015a), indirect dopamine 
agonists (Perez-Mana et al., 2011), anticonvulsants 
(Minozzi et al., 2015b), psychostimulants (Castells 
et al., 2010), antipsychotics (Alvarez et al., 2013), 
antidepressants (Pani et al., 2011) and disulfiram 
(Pani et al., 2010).
Low-moderate quality review-level evidence 
indicates that pharmacological treatments for 
cocaine dependence included in these reviews, 
delivered alone or alongside other interventions, 
were ineffective in comparison to other treatments 
including placebo, alternative medication or no 
treatment for a range of outcomes including 
cocaine use, abstinence, treatment outcomes and 
mental health symptoms. No consistent evidence 
was identified to support the use of any one type 
of pharmacological treatment. Findings were 
limited by the high risk of bias identified within the 
reviews regarding many primary studies.
Amphetamines
Two reviews rated high quality using the JBI tool 
were identified that examined the effectiveness 
of pharmacological treatments for amphetamine 
or methamphetamine dependence (Perez-Mana 
et al., 2013; Perez-Mana et al., 2011). In one 
review, psychostimulants delivered in combination 
with psychosocial interventions were examined 
(Perez-Mana et al., 2013) and low-moderate 
quality review-level evidence indicates that no 
benefits from this approach were found for 
treatment or drug use outcomes. In one review, 
indirect dopamine agonists delivered alongside 
psychotherapy were examined and low-quality 
review-level evidence indicates that treatment is 
not effective for abstinence or treatment retention 
outcomes (Perez-Mana et al., 2011).
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7.3.3 Cannabis
Cannabis is the most used illicit drug in Ireland 
and worldwide. The latest data on prevalence of 
drug use suggest that 6% of the population in 
Ireland used cannabis in the previous year (National 
Advisory Committee on Drugs and Alcohol, 2012), 
and the rate of cannabis dependence and abuse is 
estimated at 0.6% and 1.3% respectively (National 
Advisory Committee on Drugs and Alcohol, 2013). 
The data suggest that risk is highest among males 
and younger adults with lifetime cannabis use. 
Among 15–16 year-olds, use is estimated at 22% 
for boys and 15% for girls (Hibell et al., 2011). 
Treatment data indicate that in 2014 there were 
over 2,500 cases of individuals entering treatment 
for cannabis in Ireland, with the number of cases 
more than doubling over the preceding decade 
(EMCDDA, 2015b).
Relapse following treatment for cannabis use 
is common and may be linked to recognised 
symptoms of withdrawal during treatment for 
cannabis dependence. The identification of 
pharmacological treatments to reduce withdrawal 
during treatment is therefore important, but there 
is little consistent evidence supporting the use 
of any medication for this purpose. One review 
rated high quality was identified in this review 
that looked at the effectiveness of a range of 
pharmacological agents for people with cannabis 
dependence (Marshall et al., 2014; Table 21). 
Treatments included THC preparations, mixed-
action antidepressants, SSRI antidepressants, 
anticonvulsants with mood stabilisers, buspirone, 
atomoxetine and N-acetylcysteine.
The evidence identified was limited due to the 
small amount and low quality of primary evidence 
available (Table 21). Outcomes for each treatment 
agent were examined in one or two primary studies 
only, and sample sizes across these studies were 
small and the quality of review-level evidence 
was rated moderate or low for all outcomes. 
While no evidence was identified to support the 
use of pharmacological treatments for cannabis 
dependence, there was evidence to suggest that 
treatment with a range of pharmacological agents 
was no more effective than placebo in treatment 
for cannabis dependence on outcomes including 
abstinence, adverse treatment effects and 
withdrawal from treatment due to adverse effects.
7.4 Psychosocial and 
motivational treatments
It is important not only to address the physiological 
elements of drug misuse but also the many 
psychosocial factors, such as a person’s beliefs, 
attitudes, motivations and emotions, that 
significantly contribute to and maintain drug 
misuse. Behavioural and psychosocial interventions 
are recommended to people who use a range 
of drugs to treat their drug use and support 
long-term recovery (World Health Organization, 
2009). In some cases, this can be in addition 
to pharmacological treatments, but for many 
individuals these interventions can form the 
mainstay of treatment. NICE recommends that 
individuals experiencing drug misuse should have 
access to evidence-based and well-designed 
psychosocial interventions (based on behavioural, 
cognitive, motivational and social theories) in 
addition to standard care or in conjunction with 
existing pharmacological drug treatments (NICE, 
2007). NICE recommends the use of interventions 
such as brief interventions,8 contingency 
management and self-help groups.
In Ireland, evidence from 2010 suggests that in 
over half of approximately 8,000 treatment cases 
(58%), individuals received either individual or 
group counselling. In one-third of cases, a brief 
intervention was delivered (e.g. brief motivational 
interviewing) and in a quarter of cases, individual or 
group education and awareness programmes were 
provided (Bellerose et al., 2011).
There are many types of psychosocial treatments, 
including the following interventions for which 
review-level evidence on intervention effectiveness 
was identified across 10 reviews (Table 22):
8 Evidence on the effectiveness of brief interventions will be 
discussed as part of the prevention strand of this review.
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Table 21: Pharmacological treatments for cannabis – summary
Population Setting Pharmacological 
agent
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table reference
People with 
cannabis 
dependence
Community/ 
outpatient
THC preparations 1 (H 1) Marshall et al., 2014 Cannabis abstinence
Outcome table 86
Marshall et al., 2014 Treatment completion
Outcome table 87
Marshall et al., 2014 Adverse effects during 
treatment
Outcome table 88
Marshall et al., 2014 Withdrawal due to adverse 
effects
Outcome table 89
People with 
cannabis 
dependence
Community/ 
outpatient
Mixed action 
antidepressants
1 (H 1) Marshall et al., 2014 Cannabis abstinence
Outcome table 86
Marshall et al., 2014 Treatment completion
Outcome table 87
Marshall et al., 2014 Adverse effects during 
treatment
Outcome table 88
Marshall et al., 2014 Withdrawal due to adverse 
effects
Outcome table 89
People with 
cannabis 
dependence
Community/ 
outpatient
SSRI 
antidepressants
1 (H 1) Marshall et al., 2014 Cannabis abstinence
Outcome table 86
Marshall et al., 2014 Treatment completion
Outcome table 87
People with 
cannabis 
dependence
Community/ 
outpatient
Anticonvulsant and 
mood stabiliser
1 (H 1) Marshall et al., 2014 Cannabis abstinence
Outcome table 86
Marshall et al., 2014 Treatment completion
Outcome table 87
Marshall et al., 2014 Withdrawal due to adverse 
effects
Outcome table 89
People with 
cannabis 
dependence
Community/ 
outpatient
Buspirone 1 (H 1) Marshall et al., 2014 Treatment completion
Outcome table 87
Marshall et al., 2014 Adverse effects during 
treatment
Outcome table 88
Marshall et al., 2014 Withdrawal due to adverse 
effects
Outcome table 89
People with 
cannabis 
dependence
Community/ 
outpatient
Atomoxetine 1 (H 1) Marshall et al., 2014 Treatment completion
Outcome table 87
Marshall et al., 2014 Adverse effects during 
treatment
Outcome table 88
Marshall et al., 2014 Withdrawal due to adverse 
effects
Outcome table 89
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Brief interventions
In England and Wales, NICE recommends brief 
interventions as an opportunistic method of 
engaging individuals who have no contact or 
limited contact with drug services (NICE, 2007). 
Typically, these involve one to four sessions 
lasting around 10–45 minutes each, and aim to 
explore individuals’ ambivalence about changing 
their behaviour while providing supporting and 
non-judgemental feedback in a person-centred 
manner. Motivational interviewing is one example of 
a brief intervention. This person-centred method 
aims to enhance individuals’ intrinsic motivation to 
change their behaviour through investigating and 
resolving ambivalence, and helping the individual to 
recognise that changing is in line with their own key 
interests and values.
Brief interventions are a common approach for 
drug prevention: evidence on brief interventions 
delivered with the intention of preventing drug use 
(rather than treating drug misuse/dependence) 
is discussed in the prevention part of this review 
(Section 5.5).
Contingency management
Intervention approaches based on contingency 
management involve the provision of a reward 
as an incentive to reinforce a desired outcome. 
Typically, the incentive consists of a voucher or 
cash prize for achieving abstinence or attending 
treatment sessions and the value of the incentive 
may increase with repeated success or attendance.
Cognitive behavioural therapy
Cognitive behavioural therapy (CBT) focuses 
on supporting an individual in changing how 
they think and the behaviours they undertake. 
It has been demonstrated to help many mental 
health conditions such as depression, obsessive-
compulsive disorder, stress and anxiety. In England 
and Wales, CBT is recommended by NICE for the 
treatment of people with co-occurring drug use 
and mental health disorders, but not for individuals 
with drug misuse alone.
Behavioural couples therapy
Couples-focused interventions such as behavioural 
couples therapy are targeted at individuals using 
drugs who are in contact with a close, non-drug-
using partner. The treatments are developed 
from theories of relationship therapy. Normally, 
behavioural couples therapy will involve delivery of 
treatment sessions over a period of around three 
months, with a primary focus on the individual who 
is misusing drugs.
Mindfulness‑based interventions
Mindfulness-based interventions are used as 
treatment for a range of disorders and increasingly 
in drug misuse treatment. Interventions primarily 
include meditation activities based on Buddhist 
principles, but may be supplemented by a range of 
other psychosocial approaches.
Table 21 (continued): Pharmacological treatments for cannabis – summary
Population Setting Pharmacological 
agent
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table reference
People with 
cannabis 
dependence
Community/ 
outpatient
N-acetylcysteine 1 (H 1) Marshall et al., 2014 Treatment completion
Outcome table 87
Marshall et al., 2014 Adverse effects during 
treatment
Outcome table 88
Marshall et al., 2014 Withdrawal due to adverse 
effects
Outcome table 89
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Table 22: Psychosocial treatments – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Reviews(s) Outcome
Outcome table reference
Young people 
who are 
regular users 
of cannabis
Multidimensional 
family therapy
1 (H 1) Filges 2015a Drug use
Outcome table 90
1 (H 1) Filges 2015a Treatment retention
Outcome table 92
1 (H 1) Filges 2015a Education
Outcome table 93
Family behaviour 
therapy
1 (H 1) Lindstrom et al., 2015 Drug use
Outcome table 90
1 (H 1) Lindstrom et al., 2015 Criminal activity
Outcome table 91
Cognitive 
behavioural 
therapy
1 (H 1) Filges et al., 2015b Criminal activity
Outcome table 91
Adults who are 
regular users 
of cannabis
Community 
or outpatient
Cognitive 
behavioural 
therapy
1 (H 1) Cooper et al., 2015 Cannabis use
Outcome table 94
1 (H 1) Cooper et al., 2015 Cannabis dependence 
severity
Outcome table 95
1 (H 1) Cooper et al., 2015 Cannabis-related 
problems
Outcome table 96
Adults with 
drug misuse or 
dependence
Community 
or outpatient
Cognitive 
behavioural 
therapy
1 (H 1) National Collaborating 
Centre for Mental 
Health, 2008
Cocaine abstinence
Outcome table 97
Couples therapy 1 (H 1) National Collaborating 
Centre for Mental 
Health, 2008
Abstinence from drugs
Outcome table 98
Contingency 
management
2 (H 2) Benishek et al., 2014; 
National Collaborating 
Centre for Mental 
Health, 2008
Abstinence from drugs
Outcome table 99
Mindfulness-
based 
interventions
2 (H 2) Chiesa and Serretti, 
2014; Zgierska et al., 
2014
Drug use
Outcome table 100
Motivational 
interview
2 (H 2) Smedslund et al., 2011; 
Watson et al., 2013
Drug use
Outcome table 101
1 (H 1) Smedslund et al., 2011 Treatment retention
Outcome table 102
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7.4.1 Psychosocial treatments 
for young people
Three high-quality reviews were identified that 
examined the effectiveness of psychosocial 
interventions delivered to young people with 
drug misuse problems. Across the primary studies 
included in all three reviews, young people 
predominantly used cannabis as their primary drug. 
Two reviews examined evidence on family-based 
interventions including multidimensional family 
therapy (MTFD; Filges et al., 2015a) and family 
behaviour therapy (Lindstrom et al., 2015). One 
review examined evidence on CBT delivered alone 
or in combination with other interventions (Filges 
et al., 2015b).
Moderate-quality review-level evidence suggests 
that MDFT is effective in reducing drug use 
frequency and severity in comparison to other 
interventions among adolescents, including CBT, 
but it is generally no more or less effective in 
treatment retention (Filges et al., 2015a; Filges 
2015b). Low-quality review-level evidence on the 
effectiveness of family behaviour therapy on drug 
use and crime was inconclusive and was based 
on a small number of studies only (Lindstrom 
et al., 2015). Additionally, low-quality review-
level evidence, also based on low numbers of 
studies, suggests that CBT treatments do not have 
beneficial impacts on crime (Filges et al., 2015b).
7.4.2 Psychological and 
motivational treatments 
for adults
Initially, four reviews rated high quality were 
identified that examined psychosocial interventions 
including CBT for cannabis use (Cooper et al., 2015) 
and motivational interview (Smedslund et al., 2011; 
Watson et al., 2013) and contingency management 
(Benishek et al., 2014) for the treatment of a 
range of drug use disorders. In recognition of the 
lack of evidence relating to cocaine treatment, 
evidence from one additional review published 
before 2010 (National Collaborating Centre 
for Mental Health, 2008) was included; this 
examined the effectiveness of CBT and couples 
therapy treatments. Additional evidence was 
extracted from this review related to contingency 
management treatment.
CBT and couples therapy
For adults who use cannabis, moderate-quality 
evidence suggests that CBT is generally more 
effective for outcomes relating to cannabis use and 
dependency in comparison to individuals receiving 
no treatment, but it is no more or less effective 
than other interventions (Cooper et al., 2015). Low-
quality review-level evidence on the effectiveness 
of CBT combined with contingency management 
was mixed and inconclusive in comparison to other 
interventions (Cooper et al., 2015).
One review rated high quality was identified that 
examined CBT and couples therapy for treatment 
for cocaine use (National Collaborating Centre for 
Mental Health, 2008). Moderate-quality review-
level evidence indicates that couples-based 
interventions are more effective than relapse-
prevention CBT in achieving abstinence. Evidence 
indicates that CBT, including relapse-prevention 
and standard CBT, is no more or less effective than 
standard care in achieving abstinence. Couples-
based interventions were not compared with any 
treatment types other than CBT.
Contingency management
Two reviews were identified that examined the 
effectiveness of contingency management 
interventions (Benishek et al., 2014; National 
Collaborating Centre for Mental Health, 2008). 
Evidence indicates that contingency management 
may be effective in achieving abstinence among 
people who use stimulants or opioids following 
treatment, but it suggests that this effect may be 
diminished at longer-term follow-up.
Moderate-quality review-level evidence suggests 
that there is no difference for abstinence at 
six months between prize-based contingency 
management treatment and treatment as usual, 
although high-quality review-level evidence 
suggests short-term benefits in favour of 
contingency management (Benishek et al., 2014). 
Moderate-quality review-level evidence suggests 
that contingency management is more effective 
than control interventions in achieving abstinence, 
but effectiveness may not be maintained at long-
term follow-up (National Collaborating Centre for 
Mental Health, 2008).
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Motivational interview
One review was identified that looked at the 
effectiveness of motivational interviewing delivered 
to individuals with dependence on or abuse of 
alcohol, cannabis, cocaine or multiple drugs9 
(Smedslund et al., 2011). Moderate-quality evidence 
suggests that individuals who receive motivational 
interview (delivered either in a one-off session 
or over a series of sessions) may have reduced 
drug abuse in comparison to those who do not 
receive treatment. However, moderate-quality 
evidence suggests that motivational interview may 
be no more or less effective than other forms of 
treatment interventions for improving drug abuse 
and treatment retention (Smedslund et al., 2011).
In addition, one review was identified that looked 
at the provision of brief motivational interviewing 
in hospital outpatient settings to reduce drug 
abuse (Watson et al., 2013). Findings for illicit drug 
use were inconclusive and greatly limited as the 
evidence was based on two primary studies only 
(the majority of studies in the review focused on 
alcohol abuse only).
7.4.3 Mindfulness‑based 
treatments
Evidence on the effectiveness of mindfulness-
based interventions on any drug use and cocaine 
use was inconclusive. There is evidence to suggest 
that mindfulness-based interventions may result 
in reduced drug use, but this was based on limited 
primary-level evidence (Chiesa and Serretti, 2014; 
Zgierska et al., 2014).
9 Of the 59 studies within the review by Smedslund and 
colleagues, 29 studies looked at treatment for alcohol 
use only. It was not possible to separate findings for illicit 
drug treatments alone within the review findings, and thus 
findings relating to alcohol treatments are included here. 
It should be noted therefore that findings for motivational 
interview treatment presented here are from 29 studies 
for which the treated drug was alcohol. Of the remaining 
30 studies, 18 focused on multiple drugs, 8 focused on 
cannabis treatments and four focused on cocaine.
7.5 Residential rehabilitation 
treatment programmes
Residential rehabilitation is provided to a minority 
of people in drug treatment, typically those whose 
needs may not be met through community drug 
treatment services. The focus of these treatments 
is primarily on abstinence. Residential facilities 
are widely available in Ireland, with around two-
thirds based within hospital settings where a 
combination of therapeutic approaches are 
applied (EMCDDA, 2014).
Initially, no reviews rated high quality were 
identified that examined evidence on residential 
rehabilitation. Two systematic reviews were 
identified that examined the effects of residential 
rehabilitation in therapeutic communities (Table 
23; Malivert et al., 2012; Vanderplasschen et al., 
2013). Both were rated low quality using the JBI 
tool and therefore an additional review rated high 
quality published in 2008 (National Collaborating 
Centre for Mental Health, 2008) was included. In 
addition to evidence on therapeutic communities, 
one of the reviews (National Collaborating 
Centre for Mental Health, 2008) examined the 
effectiveness of residential 12–step programmes.
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The evidence on the effectiveness of residential 
rehabilitation programmes included in these 
reviews was limited and was based on low-
quality review-level evidence, and included a 
mix of community and prison-based therapeutic 
communities (Malivert et al., 2012; National 
Collaborating Centre for Mental Health, 2008; 
Vanderplasschen et al., 2013). Consequently, 
it is difficult to draw any conclusions about 
the effectiveness of residential therapeutic 
communities on drug use and recovery. However, 
low-quality review-level evidence indicates 
that participation in a residential therapeutic 
community is associated with improved 
employment outcomes (Vanderplasschen et 
al., 2013). There was no consistent evidence 
on the effectiveness of different therapeutic 
community approaches compared with one 
another. Additionally, one review examined 
evidence on residential 12–step group participation 
and evidence suggests that participation may 
have benefits for drug use over CBT and other 
residential programmes, but this was based on 
one study only and review quality evidence was 
low (National Collaborating Centre for Mental 
Health, 2008).
7.6 Interventions focusing on 
recovery and reintegration
Drug treatments such as pharmacological 
and psychosocial interventions typically focus 
primarily on reducing drug use or abstinence, and 
reducing harmful behaviours. It is recognised that 
interventions that provide support beyond the 
initial treatment period are required to support the 
long-term recovery of people who use illicit drugs. 
This includes treatments that provide social and 
emotional support and those with a wider focus on 
social reintegration. The EMCDDA points towards 
treatments that focus on housing, education 
and employment as being a significant part of 
the recovery process to enable full reintegration 
into the community following drug addiction, and 
recommend that these outcomes are integral 
parts of drug treatment programmes (Sumnall and 
Brotherhood, 2012).
Initially, only two high-quality reviews (Blodgett 
et al., 2014; Reif et al., 2014a) were identified 
that examined treatments focused on long-term 
recovery. Consequently, one low-quality review 
(Reif et al., 2014b), one medium-quality review 
(Bender et al., 2011), and one high-quality review 
published before 2008 (NCCH 2008) that examined 
additional evidence were included in this review. 
The six identified reviews (Table 24) included 
evidence on the following intervention types:
Table 23: Residential treatment programmes – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome(s)
Outcome table reference
Adults 
with drug 
misuse or 
dependence
Residential 
(community/ 
prison)
Residential 
rehab
2 (M 1; L1) Malivert et al., 2012; 
Vanderplasschen et al., 
2013
Treatment completion
Outcome table 103
3 (H 1; M 1; L 1) Malivert et al., 2012; 
National Collaborating 
Centre for Mental 
Health, 2008; 
Vanderplasschen et al., 
2013
Drug use
Outcome table 104
1 (1 M) Vanderplasschen et al., 
2013
Employment
Outcome table 105
Residential 12-step 1 (H 1) National Collaborating 
Centre for Mental 
Health, 2008
Drug use
Outcome table 104
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Interventions based on peer support
Emotional, social and informational support is 
thought to be an important factor in predicting 
long-term recovery following drug misuse. Types 
of social support interventions include peer-
based recovery interventions and programmes 
based on models of mutual aid (for example 12-
step programmes). Peer recovery interventions 
include those such as peer recovery coaching and 
recovery housing. Peer recovery housing involves 
the provision of short-term housing for people in 
recovery from drug and/or alcohol dependence. 
Peer recovery coaching is defined as a mentoring 
and support service delivered to individuals with 
drug use disorders by a peer with more experience 
of recovery, with potential benefits for both 
provider and recipient. Peer recovery coaches 
may be volunteers or paid, receive training, and 
are likely to be involved in the development and 
strategy of recovery services (White, 2009), in 
comparison to the more informal role played by 
peers in mutual aid models such as 12-step groups 
(Bassuk et al., 2016).
Mutual aid models are somewhat similar to peer-
based recovery treatments in the use of peer 
support, but differ through the role of the peer 
and the nature of the intervention. In mutual aid 
groups, individuals act informally as sponsors, 
with the emphasis being on peers supporting each 
other (as opposed to the role of peer recovery 
coaches to support those with less experience of 
recovery). Mutual aid participants follow a model 
of recovery, most prominently 12-step programmes 
such as Narcotics Anonymous (NA), whereas in 
peer recovery interventions, individuals are likely 
to be encouraged to identify recovery pathways 
that suit their needs. Self-help approaches include 
support groups, but may also involve individual 
counselling or mentoring or the use of books and 
support information. In England and Wales, NICE 
recommends that all individuals engaging with drug 
treatment services are made aware of mutual aid 
and self-help programmes and that service staff 
support interested clients in engaging with these 
services; Public Health England recommends the 
further development of mutual aid groups across 
Europe (Public Health England, 2013).
In Ireland, there are currently a large number of 
NA groups, presently providing around 212 weekly 
sessions nationwide (data obtained from Narcotics 
Anonymous Ireland website www.na-ireland.org/). 
NA is based on the 12-step model and the primary 
approach is one that involves the therapeutic 
value of addicts helping one another, while sharing 
their experiences of addiction, aspirations and 
journey towards recovery. Although not a religious 
programme, it teaches a set of spiritual principles.
Continuing care
Continuing care can be defined as a period of 
lower-intensity treatment following the completion 
of an initial high-intensity period of treatment, for 
example in a residential treatment setting (Proctor 
and Herschman, 2014). The aim of continuing care 
is to provide ongoing support to individuals with 
previous drug use problems to prevent relapse 
and encourage continued recovery. Continuing 
care encompasses a range of approaches including 
self-help groups, individual or group counselling, 
social skills training and case management. Case 
management may be used to define a range of 
strategies, but it is broadly a coordinated approach 
to deliver mental health services, treatment 
for drug abuse and social services to increase 
engagement with different services and to achieve 
common goals.
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Table 24: Treatments focusing on long‑term recovery – summary
Population Intervention Setting Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table reference
People in 
recovery 
from drug 
dependence
Continuing care Community 2 (H 1; M 1) Bender et al., 2011; 
Blodgett et al., 2014
Drug use
Outcome table 106
Case 
management
1 (H 1) Rapp et al., 2014 Treatment retention
Outcome table 107
1 (H 1) Rapp et al., 2014 Drug use
Outcome table 108
Recovery 
housing
1 (M 1) Reif et al., 2014b Drug use
Outcome table 109
1 (M 1) Reif et al., 2014b Re-incarceration
Outcome table 110
1 (M 1) Reif et al., 2014b Employment
Outcome table 111
Peer recovery 
coaching
1 (L 1) Reif et al., 2014a Drug use
Outcome table 112
Mutual aid and 
self-help
1 (H 1) NCCH, 2008 Drug use
Outcome table 113
7.6.1 Interventions based on peer 
support or mutual aid
One systematic review rated high quality was 
identified that examined the effectiveness of 
peer recovery coaching (Reif et al., 2014a). One 
additional review rated medium quality that looked 
at recovery housing was included (Reif et al., 
2014b).
One review examined evidence regarding recovery 
housing including the Oxford House recovery home 
model and other recovery housing interventions 
(Reif et al., 2014b). Moderate-quality review 
level-evidence indicates that, compared to usual 
care treatments, residency in recovery homes 
may be associated with improved drug use 
outcomes. Evidence indicates that residency in 
recovery homes may be associated with improved 
employment and reduced criminal behaviour, 
but evidence on these outcomes was limited. 
One review rated high quality examined evidence 
relating to peer recovery coaching (Reif et al., 
2014a). Low-quality review-level evidence indicates 
that peer recovery coaching interventions may be 
associated with reduced drug use in comparison 
with individuals receiving usual aftercare, but this 
evidence was further limited by the low quality of 
primary-level evidence.
One review from 2008 examined the effects 
of self-help groups and mutual aid (National 
Collaborating Centre for Mental Health, 2008). 
Evidence suggests that drug use is reduced with 
participation in 12-step groups. However, this 
evidence was limited, as review authors noted 
that self-help groups frequently formed part 
of treatment alongside other interventions and 
therefore the effectiveness of self-help groups 
alone is difficult to determine on the basis of the 
current review-level evidence available.
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7.6.2 Continuing care
One systematic review rated high quality was 
identified that examined the effectiveness of 
assertive continuing care for people recovering 
from cannabis dependency (Bender et al., 2011). No 
systematic reviews of high quality were identified 
that examined the effectiveness of continuing care 
on other drugs and one medium-quality review 
was therefore included (Blodgett et al., 2014). This 
review examined a range of treatments defined 
as continuing care for people with dependence 
on drugs including alcohol and/or illicit drugs. 
Evidence on the effectiveness of continuing care 
was mixed. Moderate-quality review-level evidence 
suggests that, compared to control treatments, 
continuing care may have a positive effect on drug 
use (Blodgett et al., 2014), but evidence regarding 
treatment with assertive continuing care found no 
difference for cannabis use compared to treatment 
as usual (Bender et al., 2011). Evidence on assertive 
continuing care was high quality but was based on 
a small number of studies.
Additionally, one systematic review looked at the 
effectiveness of a case management approach for 
people with drug dependence (Rapp et al., 2014). 
Low-quality review-level evidence suggests that, 
compared to standard care, case management may 
be an effective approach for increasing treatment 
retention. Additionally, low-quality evidence 
suggests that case management may have a small 
positive effect on drug use.
7.7 Other treatment 
approaches
Reviews of two additional treatment approaches 
were identified in this review, both targeting 
people with addictions to opioids only (Table 25). 
One review (Boyuan et al., 2014) investigated the 
effectiveness of acupuncture for drug treatment, 
which is offered as part of drug treatment in 
Ireland by both statutory and non-statutory 
providers (EMCDDA, 2015g) and one review (Wang 
et al., 2014) investigated the effectiveness of 
physical activity interventions. Physical activity 
interventions have been demonstrated to have 
positive effects on a range of mental health 
disorders such as depression (Mead et al., 2009); 
in addition, mental health disorders, including drug 
use disorders, are less prevalent among those who 
are physically active (Strohle et al., 2007).
Table 25: Other treatments – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Outcome table 
reference
People with 
addiction to 
opioids
Community/ 
outpatient
Acupuncture 1 (H 1) Boyuan et al., 2014 Opioid craving
Outcome table 114
1 (H 1) Boyuan et al., 2014 Depression
Outcome table 115
1 (H 1) Boyuan et al., 2014 Anxiety
Outcome table 116
Acupuncture and 
pharmacological 
treatment
1 (H 1) Boyuan et al., 2014 Opioid craving
Outcome table 114
1 (H 1) Boyuan et al., 2014 Anxiety
Outcome table 116
Transcutaneous 
electrical nerve 
stimulation
1 (H 1) Boyuan et al., 2014 Opioid craving
Outcome table 114
1 (H 1) Boyuan et al., 2014 Anxiety
Outcome table 116
Community/ 
outpatient
Physical activity 1 (H 1) Wang et al., 2014 Abstinence from heroin
Outcome table 117
1 (H 1) Wang et al., 2014 Anxiety
Outcome table 118
1 (H 1) Wang et al., 2014 Depression
Outcome table 119
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7.7.1 Acupuncture
One review rated high quality using the JBI tool 
examined the effects of acupuncture treatments 
on opioid craving and mental health symptoms 
(Boyuan et al., 2014). There was no evidence 
identified of the effectiveness of acupuncture 
treatments on drug use or treatment outcomes, 
as the review examined effects on psychological 
symptoms (heroin craving, anxiety and depression). 
Low-quality review-level evidence indicates 
that pharmacological treatment impact on 
opioid craving may be enhanced if delivered 
in combination with acupuncture. However, 
acupuncture alone is no more effective than 
psychosocial or pharmacological treatments, or 
placebo. Evidence is mixed on the effectiveness 
of acupuncture alone compared to no treatment. 
For mental health symptoms, evidence indicates 
that acupuncture treatments may be effective in 
reducing depression, but evidence on impact on 
anxiety status is mixed.
7.7.2 Physical activity
One review rated as high quality using the JBI 
tool examined the effects of physical activity 
interventions on abstinence from heroin and 
mental health symptoms (Wang et al., 2014). 
Evidence indicates that physical activity 
interventions are more effective than a range 
of psychosocial treatments or no treatment 
in maintaining abstinence from heroin, but 
are no more effective in reducing anxiety or 
depression symptoms.
7.8 Individuals in contact with 
the criminal justice system
There are around 800 treatment cases a year 
among prisoners in Ireland (Health Research 
Board, 2016b) and it is estimated that on any day, 
over 500 prisoners (of the total prison population 
of around 4,000) will receive OST (EMCDDA, 
2015d). The most common primary problematic 
drug is heroin, with increasing proportions of 
prisoners seeking treatment for cannabis and 
benzodiazepine use.
The Irish Prison Drugs Policy and Strategy commits 
to reducing supply of drugs into prison and 
supporting prisoners to become drug free (Irish 
Prison Service, 2006). Methadone maintenance 
treatment has been available through the Irish 
Prison Service since 2002 and prisons in Ireland 
are expected to provide a range of treatments 
including OST, detoxification programmes and 
psychosocial interventions, predominantly 
counselling and motivational interventions. 
There is a commitment to consider therapeutic 
communities to support the post-release recovery 
and reintegration of prisoners who use drugs (Irish 
Prison Service, 2015). Diversion interventions, 
such as drug treatment courts, aim to support 
individuals with drug use problems into treatment 
as an alternative to further involvement with the 
criminal justice system, such as a prison sentence. 
In Ireland, a review of the Dublin drug treatment 
court from the Irish Department of Justice, 
Equality and Law Reform (2010) concluded that the 
court has positive impacts on offenders, although 
participation was noted to be low.
Nine high-quality reviews were identified that 
examined the effectiveness of a range of 
treatments provided to people in contact with 
the criminal justice system (Table 26). Initially, 
seven reviews were identified; these looked at 
pharmacological treatments (Perry et al., 2015c; 
Hedrich et al., 2012; Larney et al., 2010) and non-
pharmacological treatments (Hayhurst et al., 2015; 
Mitchell et al., 2012; Perry et al., 2015b; Shonin 
et al., 2013). Evidence on non-pharmacological 
treatments was limited and therefore additional 
evidence was identified in two high-quality reviews 
published before 2010 (National Collaborating 
Centre for Mental Health, 2008; Perry et al., 
2009). In addition, one review rated high quality 
using the JBI tool was identified that examined the 
effectiveness of treatments for people with mental 
illness who are in contact with the criminal justice 
system (Perry et al., 2015a).
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Table 26: Treatments delivered in the criminal justice system – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Evidence table reference
People 
with opioid 
dependence 
in contact 
with the 
criminal 
justice system
Prison OST 3 (H 3) Perry et al., 2015c; 
Hedrich et al., 2012;
Larney et al., 2010
Drug use
Outcome table 120
2 (H 2) Hedrich et al., 2012;
Larney et al., 2010
Injecting drug use
Outcome table 121
2 (H 2) Hedrich et al., 2012; 
Perry et al., 2015c
Criminal activity
Outcome table 122
Community Opioid 
detoxification
1 (H 1) Perry et al., 2015c Drug use
Outcome table 123
Community Relapse 
prevention
1 (H 1) Perry et al., 2015c Drug use
Outcome table 124
1 (H 1) Perry et al., 2015c Criminal activity
Outcome table 125
People who 
misuse drugs 
in contact 
with the 
criminal 
justice system
Community Diversion 
interventions 
(including drug 
courts)
1 (H 1] Hayhurst et al., 2015 Drug use
Outcome table 126
1 (H 1) Hayhurst et al., 2015 Criminal activity
Outcome table 127
Prison Therapeutic 
communities
2 (H 2) Mitchell et al., 
2012; Perry et al., 
2009; National 
Collaborating Centre 
for Mental Health, 
2008
Drug use
Outcome table 128
3 (H 3) Mitchell et al., 
2012; National 
Collaborating Centre 
for Mental Health, 
2008; Perry et al., 
2009
Criminal activity
Outcome table 129
Boot camps 2 (H 2) Mitchell et al., 
2012; National 
Collaborating Centre 
for Mental Health, 
2008
Drug use
Outcome table 130
2 (H 2) Mitchell et al., 
2012; National 
Collaborating Centre 
for Mental Health, 
2008
Criminal activity
Outcome table 131
Psychosocial 
interventions
3 (H 3) Mitchell et al., 2012; 
Perry et al., 2015b; 
Shonin et al., 2013
Drug use
Outcome table 132
2 (H 2) Mitchell et al., 2012; 
Perry et al., 2015b
Criminal activity
Outcome table 133
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Table 26 (continued): Treatments delivered in the criminal justice system – summary
Population Setting Intervention Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Evidence table reference
People 
who misuse 
drugs with 
mental illness 
comorbidities 
in contact 
with the 
criminal 
justice system
Prison Prison-based 
therapeutic 
communities
1 (H 1) Perry et al., 2015a Drug use
Outcome table 134
1 (H 1) Perry et al., 2015a Criminal activity
Outcome table 135
Motivational 
interview and 
skills
1 (H 1) Perry et al., 2015a Drug use
Outcome table 136
Court Case 
management (via 
drug court)
1 (1 H) Perry et al., 2015a Criminal activity
Outcome table 137
7.8.1 Opioid substitution  
treatment
Three systematic reviews rated high quality were 
identified that examined the effectiveness of OST 
provided in prisons (Hedrich et al., 2012; Larney et al., 
2010; Perry et al., 2015). The evidence indicates that 
compared with no OST, OST provided in prisons is more 
effective in reducing drug use in prison (Larney et al., 
2010; Hedrich et al., 2012) and post release (Hedrich 
et al., 2012). Evidence indicates that high-dose 
methadone treatment is more effective in reducing 
drug use than low-dose methadone (Hedrich et al., 
2012), and maintenance treatment is no more or less 
effective with methadone than with buprenorphine 
(Hedrich et al., 2012; Perry et al., 2015c). The 
effectiveness of maintenance treatments on criminal 
activity is less clear and is based on low-quality review-
level evidence. Generally, from reviews of RCTs, it 
appeared that receiving maintenance treatment has 
no impact on reincarceration rate (Hedrich et al., 
2012; Perry et al., 2015) or criminal activity (Hedrich 
et al., 2012). Additionally, evidence indicates that the 
reincarceration rate does not differ when treatment is 
with methadone rather than buprenorphine (Hedrich 
et al., 2012; Perry et al., 2015c).
7.8.2 Relapse prevention
One high-quality review was identified that 
examined the effects of relapse prevention with 
naltrexone among people with opioid dependence 
on drug use and criminal activity (Perry et al., 
2015c). Low-quality review-level evidence on 
subsequent heroin use and criminal activity was 
limited by small sample sizes and suggests no 
differences between naltrexone implants and 
methadone maintenance approaches. Low-quality 
review-level evidence indicates that oral naltrexone 
may be effective in reducing reincarceration.
7.8.3 Therapeutic communities
Three reviews rated high quality were identified 
that examined the effectiveness of therapeutic 
communities provided in prison settings on drug 
and criminal activity outcomes (Mitchell et al., 
2012; National Collaborating Centre for Mental 
Health, 2008; Perry et al., 2009). Primarily 
moderate-quality review-level evidence suggests 
that therapeutic communities are effective in 
reducing drug use relapse (Mitchell et al., 2012; 
National Collaborating Centre for Mental Health, 
2008; Perry et al., 2009), recidivism (Mitchell et 
al., 2012), reincarceration (National Collaborating 
Centre for Mental Health, 2008; Perry et al., 
2009) and criminal activity post-release (National 
Collaborating Centre for Mental Health, 2008; 
Perry et al., 2009).
7.8.4 Boot camps
Two reviews rated high quality were identified 
that looked at the effectiveness of boot camps 
(Mitchell et al., 2012; National Collaborating Centre 
for Mental Health, 2008). Low-quality review-
level evidence from one study indicates that there 
are no impacts from prison-based boot camp 
participation on drug use (National Collaborating 
Centre for Mental Health, 2008) or recidivism 
(Mitchell et al., 2012; National Collaborating Centre 
for Mental Health, 2008).
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7.8.5 Psychosocial interventions
Three reviews rated high quality were identified 
that looked at the effectiveness of psychosocial 
interventions delivered in prison settings. One 
review looked at counselling interventions (Mitchell 
et al., 2012) and one looked at the provision of CBT, 
behavioural management and case management 
interventions delivered to female offenders only 
(Perry et al., 2015b). Moderate-quality review-
level evidence indicates that counselling is no 
more or less effective than other treatments or no 
treatment for drug use relapse, but is associated 
with reduced recidivism (Mitchell et al., 2012). 
Low-quality review-level evidence indicates 
that behavioural management is no more or less 
effective than treatment as usual for reducing drug 
use, and, alongside CBT and case management 
treatments, is no more or less effective than 
treatment as usual with regard to post-release 
criminal activity. Additionally, low-quality evidence 
from one review suggests that meditation-based 
intervention in prison settings may have positive 
impact on drug use (Shonin et al., 2013).
7.8.6 Diversion interventions
One review rated high quality was identified that 
examined the provision of diversion interventions 
(Hayhurst et al., 2015). A mixture of moderate- and 
low-quality review-level evidence suggests that 
diversion interventions do not affect drug use. 
Evidence on reoffending was limited in the design 
of studies and reporting of review-level evidence, 
but suggests that diversion interventions may have 
positive impacts on reoffending rates.
7.8.7 Interventions for people 
with drug use and mental 
illness comorbidities
One review rated high quality was identified that 
examined the provision of a range of treatments 
for people with both drug use and mental illness 
disorders in contact with the criminal justice 
system (Perry et al., 2015a). Low-quality review-
level evidence is inconclusive on the impact 
of therapeutic communities on drug use, but 
indicates reduced rates of reincarceration, 
compared with treatment as usual or no 
treatment. This evidence suggests no benefits of 
motivational interview with cognitive skills training 
on drug use, or of mental health courts alongside 
case management on criminal activity. For all 
comparisons, the evidence was limited by the 
small number of primary studies available for each 
outcome and the low quality of primary studies.
7.9 Individuals with drug use 
problems and co‑occurring 
mental illness
The association between mental health disorders 
and drug misuse is complex, and suggests that 
individuals with mental illness may be more at risk 
of drug misuse, and that drug misuse may increase 
risk of, or accelerate progression of, mental illness 
(see Section 5.8).
Four reviews looked at the effectiveness of 
providing treatments for people with co-occurring 
mental health and drug use problems (Table 27). Two 
reviews looked at treatments for individuals with 
trauma, including integrated treatment programmes 
(Torchalla et al., 2012) and CBT-focused 
interventions (Roberts et al., 2015); one review 
looked at a range of psychosocial interventions and 
integrated models of care for individuals with severe 
mental illness (Hunt et al., 2013) and one review 
looked at therapies for individuals with borderline 
personality disorders (Lee et al., 2015).
7.9.1 Individuals with 
co‑occurring trauma
CBT‑based interventions
One review looked at the effectiveness of 
interventions based on CBT delivered to individuals 
with drug and/or alcohol use disorder and who had 
experienced significant abuse or trauma (Roberts et 
al., 2015). Treatments included individual trauma and 
non-trauma-focused interventions and group trauma 
and non-trauma-focused interventions delivered 
alone or in combination with a psychosocial or 
pharmacological intervention for drug use.
Moderate-quality review-level evidence indicates 
that individual CBT trauma-focused interventions 
that were delivered in combination with drug use 
treatments can reduce drug use and post-traumatic 
stress disorder (PTSD), and increase treatment 
retention, compared with treatment as usual. 
Evidence indicates no benefits from non-trauma-
focused individual and group treatments however.
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Table 27: Treatments for people with drug use problems and co‑occurring mental illness – summary
Population Setting Intervention/ 
treatment
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Evidence table 
reference
People with 
trauma and 
drug use 
problems
Community/ 
outpatient
Integrated 
treatment 
programmes
1 (H 1) Torchalla et al., 2012 PTSD symptoms
Outcome table 142
SUD symptoms
Outcome table 141
People with 
trauma and 
drug use 
problems
Community/ 
outpatient
Individual CBT 
trauma-focused 
interventions 
plus substance 
use disorder 
intervention
1 (H 1) Roberts et al., 2015 Drug use
Outcome table 138
PTSD severity
Outcome table 139
Treatment retention
Outcome table 140
People with 
trauma and 
drug use 
problems
Community/ 
outpatient
Group-based 
CBT non-
trauma-focused 
interventions for 
PTSD and SUD
1 (H 1) Roberts et al., 2015 Drug use
Outcome table 138
PTSD severity
Outcome table 139
Treatment retention
Outcome table 140
People with 
trauma and 
drug use 
problems
Community/ 
outpatient
Individual CBT 
non-trauma-
focused 
intervention for 
PTSD and SUD
1 (H 1) Roberts et al., 2015 Drug use
Outcome table 138
PTSD severity
Outcome table 139
People with 
trauma and 
drug use 
problems
Community/ 
outpatient
Individual CBT 
non-trauma-
focused 
intervention for 
PTSD alone
1 (H 1) Roberts et al., 2015 Drug use
Outcome table 138
PTSD severity
Outcome table 139
People with 
severe mental 
illness and 
drug use 
problems
Community/ 
outpatient
Integrated models 
of care
1 (H 1) Hunt et al., 2013 Drug use
Outcome table 144
Lost to treatment
Outcome table 143
People with 
severe mental 
illness and 
drug use 
problems
Community/ 
outpatient
Non-integrated 
models of care
1 (H 1) Hunt et al., 2013 Lost to treatment
Outcome table 143
Number of drugs used in 
past month
Outcome table 144
People with 
severe mental 
illness and 
drug use 
problems
Community/ 
outpatient
CBT 1 (H 1) Hunt et al., 2013 Lost to treatment
Outcome table 143
Cannabis use
Outcome table 144
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Table 27 (continued): Treatments for people with drug use problems and co‑occurring mental illness – 
summary
Population Setting Intervention/ 
treatment
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Evidence table 
reference
People with 
severe mental 
illness and 
drug use 
problems
Community/ 
outpatient
Motivational 
interviewing alone
1 (H 1) Hunt et al., 2013 Lost to treatment
Outcome table 143
Alcohol dependence
Outcome table 145
Amphetamine 
dependence
Outcome table 145
Cannabis dependence
Outcome table 145
Cannabis use
Outcome table 144
Polydrug consumption
Outcome table 144
Abstinence from drugs
Outcome table 144
People with 
severe mental 
illness and 
drug use 
problems
Community/ 
outpatient
Skills training 1 (H 1) Hunt et al., 2013 Lost to treatment
Outcome table 143
People with 
severe mental 
illness and 
drug use 
problems
Community/ 
outpatient
Contingency 
management
1 (H 1) Hunt et al., 2013 Lost to treatment
Outcome table 143
Stimulant use
Outcome table 144
Cannabis use
Outcome table 144
Injection drug use
Outcome table 144
People with 
borderline 
personality 
disorders 
and drug use 
disorders
Community/ 
outpatient
Dialectical 
behaviour therapy
1 (H 1) Lee et al., 2015 Range of outcomes 
relating to drug use and 
mental health
Outcome table 146
Dynamic 
deconstructive 
psychotherapy
1 (H 1) Lee et al., 2015 Range of outcomes 
relating to drug use and 
mental health
Outcome table 146
Dual-focused 
schema therapy
1 (H 1) Lee et al., 2015 Range of outcomes 
relating to drug use and 
mental health
Outcome table 146
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Integrated treatment programmes
One review looked at the effectiveness of 
integrated treatment programmes to treat 
drug use disorder and PTSD (Torchalla et al., 
2012). Moderate-quality review-level evidence 
indicates that these programmes are no more 
or less effective than non-integrated treatment 
programmes for reducing symptoms of drug use 
disorder, or PTSD.
7.9.2 Individuals with 
co‑occurring severe 
mental illnesses
One review examined the effectiveness of 
psychosocial drug misuse treatments delivered 
to individuals with severe mental illness (Hunt 
et al., 2015). Interventions included skills 
training, motivational interviewing, contingency 
management, integrated models of care and CBT, 
and were compared with standard care. Standard 
care was defined as the treatment an individual 
would receive if they had not participated in 
the study intervention and availed of a range 
of treatments.
This review examined a wide range of drug use and 
treatment outcomes, and low-quality review-level 
evidence indicates that psychosocial interventions 
are likely to be no more or less effective for 
treating drug use in individuals with co-morbid 
severe mental illness in comparison to treatment 
as usual. This evidence was limited by the low 
number of primary studies on any individual 
intervention for this population, and the low quality 
of these studies.
7.9.3 Individuals with co‑
occurring borderline 
personality disorders
One review rated high quality using the JBI tool 
examined evidence on the effectiveness of 
interventions to treat drug use and borderline 
personality disorders (Lee et al., 2015). 
Interventions included dialectical behaviour 
therapy, dynamic deconstructive psychotherapy 
and dual-focus schema therapy. Moderate-quality 
review-level evidence indicates that dialectical 
behaviour therapy is the most effective of the 
three treatment approaches, with benefits for 
both drug use and borderline personality disorder 
treatment outcomes. It should be noted that the 
evidence is mainly from studies of the treatment 
of women. Dynamic deconstructive psychotherapy 
was also associated with positive treatment 
outcomes, but dual-focus schema therapy was 
noted to have limited impacts across outcomes.
7.10 Pregnant and 
parenting women
It is recognised that drug abuse during and 
following pregnancy has clear implications for the 
health of mothers and their children, and can have 
negative impacts on parenting skills and abilities. 
MMT is recommended for pregnant women in 
Ireland with opioid dependency (Institute of 
Obstetricians and Gynaecologists and HSE, 2015).
Five reviews were identified that looked at 
treatment provided to pregnant and parenting 
women (Table 28). One review assessed evidence 
on pharmacological treatment (MMT) for this 
population (Minozzi et al., 2013) and one review 
included a range of interventions including 
motivational and psychosocial treatments (Terplan 
et al., 2015). The remaining two reviews looked at 
the provision of integrated treatment programmes 
(Milligan et al., 2011) and home visits (Turnbull and 
Osborn, 2012).
7.10.1 Pharmacological treatments
One review rated high quality using the JBI tool 
looked at the effectiveness of MMT (Minozzi et 
al., 2013). Low-quality review-level evidence 
indicates that MMT is less effective than slow-
release morphine for heroin use and no more or 
less effective than buprenorphine for reducing 
primary and other drug use. Outcomes for MMT 
in comparison to use of buprenorphine and slow-
release morphine on birth and child outcomes 
were generally no different. The evidence was 
limited by the poor quality and small number of 
primary studies.
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7.10.2 Psychosocial treatments
One review rated high quality using the JBI tool 
looked at the effectiveness of contingency 
management and interventions based on 
motivational interview (Terplan et al., 2015). 
Interventions were compared to ‘usual care’, 
including a range of alternative pharmacological or 
psychosocial interventions. Primarily moderate- 
quality review-level evidence indicates that 
contingency management and motivational 
interview-based interventions are neither more 
nor less effective for drug use, birth or treatment 
outcomes in comparison to the provision of 
comprehensive usual care.
7.10.3 Home visits
One review rated high quality using the JBI tool 
looked at the effectiveness of home visits that 
commenced before or after childbirth targeting 
women who use drugs or alcohol (Turnbull and 
Osborn, 2012). Home visits were provided by health 
professionals, including doctors, nurses, social 
workers and counsellors. Moderate-quality review-
level evidence suggests that for outcomes including 
drug use, infant mortality and engagement with 
drug treatment programmes there were no 
differences between women who did and those 
who did not receive visits.
7.10.4 Integrated treatment 
programmes
Two reviews which looked at the effectiveness 
of integrated treatment programmes (Milligan 
et al., 2010; Milligan et al., 2011), defined these 
as programmes that include on-site services 
related to pregnancy and parenting and therefore 
may reduce potential barriers to treatment 
engagement. Evidence was inconclusive on 
the effectiveness of integrated treatments in 
comparison to non-integrated treatments for drug 
use and treatment outcomes, and was partially 
based on low-quality review-level evidence.
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Table 28: Treatments for pregnant and parenting women – summary
Population Setting Intervention/ 
treatment
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Evidence table reference
Opioid- 
dependent 
pregnant 
women
Community/ 
outpatient
Methadone 
maintenance 
treatment
1 (H 1) Minozzi et al., 2013 Drug use
Outcome table 147
1 (H 1) Minozzi et al., 2013 Heroin use
Outcome table 147
1 (H 1) Minozzi et al., 2013 Child birth weight
Outcome table 148
1 (H 1) Minozzi et al., 2013 Week of delivery
Outcome table 148
1 (H 1) Minozzi et al., 2013 Neonatal abstinence 
syndrome
Outcome table 148
1 (H 1) Minozzi et al., 2013 Prenatal and neonatal 
mortality
Outcome table 148
Pregnant/ 
parenting 
women
Community/ 
outpatient
Integrated 
treatment 
programmes
1 (H 1) Milligan et al., 2011 Length of treatment stay
Outcome table 151
1 (H 1) Milligan et al., 2011 Treatment completion
Outcome table 151
1 (H 1) Milligan et al., 2010 Maternal drug use
Outcome table 152
1 (H 1) Milligan et al., 2010 Abstinence
Outcome table 152
Pregnant/ 
parenting 
women
Community/ 
outpatient
Contingency 
management
1 (H 1) Terplan et al., 2015 Maternal drug use
Outcome table 149
1 (H 1) Terplan et al., 2015 Maternal drug use at delivery
Outcome table 149
1 (H 1) Terplan et al., 2015 Treatment completion
Outcome table 150
Pregnant/ 
parenting 
women
Community/ 
outpatient
Motivational 
interviewing
1 (H 1) Terplan et al., 2015 Maternal drug use
Outcome table 149
1 (H 1) Terplan et al., 2015 Maternal drug use at delivery
Outcome table 149
1 (H 1) Terplan et al., 2015 Treatment completion
Outcome table 150
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Table 28 (continued): Treatments for pregnant and parenting women – summary
Population Setting Intervention/ 
treatment
Number of 
systematic 
reviews (high, 
medium, low 
quality)
Review(s) Outcome
Evidence table reference
Pregnant/ 
parenting 
women
Community/ 
outpatient
Home visit 1 (H 1) Turnbull and Osborn, 
2012
Maternal drug use
Outcome table 153
1 (H 1) Turnbull and Osborn, 
2012
Maternal alcohol use
Outcome table 153
1 (H 1) Turnbull and Osborn, 
2012
Treatment programme 
uptake
Outcome table 155
1 (H 1) Turnbull and Osborn, 
2012
Infant mortality
Outcome table 154
7.11 Treatment interventions – 
key messages
Pharmacological treatments for opiate use
High-quality review-level evidence supports 
the use of methadone and buprenorphine for 
reducing use of illicit opioids, and as agents 
supporting abstinence through detoxification. 
Evidence suggests that better treatment retention 
may be achieved with methadone; in addition, 
for individuals who have not responded to 
maintenance treatment, there is moderate-quality 
evidence to support the use of injectable heroin 
prescription in combination with flexible-dose 
oral methadone. High-quality evidence suggests 
that detoxification treatments are enhanced 
when delivered in combination with structured 
psychosocial interventions. Review-level evidence 
on relapse prevention treatment with naltrexone 
was low in quality, but indicates that naltrexone 
implants (but not oral naltrexone) may effectively 
support continued abstinence among those highly 
motivated to remain abstinent.
Pharmacological treatments for stimulants 
and cannabis
Primarily low-moderate quality review-
level evidence consistently suggests that 
pharmacological treatments alone or delivered 
alongside psychosocial interventions may not be 
effective for the treatment of stimulants, including 
cocaine and amphetamines, or cannabis. Evidence 
on cannabis is limited by the low number of studies 
included in reviews examining the effectiveness of 
these treatments.
Psychosocial treatments
Moderate-quality review-level evidence 
consistently supports the use of multidimensional 
family therapy (MDFT) for the treatment of 
young people’s drug use over other psychosocial 
intervention types. This evidence supports the 
application of MDFT to cannabis use only however.
For adults, moderate-quality review-level 
evidence supports treatment with couples-based 
interventions over cognitive behavioural therapy 
(CBT) among people with cocaine dependence and 
a non-drug-dependent partner. Further moderate-
quality review-level evidence supports the use of 
contingency management for people with cocaine 
or opioid dependence, although the long-term 
impact of contingency management on abstinence 
is unclear. Additionally, moderate-quality review-
level evidence indicates that drug use treatments 
based on CBT or motivational interview may be 
effective in comparison to no treatment, but are 
no more or less effective than other psychosocial 
treatment approaches. The review-level evidence 
on mindfulness-based treatments is limited and 
of low quality, but suggests that mindfulness 
interventions may achieve reduced drug use.
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Residential rehabilitation treatments
Review-level evidence on the effectiveness of 
residential programmes is limited and of low 
quality. There is no consistent evidence on the 
effectiveness of different therapeutic community 
models or 12-step group participation in residential 
settings and it is difficult to draw conclusions due 
to the limitations of the evidence base.
Treatments focusing on long‑term recovery 
and reintegration
Review-level evidence on the effectiveness 
of interventions to support recovery and 
reintegration was limited. Evidence on peer-
supported interventions was limited and was 
based on small numbers of primary studies with 
methodological issues, but low-quality review-level 
evidence indicates that peer coaching, recovery 
housing and mutual aid approaches may have 
benefits for drug use outcomes.
Review-level evidence on the effectiveness of 
continuing care programmes is mixed and is 
based on a small number of primary studies. 
Low-quality review-level evidence suggests that 
case management approaches for people in drug 
treatment/recovery may have beneficial outcomes.
Other treatment approaches
Evidence was identified on two further approaches 
for treating illicit drug use – treatments based 
on acupuncture and physical activity. Moderate-
quality review-level evidence suggests that physical 
activity interventions as part of drug treatment 
may support abstinence from drug use, although 
this was based on a small number of primary 
studies. Additionally, low-quality review-level 
evidence suggests that acupuncture may enhance 
the effectiveness of pharmacological treatments 
for opioid craving, but it is not effective when 
delivered alone.
Treatments for individuals in contact with the 
criminal justice system
Moderate-quality review-level evidence supports 
the use of OST in prison and community settings 
to reduce drug use among people with opioid 
dependency who are in contact with the criminal 
justice system. There is low-quality review-level 
evidence suggesting that high-dose methadone 
may be more effective than low-dose methadone 
maintenance treatment (MMT), and that 
buprenorphine maintenance may be as effective 
as MMT. There is insufficient evidence to draw 
conclusions regarding detoxification and relapse 
prevention in criminal justice system settings.
There is moderate-quality review-level evidence 
to support treatment through prison-based 
therapeutic communities to reduce drug relapse 
and criminal activity among prisoners. Benefits 
were identified for therapeutic communities alone 
and with aftercare provision. Evidence on other 
treatment types for this population including drug 
courts, boot camps and psychosocial interventions 
is inconclusive and is based on small numbers 
of studies.
Treatments for individuals with co‑occurring 
drug use and mental illness
Moderate-quality review-level evidence indicates 
that individuals with co-occurring drug use and 
trauma are likely to benefit from treatments that 
include CBT interventions focusing on drug use and 
PTSD. For people with severe mental illness and 
drug misuse, there is insufficient evidence to draw 
conclusions on the effectiveness of psychosocial 
interventions. For individuals, in particular women 
with borderline personality disorders and drug use 
disorders, moderate-quality evidence suggests 
there may be benefits from treatments based 
on dialectical behaviour therapy and dynamic 
deconstructive psychotherapy.
Treatments for pregnant women
Evidence on the effectiveness of pharmacological 
treatments for pregnant women with opiate use 
is limited, but low-quality review-level evidence 
suggests that slow-release morphine may be 
more beneficial than methadone for heroin 
use and buprenorphine may be as beneficial as 
methadone on drug use outcomes. Moderate- 
quality review-level evidence indicates that home 
visit programmes are no more effective than no 
treatment, and low-moderate quality review-level 
evidence on integrated treatment programmes is 
inconclusive. Low-moderate quality review-level 
evidence based on a small number of studies did 
not support the use of psychosocial interventions 
in place of comprehensive usual care for the 
treatment of drug use in this population.
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8Conclusion
This review was undertaken to examine the extent 
to which approaches relating to drug prevention, 
harm reduction, treatment and recovery are 
likely to be effective, as indicated by high-quality 
published evidence. With regard to the review 
research questions, our review highlighted a 
number of drug prevention, harm reduction and 
treatment interventions that are supported by 
evidence as having positive effects on drug-related 
outcomes, including:
» Some well-structured manualised school-based 
drug prevention programmes that combine 
the teaching of skills such as refusal, decision-
making and coping with awareness raising 
regarding the social influences on drug use and 
information provision have a positive impact 
on cannabis use
» Universal family-based preventive interventions 
that include parents and children, with improved 
outcomes when interventions target multiple 
domains
» Peer-based interventions for reducing 
initiation of injecting behaviours
» Overdose prevention programmes with 
naloxone distribution
» Drug consumption rooms
» Needle and syringe programmes when 
combined with OST
» Prescribed methadone and buprenorphine 
to achieve abstinence among opiate users, 
including community and prison settings, and 
injectable heroin prescribing alongside oral 
methadone for those who do not respond to 
maintenance treatments
» Naltrexone implants to prevent relapse among 
opiate users who are highly motivated to 
remain abstinent.
The findings provide some answers to the primary 
research questions of this review, although it is 
clear that evidence is insufficient in some areas, 
particularly regarding approaches that promote or 
increase recovery from drug misuse following or 
alongside structured treatment.
The ‘review of reviews’ methodology was 
undertaken to allow the identification and 
synthesis of a large amount of evidence, and to 
identify broad approaches that that are likely to 
be effective, or not effective, relating to the fields 
of drug prevention, harm reduction, treatment, 
and recovery. Consequently, evidence from 97 
systematic reviews was included within this review 
which included a wide range of intervention types 
and population groups within each field. This 
allows for the identification of broad intervention 
approaches and an indication of how likely they 
are to be effective. However, it is not possible 
within the scope of this review to examine the 
detail of individual primary research studies and 
therefore it can be difficult to determine which 
characteristics of the interventions identified (for 
example, who delivers the intervention, which 
age group the intervention should be targeted 
at, the intervention intensity and duration) may 
be particularly important and likely to affect 
the impact of the intervention. Consequently, 
broad approaches have been grouped together 
(e.g. skills-based prevention; CBT) but, where 
reported within the included review articles, these 
variables have been considered in this review. It is 
important to consider that there are likely to be 
distinctions within these broad approaches at a 
primary research level that may not always have 
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been possible to identify in this review (or in the 
reviewed reviews). Therefore, where reviews have 
derived evidence from trials and evaluations of 
highly structured intervention approaches (e.g. life 
skills, prevention training, multidimensional family 
therapy), effectiveness may be dependent on a 
high level of fidelity to the original approach, and 
informal modifications and differences in coverage 
or delivery which frequently occur as interventions 
are delivered in real-world practice, and may 
fundamentally affect the likelihood of effectiveness 
of that approach in unpredictable ways.
Finally, there are a number of limitations within 
the evidence at a primary level that must be 
considered. For example, for many intervention 
types there is a lack of consistency at primary 
research level in terms of which outcomes have 
been measured and the comparisons made (i.e. 
what happened to control groups), and many 
reviews described, including poor-quality primary-
level evidence. Interventions of interest are tested 
in research trials against comparator interventions 
(i.e. control group interventions). In many primary 
studies this might be practice as normal, or no 
intervention at all. Therefore, to a large extent, 
the effectiveness of reviewed interventions 
is dependent on what they were compared 
against, and the size and direction of observed 
effect will be dependent on the effectiveness 
of the comparator. Similarly, we were unable to 
distinguish the characteristics of ‘treatment as 
usual’ where interventions were compared against 
this condition, and consequently we cannot 
assess whether this was similar or not to current 
standard treatment content and quality in Ireland. 
Additionally, as an outcomes-focused review, 
there is a gap in our understanding about the 
wider complexities of the interventions reviewed 
here: in particular, when, why, how, and in what 
circumstances these interventions work best.
The overall applicability of the reviewed evidence 
to an Irish context must be considered, and relies 
on the expert interpretation of those working 
in policy and practice. Much of the evidence 
behind this review is from North America and, 
although many reviews included evidence from 
the UK and Europe, only five reviews included 
here examined primary research that was carried 
out in Ireland. When applying the findings of this 
review to the situation in Ireland, the cultural 
and practical differences between study setting 
and Ireland must be considered. To support the 
development of policies to tackle drug misuse in 
Ireland it is important that where interventions 
are implemented in Ireland, these are evaluated 
and findings are published in peer-reviewed 
journals. Evaluation should also be embedded into 
existing and new drug interventions to develop 
understanding regarding the effectiveness of these 
approaches in Ireland.
Finally, for a range of interventions included in 
this review the evidence appears inconclusive on 
their effectiveness. In many cases, this reflects 
that at a primary research level, findings of studies 
have been mixed with different individual studies 
reporting outcomes in different directions of 
effectiveness. Inconclusive evidence may also 
reflect the lack of availability of review-level 
evidence in a particular area. For example, 
emerging or under-researched intervention 
approaches are unlikely to be the subject of a 
systematic review or, if included, may be based 
on a small amount of primary-level research 
only, which limits the conclusions that can 
be drawn regarding effectiveness. Where the 
evidence regarding an intervention approach 
appears inconclusive, this is not to say that it 
will not be effective, and further investigation 
of the published primary-level research may be 
required. In particular, in this review, a lack of 
evidence was identified relating to interventions 
promoting recovery and reintegration among 
people who formerly used drugs. The lack of 
review-level evidence is likely to reflect a lack 
of high-quality studies carried out in areas such 
as peer support groups, recovery housing and 
recovery communities.
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9Evidence outcomes tables
A summary of evidence relating to outcomes relevant to this review is presented here by intervention 
type. The evidence table number matches the ‘Evidence table reference’ positioned next to each 
outcome in the summary tables presented under each treatment type in this review.
Results are colour coded using a ‘traffic light’ system (Joanna Briggs Institute, 2014) to indicate the 
direction of evidence on the effectiveness of the treatment in comparison to the control group:
Evidence indicates effectiveness, i.e. outcome for the treatment group is significantly different 
than the control group in the desired direction (intervention performs significantly better)
Evidence indicates that there are no significant differences between the interventions and the 
control group, or evidence is mixed across studies
Evidence indicates ineffectiveness, i.e. outcome for the treatment group is significantly different 
from the control group in the unwanted direction (control performs significantly better)
www.hrb.ie86
9.1 Prevention review outcome tables
9.1.1 School‑based universal prevention programmes
Population: Children and young people
Setting: School
Intervention: School-based universal prevention programmes
Outcome Table 1: Cannabis use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Social competence 
approaches vs. usual 
curricula
Cannabis use <12 months
Faggiano et 
al., 2014 [H]
9,456 (4 RCTs) Moderate RR 0.90 
(0.81, 1.01)
No statistically significant 
differences between social 
competence programmes and 
usual curricula for cannabis use 
at <12 months FU
Social competence 
approaches vs. usual 
curricula
Cannabis use <12 months 
(continuous outcomes)
Faggiano et 
al., 2014 [H]
3,417 (1 RCT) Low One study 
only
Reduced cannabis use at <12 
months FU in one study among 
social competence participants 
compared to usual curricula
Social influence approaches 
vs. usual curricula
Cannabis use <12 months
Faggiano et 
al., 2014 [H]
10,716 (3 RCTs) Low RR 0.88 
(0.72, 1.07)
No statistically significant 
differences between social 
influence approaches and usual 
curricula for cannabis use at <12 
months FU
Social influence approaches 
vs. usual curricula
Cannabis use <12 months 
(continuous data)
Faggiano et 
al., 2014 [H]
764 (1 RCT) Low One study 
only
Reduced cannabis use at <12 
months FU in one study among 
social influence participants 
compared to usual curricula
Combined social influence 
and competence 
approaches vs. usual 
curricula
Cannabis use <12 months
Faggiano et 
al., 2014 [H]
8,701 (3 RCTs) Moderate RR 0.79 
(0.59, 1.05)
No statistically significant 
differences for cannabis use 
between combined social 
influence/competence 
approaches and usual curricula 
at <12 months FU
Combined social influence 
and competence 
approaches vs. usual 
curricula
Cannabis use <12 months 
(continuous data)
Faggiano et 
al., 2014 [H]
693 (1 RCT) Low One study 
only
No statistically significant 
difference for cannabis use 
between a combined social 
influence/competence 
approach and usual curricula at 
<12 months FU
Knowledge-based 
approaches vs. usual 
curricula or no intervention
Cannabis use <12 months
Faggiano et 
al., 2014 [H]
1,575 (1 RCT) Low One study 
only
No statistically significant 
differences for cannabis use 
between knowledge-based 
approach and usual curricula
Social competence 
approaches vs. usual 
curricula
Cannabis use >12 months
Faggiano et 
al., 2014 [H]
3,753 (2 RCTs) Moderate Two 
studies 
only
Mixed results: no statistically 
significant differences between 
social competence programmes 
and usual curricula in one study 
for cannabis use at >12 months 
FU, and reduced cannabis use 
among social competence 
participants in study
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Outcome Table 1 (continued): Cannabis use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Social influence approaches 
vs. usual curricula
Cannabis use >12 months
Faggiano et 
al., 2014 [H]
6,626 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between social 
influence approaches and usual 
curricula for cannabis use at >12 
months FU in either study
Combined social influence 
and competence 
approaches vs.  
usual curricula
Cannabis use >12 months
Faggiano et 
al., 2014 [H]
26,910 (6 
RCTs)
Moderate RR 0.83 
(0.69, 
0.99)
Significantly reduced cannabis 
use among combined social 
influence and competence 
approaches compared with 
usual curricula at >12 months FU
Combined social influence 
and competence 
approaches vs.  
usual curricula 
Cannabis use >12 months, 
continuous
Faggiano et 
al., 2014 [H]
690 (1 RCT) Low One study 
only
No statistically significant 
difference for cannabis use 
between a combined social 
influence/competence 
approach and usual curricula at 
>12 months FU
Social competence 
approaches vs.  
usual curricula 
Cannabis use at any follow-
up (additional studies not 
included in MA)
Faggiano et 
al., 2014 [H]
NR (9 RCTs) Moderate Not 
calculated
Mixed results: findings in three 
studies favoured the social 
competence approaches, in 
three studies favoured the usual 
curricula and in three studies 
there were no statistically 
significant differences between 
groups for cannabis use
Social influence approaches 
vs. usual curricula  
Cannabis use at any FU 
(studies not included in MA)
Faggiano et 
al., 2014 [H]
NR (5 RCTs) Moderate Not 
calculated
Mixed results: in four studies, 
there were no significant 
differences between social 
influence approaches and 
usual curricula, and one study 
favoured usual curricula for 
cannabis use
Combined social influence 
and competence 
approaches vs.  
usual curricula
Cannabis use >12 months (not 
included in MA)
Faggiano et 
al., 2014 [H]
NR (1 RCT) Low One study 
only
No statistically significant 
difference for cannabis use 
between a combined social 
influence/competence 
approach and usual curricula at 
>12 months FU
MA – meta-analysis. RCT – randomised controlled trial. RR – risk ratio. FU – follow-up.
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Outcome Table 2: Hard drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Social competence 
approaches vs. usual 
curricula
Hard drug use <12 months
Faggiano et 
al., 2014 [H]
2,090 (1 RCT) Low One study 
only
No statistically significant 
differences between social 
competence programmes and 
usual curricula for hard drug 
use at <12 months FU
Combined social influence 
and competence 
approaches vs. usual 
curricula
Hard drug use <12 months
Faggiano et 
al., 2014 [H]
693 (1 RCT) Low One study 
only
No statistically significant 
difference for ‘hard drug 
use’ between a combined 
social influence/competence 
approach and usual curricula at 
<12 months FU
Knowledge-based 
approaches vs. usual 
curricula or no intervention
Hard drug use <12 months
Faggiano et 
al., 2014 [H]
1,575 (1 RCT) Low One study 
only
No statistically significant 
differences for cannabis use 
between knowledge-based 
approach and usual curricula
Social competence 
approaches vs. usual 
curricula
Hard drug use >12 months
Faggiano et 
al., 2014 [H]
1,075 (1 RCT) Low One study 
only
No statistically significant 
differences between social 
competence programmes and 
usual curricula for hard drug 
use at >12 months FU
Combined social influence 
and competence 
approaches vs. usual 
curricula
Hard drug use >12 months
Faggiano et 
al., 2014 [H]
1,066 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences for ‘hard drug 
use’ between a combined 
social influence/competence 
approach and usual curricula in 
either study at >12 months FU
Social competence 
approaches vs. usual 
curricula
Hard drug use at any follow-
up (additional studies not 
included in MA)
Faggiano et 
al., 2014 [H]
NR (3 RCTs) Low Not 
calculated
No statistically significant 
differences for hard drug use 
between social competence 
approaches and usual curricula 
in any study
Social influence approaches 
vs. usual curricula
Hard drug use at any FU 
(additional studies not 
included in MA)
Faggiano et 
al., 2014 [H]
NR (1 RCT) Low Not 
calculated
Findings favoured the social 
influence approach over usual 
curricula for ‘hard drug’ use in 
one study
Combined social influence 
and competence 
approaches vs. usual 
curricula
Hard drug use >12 months 
(not included in MA)
Faggiano et 
al., 2014 [H]
NR (2 RCTs) Low Not 
calculated
Reduced hard drug use among 
the combined social influence/
competence approach 
participants compared to usual 
curricula
MA – meta-analysis. RCT – randomised controlled trial. FU – follow-up.
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Outcome Table 3: Other drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Social competence 
approaches vs. usual 
curricula
Other drug use <12 months
Faggiano et 
al., 2014 [H]
4,704 (2 RCTs) Moderate Two 
studies 
only
Mixed results: in one study, 
findings for other drug use 
favoured the social competence 
approach over usual curricula 
and in one study there was 
no statistically significant 
difference between groups at 
<12 months FU.
Social influence approaches 
vs. usual curricula
Other drug use <12 months
Faggiano et 
al., 2014 [H]
5,862 (1 RCT) Low One study 
only
No statistically significant 
difference between social 
influence approaches and usual 
curricula for ‘other drug use’ at 
<12 months FU
Knowledge-based 
approaches vs. usual 
curricula or no intervention
Other drug use <12 months
Faggiano et 
al., 2014 [H]
1,575 (1 RCT) Low One study 
only
No statistically significant 
differences for cannabis use 
between combined knowledge-
based approach and usual 
curricula
Social influence approaches 
vs. usual curricula
Other drug use >12 months
Faggiano et 
al., 2014 [H]
5,862 (1 RCT) Low One study 
only
Findings for ‘other drug use’ 
favoured usual curricula over 
social influence approach at >12 
months FU
Social competence 
approaches vs. usual 
curricula
Other drug use at any follow-
up (additional studies not 
included in MA)
Faggiano et 
al., 2014 [H]
NR (4 RCTs) Moderate Not 
calculated
Mixed results: no statistically 
significant differences for 
hard drug use between social 
competence approaches and 
usual curricula in three studies 
and results favoured the social 
competence approach in  
one study
MA – meta-analysis. RCT – randomised controlled trial. FU – follow-up
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Outcome Table 4: Any drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Social competence 
approaches vs. usual 
curricula
Any drug use <12 months
Faggiano et 
al., 2014 [H]
4,708 (3 RCTs) Moderate Not 
calculated
Mixed results: in one study 
findings for any drug use 
favoured the social competence 
approach over usual curricula 
and in two studies there were 
no statistically significant 
differences between groups at 
<12 months FU.
Combined social influence 
and competence 
approaches vs. usual 
curricula
Any drug use <12 months
Faggiano et 
al., 2014 [H]
6,362 (1 RCT) High One study 
only
Reduced use of any drugs 
among combined social 
influence/competence 
approach participants and usual 
curricula
Social competence 
approaches vs. usual 
curricula
Any drug use at any follow-
up (additional studies not 
included in MA)
Faggiano et 
al., 2014 [H]
NR (4 RCTs) Moderate Not 
calculated
Mixed results: no statistically 
significant differences for 
any drug use between social 
competence approaches and 
usual curricula in two studies; 
and in two groups.
MA – meta-analysis. RCT – randomised controlled trial. FU – follow-up
Intervention: School-based drug and sexual health prevention programmes
Outcome Table 5: Drug use and sexual health
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Curriculum intervention vs. 
control
Jackson et al., 
2012
NR (3 RCTs) Low Not 
calculated
In three studies, no significant 
differences were identified 
between intervention and 
control participants’ drug 
use. Findings for sexual risk 
behaviours and alcohol use 
were mixed, although more 
promising.
Curriculum intervention 
plus parent information plus 
student-led committee vs. 
control
Jackson et al., 
2012
NR (1 RCT) Low Not 
calculated
In one study, there was no 
significant intervention effect 
on drug use reported. The only 
sexual health measure, condom 
use, was improved among males 
only.
Whole school environment 
intervention vs. controls
Jackson et al., 
2012
NR (4 RCTs) Low Not 
calculated
Mixed results: across studies, 
drug use outcomes were 
generally not significantly 
different in intervention 
compared to control groups. 
More promising but still mixed 
results were reported for 
alcohol use and sexual risk 
behaviours.
MA – meta-analysis. RCT – randomised controlled trial. FU – follow-up
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9.1.2 Family‑based interventions
Population: Children and young people
Setting: Not reported
Intervention: Universal family intervention
Outcome Table 6: Frequency of drug use (universal interventions)
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Universal family intervention 
vs. controls
Cannabis use
Jackson et 
al., 2012 [H]; 
Patnode et 
al., 2014 [H] 
Vermeulen-
Smit et al., 
2015 [M]
NR (4 RCTs) Moderate Not 
calculated
In all three studies, there 
were significant reductions in 
cannabis use among universal 
family intervention participants 
in comparison with controls.
Universal family intervention 
vs. controls
Other drug use
Patnode et 
al., 2014 [H]; 
Vermeulen-
Smit et al., 
2015 [M]
NR (4 RCTs) Moderate Not 
calculated
Mixed findings between 
universal family intervention and 
control participants on use of 
drug use other than cannabis 
(including non-medical use of 
prescription drugs)
RCT – randomised controlled trial
Population: Adolescents already using illicit drugs recreationally
Setting: Not reported
Intervention: Targeted family intervention
Outcome Table 7: Frequency of drug use (targeted interventions)
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Targeted parent intervention 
vs.no intervention.
Vermeulen-
Smit et al., 
2015 [M]
22 (1 RCT) Low Not 
calculated
No statistically significant 
differences in cannabis 
use between adolescents 
whose parents received the 
intervention and controls
Targeted family intervention 
vs. adolescent only 
intervention
Vermeulen-
Smit et al., 
2015 [M]
315 (2 RCTs) Low Not 
calculated
Mixed results: in one study, 
cannabis use frequency was 
reduced among adolescents 
in the adolescent plus parent 
interventions groups; and in one 
study there was no difference 
between participants and 
controls.
Targeted family intervention 
vs. assessment only group
Vermeulen-
Smit et al., 
2015 [M]
232 (2 RCTs) Low Not 
calculated
In both studies cannabis use 
frequency was reduced among 
adolescents in the adolescent 
plus parent interventions 
groups.
RCT – randomised controlled trial
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Population: High-risk adolescents
Setting: Not reported
Intervention: Targeted family-based intervention
Outcome Table 8: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Targeted family 
interventions vs. controls
Any illicit drug use
Vermeulen-
Smit et al., 
2015 [M]
NR (6 RCTs) Low Not 
calculated
In five studies there were no 
statistically significant effects 
of targeted family interventions 
when high-risk populations 
were compared to controls.
Targeted family 
interventions vs. controls
Frequency of cannabis use
Vermeulen-
Smit et al., 
2015 [M]
NR (7 RCTs) Low Not 
calculated
Mixed results: in four studies 
cannabis use frequency 
decreased among family 
intervention participants in 
comparison with controls, 
but in two studies frequency 
increased in comparison with 
controls and in one study there 
was no statistically significant 
difference.
Targeted family 
interventions vs. controls
Frequency of hard drug use
Vermeulen-
Smit et al., 
2015 [M]
NR (3 RCTs) Low Not 
calculated
Reductions in hard drug use in 
high-risk adolescents targeted 
by family interventions in 
comparison to controls in all 
three studies
RCT – randomised controlled trial
Population: At-risk populations
Setting: Not reported
Intervention: Targeted family interventions
Outcome Table 9: Drug dependence or disorder
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Targeted family 
interventions vs. control
Cannabis dependence
Vermeulen-
Smit et al., 
2015 [M]
519 (2 RCTs) Low Not 
calculated
Mixed results: one study 
reported a reduced risk of 
cannabis disorder among boys 
in the family intervention 
group, but for girls and in the 
remaining studies there were 
no statistically significant 
differences between groups on 
cannabis disorder/dependence.
Targeted family intervention 
vs. limited intervention 
control
Illicit drug abuse or 
dependence
Vermeulen-
Smit et al., 
2015 [M]
240 (1 RCT) Low One study 
only
No statistically significant 
difference between family-
based intervention and 
reduced intervention control 
participants at long-term 
follow-up
RCT– randomised controlled trial
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9.1.3 Brief and/or motivational interventions
Population: Children and young people
Setting: Emergency department
Intervention: Motivational interview
Outcome Table 10: Cannabis use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview vs. 
handout
Cannabis abstinence
Newton et al., 
2013 [H]
1,063 (2 RCTs) Low Two 
studies 
only
Findings favoured MI 
participants compared with 
handout-only control.
Motivational interview vs. 
handout
Cannabis use
Newton et al., 
2013 [H]
210 (1 RCT) Low One study 
only
No statistically significant 
differences between MI and 
handout-only groups
MI – motivational interview. RCT – randomised controlled trial
Outcome Table 11: Alcohol use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview vs. 
handout
Newton et al., 
2013 [H]
210 (1 RCT) Low One study 
only
On a range of outcomes 
relating to alcohol consumption 
including, drinking days per 
month, quantity, drinks per 
week and maximum drinks per 
day, there were no statistically 
significant differences between 
MI and handout-only groups.
MI – motivational interview. RCT – randomised controlled trial
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Setting: Primary care
Intervention: Motivational interview
Outcome Table 12: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview vs. 
usual care 
Cannabis use
VanBuskirk 
and Wetherell, 
2014
64 (1 RCT) Low One study 
only
Reduced cannabis use in the MI 
group in comparison to usual 
care
Motivational interview vs. 
control
Drug use
VanBuskirk 
and Wetherell, 
2014
28 (1 RCT) Low One study 
only
No statistically significant 
difference between groups on 
frequency or amount of drug use
Motivational interview vs. 
control
Drug use before sexual 
activity
VanBuskirk 
and Wetherell, 
2014
28 (1 RCT) Low One study 
only
Reduced drug use prior to 
sexual activity in MI participants 
in comparison to controls
MI – motivational interview. RCT – randomised controlled trial
Outcome Table 13: Trouble due to alcohol use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview vs. 
control
VanBuskirk 
and Wetherell, 
2014
28 (1 RCT) Low One study 
only
Reduced trouble due to 
alcohol use in MI participants in 
comparison to controls
MI – motivational interview. RCT – randomised controlled trial
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Intervention: Brief intervention
Outcome Table 14: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Brief intervention vs. control
Cannabis initiation
Patnode et al., 
2014
2,695 (1 quasi-
RCT)
Low One study 
only
Mixed results: in one arm of the 
study, cannabis initiation was 
lower among BI participants and 
in one arm of the study there 
was no BI effect in comparison 
to controls.
Brief intervention vs. control
Cannabis use
Patnode et al., 
2014
 3,023 (1 RCT, 
1 quasi-RCT)
Low Two 
studies 
only
Mixed results: in one study, 
cannabis use was reduced 
among BI participants in 
comparison to controls in one 
arm of the study, but not in 
a second, and in one study 
there was no BI effect on 
cannabis use.
Brief intervention vs. control
Cannabis cessation
Patnode et al., 
2014
2,695 (1 quasi-
RCT)
Low One study 
only
Mixed results: in one arm of the 
study, cannabis cessation was 
greatest amongt BI participants 
and in one arm of the study 
there was no BI effect in 
comparison to controls.
Brief intervention vs. control
Illicit drug use
Patnode et al., 
2014
 369 (2 RCTs) Low Two 
studies 
only
Mixed results: in one study 
the BI had no impact when 
compared to the control, and in 
one study there was no impact 
of a therapist-led BI had no 
impact but participants who 
received a computer BI had 
reduced drug use in comparison 
to controls.
BI – brief intervention. RCT – randomised controlled trial
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Setting: School
Intervention: Brief interventions
Outcome Table 15: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Brief intervention vs. 
information provision
Any drug use
Carney et al., 
2014 [H]
732 (3 RCTs) Moderate SMD -0.06 
(-0.20, 
0.09)
No statistically significant 
difference between BI and 
information only participants
Brief intervention vs. 
assessment only
Any drug use
Carney et al., 
2014 [H]
424 (3 RCTs) Moderate Not 
calculated
Mixed results: findings 
favoured the BI group over 
the assessment only control in 
two studies and there were no 
significant differences between 
groups in one study.
Brief intervention vs. 
information provision
Cannabis quantity
Carney et al., 
2014 [H]
326 (1 RCT) Moderate One study 
only
No statistically significant 
differences between BI and 
information only participants
Brief intervention vs. 
assessment only
Cannabis quantity
Carney et al., 
2014 [H]
179 (1 RCT) Low One study 
only
Findings favoured BI 
participants over assessment 
only controls
BI vs. information provision
Cannabis frequency
Carney et al., 
2014 [H]
531 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
differences between BI and 
information only participants in 
either study
BI vs. assessment only
Cannabis frequency
Carney et al., 
2014 [H]
407 (3 RCTs) Moderate SMD -0.22 
(-0.43, 
-0.02)
Findings for cannabis frequency 
favoured BI over assessment 
only participants
Brief intervention vs. 
information provision
Cannabis dependence
Carney et al., 
2014 [H]
531 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
differences between BI and 
information only participants 
for cannabis dependence in 
either study
Brief intervention vs. 
assessment only
Cannabis dependence
Carney et al., 
2014 [H]
189 (1 RCT) Low One study 
only
No statistically significant 
differences between BI and 
assessment only participants for 
cannabis dependence
BI – brief intervention. RCT – randomised controlled trial. SMD – standardised mean difference
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Outcome Table 16: Alcohol use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Brief intervention vs. 
information provision
Alcohol frequency
Carney et al., 
2014 [H]
527 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
difference between BI and 
information only participants 
in either study for alcohol 
frequency
Brief intervention vs. 
assessment only
Alcohol frequency
Carney et al., 
2014 [H]
424 (3 RCTs) Moderate Not 
calculated
Mixed results: findings 
favoured the BI group over 
the assessment only control in 
two studies and there were no 
significant differences between 
groups in one study for alcohol 
frequency.
Brief intervention vs. 
information provision
Alcohol quantity
Carney et al., 
2014 [H]
527 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
difference between BI and 
information only participants in 
either study for alcohol quantity
Brief intervention vs. 
assessment only
Alcohol quantity
Carney et al., 
2014 [H]
179 (1 RCT) Low One study 
only
No statistically significant 
differences between BI and 
assessment only participants for 
alcohol quantity
BI – brief intervention. RCT – randomised controlled trial
Outcome Table 17: Combined behavioural outcomes
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Brief intervention vs. 
information provision
Carney et al., 
2014 [H]
531 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
differences between BI and 
information only participants on 
behavioural outcomes in either 
study
Brief intervention vs. 
assessment only
Carney et al., 
2014 [H]
421 (3 RCTs) Low Not 
calculated
Mixed results: in two studies, 
findings favoured BI and in one 
study there was no statistically 
significant difference between 
groups.
BI – brief intervention. RCT – randomised controlled trial
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9.1.4 Media campaigns including computer/Internet interventions
Population: Children and young people
Setting: Community
Intervention: Multicomponent media campaign
Outcome Table 18: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Multicomponent 
intervention and school-
wide campus intervention 
vs. no intervention
Drug use
Ferri et al., 
2013 [H]
825 (1 CBA) Low One study 
only
No statistically significant 
difference in drug use following 
the multicomponent campaign 
compared to the control school 
campus
TV/radio advertisement vs. 
no intervention
Drug use
Ferri et al., 
2013 [H]
(1 ITS) Low One study 
only
Reduced downward trend in 
cannabis after exposure to the 
campaign
Multicomponent 
intervention vs. no 
intervention
Methamphetamine use
Ferri et al., 
2013 [H]
26,405 (4 ITS, 
1 CBA)
Low Not 
calculated
Mixed results across studies
Multicomponent 
intervention (TV/radio/
printed advert and Internet) 
vs. no intervention
Methamphetamine use
Ferri et al., 
2013 [H]
26,405 (4 ITS, 
1 CBA)
Low Not 
calculated
Mixed results across studies
Multicomponent 
intervention (TV/radio/
printed advert) vs. no 
intervention
Methamphetamine use
Ferri et al., 
2013 [H]
26,405 (4 ITS, 
1 CBA)
Low Not 
calculated
Mixed results across studies
Multicomponent 
intervention (TV/radio/
printed advert and Internet) 
vs. control
Cannabis use
Ferri et al., 
2013 [H]
(1 ITS, 2 
cohort)
Low Not 
calculated
Mixed results: one study 
reported reduced cannabis 
use for younger girls only 
and in one study cannabis 
use was reported to increase 
following campaign exposure. 
Additionally, in one study there 
was no statistically significant 
change in cannabis use following 
a campaign.
Multicomponent 
intervention vs. control
Cannabis use
Ferri et al., 
2013 [H]
(1 ITS, 2 
cohort)
Low Not 
calculated
Mixed results: one study 
reported reduced cannabis 
use for younger girls only 
and in one study cannabis 
use was reported to increase 
following campaign exposure. 
Additionally, in one study there 
was no statistically significant 
change in cannabis use following 
a campaign.
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Outcome Table 18 (continued): Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Multicomponent 
intervention vs. control
Cannabis use
Ferri et al., 
2013 [H]
Not reported 
(1 ITS, 2 
cohort, 1 RCT)
Low Not 
calculated
Mixed results: one study 
reported reduced cannabis 
use following a community-
level campaign compared with 
no intervention and one study 
reported reduced cannabis 
use for younger girls only. In 
one study, cannabis use was 
reported to increase following 
campaign exposure and in one 
study, there was no statistically 
significant change in cannabis 
use following a campaign.
CBA – controlled before and after study. ITS – interrupted time series. RCT – randomised controlled trial
Intervention: TV/radio standalone commercial
Outcome Table 19: Any drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
TV/radio advertisement vs. 
no intervention
Ferri et al., 
2013 [H]
(1 ITS) Low One study 
only
Reduced downward trend in 
cannabis use after exposure to 
the campaign
ITS – Interrupted time series
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Population: Children and young people
Setting: School and community
Intervention: Internet and computer-based interventions
Outcome Table 20: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Universal Internet 
and computer-based 
intervention vs. no 
intervention or alternative 
intervention
Cannabis use, post-
intervention follow-up
Ferri et al., 
2013 [H]; 
Wood et al., 
2014 [H]
1,272 (3 RCTs) Low Not 
calculated
No statistically significant 
differences between Internet-
based intervention and control 
participants on cannabis use 
immediately following the 
intervention in any study
Universal Internet 
and computer-based 
intervention vs. no 
intervention or alternative 
intervention
Cannabis use, medium-term 
follow-up
Ferri et al., 
2013 [H]; 
Wood et al., 
2014 [H]
1,000 (2 RCTs) Low Two 
studies 
only
By medium-term follow-up, 
cannabis use was reduced in 
the Internet-based intervention 
groups in comparison to control 
groups in both studies.
Universal Internet 
and computer-based 
intervention vs. no 
intervention or alternative 
intervention
Tait et al., 
2013 [H]
4,125  
(10 RCTs)
High ES 0.16 
(0.09, 
0.22)
Cannabis use reduced in the 
Internet-based intervention 
groups in comparison to 
controls
Universal Internet 
and computer-based 
intervention vs. no 
intervention or alternative 
intervention
Polydrug use, post-
intervention follow-up
Wood et al., 
2014 [H]
236 (1 RCT) Low One study 
only
No statistically significant 
differences between Internet-
intervention and no intervention 
participants for any drug use in 
one study immediately following 
the intervention.
Universal Internet 
and computer-based 
intervention vs. no 
intervention or alternative 
intervention
Polydrug use, medium-term 
follow-up
Wood et al., 
2014 [H]
236 (1 RCT) Low One study 
only
By medium-term follow-up, 
cannabis use was reduced in 
the Internet-based intervention 
groups in comparison to control 
groups in one study.
Universal Internet 
and computer-based 
intervention vs. no 
intervention or alternative 
intervention
Any drug use, post-
intervention follow-up
Wood et al., 
2014 [H]
230 (1 RCT) Low One study 
only
No statistically significant 
differences between Internet-
intervention and no intervention 
participants for any drug use in 
one study
RCT– randomised controlled trial. CBA – controlled before and after study. ES – effect size
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Population: Targeted at recreational drug users
Setting: College; Internet
Intervention: Internet and computer-based interventions
Outcome Table 21: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Internet and computer-
based interventions 
targeting recreational drug 
users vs. no intervention
Ferri et al., 
2013; Wood et 
al., 2014 [H]
1,633 (2 RCTs) Low Two 
studies 
only
Mixed results: one study 
reported a reduction in 
recreational drug use following 
an Internet-based intervention, 
and one study reported 
no statistically significant 
differences.
RCT – randomised controlled trial
9.1.5 Mentoring interventions
Population: Children and young people who are high risk
Setting: Community
Intervention: Mentoring
Outcome Table 22: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Mentoring intervention vs. 
no intervention
Cannabis use
Thomas et al., 
2013 [M]
358 (1 RCT) Low One study 
only
Cannabis use reduced in 
the mentoring participants 
compared to no intervention
Mentoring intervention vs. 
no or limited intervention 
control
Illegal drug use
Thomas et al., 
2013 [M]
285 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences relating to illicit 
drug use between either of the 
mentoring intervention groups 
in comparison to controls
Mentoring intervention vs. 
no intervention
Initiation of illicit drug use
Thomas et al., 
2013 [M]
1,138 (1 RCT) Low One study 
only
No statistically significant 
difference in illicit drug use 
initiation between mentoring 
and no intervention groups.
Mentoring intervention vs. 
no or limited intervention 
control
Any drug use including 
alcohol, tobacco and illegal 
drugs
Thomas et al., 
2013 [M]
719 (2 RCTs) Low Two 
studies 
only
Mixed results: in one study 
mentoring was associated  
with less use of any drugs 
among those who attended 
mentoring sessions only in 
comparison with controls, and 
in one study there were no 
significant differences between 
mentoring and control groups 
for any drug use.
RCT – randomised controlled trial
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Outcome Table 23: Alcohol use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Mentoring intervention vs. 
no or limited intervention
Alcohol use
Thomas et al., 
2013 [M]
486 (2 RCTs) Low Two 
studies 
only
There were no statistically 
significant differences for 
alcohol use between mentoring 
and control groups in either 
study.
Mentoring intervention vs. 
no intervention
Initiation of alcohol use
Thomas et al., 
2013 [M]
1,138 (1 RCT) Low One study 
only
There was no statistically 
significant difference for 
initiation of alcohol use 
between mentoring and control 
groups in one study.
RCT – randomised controlled trial
Population: Adolescents who are homeless
Setting: Community
Intervention: Mentoring and drug use treatment
Outcome Table 24: Drug use
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
Eeidence
Effect size 
(95% CI)
Overall results (combined)
Mentoring intervention 
with drug use treatment 
vs. treatment only or no 
intervention control.
Thomas et al., 
2013 [M]
90 (1 RCT) Low One study 
only
There were no statistically 
significant differences for drug 
use between the combined 
mentoring and treatment and 
control groups.
RCT – randomised controlled trial
Outcome Table 25: Alcohol use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Mentoring intervention 
with drug use treatment 
vs. treatment only or no 
intervention control
Thomas et al., 
2013 [M]
90 (1 RCT) Low One study 
only
There were no statistically 
significant differences for 
alcohol use between the 
combined mentoring and 
treatment and control groups.
RCT – randomised controlled trial
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9.1.6 Interventions for people with mental health disorders
Population: Children with disruptive behavioural disorder
Setting: Psychiatric clinics and mental health centres
Intervention: Mentoring and drug use treatment
Outcome Table 26: Cannabis use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Multicomponent 
intervention including 
coping and social skills 
training, parent intervention 
and CBT vs. usual care and 
healthy control groups
Salvo et al., 
2012 [H]
77 (1 RCT) Low One study 
only
Children who received the 
multicomponent intervention 
had lower cannabis use than 
those who received usual care, 
and their cannabis use was not 
significantly different to healthy 
controls.
CBT – cognitive behavioural therapy. RCT – randomised controlled trial
Population: Adolescents with ADHD
Setting: Psychiatric and non-psychiatric settings
Intervention: ADHD medication
Outcome Table 27: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
ADHD medication vs. non-
medicated controls
Drug disorders
Salvo et al., 
2012 [H]
260 (1 cohort) Low One study 
only
There were no statistically 
significant differences 
between those who received 
medication and those who 
did not for any drug disorders, 
including cannabis, cocaine or 
hallucinogens.
ADHD medication vs. non-
medicated controls
Drug use
Salvo et al., 
2012 [H]
260 (1 cohort) Low One study 
only
Mixed results: lower alcohol use 
in males but not females
ADHD – attention deficit hyperactivity disorder
Population: Adolescents and young adults at high risk of developing psychosis
Setting: Not reported
Intervention: MI and CBT (cannabis users) or brief advice (non-users)
Outcome Table 28: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MI and CBT (cannabis users) 
or brief advice with or 
without reinforcement (non-
users)
Salvo et al., 
2012 [H]
58 (1 UBA) Low One study 
only
Reductions in cannabis use 
and polydrug use following the 
intervention
MI – motivational interview. CBT – cognitive behavioural therapy. UBA – uncontrolled before and after study
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9.2 Harm reduction review outcome tables
9.2.1 Needle and syringe programmes
Population: People who use drugs
Setting: Community
Intervention: Needle and syringe programmes
Outcome Table 29: Blood‑borne viruses
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
NSP exposure
Risk of HIV transmission
Aspinall et al., 
2013 [H]
Not reported 
(12: 10 
cohort; 1 
case-control; 
1 cross-
sectional)
Moderate ES 0.66 
(0.43, 1.01)
NSP exposure associated with a 
reduction in HIV transmission, 
although findings were not 
statistically significant
Coverage of at least 10 
needles/syringes per PWID 
and at least 50% coverage 
of PWID population by NSP 
vs. controls
HIV/HCV prevalence
Abdul-Quader 
et al., 2013 [H]
 Not reported 
(15 studies)
Low Not 
calculated
Mixed results across individual 
studies, with the majority of 
studies suggesting significant 
reductions in HIV and/or HCV 
prevalence at the population 
level
Full harm reduction vs. 
partial or no harm reduction
HCV incidence
Hagan et al., 
2011 [H]
Not reported 
(7: 6 cohort, 1 
case-control)
Low ES 1.62 
(1.04, 2.52)
Statistically significant increased 
risk of HCV among people who 
used NSP
Provision of non-
needle/syringe injecting 
paraphernalia
HCV prevalence
Gillies et al., 
2010 [H]
275 (1 cross-
sectional 
study)
Low One study 
only
Access to paraphernalia 
including sterile cookers and 
water was associated with 
reduced prevalence of HCV
NSP – Needle and syringe programme. ES – effect size
Outcome Table 30: Injection risk behaviours
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Provision of non-
needle/syringe injecting 
paraphernalia
Gillies et al., 
2010 [H]
 (8 cross-
sectional)
Low Not 
calculated
Individual effect sizes suggested 
a reduction in the odds of 
sharing injecting paraphernalia 
other than needles and syringes
NSP vs. control Jones et al., 
2010 [H]
(3 cross-
sectional)
Low Not 
calculated
Mixed results: one study 
reported significant decrease in 
using pre-used syringes and two 
studies reported no significant 
difference in receptive sharing.
NSP – Needle and syringe programme
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Intervention: Needle and syringe programmes and OST
Outcome Table 31: Blood‑borne viruses
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
auality of 
review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Full harm reduction (OST 
plus NSP coverage where 
needles per injection 
≥100%) vs. minimal harm 
reduction (no OST plus 
<100% NSP coverage)
New HCV infection
Turner et 
al., 2011 [not 
applicable]
533 (6 studies) Not 
applicable
AOR 0.21 
(0.08, 
0.52)
Full harm reduction (OST plus 
NSP coverage where needles 
per injection ≥100%) was 
associated with an 80% lower 
risk of new HCV infection, 
compared to minimal harm 
reduction
Full participation in harm 
reduction (NSP plus OST) vs. 
incomplete harm reduction.
HIV incidence
Jones et al., 
2010 [H]
952 (1 cohort) Low One study 
only
Full participation in harm 
reduction was associated with a 
reduction in HIV incidence.
Full participation in harm 
reduction (NSP plus OST) vs. 
incomplete harm reduction.
HCV incidence
Jones et al., 
2010 [H]
952 (1 cohort) Low One study 
only
Full participation in harm 
reduction was associated with a 
reduction in HCV incidence.
OST – opioid substitution therapy. NSP – needle and syringe programme. AOR – adjusted odds ratio
Outcome Table 32: Injection risk behaviours
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
rvidence
Effect size 
(95% CI)
Overall results (combined)
Full harm reduction (OST 
plus NSP coverage where 
needles per injection 
≥100%) vs. minimal harm 
reduction (no OST plus 
<100% NSP coverage)
Needle sharing
Turner et 
al., 2011 [not 
applicable]
1,335 (6 
studies)
Not 
applicable
AOR 0.52 
(0.32, 
0.83)
Reduced sharing of needles 
among those receiving full 
harm reduction (OST plus 
NSP) compared to minimal 
engagement with harm 
reduction
Full harm reduction (OST 
plus NSP coverage where 
needles per injection 
≥100%) vs. minimal harm 
reduction (no OST plus 
<100% NSP coverage)
Mean number of injections
Turner et 
al., 2011 [not 
applicable]
1,335 (6 
studies)
Not 
applicable
MD -20.8 
(-27.3, 
-14.4)
Reduced injection frequency 
among those receiving full 
harm reduction (OST plus 
NSP) compared to minimal 
engagement with harm 
reduction
OST – opioid substitution therapy. NSP – needle and syringe programme. AOR – adjusted odds ratio
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Intervention: Psychosocial and behavioural interventions
Outcome Table 33: Blood‑borne viruses
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Peer education training vs. 
control
HCV infection
Hagan et 
al., 2011 [H]; 
Sacks-Davis et 
al., 2012 [H]
854 (1 RCT) Low One study 
only
No significant difference 
following peer education 
training compared to controls 
for HCV infection
Motivational interview vs. 
control
HCV infection
Hagan et al., 
2011 [H]
89 (1 RCT) Low One study 
only
No significant difference 
between motivational interview 
and control groups for HCV 
infection
Counselling vs. control
HCV infection
Sacks-Davis et 
al., 2012 [H]
187 (2 RCTs) Low Two 
studies 
only
No significant difference 
between counselling and 
control groups for HCV 
infection
RCT – randomised controlled trial
Outcome Table 34: Injection risk behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Multisession psychosocial 
intervention vs. standard 
education
Injection risk behaviours: 
3–6 months
Meader et al., 
2010 [H]
1,044 (6: 5 
RCTs; 1 quasi-
RCT)
Moderate SMD 0.04 
(-0.31, 
0.23)
No significant differences 
in injection risk behaviours 
between multisession 
psychosocial and standard 
education interventions
Multisession psychosocial 
intervention vs. standard 
education
Injection risk behaviours: >6 
months
Meader et al., 
2010 [H]
73 (1 RCT) Low One study 
only
In one study, injection risk 
behaviours were significantly 
reduced in multisession 
psychosocial intervention 
participants in comparison to 
standard education controls at 
greater than six month follow-
up.
Multisession psychosocial 
intervention vs. minimum 
control
Injection risk behaviours: 
3–6 months
Meader et al., 
2010 [H]
262 (3 RCTs) Moderate SMD -0.06 
(-0.30, 
0.19)
No significant differences 
in injection risk behaviours 
between multisession 
psychosocial and minimum 
control interventions
Multisession psychosocial 
intervention vs. standard 
education
Safer injection behaviours: 
3–6 months
Meader et al., 
2010 [H]
6,562 (13: 4 
RCTs, 9 quasi- 
RCTs)
Moderate RR 1.03 
(0.95, 1.11)
No significant differences in 
safer injection behaviours 
between multisession 
psychosocial and standard 
education interventions
Multisession psychosocial 
intervention vs. minimum 
control
Safer injection behaviours: 
3–6 months
Meader et al., 
2010 [H]
510 (4 RCTs) Moderate RR 1.10 
(0.92, 1.31)
No significant differences in 
safer injection behaviours 
between multisession 
psychosocial and minimal 
control interventions
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Outcome Table 34 (continued): Injection risk behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Peer education training vs. 
control
Injection risk behaviours
Sacks-Davis et 
al., 2012 [H]
1,272 (2 RCTs) Moderate Two 
studies 
only
In both studies, injection risk 
behaviours were reduced 
following peer education 
training in comparison to 
controls
Counselling vs. control
Injection risk behaviours
Sacks-Davis et 
al., 2012 [H]
1,200 (4 RCTs) Moderate Not 
calculated
No statistically significant 
differences between injection 
risk behaviours following 
peer education training in 
comparison to controls
Peer education training vs. 
control
Refraining from injecting
Sacks-Davis et 
al., 2012 [H]
418 (1 RCT) Low One study 
only
Injecting frequency was 
significantly reduced at three-
month and six-month follow-
up following peer education 
training, compared with 
controls
Counselling vs. control
Refraining from injecting
Sacks-Davis et 
al., 2012 [H]
78 (1 RCT) Low One study 
only
No statistically significant 
differences between counselling 
and control groups on either 
measure of injection frequencyCounselling vs. control
Mean number of days 
injected
Sacks-Davis et 
al., 2012 [H]
109 (1 RCT) Low One study 
only
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 35: Sexual risk behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Multisession psychosocial 
intervention vs. standard 
education
Meader et al., 
2013 [H]
16,504 (46: 
26 RCTs; 20 
quasi-RCTs)
Moderate OR 0.86 
(0.77, 0.96)
Significantly greater reduction 
in sexual risk behaviours among 
multisession psychosocial 
intervention participants in 
comparison to those receiving 
standard education
Multisession psychosocial 
intervention vs. minimal 
control
Meader et al., 
2013 [H]
3,208 (7: 6 
RCTs; 1 quasi-
RCT)
Moderate OR 0.60 
(0.46, 
0.78)
Significantly greater reduction 
in sexual risk behaviours among 
multisession psychosocial 
intervention participants in 
comparison to those receiving 
minimal control
RCT – randomised controlled trial. OR – Odds ratio
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Intervention: Overdose prevention interventions
Outcome Table 36: Overdose‑related outcomes
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Community OOPPs with 
naloxone
Opioid overdose mortality
Clark et al., 
2014 [M]
Not reported 
(1 cohort)
Low One study 
only
Lower rates of opioid-related 
deaths in areas with higher 
administration of OOPPs
Community OOPPs with 
naloxone
Response to overdose
Clark et al., 
2014 [M]
66 (3 cohort) Low Not 
calculated
Improved correct responses 
to overdose and reduced 
inappropriate response to 
victims
Community OOPPs
Naloxone administration
Clark et al., 
2014 [M]
Not reported 
(18: 14 cohort, 
3 descriptive, 
2 qualitative)
Low Not 
calculated
Naloxone was administered 
successfully in all but one 
programme on a total of 1,949 
occasions and unsuccessfully on 
a total of 12 occasions.
OOPP – opioid overdose prevention programme
Intervention: Drug consumption rooms
Outcome Table 37: Overdose
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
SIF implementation Potier et al., 
2014 [M]
Not reported 
(7 studies)
Moderate Not 
calculated
SIFs were associated across 
studies with reductions in the 
number of lethal overdoses in 
local areas.
SIF – safer injection facilities
Outcome Table 38: Injection risk behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
SIF attendance
Sharing and reuse of syringes
Potier et al., 
2014 [M]
9,384 (7 
studies)
Moderate Not 
calculated
SIFs were associated with 
improved outcomes including 
syringe sharing and reuse, use of 
sterile equipment and requests 
for education.
SIF implementation
Injection drug use
Potier et al., 
2014 [M]
1,936 (2 
studies)
Low Not 
calculated
No change in the number 
of people who inject drugs 
following SIF opening
SIF – safer injection facilities
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Outcome Table 39: Drug‑related litter
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
SIF implementation
Drug-related litter
Potier et al., 
2014 [M]
Not reported 
(1 before and 
after study)
Low One study 
only
In one study, there was a 
significant reduction in drug-
related litter after SIF opening.
SIF attendance
Number of syringes dropped 
in public
Potier et al., 
2014 [M]
Not reported 
(1 before and 
after study)
Low One study 
only
In one study, there was a 
significant reduction in the 
number of syringes dropped in 
public after SIF opening.
SIF attendance
Injection in public spaces
Potier et al., 
2014 [M]
760 (1 
observational 
study)
Low One study 
only
In one study, regular use of SIF 
was associated with reduced 
injection in public areas.
SIF – safer injection facilities
Intervention: Route transition interventions
Outcome Table 40: Injecting drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Peer-based behaviour 
modification (before and 
after study)
Peer injection behaviours
Werb et al., 
2013 [H]
Not reported 
(2 cross-
sectional 
studies)
Low Not 
calculated
Significantly lower likelihood 
of injecting in front of a non-
injector and willingness to 
initiate a non-injector following 
the intervention
Peer-based behaviour 
modification vs. control
Injection initiation
Werb et al., 
2013 [H]
Not reported 
(1 RCT)
Low Not 
calculated
Significantly lower rate of 
injecting drugs among peer-
based behaviour modification 
participants than among 
controls
Law enforcement
Injection initiation
Werb et al., 
2013 [H]
Not reported 
(2 before and 
after studies)
Low Two 
studies 
only
No significant association 
between increased police 
deterrence and injection 
initiation
RCT – randomised controlled trial
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Intervention: Blood-borne virus testing
Outcome Table 41: Uptake of blood‑borne virus testing
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Targeted case finding 
in primary care vs. no 
intervention control
People who inject drugs
Jones et al., 
2013 [H]
2,079 (1 quasi-
RCT)
Low One study 
only
Positive intervention impact 
on uptake of HCV testing in 
primary care with targeted 
case management compared to 
control
Targeted case finding 
in primary care vs. no 
intervention control
People who formerly 
injected drugs
Jones et al., 
2013 [H]
27,226 (1 
quasi-RCT)
Low One study 
only
Positive intervention impact 
on uptake of HCV testing in 
primary care with targeted 
case management compared to 
control.
DBST vs. venepuncture only 
testing
Jones et al., 
2013 [H]
12,250 (1 RCT) Low One study 
only
Greater uptake of HCV testing 
in services offering DBST 
compared to those offering 
venepuncture testing only
DBST – dry blood spot test. RCT – randomised controlled trial. HCV – hepatitis C virus
Population: People who use drugs who are living with HIV
Setting: Community
Intervention: HIV treatment approaches
Outcome Table 42: HIV treatment outcomes
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
HAART
Adherence to treatment
Malta et al., 
2010 [M]
14,960 (38: 
study design 
not reported)
Low Proportion 
maintaining 
adherence: 
0.60 (0.52-
0.68)
Adherence among drug users 
comparable1 to among non-drug 
users
HAART plus OST vs. HAART 
alone
Adherence to treatment
Malta et al., 
2010 [M]
Not reported 
(5: study 
design not 
reported)
Low Not 
calculated
Drug users engaged in OST had 
increased adherence to HAART 
and better treatment outcomes
DAART
Treatment and virological 
outcomes
Camp Binford 
et al., 2012 [H]
Not reported 
(45: study 
design not 
reported)
Low Not 
calculated
Evidence supporting DAART 
alone and integrated in 
medication-assisted therapy 
to improve treatment and 
virological outcomes
Contingency management
Treatment and virological 
outcomes
Camp Binford 
et al., 2012 [H]
Low Not 
calculated
Findings are inconsistent but 
suggested to be promising 
in favour of contingency 
management
Nurse-delivered 
interventions
Treatment and virological 
outcomes
Camp Binford 
et al., 2012 [H]
Low Not 
calculated
Findings are inconsistent but 
suggested to be promising 
in favour of nurse-delivered 
interventions
HAART – highly active antiretroviral therapy. DAART – directly administered antiretroviral therapy. RCT – randomised controlled 
trial
1 – Indicates that the intervention appears suitable for people who use drugs
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Intervention: ‘Risk reduction’ interventions
Outcome Table 43: Risky behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Harm reduction 
interventions vs. controls
Drug use
Wang et al., 
2013 [H]
1,246 (3 RCTs) Moderate ES -0.26 
(-0.51, 
0.01)
Individuals who received harm 
reduction were significantly 
more likely to reduce drug use.
Harm reduction 
interventions vs. controls
Needle sharing
Wang et al., 
2013 [H]
1,246 (3 RCTs) Moderate ES -0.15 
(0.43, 0.13)
No significant differences 
in needle sharing between 
individuals who received harm 
reduction and controls
RCT – randomised controlled trial. ES – effect size
Population: People who use drugs who are living with HCV
Setting: Community
Intervention: Combination treatment of HCV
Outcome Table 44: HCV treatment outcomes
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Prevalence 
(95% CI)
Overall results (combined)
Combination treatment with 
ribavirin plus recombinant, 
or pegylated interferon-α, 
for chronic hepatitis C 
among IDUs vs. non-IDUs
Sustained virological 
response
Zanini et al., 
2010 [H]
953 (16 
prospective 
cohort 
studies)
High 0.52 (0.44, 
0.60)
No significant differences1 
in BBV treatment drop out 
between IDUs and non-IDUs 
who received combination 
treatment for hepatitis C
Combination treatment with 
ribavirin plus recombinant, 
or pegylated interferon-α, 
for chronic hepatitis C 
among IDUs vs. non-IDUs
BBV treatment drop out
Zanini et al., 
2010 [H]
953 (16 
prospective 
cohort 
studies)
High 0.26 (0.18, 
0.35)
No significant differences1 
in BBV treatment drop out 
between IDUs and non-IDUs 
who received combination 
treatment for hepatitis C
IDU – injecting drug user. BBV – blood-borne virus
1 – Indicates that the intervention appears suitable for people who use drugs
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Population: People who use drugs who are in contact with the criminal justice system
Setting: Prison
Intervention: Needle and syringe programmes
Outcome Table 45: Blood‑borne viruses
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Distribution of injecting 
equipment
BBV infection
Jones et al., 
2008 [H]
Not 
reported (2 
uncontrolled 
before and 
after)
Low Not calculated There were no new cases of 
HIV, HBV or HCV observed 
at follow-up in any of 
the uncontrolled studies 
included in the reviews.
BBV – blood-borne virus. HBV – hepatitis B virus. HCV – hepatitis C virus
Setting: Prison and community
Intervention: HIV risk reduction interventions
Outcome Table 46: Blood‑borne viruses
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
HIV risk reduction 
interventions
BBV incidence
Underhill et 
al., 2014 [H]
694 (5 RCTs) High Not 
calculated
No statistically significant 
differences in BBV infection 
between groups in any study
RCT – randomised controlled trial
Outcome Table 47: Injection risk behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
HIV risk reduction 
intervention vs. control
Underhill et 
al., 2014 [H]
Not reported Moderate Not 
calculated
In the majority of studies, there 
were no significant differences 
between risk reduction and 
control groups on injection risk 
behaviours.
Outcome Table 48: Sexual risk behaviours
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
HIV risk reduction 
intervention vs. control
Underhill et 
al., 2014 [H]
Not reported Low Not 
calculated
In the majority of studies, there 
were no significant differences 
or mixed results between risk 
reduction and control groups 
on sexual risk behaviours.
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Intervention: BBV testing
Outcome Table 49: BBV testing uptake
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Offer of on-site HIV testing 
compared to referral off-
site
Underhill et 
al., 2014 [H]
697 (1 RCT) Moderate Not 
calculated
Significant increase in uptake of 
HIV testing in favour of on-site 
testing prevention in probation 
compared to off-site referral
Offer of immediate HIV 
testing compared to delayed 
referral
Underhill et 
al., 2014[H]
621 (2 quasi-
RCTs)
Moderate Not 
calculated
Significant increase in uptake of 
HIV testing in favour of offering 
immediate rather than delayed 
referral in both studies
RCT – randomised controlled trial. ES – effect size
Population: Sex workers who use drugs
Setting: Community
Intervention: Harm reduction interventions
Outcome Table 50: Risk behaviours
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Harm reduction 
interventions
Sexual risk behaviours
Abad et al., 
2015 [H]
Not reported 
(10 studies)
Low Not 
calculated
Mixed results across studies
Harm reduction 
interventions
Sex work
Abad et al., 
2015 [H]
Not reported 
(5 studies)
Low Not 
calculated
Mixed results across studies
Harm reduction 
interventions
Drug risk behaviours
Abad et al., 
2015 [H]
Not reported 
(10 studies)
Low Not 
calculated
Mixed results across studies
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9.3 Treatment interventions
9.3.1 Pharmacological treatments ‑ opiates
Population: People with opioid dependence
Setting: Community
Intervention: Opioid substitution therapy
Outcome Table 51: Retention in treatment
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MMT vs. no MMT Mattick et al., 
2009 [H]
750 (4 RCTs) High RR 4.44 
(3.26, 
6.04)
Methadone more effective 
than non-pharmacological 
approaches
Low-dose BMT (2–6 mg) vs. 
placebo
Mattick et al., 
2014 [H]
1,131 (5 RCTs) Moderate RR 1.50 
(1.19, 1.88)
Low doses of buprenorphine 
more effective than placebo
Medium-dose BMT (7–15 mg) 
vs. placebo
Mattick et al., 
2014 [H]
887 (4 RCTs) Moderate RR 1.74 
(1.06, 2.87)
Medium doses of buprenorphine 
more effective than placebo
High-dose BMT (16 mg) vs. 
placebo
Mattick et al., 
2014 [H]
1,001 (5 RCTs) Moderate RR 1.82 
(1.15, 2.90)
High doses of buprenorphine 
more effective than placebo
Flexible-dose BMT vs. 
flexible-dose MMT
Mattick et al., 
2014 [H]
1,391 (11 RCTs) High RR 0.83 
(0.73, 
0.95)
Flexible-dose BMT less effective 
than flexible-dose MMT
Supervised injected heroin 
plus methadone vs. oral 
methadone
Ferri et al., 
2011 [H]
1,388 (4 RCTs) Moderate RR 1.44 
(1.19, 1.75)
Injected heroin with 
methadone more effective 
than oral methadone alone 
among individuals who had 
not responded to previous 
treatment
MMT – methadone maintenance therapy. BMT – buprenorphine maintenance therapy. RCT – randomised controlled trial. RR – 
risk ratio. SMD – standardised mean difference
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Outcome Table 52: Opioid use
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
rvidence
Effect size 
(95% CI)
Overall results (combined)
MMT vs. no MMT
Morphine-positive urinalysis
Mattick et al., 
2009 [H]
1,129 (6 RCTs) High RR 0.66 
(0.56, 
0.78)
Methadone more effective 
than non-pharmacological 
approaches
MMT vs. no MMT
Self-reported heroin use
Mattick et al., 
2009 [H]
Not reported 
(6 RCTs)
Moderate Not 
reported
Low-dose BMT vs. placebo
Morphine-positive urinalysis
Mattick et al., 
2014 [H]
487 (2 RCTs) Moderate SMD 0.10 
(-0.80, 
1.01)
No statistically significant 
difference between low-dose 
buprenorphine compared to 
placebo
Medium-dose BMT vs. 
placebo
Morphine-positive urinalysis
Mattick et al., 
2014 [H]
463 (2 RCTs) Moderate SMD -0.08 
(-0.78, 
0.62)
No statistically significant 
difference between medium-
dose buprenorphine compared 
to placebo
High-dose BMT vs. placebo
Morphine-positive urinalysis
Mattick et al., 
2014 [H]
729 (3 RCTs) Moderate SMD -1.17 
(-1.85, 
-0.49)
High-dose buprenorphine more 
effective than placebo
Flexible-dose BMT vs. 
flexible-dose MMT
Morphine-positive urinalysis
Mattick et al., 
2014 [H]
1,027 (8 RCTs) High SMD -0.11 
(-0.23, 
0.02)
No statistically significant 
difference between flexible-
dose BMT compared to flexible-
dose MMT
Flexible-dose BMT vs. 
flexible-dose MMT
Self-reported heroin use
Mattick et al., 
2014 [H]
501 (4 RCTs) High SMD -0.11 
(-0.28, 
0.07)
Supervised injectable heroin 
with methadone vs. oral 
methadone only
Ferri et al., 
2011 [H]
Not reported 
(5 RCTs)
Moderate Not 
calculated
Supervised injectable heroin 
with methadone more effective 
for illicit heroin use than oral 
methadone only in each of the 
five studies
MMT – methadone maintenance therapy. BMT – buprenorphine maintenance therapy. RCT – randomised controlled trial. RR – 
risk ratio. SMD – standardised mean difference
Outcome Table 53: Non‑opioid drug use
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Flexible-dose BMT vs. 
flexible-dose MMT
Cocaine positive urinalysis
Mattick et al., 
2014 [H]
919 (6 RCTs) High SMD 0.10 
(-0.05, 
0.25)
No statistically significant 
difference between flexible-
dose BMT compared to flexible-
dose MMT
Flexible-dose BMT vs. 
flexible-dose MMT
Benzodiazepine positive 
urinalysis
Mattick et al., 
2014 [H]
859 (6 RCTs) High SMD 0.05 
(-0.12, 
0.22)
No statistically significant 
difference between flexible-
dose BMT compared to flexible-
dose MMT
MMT – methadone maintenance therapy. BMT – buprenorphine maintenance therapy. RCT – randomised controlled trial. RR – 
risk ratio. SMD – standardised mean difference
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Outcome Table 54: Criminal activity
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MMT vs. no MMT Mattick et al., 
2009 [H]
363 (3 RCTs) Moderate RR 0.39 
(0.12, 1.25)
No statistically significant 
difference between 
methadone compared to non-
pharmacological approaches
Flexible-dose BMT vs. 
flexible-dose MMT
Mattick et al., 
2014 [H]
328 (2 RCTs) Moderate SMD -0.10 
(-0.31, 
0.12)
No statistically significant 
difference between flexible-
dose BMT compared to flexible-
dose MMT
Supervised injectable heroin 
with methadone vs oral 
methadone only
Criminal offence
Ferri et al., 
2011 [H]
NR (3 RCTs) Moderate Not 
calculated
Mixed results between 
studies. Findings favoured 
supervised injectable heroin 
with methadone over oral 
methadone in two studies, 
and there was no significant 
difference between treatments 
for criminal activity in one 
study.
Supervised injectable heroin 
with methadone vs oral 
methadone only
Incarceration
Ferri et al., 
2011 [H]
NR (1 RCT) Moderate Not 
calculated
Reduced incarceration among 
individuals receiving heroin with 
methadone compared to those 
receiving methadone alone, in 
one study
MMT – methadone maintenance therapy. BMT – buprenorphine maintenance therapy. RCT – randomised controlled trial. RR – 
risk ratio. SMD – standardised mean difference
Outcome Table 55: Mortality
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MMT vs. no MMT Mattick et al., 
2009 [H]
576 (4: RCTs) Moderate RR 0.48 
(0.10, 2.39)
No statistically significant 
difference between 
methadone compared to non-
pharmacological approaches
Supervised injected heroin 
with methadone vs oral 
methadone only
Ferri et al., 
2011 [H]
1,477 (4 RCTs) Moderate RR 0.65 
(0.25, 1.69)
No statistically significant 
difference between heroin and 
other treatment approaches 
among individuals who had 
not responded to treatment 
previously
MMT – methadone maintenance therapy. BMT – buprenorphine maintenance therapy. RCT – randomised controlled trial. RR – 
risk ratio. SMD – standardised mean difference
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Outcome Table 56: Adverse effects
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Injectable heroin plus 
methadone vs. oral 
methadone
Ferri et al., 
2011 [H]
373 (3 RCTs) Moderate RR 1.44 
(1.19, 1.75)
Greater adverse events among 
individuals receiving injectable 
heroin and methadone in 
comparison to those receiving 
oral methadone only
MMT – methadone maintenance therapy. BMT – buprenorphine maintenance therapy. RCT – randomised controlled trial. RR – 
risk ratio. SMD – standardised mean difference
Intervention: Opioid detoxification and psychosocial interventions
Outcome Table 57: Retention in treatment
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Any psychosocial 
intervention plus OST vs. 
OST alone
Amato et al., 
2011b [H]
3,124 (27: 27 
RCTs)
High RR 1.03 
(0.98, 1.07)
No statistically significant 
difference between 
psychosocial interventions plus 
OST and OST alone
Any behavioural intervention 
plus OST vs. OST alone
Amato et al., 
2011b [H]
2,065 (19: 19 
RCTs)
High RR 1.01 
(0.95, 1.06)
No statistically significant 
difference between behavioural 
interventions plus OST and OST 
alone
Contingency management 
plus OST vs. OST alone
Amato et al., 
2011b [H]
1,616 (14: 14 
RCTs)
High RR 1.02 
(0.96, 1.08)
No statistically significant 
difference between contingency 
management plus OST and OST 
alone
Psychoanalytic-oriented 
intervention plus OST vs. 
OST alone
Amato et al., 
2011b [H]
212 (3: 3 RCTs) Moderate RR 0.90 
(0.75, 1.07)
No statistically significant 
difference between 
psychoanalytic-oriented 
interventions plus OST and OST 
alone
Counselling plus OST vs. OST 
alone
Amato et al., 
2011b [H]
769 (4: 4 RCTs) High RR 1.07 
(0.98, 1.15)
No statistically significant 
difference between counselling 
plus OST and OST alone
CBT – cognitive behavioural therapy. OST – opioid substitution therapy. RCT – randomised controlled trial. RR – risk ratio
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Outcome Table 58: Abstinence
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Any psychosocial 
interventions plus OST vs. 
OST alone
Opioid abstinent for at least 
three weeks
Amato et al., 
2011b [H]
1,002 (8 RCTs) High RR 1.12 
(0.92, 1.37)
No statistically significant 
difference between 
psychosocial interventions plus 
OST and OST alone
Any psychosocial 
interventions plus OST vs. 
OST alone
Opioid abstinent at the end 
of follow-up
Amato et al., 
2011b [H]
181 (3 RCTs) High RR 1.15 
(0.98, 1.36)
No statistically significant 
difference between 
psychosocial interventions plus 
OST and OST alone
Any behavioural intervention 
plus OST vs. OST alone
Opioid abstinent for at least 
three weeks
Amato et al., 
2011b [H]
448 (4 RCTs) Moderate RR 1.04 
(0.89, 1.21)
No statistically significant 
difference between behavioural 
interventions plus OST and OST 
alone
Any behavioural 
interventions plus OST vs. 
OST alone
Opioid abstinent at the end 
of follow-up
Amato et al., 
2011b [H]
123 (3 RCTs) Moderate RR 1.18 
(0.98, 1.41)
No statistically significant 
difference between behavioural 
interventions plus OST and OST 
alone
Psychoanalytic-oriented 
intervention plus OST vs. 
OST alone
Opioid abstinent for at least 
three weeks
Amato et al., 
2011b [H]
127 (2 RCTs) Moderate RR 1.21 
(0.82, 1.78)
No statistically significant 
difference between 
psychoanalytic-oriented 
interventions plus OST and OST 
alone
Counselling plus OST vs. OST 
alone
Opioid abstinent for at least 
three weeks
Amato et al., 
2011b [H]
335 (1 RCT) Low One study 
only
No statistically significant 
difference between counselling 
plus OST and OST alone
CBT – cognitive behavioural therapy. OST – opioid substitution therapy. RCT – randomised controlled trial. RR – risk ratio
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Intervention: Opioid detoxification
Outcome Table 59: Treatment completion
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Tapered methadone vs. any 
other treatment
Amato et al., 
2013 [H]
1,381 (16 RCTs) High RR 1.08 
(0.97, 1.21)
No statistically significant 
difference between 
methadone compared to other 
pharmacological treatments 
aimed at detoxification
Buprenorphine vs. 
methadone
Gowing et al., 
2009a [H]
168 (4 RCTs) Low RR 1.18 
(0.93, 1.49)
No statistically significant 
difference between 
buprenorphine compared to 
methadone
Alpha2-adrenergic agonist 
vs. placebo
Gowing et al., 
2014 [H]
148 (3 RCTs) Moderate RR 1.95 
(1.34, 2.84)
Alpha2-adrenergic agonists 
significantly more effective than 
placebo
Alpha2-adrenergic agonist 
vs. methadone
Gowing et al., 
2014 [H]
659 (9 RCTs) Moderate RR 0.85 
(0.69, 1.05)
No statistically significant 
difference between alpha2-
adrenergic agonists compared 
to reducing doses of methadone
Naltrexone regime vs. 
adrenergic agonist
Gowing et al., 
2009b [H]
Not calculated 
(4 studies; 
2 RCTs, 2 
cohort)
Low Not 
calculated
Naltrexone-induced withdrawal 
associated with significantly 
higher rates of completion 
of treatment than withdrawal 
managed with an adrenergic 
agonist alone, but not 
consistently across studies
Naloxone regime vs. 
adrenergic agonist
Gowing et al., 
2009b [H]
Not calculated 
(5 studies; 
4 RCTs, 1 
cohort)
Low Not 
calculated
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 60: Abstinence
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Tapered methadone versus 
any other treatment
Abstinence at follow-up (up 
to six months)
Amato et al., 
2013 [H]
386 (3 RCTs) High RR 0.98 
(0.70, 1.37)
No statistically significant 
difference between 
methadone compared to other 
pharmacological treatments 
aimed at detoxification
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
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Outcome Table 61: Withdrawal severity
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Alpha2-adrenergic agonist 
vs. placebo
Peak withdrawal severity
Gowing et al., 
2014 [H]
Not reported 
(2 RCTs)
Low Not 
calculated
Alpha2-adrenergic agonists 
more effective than placebo in 
ameliorating withdrawal
Alpha2-adrenergic agonist 
vs. placebo
Severe withdrawal
Gowing et al., 
2014 [H]
148 (3 RCTs) Low SMD 0.32 
(0.18, 0.57)
Alpha2-adrenergic agonist 
vs. methadone
Peak withdrawal severity
Gowing et al., 
2014 [H]
263 (2 RCTs) Moderate SMD 0.22 
(-0.02, 
0.46)
Alpha2-adrenergic agonists less 
effective than reducing doses of 
methadone
Alpha2-adrenergic agonist 
vs. methadone
Severe withdrawal
Gowing et al., 
2014 [H]
340 (5 RCTs) Low RR 1.18 
(0.81, 1.73)
Alpha2-adrenergic agonist 
vs. methadone
Overall withdrawal severity
Gowing et al., 
2014 [H]
119 (3 RCTs) Moderate SMD 0.13 
(-0.24, 
0.49)
Naltrexone regime vs. 
adrenergic agonist
Peak withdrawal severity
Gowing et al., 
2009 [H]
Not reported 
(2 RCTs)
Low Not 
calculated
Withdrawal induced by opioid 
antagonists (naltrexone or 
naloxone) in combination 
with an adrenergic agonist is 
more intense than withdrawal 
managed with an adrenergic 
agonist alone, but the overall 
severity is less.
Naltrexone regime vs. 
adrenergic agonist
Overall withdrawal severity
Gowing et al., 
2009 [H]
Not reported 
(3 RCTs)
Low Not 
calculated
Naloxone regime vs. 
adrenergic agonist
Peak withdrawal severity
Gowing et al., 
2009 [H]
Not reported 
(1 RCT)
Low Not 
calculated
Naloxone regime vs. 
adrenergic agonist
Overall withdrawal severity
Gowing et al., 
2009 [H]
Not reported 
(1 RCT)
Low Not 
calculated
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
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Intervention: Opioid detoxification delivered with psychosocial intervention
Outcome Table 62: Drop out from treatment
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Detoxification plus 
psychosocial intervention vs. 
pharmacological treatment 
alone
Amato et al., 
2011a [H]
426 (6 RCTs) High RR 0.71 
(0.59, 
0.85)
Detoxification with psychosocial 
intervention more effective in 
reducing drop out than with 
pharmacological treatment 
alone
Detoxification plus 
contingency management vs. 
pharmacological treatment 
alone
Amato et al., 
2011a [H]
134 (4 RCTs) High RR 0.69 
(0.50, 
0.93)
Detoxification with contingency 
management more effective 
in reducing drop out than with 
pharmacological treatment 
alone.
Detoxification plus 
psychotherapeutic 
counselling vs. 
pharmacological treatment 
alone
Amato et al., 
2011a [H]
290 (2 RCTs) High Two 
studies 
only
Detoxification with 
psychotherapeutic counsellling 
more effective in reducing drop 
out than with pharmacological 
treatment alone.
RCT – randomised controlled trial. RR – risk ratio. RR – risk ratio
Outcome Table 63: Opioid use
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Detoxification plus 
psychosocial intervention vs. 
pharmacological treatment 
alone
During treatment
Amato et al., 
2011a [H]
320 (4 RCTs) Moderate RR 0.82 
(0.71, 0.93)
Detoxification with psychosocial 
intervention more effective in 
reducing drop out than with 
pharmacological treatment 
alone
Detoxification plus 
psychosocial intervention vs. 
pharmacological treatment 
alone
At follow-up
Amato et al., 
2011a [H]
208 (3 RCTs) Low RR 0.0.66 
(0.53, 
0.82)
Mixed results
Detoxification plus 
contingency management vs. 
pharmacological treatment 
alone
During treatment
Amato et al., 
2011a [H]
270 (3 RCTs) Moderate RR 0.82 
(0.70, 
0.97)
Detoxification with 
psychotherapeutic counsellling 
more effective in reducing drop 
out than with pharmacological 
treatment alone
RCT – randomised controlled trial. RR – risk ratio. RR – risk ratio
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Intervention: Relapse prevention with naltrexone
Outcome Table 64: Treatment retention
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oral naltrexone vs. placebo 
or no pharmacological 
treatment
Minozzi et al., 
2011 [H]
393 (6 RCTs) Moderate RR 1.43 
(0.72, 
2.82)
No statistically significant 
difference between naltrexone 
compared to placebo or no 
treatment
Oral naltrexone plus 
psychotherapy vs. 
benzodiazepines plus 
psychosocial therapy
Minozzi et al., 
2011 [H]
140 (1 RCT) Low Single 
study
No statistically significant 
difference between naltrexone 
and psychotherapy compared 
to benzodiazepines and 
psychosocial therapy
Oral naltrexone plus 
psychotherapy vs. 
buprenorphine plus 
psychotherapy
Minozzi et al., 
2011 [H]
87 (1 RCT) Low Single 
study
No statistically significant 
difference between naltrexone 
and psychotherapy compared 
to buprenorphine and 
psychotherapy
Naltrexone implants vs. 
placebo
Larney et al., 
2014 [H]
Not reported 
(2 RCTs)
Low RR 3.20 
(2.17, 4.72)
Naltrexone implants more 
effective than placebo
Naltrexone implants vs. oral 
naltrexone
Larney et al., 
2014 [H]
Not reported 
(1 RCT)
Low Single 
study
Naltrexone implants more 
effective than oral naltrexone
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 65: Abstinence
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oral naltrexone vs. placebo 
or no pharmacological 
treatments
Abstinence at end of 
treatment
Minozzi et al., 
2011 [H]
143 (4 RCTs) Low RR 1.39 
(0.61, 3.17)
No statistically significant 
difference between naltrexone 
compared to placebo or no 
treatment
Oral naltrexone vs. placebo 
or no pharmacological 
treatments
Abstinence at follow-up (up 
to 12 months)
Minozzi et al., 
2011 [H]
116 (3 RCTs) Low RR 1.28 
(0.80, 
2.05)
No statistically significant 
difference between naltrexone 
compared to placebo or no 
treatment
Oral naltrexone vs. 
psychotherapy
Abstinence at follow-up (up 
to 12 months)
Minozzi et al., 
2011 [H]
38 (1 RCT) Low Not 
calculated
No statistically significant 
difference between naltrexone 
compared to psychotherapy
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
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Outcome Table 66: Opioid use
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Naltrexone implants vs. 
placebo
Larney et al., 
2014 [H]
Not reported 
(2 RCTs)
Low RR 0.57 
(0.48, 
0.68)
Naltrexone implants more 
effective than placebo
Naltrexone implants vs. oral 
naltrexone
Larney et al., 
2014 [H]
Not reported 
(2 RCTs)
Low RR 0.57 
(0.47, 0.70)
Naltrexone implants more 
effective than oral naltrexone
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 67: Reincarceration
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oral naltrexone vs. placebo 
or no pharmacological 
treatments
Minozzi et al., 
2011 [H]
86 (2 RCTs) Low RR 0.47 
(0.26, 
0.84)
Naltrexone more effective than 
placebo or no treatment
Oral naltrexone vs. 
psychotherapy
Minozzi et al., 
2011 [H]
38 (1 RCT) Low Not 
calculated
No statistically significant 
difference between naltrexone 
compared to psychotherapy
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Population: People with opioid dependence and recent history of IDU
Setting: Community/outpatient
Intervention: Opioid maintenance
Outcome Table 68: Opioid use
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
OST Gowing et al., 
2011 [H]
Not reported 
(11 studies; all 
observational, 
prospective)
Moderate Not 
calculated
All studies showed statistically 
significant decreases in opioid 
use following a period of 
substitution treatment.
OST – opioid substitution therapy. RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
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Outcome Table 69: Injecting behaviours
Comparison  Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
OST
Injecting drug use
Gowing et al., 
2011 [H]
Not reported 
(11 studies; all 
observational, 
prospective)
Moderate Not 
calculated
All studies showed statistically 
significant decreases in 
injecting following a period of 
substitution therapy.
OST
Injecting risk behaviours
Gowing et al., 
2011 [H]
Not reported 
(12 studies; 
observational, 
prospective)
Moderate Not 
calculated
All studies showed a reduction 
in sharing of injection 
equipment following a period 
of substitution therapy (11/12 
studies statistically significant).
OST – opioid substitution therapy. RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 70: HIV risk
Comparison Reference(s) 
(JBI rating)
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
OST MacArthur et 
al., 2012 [H]
23,608 PYFU 
(9 studies; 
8 cohort, 1 
nested case-
control)
Moderate RR 0.46 
(0.32, 
0.67)
Opioid substitution therapy 
associated with a statistically 
significant reduction in the risk 
of HIV infection
OST – opioid substitution therapy. PYFU – person years of follow-up. RCT – randomised controlled trial. RR – risk ratio. SMD – 
standardised mean difference
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9.3.2 Pharmacological treatments ‑ stimulants
Population: People with cocaine dependence
Setting: Community
Intervention: Pharmacological treatments
Outcome Table 71: Cocaine abstinence
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Dopamine agonist vs. 
placebo/alternative 
medication
End of treatment
Minozzi et al., 
2015a [H]
731 (11 RCTs) Moderate RR 1.12 
(0.85, 1.47)
No statistically significant 
difference between approaches
Dopamine agonist vs. 
placebo/alternative 
medication
Follow-up (mean four 
months)
136 (4 RCTs) High RR 1.10 
(0.61, 1.98)
No statistically significant 
difference between approaches
Psychostimulants vs. 
placebo
Castells et al., 
2010 [H]
801 (8 RCTs) Moderate RR 1.41 
(0.98, 
2.02)
No statistically significant 
difference between approaches
Disulfiram vs. placebo Pani et al., 
2010 [H]
20 (1 RCTs) Low One study 
only
Placebo was more effective 
than disulfiram
Disulfiram vs. no 
pharmacological treatment
Pani et al., 
2010 [H]
90 (2 RCTs) Low Not 
calculated
Mixed findings between two 
studies
Indirect dopamine agonists 
plus psychotherapy vs. 
placebo
Perez-Mana et 
al., 2011 [H]
NR (19 RCTs) Low SMD 0.21 
(0.06, 
0.37)
Indirect dopamine agonists and 
psychotherapy more effective 
for abstinence
Antidepressants vs. placebo
Abstinence for three 
consecutive weeks
Pani et al., 
2011 [H]
942 (8 RCTs) High RR 1.22 
(0.99, 1.51)
No statistically significant 
difference between approaches
Antidepressants vs. placebo
Number of weeks abstinent
1,062 (7 RCTs) High SMD 0.00 
(0.21, 0.22)
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
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Outcome Table 72: Cocaine use
Comparison Reference(s) 
(JBI rating)
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Anticonvulsant vs. placebo Minozzi et al., 
2015b [H]
426 (11 RCTs) Moderate RR 0.92 
(0.84, 1.02)
No statistically significant 
difference between approaches
Psychostimulants vs. 
placebo
Verified through urine 
analysis
Castells et al., 
2010 [H]
469 (7 RCTs) Moderate SMD 0.11 
(-0.07, 
-0.29)
No statistically significant 
difference between approaches
Antipsychotic vs. placebo
Verified through urine 
analysis
Alvarez et al., 
2013 [H]
525 (7 RCTs) Moderate MD 0.01 
(-0.12, 
0.13)
No statistically significant 
difference between approaches
Antipsychotic vs. placebo
Self-report
133 (5 RCTs) Moderate MD 0.17 
(-0.03, 
0.38)
No statistically significant 
difference between approaches
Antidepressants plus vs. 
placebo
Pani et al., 
2011 [H]
251 (4 RCTs) Moderate RR 1.05 
(0.91, 1.21)
No statistically significant 
difference between approaches
Disulfiram vs. placebo
Frequency
Pani et al., 
2010 [H]
53 (1 RCT) Low Not 
calculated
No statistically significant 
difference between approaches
Disulfiram vs. placebo
Amount in grams/week
43 (1 RCT) Low Not 
calculated
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 73: Cocaine craving
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Antidepressants vs. placebo Pani et al., 
2011 [H]
636 (9 RCTs) Moderate SMD 0.02 
(-0.13, 
0.18)
No statistically significant 
difference between approaches
Psychostimulants vs. 
placebo
Castells et al., 
2010 [H]
340 (3 RCTs) Moderate SMD 0.06 
(-0.15, 
0.27)
No statistically significant 
difference between approaches
Antipsychotic vs. placebo Alvarez et al., 
2013 [H]
255 (7 RCTs) Moderate SMD 0.12 
(0.02, 
0.22)
Craving reduction greater in 
placebo treatment
Dopamine agonist vs. 
placebo/alternative 
medication
Minozzi et al., 
2015a [H]
151 (3 RCTs) Low SMD 0.20 
(-0.35, 
0.74)
No statistically significant 
difference between approaches
Anti-convulsant vs. placebo Minozzi et al., 
2015b [H]
428 (7 RCTs) Moderate SMD -0.25 
(-0.59, 
0.09)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. SMD – standardised mean difference
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Outcome Table 74: Treatment retention
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Antidepressants vs. placebo Pani et al., 
2011 [H]
705 (8 RCTs) High SMD 0.34 
(0.22, 
0.47)
Greater treatment retention 
through antidepressant 
compared to placebo 
approaches
Indirect dopamine agonists 
vs. placebo
Perez-Mana et 
al., 2011 [H]
NR (24 RCTs) Low RR 0.99 
(0.92, 1.05)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio. SMD –mean difference
Outcome Table 75: Drop out during treatment
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Dopamine agonists vs. 
placebo
Minozzi et al., 
2015a [H]
1,656 (20 
RCTs)
Moderate RR 1.04 
(0.94, 1.14)
No statistically significant 
difference between approaches
Anticonvulsant vs. placebo Minozzi et al., 
2015b [H]
1,695 (20 
RCTs)
Moderate RR 0.95 
(0.86, 1.05)
No statistically significant 
difference between approaches
Antipsychotic vs. placebo Alvarez et al., 
2013 [H]
804 (12 RCTs) Moderate RR 0.91 
(0.82, 1.02)
No statistically significant 
difference between approaches
Antidepressants vs. placebo
All drop-outs
Pani et al., 
2011 [H]
1,588 (31 
RCTs)
High RR 1.03 
(0.93, 1.14)
No statistically significant 
difference between approaches
Antidepressants vs. placebo
Due to adverse effects
Pani et al., 
2011 [H]
1,396 (13 RCTs) High RR 1.39 
(0.91, 2.12)
No statistically significant 
difference between approaches
Disulfiram vs. placebo Pani et al., 
2010 [H]
194 (3 RCTs) Low RR 0.64 
(0.35, 1.20)
No statistically significant 
difference between approaches
Disulfiram vs. naltrexone Pani et al., 
2010 [H]
131 (3 RCTs) Low RR 0.67 
(0.45, 1.01)
No statistically significant 
difference between approaches
Psychostimulants vs. 
placebo
Castells et al., 
2010 [H]
964 (11 RCTs) Low RR 0.01 
(-0.02, 
0.03)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio
Outcome Table 76: Treatment completion
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Psychostimulant vs. placebo Castells et al., 
2010 [H]
1,345 (16 
RCTs)
Moderate RR 0.97 
(0.89, 1.07)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio
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Outcome Table 77: Treatment compliance
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Anticonvulsant vs. placebo
Dichotomous measures
Minozzi et al., 
2015b [H]
343 (6 RCTs) Low RR 1.01 
(0.93, 1.08)
No statistically significant 
difference between approaches
Anticonvulsant vs. placebo
Continuous measures
Minozzi et al., 
2015b [H]
426 (5 RCTs) Moderate SMD 1.42 
(-4.80, 
7.64)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio. SMD – standardised mean difference
Outcome Table 78: Adverse effects during treatment
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Dopamine agonists vs. 
placebo
Minozzi et al., 
2015a [H]
252 (7 RCTs) Low RR 1.27 
(0.66, 
2.44)
No statistically significant 
difference between approaches
Anticonvulsant vs. placebo Minozzi et al., 
2015b [H]
775 (8 RCTs) Moderate RR 1.39 
(1.01, 1.9)
Adverse effects reduced in 
placebo treatment
RCT – randomised controlled trial. RR – risk ratio
Outcome Table 79: Anxiety
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Anticonvulsant vs. placebo Minozzi et al., 
2015b [H]
78 (3 RCTs) Low MD 1.79 
(-1.02, 
4.60)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. MD – mean difference
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Outcome Table 80: Depression
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Anticonvulsant vs. placebo Minozzi et al., 
2015b [H]
80 (3 RCTs) Low MD 1.80 
(-0.59, 
4.19)
No statistically significant 
difference between approaches
Antidepressants vs. placebo
Beck
Pani et al., 
2011 [H]
98 (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between approaches
Antidepressants vs. placebo Pani et al., 
2011 [H]
420 (6 RCTs)
Hamilton 
depression 
scale
Moderate MD -1.41 
(-2.44, 
-0.37)
No statistically significant 
difference between approaches
Antidepressants vs. placebo Pani et al., 
2011 [H]
390 (4 RCTs)
2 CGI 
depression 
severity score
High MD -0.08 
(-0.35, 
0.18)
No statistically significant 
difference between approaches
Antidepressants vs. placebo Pani et al., 
2011 [H]
98 (2 RCTs)
4 Brief 
Psychiatric 
Rating Scale
Low Two 
studies 
only
Results favoured treatment with 
antidepressants.
Psychostimulant vs. placebo Castells et al., 
2010 [H]
90 (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio. MD – mean difference
Population: People with amphetamine dependence
Setting: Community
Intervention: Pharmacological treatment for amphetamine use
Outcome Table 81: Psychostimulant abstinence
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Psychostimulant medication 
and psychosocial 
intervention
Verified through urine 
analysis
Perez-Mana et 
al., 2013 (H)
559 (6 RCTs) Moderate RR 1.12 
(0.84, 1.49)
No statistically significant 
difference between approaches
Indirect dopamine agonists 
plus psychotherapy vs. 
placebo
Perez-Mana et 
al., 2011 [H]
NR (3 RCTs) Low MD 0.17 
(-0.25, 
0.59)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio. MD – mean difference
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Outcome Table 82: Amphetamine use
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Psychostimulant medication 
and psychosocial 
intervention
Verified through urine 
analysis
Perez-Mana et 
al., 2013 (H)
463 (7 RCTs) Moderate MD -0.26 
(-0.85, 
0.33)
No statistically significant 
difference between approaches
Psychostimulant medication 
and psychosocial 
intervention
Verified through hair analysis
Perez-Mana et 
al., 2013 (H)
22 (1 RCT) Low One study 
only
No statistically significant 
difference between approaches
Psychostimulant medication 
and psychosocial 
intervention
Self-report
Perez-Mana et 
al., 2013 (H)
463 (3 RCTs) Low MD -0.81 
(-6.16, 
4.54)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio. MD – mean difference
Outcome Table 83: Amphetamine craving
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Psychostimulant vs. placebo Perez-Mana et 
al., 2013 [H]
Not reported 
(2 RCTs)
Low Two 
studies 
only
No statistically significant 
difference between approaches
RCT – randomised controlled trial
Outcome Table 84: Drop out during treatment
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Psychostimulant vs. placebo
Drop outs due to adverse 
events
Perez-Mana et 
al., 2013 [H]
640 (10 RCTs) Moderate RR 0.01 
(-0.03, 
0.04)
No statistically significant 
difference between approaches
Psychostimulant vs. placebo
Drop outs due to 
cardiovascular events
Perez-Mana et 
al., 2013 [H]
370 (8 RCTs) Moderate RR 0.01 
(-0.03, 
0.04)
No statistically significant 
difference between approaches
Psychostimulant vs. placebo
Drop outs due to psychiatric 
events
Perez-Mana et 
al., 2013 [H]
290 (7 RCTs) Moderate RR -0.02 
(-0.06, 
0.02)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio
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Outcome Table 85: Treatment retention
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Psychostimulant medication 
and psychosocial 
intervention
Perez-Mana et 
al., 2013 [H]
592 (11 RCTs) Moderate RR 1.01 
(0.90-1.14)
No statistically significant 
difference between approaches
Indirect dopamine agonists 
and psychotherapy vs. 
placebo
Perez-Mana et 
al., 2011 [H]
NR (4 RCTs) Low RR 0.95 
(0.74, 1.21)
No statistically significant 
difference between approaches
RCT – randomised controlled trial. RR – risk ratio
9.3.3 Pharmacological treatments – cannabis
Population: People with cannabis dependence
Setting: Community
Intervention: Pharmacological treatment for cannabis use
Outcome Table 86: Abstinence
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
THC preparations vs. 
placebo
Marshall et al., 
2014 [H]
156 (1 RCT) Moderate One study 
only
No statistically significant 
differences between 
approaches
Mixed action 
antidepressants vs. placebo
Marshall et al., 
2014 [H]
179 (2 RCTs) Low Two 
studies 
only
Mixed results
SSRI antidepressants vs. 
placebo
Marshall et al., 
2014 [H]
52 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Anticonvulsant and mood 
stabiliser vs. placebo
Marshall et al., 
2014 [H]
19 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
THC – tetrahydrocannabinol. RCT – randomised controlled trial.
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Outcome Table 87: Treatment completion
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
THC preparations vs. 
placebo
Marshall et al., 
2014 [H]
207 (1 RCT) Moderate One study 
only
THC preparations more 
effective than placebo
Mixed-action 
antidepressants vs. placebo
Marshall et al., 
2014 [H]
169 (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between approaches
SSRI antidepressants vs. 
placebo
Marshall et al., 
2014 [H]
122 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
difference between approaches
Anticonvulsant and mood 
stabiliser vs. placebo
Marshall et al., 
2014 [H]
75 (2 RCTs) Moderate Two 
studies 
only
No statistically significant 
difference between approaches
Buspirone vs. placebo Marshall et al., 
2014 [H]
50 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Atomoxetine vs. placebo Marshall et al., 
2014 [H]
38 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
N-acetylcysteine vs. placebo Marshall et al., 
2014 [H]
116 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
THC – tetrahydrocannabinol. RCT – randomised controlled trial.
Outcome Table 88: Adverse effects during treatment
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
THC preparations vs. 
placebo
Marshall et al., 
2014 [H]
156 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Mixed action 
antidepressants vs. placebo
Marshall et al., 
2014 [H]
179 (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between approaches
Buspirone vs. placebo Marshall et al., 
2014 [H]
50 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Atomoxetine vs. placebo Marshall et al., 
2014 [H]
38 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
N-acetylcysteine vs. placebo Marshall et al., 
2014 [H]
116 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
THC – tetrahydrocannabinol. RCT – randomised controlled trial
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Outcome Table 89: Withdrawal due to adverse effects
Comparison Reference(s) 
(JBI rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
THC preparations vs. 
placebo
Marshall et al., 
2014 [H]
156 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Mixed-action 
antidepressants vs. placebo
Marshall et al., 
2014 [H]
179 (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between approaches
Anticonvulsant and mood 
stabiliser vs. placebo
Marshall et al., 
2014 [H]
50 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Buspirone vs. placebo Marshall et al., 
2014 [H]
50 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
Atomoxetine vs. placebo Marshall et al., 
2014 [H]
38 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
N-acetylcysteine vs. placebo Marshall et al., 
2014 [H]
116 (1 RCT) Moderate One study 
only
No statistically significant 
difference between approaches
THC – tetrahydrocannabinol. RCT – randomised controlled trial.
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9.3.4 Psychosocial treatments
Population: Young people in recovery from drug and/or alcohol dependence
Intervention: Psychosocial interventions
Setting: Community
Outcome Table 90: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MDFT vs. other 
interventions1 or TAU
Drug problem severity: six 
months follow-up
Filges et al., 
2015a [H]
830 (5 RCTs) Moderate SMD -0.35 
(-0.59, 
-0.11)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions2 or TAU
Drug problem severity: six 
months follow-up
Filges et al., 
2015a [H]
831 (5 RCTs) Moderate SMD -0.33 
(-0.59, 
-0.08)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions3 or TAU
Drug problem severity: six 
months follow-up
Filges et al., 
2015a [H]
836 (5 RCTs) Moderate SMD -0.31 
(-0.53, 
-0.10)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions4 or TAU
Drug problem severity: six 
months follow-up
Filges et al., 
2015a [H]
837 (5 RCTs) Moderate SMD -0.30 
(-0.53, 
-0.07)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions1 or TAU
Drug problem severity: 12 
months follow-up
Filges et al., 
2015a [H]
826 (5 RCTs) Moderate SMD -0.25 
(-0.39, 
-0.04)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions2 or TAU
Drug problem severity: 12 
months follow-up
Filges et al., 
2015a [H]
827 (5 RCTs) Moderate SMD -0.23 
(-0.39, 
-0.06)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions3 or TAU
Drug problem severity: 12 
months follow-up
Filges et al., 
2015a [H]
832 (5 RCTs) Moderate SMD -0.27 
(-0.43, 
-0.11)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions4 or TAU
Drug problem severity: 12 
months follow-up
Filges et al., 
2015a [H]
833 (5 RCTs) Moderate SMD -0.25 
(-0.43, 
-0.07)
Drug problem severity 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions5
Drug abuse frequency: six 
months follow-up
Filges et al., 
2015a [H]
769 (4 RCTs) Moderate SMD -0.24 
(-0.43, 
-0.06)
Drug abuse frequency 
significantly reduced with 
MDFT compared with other 
interventions or TAU
MDFT vs. other 
interventions6 or TAU
Drug abuse frequency: six 
months follow-up
Filges et al., 
2015a [H]
770 (4 RCTs) Moderate SMD -0.25 
(-0.40, 
-0.11)
Drug abuse frequency 
significantly reduced with 
MDFT compared with other 
interventions or TAU
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Outcome Table 90 (continued): Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MDFT vs. other 
interventions5 or TAU
Drug abuse frequency: 12 
months follow-up
Filges et al., 
2015a [H]
765 (4 RCTs) Moderate SMD -0.28 
(-0.63, 
0.07)
No statistically significant 
differences between treatments
MDFT vs. other 
interventions6 or TAU
Drug abuse frequency: 12 
months follow-up
Filges et al., 
2015a [H]
766 (4 RCTs) Moderate SMD -0.28 
(-0.63, 
0.07)
No statistically significant 
differences between treatments
FBT vs. counselling
Drug use reduction: end of 
treatment
Lindstrom et 
al., 2015
77 (2 RCTs) Low Two 
studies 
only
Mixed results between studies
FBT vs. counselling
Drug use reduction: 12 
months follow-up
Lindstrom et 
al., 2015
50 (1 RCT) Moderate One study 
only
No statistically significant 
differences between treatments
MDFT – multi-dimensional Family Therapy. TAU – treatment as usual. FBT – family behaviour therapy. RCT – randomised 
controlled trial
1 – adolescent group therapy, cognitive behavioural therapy, peer group therapy.
2 – adolescent community reinforcement approach, adolescent group therapy, cognitive behavioural therapy, peer group 
therapy
3 – cognitive behavioural therapy, multifamily educational therapy, peer group therapy
4 – adolescent community reinforcement approach, cognitive behavioural therapy, multifamily educational therapy, peer group 
therapy
5 – cognitive behavioural therapy, peer group therapy
6 – adolescent community reinforcement approach, cognitive behavioural therapy, peer group therapy
www.hrb.ie136
Outcome Table 91: Criminal activity
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
FBT vs. counselling
Arrests at end of treatment
Lindstrom et 
al., 2015 [H]
77 (2 RCTs) Low Two 
studies 
only
Mixed results between studies
FBT vs. counselling
Arrests at 12 months follow-
up
Lindstrom et 
al., 2015 [H]
50 (1 RCT) Low One study 
only
Arrests significantly reduced 
following FBT in comparison to 
counselling
CBT vs. alternative 
treatment: end of treatment 
– six months follow-up
Filges et al., 
2015b [H]
NR (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between treatments
CBT vs. alternative 
treatment: 6–12 months 
follow-up
Filges et al., 
2015b [H]
NR (3 RCTs) Low SMD -0.02 
(-0.28, 
0.25)
No statistically significant 
difference between treatments
CBT vs. alternative 
treatment: end of treatment 
– 12 months plus follow-up
Filges et al., 
2015b [H]
121 (2 RCTs) Low Two 
studies 
only
No statistically significant 
difference between treatments
CBT with add-on 
component vs. alternative 
treatment: end of treatment 
– six months follow-up
Filges et al., 
2015b [H]
61 (1 RCT) Low One study 
only
Crime significantly reduced in 
alternative treatment compared 
with CBT with add-on
CBT with add-on component 
vs. alternative treatment: 
6–12 months follow-up
Filges et al., 
2015b [H]
61 (1 RCT) Low One study 
only
No statistically significant 
difference between treatments
FBT – family behaviour therapy. CBT – cognitive behavioural therapy. RCT – randomised controlled trial. OR – odds ratio
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Outcome Table 92: Treatment retention
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MDFT vs. other 
interventions1 or TAU
Grade point average: six 
months follow-up
Filges et al., 
2015a [H]
1,077 (5 RCTs) Moderate OR 0.44 
(0.21, 0.94)
Retention significantly greater 
in MDFT compared to other 
interventions
MDFT vs. other 
interventions2 or TAU
Grade point average: six 
months follow-up
Filges et al., 
2015a [H]
1,077 (5 RCTs) Moderate OR 0.45 
(0.21, 0.95)
Retention significantly greater 
in MDFT compared to other 
interventions
MDFT vs. other 
interventions3 or TAU
Grade point average: six 
months follow-up
Filges et al., 
2015a [H]
1,076 (5 RCTs) Moderate OR 0.48 
(0.22, 1.05)
No statistically significant 
difference between treatments
MDFT vs. other 
interventions4 or TAU
Grade point average: six 
months follow-up
Filges et al., 
2015a [H]
1,076 (5 RCTs) Moderate OR 0.49 
(0.22, 1.07)
No statistically significant 
difference between treatments
MDFT – multidimensional family behaviour therapy. RCT – randomised controlled trial.
1 – adolescent group therapy, cognitive behavioural therapy, peer group therapy
2 – adolescent community reinforcement approach, adolescent group therapy, cognitive behavioural therapy, peer group 
therapy
3 – CBT, multifamily educational therapy, peer group therapy
4 – adolescent community reinforecement approach, CBT, multifamily educational therapy, peer group therapy
Outcome Table 93: Education
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MDFT vs. AGT or PGT
Grade point average: six 
months follow-up
Filges et al., 
2015a [H]
144 (2 RCTs) Low Two 
studies 
only
Mixed results between studies
MDFT vs. MEI or PGT
Grade point average: six 
months follow-up
Filges et al., 
2015a [H]
150 (2 RCTs) Moderate Two 
studies 
only
Grade point significantly greater 
in MDFT compared to other 
interventions
MDFT – multidimensional family therapy. PGT – peer group therapy. MEI – multifamily educational therapy. RCT – randomised 
controlled trial
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Population: Adults who are regular users of cannabis
Intervention: CBT
Setting: Community or outpatient
Outcome Table 94: Cannabis use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
CBT vs. wait list control Cooper et al., 
2015 [H]
3,831 (12 RCTs) Moderate Not 
calculated
CBT generally more effective 
than wait list control
CBT vs. other interventions Moderate Not 
calculated
Mixed results or no statistical 
difference between treatments 
when CBT compared to other 
interventions
CBT plus contingency 
management vs. other 
interventions
Cooper et al., 
2015 [H]
680 (5 RCTs) Low Not 
calculated
Mixed results
CBT – cognitive behavioural therapy. MI – motivational interviewing. RCT – randomised controlled trial. ES – effect size
Outcome Table 95: Cannabis dependence severity
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
CBT vs. wait list control Cooper et al., 
2015 [H]
2,327 (10 
RCTs)
Moderate Not 
calculated
CBT (including telephone-based 
or Internet-based) generally 
more effective than wait list 
control over short term
CBT vs. other interventions Moderate Not 
calculated
CBT more effective than 
brief MI in one study but 
no statistically significant 
difference in three studies. 
No statistically significant 
difference between CBT and 
case management
CBT plus contingency 
management vs. other 
interventions
Cooper et al., 
2015 [H]
300 (2 RCTs) Low Two 
studies 
only
Mixed results
CBT – cognitive behavioural therapy. MI – motivational interviewing. RCT – randomised controlled trial
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 139
Outcome Table 96: Cannabis‑related problems
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
CBT vs. wait list control or 
other intervention
Cooper et al., 
2015 [H]
2,187 (9 RCTs) Moderate Not 
calculated
CBT (including telephone-based 
or Internet-based) generally 
more effective than wait list 
control over short to medium 
term (up to nine months in one 
study)
CBT vs. other interventons Not 
calculated
Mixed results. CBT more 
effective than brief MI in 
one study but no statistically 
significant difference in 
three studies. No statistically 
significant difference between 
CBT and social support or case 
management
CBT plus contingency 
management vs. other 
interventions
Cooper et al., 
2015 [H]
575 (4 RCTs) Low Not 
calculated
Mixed results
CBT – cognitive behavioural therapy. MI – motivational interviewing. RCT – randomised controlled trial
Population: People with cocaine misuse or dependence
Intervention: CBT
Setting: Community or outpatient
Outcome Table 97: Abstinence
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Relapse-prevention CBT vs. 
standard care
Cocaine abstinent at 
endpoint
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
469 (4 RCTs)
USA
Moderate RR 1.13 
(0.95, 1.34)
No statistically significant 
difference between relapse-
prevention CBT and standard 
care
Standard CBT vs. standard 
care
Cocaine abstinent at 
endpoint
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
370 (2 RCTs)
USA
Moderate RR 1.00 
(0.78, 1.30)
No statistically significant 
difference between standard 
CBT and standard care
CBT – cognitive behavioural therapy. RCT – randomised controlled trial. RR – risk ratio. ES – effect size
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Intervention: Couples-based interventions
Outcome Table 98: Abstinence
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Couples-based 
interventions vs. relapse-
prevention CBT
Days abstinent from all drugs 
in past three months at study 
endpoint
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
198 (3 RCTs)
USA
Moderate SMD -0.38 
(-0.66, 
-0.09)
Couples-based interventions 
more effective than relapse-
prevention CBT
Couples-based 
interventions vs. relapse-
prevention CBT
Days abstinent from all drugs 
in past three months at six 
months follow-up
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
198 (3 RCTs)
USA
Moderate SMD -0.52 
(-0.81, 
-0.24)
Couples-based interventions 
more effective than relapse-
prevention CBT
Couples-based 
interventions vs. relapse-
prevention CBT
Days abstinent from all drugs 
in past three months at 12 
months follow-up
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
198 (3 RCTs)
USA
Moderate SMD -0.34 
(-0.62, 
-0.06)
Couples-based interventions 
more effective than relapse-
prevention CBT
CBT – cognitive behavioural therapy. RCT – randomised controlled trial. RR – risk ratio. ES – effect size
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 141
Population: People with stimulant, cocaine and/or opioid misuse or dependence
Intervention: Contingency management
Setting: Community or outpatient
Outcome Table 99: Abstinence
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Contingency management 
vs. control
Continuous abstinence at 12 
weeks
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
173 (2 RCTs) Moderate RR 5.61 
(2.31, 
13.62)
Abstinence increased with 
contingency management
Contingency management 
vs. control
Cocaine continuous 
abstinence for at least 12 
weeks
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
568 (4 RCTs) High RR 4.24 
(2.52, 7.15)
Abstinence increased with 
contingency management
Contingency management 
vs. relapse-prevention CBT
Continuous abstinence at 
three weeks
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
82 (1 RCT) Moderate RR 1.66 
(1.11, 2.47)
Abstinence increased with 
contingency management
Contingency management 
vs. relapse-prevention CBT
Point abstinence at 12 
months follow-up
National 
Collaborating 
Centre for 
Mental Health, 
2008 [H]
82 (1 RCT) Moderate RR 0.89 
(0.71, 1.13)
No statistically significant 
difference between contingency 
management and relapse-
prevention CBT
Prize-based contingency 
management vs. TAU
Abstinence at end of 
treatment
Benishek et 
al., 2014 [H]
Not reported 
(19 RCTs)
High d=0.46 
(0.37, 
0.54)
Abstinence increased with 
contingency management
Prize-based contingency 
management vs. TAU
Abstinence at three months
Benishek et 
al., 2014 [H]
Not reported 
(19 RCTs)
High d=0.33 
(0.12, 0.54)
Abstinence increased with 
contingency management
Prize-based contingency 
management vs. TAU
Abstinence at six months
Benishek et 
al., 2014 [H]
Not reported 
(5 RCTs)
Low ES −0.09 
(−0.28, 
0.10)
No statistically significant 
difference between treatments
CBT – cognitive behavioural therapy. TAU – treatment as usual. RCT – randomised controlled trial. RR – risk ratio. ES – effect 
size. SMD – standardised mean difference.
Intervention: Mindfulness-based treatments
Outcome Table 100: Drug use
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Mindfulness-based 
intervention vs. treatment as 
usual or other intervention
Chiesa and 
Serretti, 2014 
[H]; Zgierska 
et al., 2009 
[H]
1,697 (16: 12 
RCTs; 4 non-
RCTs)
Low Not 
calculated
Mixed results
RCT – randomised controlled trial
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Population: People with drug abuse or dependence
Intervention: Motivational interview
Setting: Community or outpatient
Outcome Table 101: Drug use
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview vs. no 
intervention
Short term
Smedslund et 
al., 2011 [H]
2,327 (15 
RCTs)
Moderate SMD 0.17 
(0.09, 
0.26)
Reduced drug use with 
motivational interview 
compared to no intervention 
at short- and medium-term 
follow-upMotivational interview vs. no 
intervention
Medium-term follow up
Smedslund et 
al., 2011 [H]
2,326 (12 
RCTs)
Moderate SMD 0.15 
(0.04, 
0.25)
Motivational interview vs. no 
intervention
Long-term follow-up
Smedslund et 
al., 2011 [H]
363 (1 RCT) Low One study 
only
No significant differences on 
drug use between motivational 
interview and no intervention 
group at long-term follow-up in 
one study
Motivational interview vs. 
treatment as usual
Short term
Smedslund et 
al., 2011 [H]
2,102 (10 
RCTs)
Moderate SMD 0.01 
(-0.08, 
0.10)
No significant differences on 
drug use between motivational 
interview and treatment as 
usual at short- or medium-term 
follow-upMotivational interview vs. 
treatment as usual
Medium-term follow-up
Smedslund et 
al., 2011 [H]
890 (5 RCTs) Moderate SMD 0.08 
(-0.05, 
0.21)
Motivational interview vs. 
assessment and feedback
Short-term follow-up
Smedslund et 
al., 2011 [H]
986 (7 RCTs) Moderate SMD 0.12 
(-0.01, 
0.24)
No significant differences 
between motivational interview 
and assessment and feedback 
treatment groups on drug use 
at short-term follow-up and 
there were mixed results at 
medium-term follow-up
Motivational interview vs. 
assessment and feedback
Medium-term follow-up
Smedslund et 
al., 2011 [H]
265 (2 RCTs) Moderate Two 
studies 
only
Motivational interview vs. 
other active intervention
Short-term
Smedslund et 
al., 2011 [H]
2,137 (12 RCTs) Moderate SMD 0.02 
(-0.07, 
0.12)
No significant differences for 
drug use between motivational 
interview and other active 
intervention groups at any 
follow-up time.Motivational interview vs. 
other active intervention
Medium-term follow-up
Smedslund et 
al., 2011 [H]
1,586 (6 RCTs) Moderate SMD -0.02 
(-0.16, 
0.13)
Motivational interview vs. 
other active intervention
Long-term follow-up
Smedslund et 
al., 2011 [H]
437 (2 RCTs) Moderate Two 
studies 
only
Video doctor based on 
motivational interview plus 
booster phone session vs. 
treatment as usual
Medium-term follow-up
Watson et al., 
2013 [H]
476 (1 CCT) Low One study 
only
Reduced ‘any’ drug use 
among motivational interview 
treatment individuals compared 
to treatment as usual, but no 
significant differences between 
groups for past month drug use 
or risky alcohol use
Motivational interview, 
handout and booster phone 
call vs. handout only
Medium-term follow-up: 
Cocaine
Watson et al., 
2013 [H]
1,175 (1 CCT) Low One study 
only
Reduced cocaine use among 
individuals who received the 
motivational interview, with 
handout treatment compared 
to handout-only controls
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Outcome Table 101 (continued): Drug use
Comparison Reference(s) 
[JBI rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview, 
handout and booster phone 
call vs. handout only
Medium-term follow-up: 
Opiates
Watson et al., 
2013 [H]
1,175 (1 CCT) Low One study 
only
No statistically significant 
differences for opiate use 
between motivational interview 
with handout treatment and 
handout-only control groups
RCT – randomised controlled trial. CCT – controlled clinical trial. SMD – standardised mean difference
Outcome Table 102: Treatment retention
Comparison Reference(s) 
[JBI rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Motivational interview vs. no 
intervention
Short term
Smedslund et 
al., 2011 [H]
427 (2 RCTs) Moderate Two 
studies 
only
Mixed results: retention 
favoured the motivational 
group in one study and in 
one study there were no 
significant differences between 
motivational interview and no 
intervention treatment groups
Motivational interview vs. 
treatment as usual
Medium-term follow-up
Smedslund et 
al., 2011 [H]
1,354 (4 RCTs) Moderate SMD -0.11 
(-0.41, 
0.19)
No significant differences for 
retention between motivational 
interview and treatment as 
usual groups
Motivational interview vs. 
other active intervention
Short term
Smedslund et 
al., 2011 [H]
447 (5 RCTs) Moderate SMD 0.01 
(-0.45, 
0.47)
No significant differences for 
retention between motivational 
interview and other active 
intervention treatment groups
RCT – randomised controlled trial. SMD – standardised mean difference
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9.3.5 Residential rehabilitation
Population: People with drug misuse or dependence
Intervention: Residential rehabilitation
Setting: Residential
Outcome Table 103: Treatment completion
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Residential TC vs. day 
treatment TC
Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
Not reported 
(1 RCT)
Low Not 
calculated
No statistically significant 
difference in the number of 
clients completing treatment 
at 6, 12 and 18-month follow-
ups. Time to drop out was not 
statistically significant between 
groups
Standard TC vs. 
enhanced abbreviated 
TC
Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
Not reported 
(1 RCT)
Low RR 1.15 
(0.89, 1.50)
No statistically significant 
difference between standard TC 
and enhanced abbreviated TC
Modified TC: planned 
duration three months 
vs. planned duration six 
months
Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
Not reported 
(1 RCT)
Low RR 1.83 
(1.45, 2.31)
Significantly more clients 
completed treatment in the 
three-month TC compared with 
the six-month TC
Traditional TC: planned 
duration six months vs. 
planned duration 12 
months
Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
Not reported 
(1 RCT)
Low RR 1.59 
(0.97, 
2.63)
No statistically significant 
difference between six-month 
TC compared with the 12-month 
TC
TC – therapeutic community. RCT – randomised controlled trial. RR – relative risk
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Outcome Table 104: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Residential TC vs. day 
treatment TC
Point abstinence at 12 
months follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 
[H]; Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
261 (1 RCT) Low RR 0.90 
(0.67, 1.22)
Significantly more clients were 
abstinent at six months follow-
up in residential treatment 
compared with day treatment 
but differences were no longer 
statistically significant at 12 and 
18- month follow-up.
Standard TC vs. 
enhanced abbreviated 
TC
Point abstinence from 
crack/cocaine at 12 
months follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 
[H]; Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
412 (1 RCT) Low RR 1.10 
(0.90, 
1.35)
No statistically significant 
difference between standard TC 
and enhanced abbreviated TC.
Modified TC: planned 
duration three months 
vs. planned duration 6 
months
Time to first drug use 
(days from admission)
Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
Not reported 
(1 RCT)
Low HR 0.81 
(0.65, 1.01)
No statistically significant 
difference between three-
month and six-month groups.
Traditional TC: planned 
duration six months vs. 
planned duration 12 
months
Time to first drug use 
(days from admission)
Malivert et 
al., 2012 [L]; 
Vanderplasschen 
et al., 2013 [M]
Not reported 
(1 RCT)
Low HR 0.91 
(0.66, 1.27)
No statistically significant 
difference between 6-month 
and 12-month groups.
Residential 12-step 
vs. residential relapse 
prevention CBT
Point abstinence at 12 
months follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]
3,018 (1 
cohort)
Low RR 1.25 
(1.13, 1.39)
Significantly more clients were 
abstinent at 12-month follow-
up, in the residential 12-step-
based treatment compared with 
relapse prevention CBT.
Residential 12-step vs. 
eclectic residential
Point abstinence at 12 
months follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]
3,018 (1 
cohort)
Low RR 1.13 
(1.01, 1.25)
Significantly more clients were 
abstinent at 12-month follow-up 
in the residential 12-step-based 
treatment compared with 
eclectic programmes.
CBT – cognitive behavioural therapy. TC – therapeutic community. HR – hazard ratio. RR – relative risk
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Outcome Table 105: Employment
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Residential TC vs. other 
type of TC
Employment at 12 months 
follow-up
Vanderplasschen 
et al., 2013 [M]
Not reported 
(2 RCTs)
Low Not 
calculated
Significantly better employment 
rates among residential TC 
participants compared to other 
types of TC.
Residential TC vs. 
treatment as usual
Employment at 12 months 
follow-up
Vanderplasschen 
et al., 2013 [M]
Not reported 
(2 prospective 
controlled)
Low Not 
calculated
Significantly better employment 
rates among residential TC 
participants compared to 
treatment as usual.
TC – therapeutic community. RCT – randomised controlled trial
9.3.6 Treatments focusing on long‑term recovery
Population: People in recovery from drug and/or alcohol dependence
Setting: Community
Intervention: Continuing care
Outcome Table 106: Drug use
Comparison Reference(s) No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Continuing care vs. no or 
minimal treatment
Drug use at follow-up
Blodgett et al., 
2014 [M]
Not reported 
(13)
Moderate ES 0.27 
(Not 
reported)
Continuing care more effective 
than control.
CBT-based continuing 
care vs. non-CBT 
continuing care
Drug use at end of 
treatment
Blodgett et al., 
2014 [M]
Not reported 
(13)
Moderate ES 0.12 
(Not 
reported)
CBT-based continuing care 
more effective than non-CBT 
continuing care.
ACC vs. treatment as 
usual
Cannabis use at three-
month follow-up
Bender et al., 
2011 [H]
290 (2 RCTs) High Two 
studies 
only
No statistically significant 
difference between treatments
ACC vs. treatment as 
usual
Cannabis use at nine-
month follow-up
Bender et al., 
2011 [H]
132 (1 RCT) High One study 
only
No statistically significant 
difference between treatments
CBT – cognitive behavioural therapy. ACC – assertive continuing care. ES – effect size
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Intervention: Case management
Outcome Table 107: Treatment retention
Comparison Reference(s) No of 
participants 
(studies: 
design)
Level of 
quality 
fo review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Case management vs. 
standard care
Drug use at follow-up
Rapp et al., 2014 
[H]
Not reported 
(unclear)
Low SMD 0.36 
(Not 
reported)
Case management more 
effective than standard care
SMD – standardised mean difference
Outcome Table 108: Drug use
Comparison Reference(s) No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Continuing care vs. no or 
minimal treatment
Drug use at follow-up
Rapp et al., 2014 
[H]
Not reported 
(unclear)
Low SMD 0.08 
(Not 
reported)
Case management more 
effective than standard care
SMD – standardised mean difference
Intervention: Recovery housing
Outcome Table 109: Drug use
Comparison Reference(s) No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Recovery housing vs. 
usual care
Reif et al., 2014b 
[M]
Not reported 
(3: 2 RCTs; 
1 quasi-
experimental)
Moderate Not 
calculated
Recovery housing more 
effective than usual care
RCT – randomised controlled trial
Outcome Table 110: Reincarceration
Comparison Reference(s) No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oxford House recovery 
housing vs. usual 
aftercare
Reif et al., 2014b 
[M]
Not reported 
(1 RCT)
Low Not 
calculated
Reincarceration rates lower 
in Oxford House group than in 
usual aftercare
RCT – randomised controlled trial
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Outcome Table 111: Employment
Comparison Reference(s) No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oxford House recovery 
housing vs. usual 
aftercare
Reif et al., 2014b 
[M]
Not reported 
(1 RCT)
Low Not 
calculated
Employment rates higher in 
Oxford House group than in 
usual aftercare
RCT – randomised controlled trial
Intervention: Peer recovery coaching
Outcome Table 112: Drug use
Comparison Reference(s) No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Peer recovery coaching Reif et al., 2014a 
[H]
Not reported 
(4 studies; 1 
RCT; 3 pre 
and post)
Low Not 
calculated
Improved drug use outcomes 
related to the peer recovery 
support intervention
RCT – randomised controlled trial
Intervention: Mutual aid and self-help support
Outcome Table 113: Drug use
Comparison Reference(s) No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
12-step-based self-help 
groups
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]
Not reported 
(6 studies; 
1 RCT; 2 
cohorts; 1 
longitudinal; 
1 case series, 
1 RCT sub-
group analysis)
Low Not 
calculated
Active participation in self-
help groups improved drug 
outcomes at follow-up
RCT – randomised controlled trial
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9.3.7 Other treatment approaches
Population: People addicted to opioids
Setting: Community/outpatient
Intervention: Acupuncture
Outcome Table 114: Opioid craving
Comparison Reference(s) (JBI 
rating)
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Acupuncture vs. placebo Boyuan et al., 
2014 [H]
172 (3 RCTs) Moderate SMD -0.04 
(-0.40, 
0.33)
No statistically significant 
differences between 
approaches
Acupuncture vs. no 
treatment
Boyuan et al., 
2014 [H]
95 (2 RCTs) Low Two 
studies 
only
Mixed findings between studies
Acupuncture vs. 
pharmacological 
treatment
Boyuan et al., 
2014 [H]
280 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between 
approaches
Acupuncture with 
pharmacological 
treatment vs. 
pharmacological 
treatment alone
Boyuan et al., 
2014 [H]
256 (4 RCTs) Low SMD 0.24 
(-0.03, 
0.52)
Acupuncture with drug 
therapy more effective than 
pharmacological treatment 
alone
TENS vs. sham TENS Boyuan et al., 
2014 [H]
229 (2 RCTs) Low Two 
studies 
only
Mixed findings between studies
TENS  – transcutaneous electrical nerve stimulation. RCT – randomised controlled trial. SMD – standardised mean difference.
Outcome Table 115: Depression
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Acupuncture vs. placebo Boyuan et al., 
2014 [H]
60 (1 RCT) Low Not 
calculated
Acupuncture more effective 
than placebo
Acupuncture vs. no 
treatment
Boyuan et al., 
2014 [H]
120 (2 RCTs) Low Not 
calculated
Acupuncture more effective 
than no treatment
RCT – randomised controlled trial
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Outcome Table 116: Anxiety
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Acupuncture vs. placebo Boyuan et al., 
2014[H]
241 (2 RCTs) Low Not 
calculated
Acupuncture more effective 
than placebo
Acupuncture vs. no 
treatment
Boyuan et al., 
2014 [H]
122 (2 RCTs) Low Not 
calculated
Mixed findings between studies
Acupuncture vs. 
pharmacological 
treatment
Boyuan et al., 
2014 [H]
281 (2 RCTs) Low Not 
calculated
No statistically significant 
differences between 
approaches
Acupuncture with 
pharmacological 
treatment vs. 
pharmacological 
treatment alone
Boyuan et al., 
2014 [H]
185 (2 RCTs) Low Not 
calculated
Mixed findings between studies
RCT – randomised controlled trial
Intervention: Physical activity
Outcome Table 117: Abstinence
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Physical activity vs. 
psychosocial treatments 
or no treatment
Wang et al., 2014 
[H]
315 (3 RCTs) Moderate OR 4.13 
(2.39, 7.14)
Physical activity treatments 
more effective than other or no 
treatments
RCT – randomised controlled trial. OR – odds ratio
Outcome Table 118: Depression
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Physical activity vs. 
psychosocial treatments 
or no treatments
Wang et al., 2014 
[H]
176 (3 RCTs) Moderate SMD -0.77 
(-1.73, 
0.19)
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial. SMD – standardised mean difference
Outcome Table 119: Anxiety
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Physical activity vs. 
psychosocial treatments 
or no treatments
Wang et al., 2014 
[H]
271 (3 RCTs) Moderate SMD -0.40 
(-0.64, 
-0.16)
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial. SMD – standardised mean difference
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 151
9.3.8 Treatments delivered within the criminal justice system
Population: People with opioid dependency in contact with the criminal justice system
Setting: Prison
Intervention: Opioid maintenance
Outcome Table 120: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
OST vs. no OST
Heroin use in prison 
(biological and/or self-
report)
Larney, 2010 [H]; 
Hedrich et al., 
2012 [H]
545 (3: 1 RCT; 
1 quasi-RCT; 1 
retrospective 
cohort)
Moderate Not 
calculated
OST more effective than no OST.
OST vs. no OST
Heroin use post-release 
(biological and/or self-
report)
Hedrich et al., 
2012 [H]
566 (5: 3 
RCTs; 2 
prospective 
cohorts)
Moderate Not 
calculated
Mixed results but four of five 
studies found OST associated 
with significantly greater 
reductions.
High-dose MMT (>50mg) 
vs. low-dose MMT
Heroin use in prison 
(biological and/or self-
report)
Hedrich et al., 
2012 [H]
294 (2 
prospective 
cohorts)
Low Not 
calculated
High-dose MMT more effective 
than low-dose MMT
Buprenorphine 
maintenance treatment 
vs. MMT
Heroin use post-release 
(self-report)
Hedrich et al., 
2012 [H]; Perry et 
al., 2015 [H]
133 (1 RCT) Low RR 1.23 
(0.86, 1.76)
No statistically significant 
difference between 
buprenorphine maintenance 
treatment and MMT
RCT – randomised controlled trial. OST – opioid substitution therapy. MMT – methadone maintenance treatment. MD – mean 
difference
Outcome Table 121: Injecting drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
OST vs. no OST
Injecting drug use in 
prison (self-report)
Larney, 2010 [H]; 
Hedrich et al., 
2012 [H]
687 (3: 1 RCT; 
1 quasi-RCT; 1 
retrospective 
cross-
sectional)
Moderate Not 
calculated
OST more effective than no OST.
RCT – randomised controlled trial. OST – opioid substitution therapy
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Outcome Table 122: Criminal activity
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality of 
evidence
Effect size 
(95% CI)
Overall results (combined)
OST vs. no OST
Criminal activity (self-
report)
Hedrich et al., 
2012 [H]
356 (2 RCTs) Low Two 
studies 
only
Mixed results: generally 
no statistically significant 
difference between OST and 
no OST
OST vs. no OST
Reincarceration
Hedrich et al., 
2012 [M]
Not reported 
(9: 3 RCTs; 
1 case-
control; 5 
retrospective 
cohort)
Low Two 
studies 
only
Mixed results: four studies 
report OST more effective than 
no OST and five studies report 
no differences
OMT vs. no OMT
Reincarceration
Perry et al., 2015 
[H]
472 (3 RCTs) Low RR 0.77 
(0.36, 1.64)
No statistically significant 
difference between OMT and 
no OMT
Buprenorphine vs. 
methadone
Reincarceration
Hedrich et al., 
2012 [H]; Perry et 
al., 2015 [H]
133 (1 RCT) Low RR 1.25 
(0.83, 1.88)
No statistically significant 
difference between 
buprenorphine and methadone
RCT – randomised controlled trial. OMT – opioid maintenance treatment
Intervention: Opioid detoxification
Outcome Table 123: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality of 
evidence
Effect size 
(95% CI)
Overall results (combined)
Buprenorphine 
detoxification treatment 
vs. methadone 
detoxification treatment
Abstinence at three 
months (biological)
Perry et al., 2015c 
[H]
289 (1 RCT) Moderate RR 0.83 
(0.52, 1.32)
No statistically significant 
difference between 
buprenorphine detoxification 
treatment and methadone 
detoxification treatment
RCT – randomised controlled trial. OMT – opioid maintenance treatment. MMT – methadone maintenance treatment. MD – mean 
difference
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Intervention: Relapse prevention
Outcome Table 124: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oral naltrexone vs. 
treatment as usual
Heroin use at six months 
(self-report)
Perry et al., 2015c 
[H]
63 (1 RCT) Low RR 0.69 
(0.28, 1.70)
No difference between oral 
naltrexone and treatment as 
usual
Naltrexone implants vs. 
MMT
Heroin use post-prison 
release (self-report)
Perry et al., 2015c 
[H]
46 (1 RCT) Low MD 4.60 
(-3.54, 
12.74)
No statistically significant 
difference between naltrexone 
implants and MMT.
RR – risk difference. MD – mean difference
Outcome Table 125: Criminal activity
Comparison Reference(s) [JBI 
rating]
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Oral naltrexone vs. 
treatment as usual
Reincarceration at six 
months follow-up
Perry et al., 2015c 
[H]
114 (2 RCTs) Moderate RR 0.40 
(0.21, 0.74)
Oral naltrexone more effective 
than treatment as usual
Naltrexone implants vs. 
methadone
Criminal activity (self-
report)
Perry et al., 2015c 
[H]
46 (1 RCT) Low MD -0.50 
(-8.04, 
7.04)
No statistically significant 
difference between naltrexone 
implants and methadone
Naltrexone implants vs. 
methadone
Reincarceration
Perry et al., 2015c 
[H]
46 (1 RCT) Low RR 1.10 
(0.37, 3.26)
No statistically significant 
difference between naltrexone 
implants and methadone
RR – risk difference. MD – mean difference. RCT – randomised controlled trial
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Population: People who use drugs and are in contact with the criminal justice system
Setting: Community
Intervention: Diversion (including drug courts)
Outcome Table 126: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Diversion intervention vs. 
no intervention
Primary drug use 
(biological and/or self- 
report)
Hayhurst et al., 
2015 [H]
Not reported 
(3 studies: 2 
concurrent 
group 
comparisons; 
1 case series)
Moderate OR 1.68 
(1.12, 2.53)
Diversion intervention more 
effective than no intervention
Diversion intervention vs. 
no intervention
Other drug use 
(biological and/or self- 
report)
Hayhurst et al., 
2015 [H]
Not reported 
(3 concurrent 
group 
comparisons)
Low OR 2.60 
(1.70, 3.98)
Diversion intervention more 
effective than no intervention
OR – odds ratio. RCT – randomised controlled trial
Outcome Table 127: Criminal activity
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Diversion intervention vs. 
other intervention
General reoffending
Hayhurst et al., 
2015 [H]
Not reported 
(1 longitudinal 
follow-up; 1 
concurrent 
group 
comparison; 1 
correlational)
Low OR 4.06 
(not 
reported)
Evidence of a fairly substantive 
decrease in general reoffending 
following treatment
OR – odds ratio. RCT – randomised controlled trial
Setting: Prison
Intervention: Therapeutic communities
Outcome Table 128: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Therapeutic community 
work-release programme 
vs. standard aftercare
Relapse six-month 
follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]; 
Perry et al., 2009 
[H]
688 (1 RCT) Low One study 
only
Therapeutic communities 
associated with reductions in 
relapse
Therapeutic community 
vs. no treatment or other 
intervention
Relapse
Mitchell et al., 
2012 [H]
Not reported 
(13 studies: 
not reported)
Moderate 1.33 (0.92, 
1.93)
Therapeutic communities 
associated with reductions in 
relapse
RCT – randomised controlled trial
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Outcome Table 129: Criminal activity
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Therapeutic 
communities vs. no 
treatment or other 
intervention
General recidivism
Mitchell et al., 
2012 [H]
Not reported 
(35 studies:
Not reported)
Moderate OR 1.40 
(1.14, 1.71)
Therapeutic communities 
associated with reductions in 
recidivism
Therapeutic community 
and aftercare vs. 
treatment as usual
Reincarceration at 12 
months follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]; 
Perry et al., 2009 
[H]
854 (2 RCTs) Moderate RR 0.48 
(0.20, 1.12)
Therapeutic communities 
associated with reductions 
in reincarceration, criminal 
activity and recidivism
Therapeutic community 
and aftercare vs. 
treatment as usual
Reincarceration at five 
years follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]; 
Perry et al., 2009 
[H]
715 (1 RCT) Moderate RR 0.93 
(0.87, 
0.99)
Therapeutic community 
and aftercare vs. 
treatment as usual
Criminal activity
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]; 
Perry et al., 2009 
[H]
139 (1 RCT) Moderate RR 0.69 
(0.52, 
0.93)
OR – odds ratio. RR – relative risk. RCT – randomised controlled trial
Intervention: Boot camps
Outcome Table 130: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Boot camps vs. 
traditional juvenile camp
Illicit drug use 12-month 
follow-up
National 
Collaborating 
Centre for Mental 
Health, 2008 [H]
200 (1 
retrospective 
cohort)
Low One study 
only
No statistically significant 
difference between treatments
Outcome Table 131: Criminal activity
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Boot camps vs. 
traditional juvenile camp
General recidivism
Mitchell et al., 
2012 [H]; National 
Collaborating 
Centre for Mental 
Health, 2008 [H]
854 (1 
retrospective 
cohort)
Low OR 1.10 
(0.48, 
2.50)
No statistically significant 
difference between treatments
OR – odds ratio
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Intervention: Psychosocial interventions
Outcome Table 132: Drug use
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Behavioural management 
vs. TAU
Drug use at nine-month 
follow-up
Perry et al., 2015b 
[H]
77 (11 RCTs) Low One study 
only
No statistically significant 
differences between treatments
Counselling vs. no 
treatment or other 
intervention
Drug relapse
Mitchell et al., 
2012 [H]
Not reported 
(3 studies: not 
reported)
Moderate OR 0.77 
(0.35, 1.70) 
(1.20, 1.94)
No statistically significant 
differences between treatments
Vipassana meditation 
vs. TAU
Drug use
Shonin et al., 2013 
[H]
305 (1 quasi-
experimental)
Low One study 
only
Meditation associated with 
reduced drug use
TAU – treatment as usual. RCT – randomised controlled trial. OR – odds ratio
Outcome Table 133: Criminal activity
Comparison Reference(s) [JBI 
rating]
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Counselling vs. no 
treatment or other 
intervention
General recidivism
Mitchell et al., 
2012 [H]
Not reported 
(26 studies: 
Not reported)
Moderate OR 1.53 
(1.20, 1.94)
Counselling generally associated 
with statistically significant 
reductions in recidivism
CBT vs. TAU
General recidivism
Perry et al., 2015b 
[H]
44 (1 RCT) Low One study 
only
No statistically significant 
differences between treatments
Behavioural management 
vs. TAU
General recidivism
Perry et al., 2015b 
[H]
19 (1 RCT) Low One study 
only
No statistically significant 
differences between treatments
Case management vs. 
TAU
Arrests
Perry et al., 2015b 
[H]
183 (1 RCT) Low One study 
only
No statistically significant 
differences between treatments
CBT – cognitive behavioural therapy. TAU – treatment as usual. RCT – randomised controlled trial. OR – odds ratio
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Population: People with drug use and mental illness in contact with the criminal justice system
Setting: Prison
Intervention: Therapeutic communities
Outcome Table 134: Drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Therapeutic community 
vs. no treatment or 
treatment as usual
Self-reported use
Perry et al., 2015a 
[H]
715 (2 RCTs) Low Two 
studies 
only
Mixed results between studies
CBT – cognitive behavioural therapy. RCT – randomised controlled trial. SMD – standardised mean difference
Outcome Table 135: Criminal activity
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
TC vs. TAU
Re-arrest
Perry et al., 2015a 
[H]
428 (1 RCT) Low One study 
only
No statistically significant 
difference between treatments
TC vs. TAU
Reincarceration: 
Dichotomous
Perry et al., 2015a 
[H]
266 (2 RCTs) Low Two 
studies 
only
Reduced reincarceration 
associated with TC participation
TC vs. TAU or no 
treatment
Reincarceration: 
Continuous
Perry et al., 2015a 
[H]
361 (2 RCTs) Low Two 
studies 
only
Reduced reincarceration 
associated with TC participation
TC – therapeutic community. TAU – treatment as usual. RCT – randomised controlled trial
Intervention: Motivational interview and cognitive skills
Outcome Table 136: Drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MI plus cognitive skills vs. 
relaxation therapy
Perry et al., 2015a 
[H]
162 (1 RCT) Low One study 
only
No statistically significant 
difference between treatments
MI – motivational interview. RCT – randomised controlled trial
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Intervention: Mental health and court management
Outcome Table 137: Criminal activity
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MHC and case 
management vs. TAU
Perry et al., 2015a 
[H]
235 (1 RCT) Low One study 
only
No statistically significant 
difference between treatments
MHC – mental health court. TAU – treatment as usual. RCT – randomised controlled trial
9.3.9 Treatments for people with drug use and mental health disorders
Population: People with trauma and drug use problems
Setting: Community/outpatient
Intervention: CBT-based interventions
Outcome Table 138: Drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Individual CBT trauma-
focused interventions 
plus SUD intervention 
vs. TAU
Roberts et al., 
2015 [H]
388 (3 RCTs) Moderate SMD -0.28 
(-0.48, 
-0.07)
CBT trauma-focused 
interventions better than 
treatment as usual
Group-based CBT 
non-trauma-focused 
interventions vs. TAU
Roberts et al., 
2015 [H]
572 (4 RCTs) Moderate SMD 
-0.006 
(-0.23, 
0.11)
No statistically significant 
differences between treatment 
approaches
Individual CBT non-
trauma-focused 
intervention for PTSD 
and SUD vs. psychosocial 
treatments for SUD only
Roberts et al., 
2015 [H]
128 (2 RCTs) Low Not 
calculated
No statistically significant 
differences between treatment 
approaches
CBT – cognitive behavioural therapy. TAU – treatment as usual. PTSD – post-traumatic stress disorder. RCT – randomised 
controlled trial. SMD – standardised mean difference
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Outcome Table 139: Post‑traumatic stress disorder severity
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality of 
evidence
Effect size 
(95% CI)
Overall results (combined)
Individual CBT trauma-
focused interventions 
plus SUD intervention 
vs. TAU
Roberts et al., 
2015 [H]
388 (4 RCTs) Moderate SMD -0.33 
(-0.58, 
-0.10)
CBT trauma-focused 
interventions better than 
treatment as usual
Group-based CBT 
non-trauma-focused 
interventions vs. TAU
Roberts et al., 
2015 [H]
566 (4 RCTs) Moderate SMD -0.14 
(0.31, 0.03)
No statistically significant 
differences between treatment 
approaches
Individual CBT non-
trauma-focused 
intervention for PTSD 
and SUD vs. psychosocial 
treatments for SUD only
Roberts et al., 
2015 [H]
128 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between treatment 
approaches
Individual CBT non-
trauma-focused 
intervention for PTSD 
only vs. treatment as 
usual
Roberts et al., 
2015 [H]
44 (1 RCT) Moderate One study 
only
No statistically significant 
differences between treatment 
approaches
CBT – cognitive behavioural therapy. TAU – treatment as usual. PTSD – post-traumatic stress disorder. RCT – randomised 
controlled trial. SMD – standardised mean difference
Outcome Table 140: Treatment retention
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Individual CBT trauma-
focused interventions 
plus SUD intervention 
vs. TAU.
Roberts et al., 
2015 [H]
316 (3 RCTs) Moderate RR 0.78 
(0.64, 
0.96)
CBT trauma-focused 
interventions better than 
treatment as usual
Group-based CBT 
non-trauma-focused 
interventions vs. TAU
Roberts et al., 
2015 [H]
381 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between treatment 
approaches
CBT – cognitive behavioural therapy. TAU – treatment as usual. RCT – randomised controlled trial. SMD – standardised mean 
difference
Intervention: Integrated treatment programmes
Outcome Table 141: Drug use disorder symptoms
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
IT programmes vs. non-
IT programmes
Torchalla et al., 
2012 [H]
NR (9 
controlled 
trials)
High d=0.10 
(0.01, 0.21)
No statistically significant 
difference between approaches
IT – Integrated treatment
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Outcome Table 142: PTSD symptoms
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
IT programmes vs. non-
IT programmes
Torchalla et al., 
2012 [H]
NR (9 
controlled 
studies)
High d=0.08 
(-0.03, 
0.19)
No statistically significant 
difference between approaches
IT – Integrated treatment
Population: People with severe mental illnesses
Intervention: Psychosocial interventions
Outcome Table 143: Lost to treatment
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Integrated models of 
care vs. TAU
36 months
Hunt et al., 2013 
[H]
603 (3 RCTs) Moderate RR 1.09 
(0.82, 1.45)
No statistically significant 
differences between treatment 
approaches
Non-integrated models 
of care vs. TAU
6 months
Hunt et al., 2013 
[H]
134 (3 RCTs) Moderate Not 
calculated
No statistically significant 
differences between treatment 
approaches
Non-integrated models 
of care vs. TAU
12 months
Hunt et al., 2013 
[H]
134 (3 RCTs) Moderate Not 
calculated
No statistically significant 
differences between treatment 
approaches
Non-integrated models 
of care vs. TAU
18 months
Hunt et al., 2013 
[H]
134 (3 RCTs) Moderate RR 1.35 
(0.83, 2.19)
No statistically significant 
differences between treatment 
approaches
CBT plus motivational 
interview vs. TAU
6 months
Hunt et al., 2013 
[H]
605 (3 RCTs) Moderate RR 1.02 
(0.68, 1.54)
No statistically significant 
differences between treatment 
approaches
CBT plus motivational 
interview vs. TAU
12 months
Hunt et al., 2013 
[H]
327 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
CBT alone vs. treatment 
as usual
Hunt et al., 2013 
[H]
152 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between treatment 
approaches
Motivational interview 
alone vs. TAU
Hunt et al., 2013 
[H]
62 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Skills training vs. TAU Hunt et al., 2013 
[H]
47 (1 RCT) Low One study 
only
Treatment as usual better than 
skills training
Contingency 
management vs. TAU
Hunt et al., 2013 
[H]
206 (2 RCTs) Low Two 
studies 
only
Mixed results between studies
CBT – cognitive behavioural therapy. TAU – treatment as usual. RCT – randomised controlled trial. RR – risk ratio
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Outcome Table 144: Drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
CBT plus motivational 
interview vs. TAU
Cannabis use
Hunt et al., 2013 
[H]
42 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
CBT alone vs. TAU
Cannabis use
Hunt et al., 2013 
[H]
47 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Motivational interview 
alone vs. TAU
Cannabis use
Hunt et al., 2013 
[H]
62 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Contingency 
management vs. TAU
Cannabis use
Hunt et al., 2013 
[H]
176 (1 RCT) Low One study 
only
Treatment as usual better than 
contingency management
Integrated models of 
care vs. TAU
Not in remission – 36 
months
Hunt et al., 2013 
[H]
143 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
CBT plus motivational 
interview vs. TAU
Number of drugs used in 
past month
Hunt et al., 2013 
[H]
119 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Motivational interview 
alone vs. TAU
Polydrug use
Hunt et al., 2013 
[H]
89 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Motivational interview 
alone vs. TAU
Abstinence from drugs
Hunt et al., 2013 
[H]
25 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Contingency 
management vs. TAU
Injection drug use: during 
treatment
Hunt et al., 2013 
[H]
176 (1 RCT) Low One study 
only
Reduced injecting in 
contingency management 
treatment compared to 
treatment as usual
Contingency 
management vs. TAU
Injection drug use: 
follow-up
Hunt et al., 2013 
[H]
176 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
Contingency 
management vs. TAU
Stimulant use
Hunt et al., 2013 
[H]
176 (1 RCT) Low One study 
only
No statistically significant 
differences between treatment 
approaches
CBT – cognitive behavioural therapy. TAU – treatment as usual. RCT – randomised controlled trial
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Outcome Table 145: Drug dependence
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
ot review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MI alone vs. TAU
Amphetamine 
dependence
Hunt et al., 2013 
[H]
19 (1 RCT) Low Not 
calculated
No statistically significant 
differences between treatment 
approaches
MI alone vs. TAU
Cannabis dependence
Hunt et al., 2013 
[H]
62 (1 RCT) Low Not 
calculated
No statistically significant 
differences between treatment 
approaches
MI alone vs. TAU
Alcohol dependence
Hunt et al., 2013 
[H]
52 (1 RCT) Low Not 
calculated
No statistically significant 
differences between treatment 
approaches
MI – motivational interview. TAU – treatment as usual. RCT – randomised controlled trial. RR – risk ratio
Population: People with borderline personality disorder
Setting: Community/outpatient
Intervention: Range of therapies
Outcome Table 146: Range of outcomes
Comparison Reference(s) (JBI 
rating)
No of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Dialectical behaviour 
therapy vs. control
Lee et al., 2015 
[H]
NR (4 RCTs) Moderate Not 
calculated
Reductions in drug use, suicidal 
and self-harm behaviours and 
improvements in treatment 
retention, global functioning 
and social functioning were 
associated with dialectical 
behaviour therapy compared 
with control conditions
Dual focus schema 
therapy vs. control
Lee et al., 2015 
[H]
NR (3 RCTs) Moderate Not 
calculated
Few differences reported on 
any outcomes among those 
receiving dual focus schema 
therapy compared to control 
conditions
Dynamic deconstructive 
psychotherapy vs. 
control
Lee et al., 2015 
[H]
NR (3 RCTs) Moderate Not 
calculated
Reductions in drug use, suicidal 
behaviour and personality 
disorders associated with 
dynamic deconstructive 
psychotherapy compared with 
control conditions
RCT – randomised controlled trial
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9.3.10 Treatments delivered to pregnant and parenting women
Population: Pregnant women who are opioid dependent
Setting: Community/outpatient
Intervention: Methadone maintenance treatment
Outcome Table 147: Maternal drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MMT vs. slow-release 
morphine
Heroin use
Minozzi et al., 
2013 [H]
48 (1 RCT) Low One study 
only
Slow-release morphine was 
more effective than MMT
MMT vs. buprenorphine
Use of primary drug of 
abuse
Minozzi et al., 
2013 [H]
151 (2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between 
approaches
MMT vs. buprenorphine
Use of other drug
Minozzi et al., 
2013 [H]
(2 RCTs) Low Two 
studies 
only
No statistically significant 
differences between 
approaches
MMT – methadone maintenance treatment. RCT – randomised controlled trial
Outcome Table 148: Birth outcomes
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
MMT vs. buprenorphine
Neonatal abstinence 
syndrome
Minozzi et al., 
2013 [H]
166 (3 RCTs) Low RR 1.22 
(0.89, 1.67)
No statistically significant 
differences between 
approaches
MMT vs. buprenorphine
Birth weight
Minozzi et al., 
2013 [H]
150 (2 RCTs) Low Two 
studies 
only
Buprenorphine was more 
effective than MMT
MMT vs. slow-release 
morphine
Birth weight
Minozzi et al., 
2013 [H]
48 (1 RCT) Low One study 
only
No statistically significant 
differences between 
approaches
MMT vs. slow-release 
morphine
Week of delivery
Minozzi et al., 
2013 [H]
48 (1 RCT) Low Two 
studies 
only
No statistically significant 
differences between 
approaches
MMT vs. slow-release 
morphine
Pre- and neonatal 
mortality
Minozzi et al., 
2013 [H]
48 (1 RCT) Low One study 
only
No statistically significant 
differences between 
approaches
MMT – methadone maintenance treatment. RCT – randomised controlled trial. RR – risk ratio
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Population: Pregnant or parenting women
Setting: Community/outpatient
Intervention: Pyschosocial interventions
Outcome Table 149: Maternal drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Contingency 
management vs. usual 
care
Drug use
Terplan et al., 
2015 [H]
89 (1 RCT) Moderate One study 
only
No statistically significant 
differences between 
approaches
Motivational interview-
based intervention vs. 
treatment as usual
Drug use
Terplan et al., 
2015 [H]
159 (1 RCT) Low One study 
only
No statistically significant 
differences between 
approaches
Contingency 
management vs. usual 
care
Drug use at delivery
Terplan et al., 
2015 [H]
89 (1 RCT) Moderate One study 
only
No statistically significant 
differences between 
approaches
Motivational interview-
based intervention vs. 
treatment as usual
Drug use at delivery
Terplan et al., 
2015 [H]
128 (1 RCT) Moderate One study 
only
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial
Outcome Table 150: Treatment completion
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Contingency 
management vs. usual 
care
Terplan et al., 
2015 [H]
388 (6 RCTs) Moderate RR 1.03 
(0.92, 1.16)
No statistically significant 
differences between 
approaches
Motivational interview-
based intervention vs. 
treatment as usual
Terplan et al., 
2015 [H]
355 (3 RCTs) Low RR 0.97 
(0.89, 1.06)
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial. RR – risk ratio
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Intervention: Integrated treatment programmes
Outcome Table 151: Treatment outcomes
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
fo review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Integrated vs. non-
integrated treatment
Treatment length
Milligan et al., 
2011 [H]
1,910 (3: 2 
RCTs, 1 quasi-
experimental)
Low d=0.35 
(0.28, 0.47)
Integrated treatment more 
effective than non-integrated 
treatment
Integrated vs. non-
integrated treatment
Treatment completion
Milligan et al., 
2011 [H]
2,504 (6: 2 
RCTs, 4 quasi-
experimental)
Moderate d=0.38 
(-0.05, 
0.80)
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial
Outcome Table 152: Maternal drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Integrated vs. no 
treatment
Drug use
Milligan et al., 
2010 [H]
1,487 (2 quasi 
experimental)
Moderate Two 
studies 
only
Integrated treatment more 
effective than no treatment
Integrated vs. non-
integrated treatment
Drug use
Milligan et al., 
2010 [H]
278 (4: 2 
RCTs, 2 quasi 
experimental)
Low d=-0.09 
(0.41, 0.23)
No statistically significant 
differences between 
approaches
Integrated vs. non-
integrated treatment
Abstinence
Milligan et al., 
2010 [H]
89 (2 quasi-
experimental)
Low Two 
studies 
only
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial
Intervention: Home visits
Outcome Table 153: Maternal drug use
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Home visits before or 
after birth vs. no home 
visits
Illicit drug use
Turnbull and 
Osborn, 2012 [H]
384 (3 RCTs) Moderate RR 1.05 
(0.89-1.24)
No statistically significant 
differences between 
approaches
Home visits before or 
after birth vs. no home 
visits
Alcohol use
Turnbull and 
Osborn, 2012 [H]
379 (3 RCTs) Moderate RR 1.18 
(0.96-1.46)
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial. RR – risk ratio
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Outcome Table 154: Infant mortality
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Home visits before or 
after birth vs. no home 
visits
Turnbull and 
Osborn, 2012 [H]
288 (2 RCTs) High Two 
studies 
only
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial
Outcome Table 155: Treatment programme uptake
Comparison Reference(s) (JBI 
rating)
No. of 
participants 
(studies: 
design)
Level of 
quality 
of review 
evidence
Effect size 
(95% CI)
Overall results (combined)
Home visits before or 
after birth vs. no home 
visits
Turnbull and 
Osborn, 2012 [H]
211 (2 RCTs) Moderate Not 
calculated
No statistically significant 
differences between 
approaches
RCT – randomised controlled trial
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 167
10
References
10.1 General references
Abram KM (2016) New evidence for the role of 
mental disorders in the development of drug 
abuse. Journal of the American Academy of Child 
and Adolescent Psychiatry, 55(4): 265-266.
Alado A, Nolen-Hoeksema N and Schweizer S 
(2010) Emotion-regulation strategies across 
psychopathology: A meta-analytic review. Clinical 
Psychology Review, 30(2): 217-237.
ACMD (2013) What recovery outcomes does 
the evidence tell us we can expect? Home 
Office, London.
ALICE RAP (2014) Prevention programmes. [online] 
ALICE RAP. Available at: www.alice-rap.prevention-
standards.eu/prevention-programmes/ [Accessed 
6 April 2016].
Anda RF, Felitti VJ, Brener JD, Whitfield C, Perry 
BD, Dube SR et al. (2006) The enduring effects of 
abuse and related adverse experiences in children. 
A convergence of evidence from neurobiology and 
epidemiology. European Archives of Psychiatry and 
Clinical Neuroscience, 256: 174-186.
Bates G, Ross K, Cochrane M, Sumnall HR (2016) 
The drugs situation in Ireland: a review of the 
evidence since 2005 report. Health Research 
Board: Dublin.
Bellerose D, Carew AM and Lyons S (2011) Trends 
in treated problem drug use in Ireland 2005-2010. 
Health Research Board: Dublin
Brady KT and Sinha R (2005) Co-occurring mental 
and drug use disorders: the neurobiological effects 
of chronic stress. American Journal of Psychiatry, 
162(8): 1483-1493.
Boyer EW (2012) Management of opioid analgesic 
overdose. The New England Journal of Medicine, 
367: 146-155.
Broning S, Kumpfer K, Kruse K, Sack P, Schaunig-
Busch I and Ruths S et al. (2012) Selective 
prevention programs for children from drug-
affected families: a comprehensive systematic 
review. Substance Abuse Treatment, Prevention, 
and Policy, 7:23.
Carneiro M, Fuller C, Doherty MC and Vlahov D 
(2000) HIV prevalence and risk behaviors among 
new initiates into injection drug use over the age 
of 40 years old. Drug and Alcohol Dependence, 54: 
83–86.
Cox G and Whitaker T (2009) Drug Use, Sex Work 
and the Risk Environment in Dublin. Dublin: National 
Advisory Committee on Drugs. Available at: http://
www.drugs.ie/resourcesfiles/research/2009/
Druguse_SexWork-Web.pdf
Dennhardt AA and Murphy JG (2013) Prevention and 
treatment of college student drug use: A review 
of the literature. Addictive Behaviors, 38 (10): 
2607-2618.
Degenhardt L, Stockings E, Patton G, Hall WD 
and Lynskey M (2016) The increasing global health 
priority of drug use in young people. Lancet 
Psychiatry, 3 (3): 251-264
www.hrb.ie168
Ditmore MH (2013) When sex work and drug use 
overlap. Considerations for advocacy and practice. 
Harm Reduction International.  
Available at: www.ihra.net
Drummond A, Codd M, Donnelly N, McCausland 
N, Mehegan J, Daly L et al. (2014) Study on the 
prevalence of drug use, including intravenous drug 
use, and blood-borne viruses among the Irish 
prisoner population. Dublin: National Advisory 
Committee on Drugs and Alcohol. Available at: 
www.drugsandalcohol.ie/21750/
Department of Health (2014) National Drugs 
Strategy 2009-2016: progress report to end 2013. 
Dublin: Department of Health. Available at:  
www.drugsandalcohol.ie/21621/
Department of Health (2015) National Drugs 
Strategy 2009-2016: progress report to end 2014. 
Dublin: Department of Health. Available at:  
www.drugsandalcohol.ie/23935/
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (2013) Perspective on drugs: 
Mass-media campaigns for the prevention of drug 
use in young people. Available at:  
http://www.drugsandalcohol.ie/21978/ 
[Accessed 6 April 2016].
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (2015a) European Drug Report 
2015. Lisbon: EMCDDA.
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (2015b) Best practice in 
drug interventions [online]. EMCDDA. Available at: 
http://www.emcdda.europa.eu/topics/prevention 
[Accessed 6 April 2016].
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (2015c) Harm reduction 
overview for Ireland [online] EMCDDA. Available 
at: http://www.emcdda.europa.eu/country-data/
harm-reduction/Ireland [Accessed 6 April 2016].
European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) (2015d). Data and 
statistics [online] EMCDDA. Available at: www.
emcdda.europa.eu/data/stats2015 [Accessed 
January 2016].
European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) (2015e) Preventing 
fatal overdoses: a systematic review of the 
effectiveness of take-home naloxone. EMCDDA 
papers. Luxembourg: Publications Office of the 
European Union.
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (2015f) Perspectives on drugs: 
Drug consumption rooms: an overview of provision 
and evidence. Luxembourg: EMCDDA papers, 
Publications Office of the European Union.
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (2015g) Drug treatment 
overview for Ireland [online]. EMCDDA. Available at:  
www.emcdda.europa.eu/data/treatment-
overviews/Ireland  
[Accessed 6 April 2016].
European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) (2016a) Emergency 
department-based brief interventions for 
individuals with drug-related problems: a review 
of effectiveness. EMCDDA Papers. Luxembourg: 
Publications Office of the European Union.
European Monitoring Centre for Drugs and Drug 
Addiction (2016b). Ireland country overview 
[online]. EMCDDA. Available at:  
www.emcdda.europa.eu/countries/ireland 
[Accessed 19 February 2016].
Fletcher A, Calafat A, Pirona A and Olszewski D 
(2010) Young people, recreational drug use and 
harm reduction. In EMCDDA Monographs 10. Harm 
Reduction: evidence, impacts and challenges. 
EMCDDA papers. Luxembourg: Publications Office 
of the European Union.
Hartz SM, Pato CN, Mederios H, Cavazos-Rehg P, 
Sobell JL, Knowles JA et al. (2014) Comorbidity of 
severe psychotic disorders with measures of drug 
use. Journal of American Medical Association, 71(3): 
248-254.
Health Protection Surveillance Centre (2013) 
HIV in Ireland 2012 Report. Dublin: Health 
Service Executive.
Health Protection Surveillance Centre (2014) HIV 
in Ireland 2013 Report. Dublin: Health Protection 
Surveillance Centre.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 169
Health Protection Surveillance Centre (2015). 
HIV in Ireland. Quarter 1&2 2015. Retrieved 
from: www.hpsc.ie/A-Z/HIVSTIs/HIVandAIDS/
SurveillanceReports/File,14947,en.pptx  
[Accessed December 2015].
Health Research Board (2016a) Irish National Focal 
Point to the European Monitoring Centre for Drugs 
and Drug Addiction. Ireland: National report for 
2015 – harms and harm reduction. Dublin: Health 
Research Board.
Health Research Board (2016b) Irish National Focal 
Point to the European Monitoring Centre for Drugs 
and Drug Addiction. Ireland: national report for 
2015 – treatment. Dublin: Health Research Board.
Huang GC, Unger JB, Soto D, Fujimoto K, Pentz MA, 
Jorden-Marsh M et al. (2014) Peer influences: the 
impact of online and offline friendship networks 
on adolescent smoking and alcohol use. Journal of 
Adolescent Health, 54(5): 508-514.
Hibell B, Guttormsson U, Ahlström S, Balakireva O, 
Bjarnason T, Kokkevi A and Kraus L (2012) The 2011 
ESPAD report. Substance Use Among Students in 36 
European Countries. Stockholm: Swedish Council 
for Information on Alcohol and Other Drugs (CAN).
Hunt N (2003) A review on the evidence base  
for harm reduction approaches to drug use. 
Available at: www.ihra.net/files/2010/05/31/
HIVTop50Documents11.pdf  
[Accessed February 2016]
Institute of Obstetricians and Gynaecologists, 
Health Service Executive (2015) Clinical 
Practice Guideline: methadone Prescribing and 
Adminstration in Pregnancy. Dublin: Royal College 
of Physicians of Ireland.
Jeal N and Salisbury C (2004) A health needs 
assessment of street-based prostitutes: cross-
sectional survey. Journal of Public Health, 26 
(2):147-151.
Joanna Briggs Institute (2014) Reviewers’ Manual 
2014 Methodology for JBI Umbrella Reviews. 
University of Adelaide: The Joanna Briggs Institute. 
Available at: www.joannabriggs.org/assets/docs/
sumari/ReviewersManual-Methodology-JBI_
Umbrella%20Reviews-2014.pdf
Jones L, Sumnall H, Witty K, Wareing M, McVeigh 
J, Bellis M et al. (2006) A review of community-
based interventions to reduce drug misuse among 
vulnerable and disadvantaged young people.
Liverpool: National Collaborating Centre for Drug 
Prevention, Centre for Public Health.
Jones L, Bates G and McVeigh J (2014) Update 
of NICE Guidance PH18 on ‘Needle and syringe 
programmes’. Liverpool: Centre for Public Health.
Kendler KS, Prescott CA, Myers J and Neale MC 
(2003) The structure of genetic and environmental 
risk factors for common psychiatric and drug use 
disorders in men and women. Archives of General 
Psychiatry, 60(9): 929-937.
Kerr T and Palepu A (2001) Safe injection facilities 
in Canada: Is it time? CMAJ: Canadian Medical 
Association Journal, 165: 436-437.
Kools J (2009) The Dutch experience in promoting 
transition away from injecting drug use, 1991-2009. 
Oral evidence to ACMD meeting, 29 October 2009.
Lai HMX, Cleary M, Sitharthan T and Hunt GE (2015) 
Prevalence of comorbid substance use, anxiety and 
mood disorders in epidemiological surveys, 1990–
2014: A systematic review and meta-analysis. Drug 
and Alcohol Dependence, 154: 1-13.
Lemstra M, Bennett N, Nannapaneni U, Neudorf 
C, Warren L, Kershaw T et al. (2010) A systematic 
review of school-based marijuana and alcohol 
prevention programs targeting adolescents aged 
10-15. Addiction Research & Theory, 18(1): 84-96.
Mathers BM, Degenhardt, L, Bucello C, Lemon J, 
Wiessing L and Hickman M (2013) Mortality among 
people who inject drugs: a systematic review 
and meta-analysis. Bulletin of the World Health 
Organization, 91: 102-123.
National Advisory Committee on Drugs and Alcohol 
(2012) Drug use in Ireland and Northern Ireland 
drug prevalence survey 2010/11: Regional Drug 
Task Force (Ireland) and Health and Social Services 
Trust (Northern Ireland) results. Bulletin 2. Dublin: 
National Advisory Committee on Drugs & Public 
Health Information and Research Branch.
National Advisory Committee on Drugs and Alcohol 
(2016) Prevalence of drug use and gambling in 
Ireland and Northern Ireland. Bulletin One. Dublin: 
Department of Health.
www.hrb.ie170
Nelson PK, Mathers BM, Cowie B, Hagan H, 
Des Jarlais D, Horyniak D et al. (2011) Global 
epidemiology of hepatitis B and hepatitis C in 
people who inject drugs: results of systematic 
reviews. The Lancet, 378(9791): 571-583.
O’Donnell A, Anderson P, Newbury-Birch D, Schulte 
B, Schmidt C, Reimer J and Kaner E (2014) The 
Impact of Brief Alcohol Interventions in Primary 
Healthcare: A Systematic Review of Reviews. 
Alcohol and Alcoholism, 49: 66-78.
O’Shea M (2007) Introducing safer injecting 
facilities (SIFs) in the Republic of Ireland: ‘Chipping 
away’ at policy change. Drugs: Education, 
Prevention and Policy, 14(1): 75-88.
Petosa RL and Smith LH (2014) Peer mentoring 
for health behavior change: A systematic review. 
American Journal of Health Education, 45: 351-357.
Proctor SL and Herschman PL (2014) The 
Continuing Care Model of Substance Use 
Treatment: What Works, and When Is “Enough” 
“Enough”. Psychiatry Journal 2014: 16.
Public Health England (2015) Shooting Up. 
Infections among people who inject drugs in the 
UK, 2014. London: Public Health England.
Salvy SJ, De La Haye K, Bowker JC and Hermans RC 
(2012). Influence of peers and friends on children’s 
and adolescents’ eating and activity behaviors. 
Physiology and Behavior, 106(3): 369-378.
Slater MD, Kelly KJ, Edwards RW, Thurman PJ, 
Plested BA, Keefe TJ et al. (2006) Combining 
in-school and community-based media efforts: 
reducing marijuana and alcohol uptake among 
younger adolescents. Health Education Research, 
21(1): 157-167.
Stockings E, Hall WD, Lynskey M, Morley KI, 
Reavley N, Strang J et al. (2016) Prevention early 
intervention, harm reduction, and treatment 
of drug use in young people. Lancet Psychiatry, 
3: 280-296.
Strohle A, Hofler M, Pfister H, Muller AG, Hoyer J, 
Wittchen HU and Lieb R (2007) Physical activity 
and prevalence and incidence of mental disorders 
in adolescents and young adults. Psychol Med, 
37: 1657-66.
Sumnall HR and Brotherhood A (2012) Social 
reintegration and employment: evidence and 
interventions for drug users in treatment. 
Lisbon: EMCDDA.
Tanner-Smith ET and Lipsey MW (2015) Brief 
alcohol interventions for adolescents and young 
adults: A systematic review and meta-analysis. 
Journal of Drug Abuse Treatment, 51: 1-18.
UNESCO Child & Family Research Centre (2012) 
Mobilising Peer Support in Schools: An evaluation 
of the BBS school based mentoring programme. 
Available at: www.foroige.ie/sites/default/files/
bbbs_evaluation_report.pdf  
[Last accessed 9/12/16]
van Hasselt N, Hughes K, Burkhart G and 
Gyarmathy VA (2012) Responding to drug use 
and related problems in recreational settings. 
Lisbon: European Monitoring Centre for Drugs 
and Drug Addiction.
Volkow ND, Baler RD, Wilson M, Compton MD 
and Weiss SRB (2014) Adverse health effects of 
marijuana use. New England Journal of Medicine, 
370: 2219-2227.
Wakefield MA, Loken B and Hornik RC (2010) 
Use of mass-media campaigns to change health 
behaviour. The Lancet, 376: 1261-1271.
White W (2009) Peer-based Addiction Recovery 
Support: History, Theory, Practice and Scientific 
Evaluation. Chicago, IL: Great Lakes Addiction 
Technology Transfer Center and Philadelphia 
Department of Behavioral Health.
Whiteford HA, Degenhardt L, Rehm J, Baxter A, 
Ferrari A, Erskine H et al. (2013) Global burden 
of disease attributable to mental and drug use 
disorders: findings from the Global Burden of 
Disease Study. The Lancet, 382(9904): 9-15.
World Health Organization (2004) Policy brief: 
Provision of sterile injecting equipment to reduce 
HIV transmission. Available at: www.who.int/hiv/
pub/advocacy/en/provisionofsterileen.pdf  
[Last accessed 9/12/16]
World Health Organization (2009) Guidelines 
for the Psychosocially Assisted Pharmacological 
Treatment of Opioid Dependence. Geneva: World 
Health Organization
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 171
World Health Organization (2014) Information sheet 
on opioid overdose. Available at: www.who.int/
drug_abuse/information-sheet/en/  
[Last accessed 9/12/16]
10.2 References to 
included articles
10.2.1 Prevention review (n=13)
Carney T, Myers Bronwyn J, Louw J and Okwundu 
CI (2014). Brief school-based interventions and 
behavioural outcomes for drug-using adolescents. 
Cochrane Database of Systematic Reviews (2). 
http://www.drugsandalcohol.ie/14921/
[last accessed 9/12/16]
Faggiano F, Minozzi S, Versino E and Buscemi D 
(2014) Universal school-based prevention for 
illicit drug use. Cochrane Database of Systematic 
Reviews (12).
Ferri M, Allara E, Bo A, Gasparrini A and Faggiano F 
(2013) Media campaigns for the prevention of illicit 
drug use in young people. Cochrane Database of 
Systematic Reviews (6).
Jackson C, Geddes R, Haw S and Frank J (2012) 
Interventions to prevent drug use and risky sexual 
behaviour in young people: A systematic review. 
Addiction, 107(4):733-47.
Newton AS, Dong K, Mabood N, Ata N, Ali S, 
Gokiert R et al. (2013) Brief emergency department 
interventions for youth who use alcohol and other 
drugs: a systematic review. Pediatric Emergency 
Care, 29(5):673-84.
Norberg MM, Kezelman S and Lim-Howe N (2013) 
Primary prevention of cannabis use: a systematic 
review of randomized controlled trial PLoS One, 
8(1):[e53187].
Patnode CD, O’Connor E, Rowland M, Burda BU, 
Perdue LA and Whitlock EP (2014) Primary care 
behavioral interventions to prevent or reduce illicit 
drug use and nonmedical pharmaceutical use in 
children and adolescents: a systematic evidence 
review for the U.S. Preventive Services Task Force. 
Database of Abstracts of Reviews of Effects, 
(2):612-20.
Salvo N, Bennett K, Cheung A and Bowlby A (2012) 
Prevention of drug use in children/adolescents 
with mental disorders: A systematic review. Journal 
of the Canadian Academy of Child and Adolescent 
Psychiatry/Journal de l’Académie canadienne 
de psychiatrie de l’enfant et de l’adolescent, 
21(4):245-52.
Tait RJ, Spijkerman R and Riper H (2013) 
Internet and computer based interventions for 
cannabis use: A meta-analysis. Drug and Alcohol 
Dependence, 133: 295-304.
Thomas RE, Lorenzetti DL and Spragins W (2013) 
Systematic review of mentoring to prevent or 
reduce alcohol and drug use by adolescents. 
Academic Pediatrics, 13(4):292-9.
VanBuskirk KA and Wetherell JL (2014) Motivational 
interviewing with primary care populations: A 
systematic review and meta-analysis. Journal of 
Behavioral Medicine, 37(4):768-80.
Vermeulen-Smit E, Verdurmen JEE and Engels 
RCME (2015) The effectiveness of family 
interventions in preventing adolescent illicit drug 
use: A systematic review and meta-analysis of 
randomized controlled trials. Clinical Child and 
Family Psychology Review, 18:218-239.
Wood SK, Eckley L, Hughes K, Hardcastle KA, Bellis 
MA, Schrooten J et al. (2014) Computer-based 
programmes for the prevention and management 
of illicit recreational drug use: A systematic review. 
Addictive Behaviors, 39(1):30-8.
10.2.2 Harm reduction review 
(n=24)
Abad N, Baack BN, O’Leary A, Mizuno Y, Herbst JH 
and Lyles CM (2015) A systematic review of HIV and 
STI behavior change interventions for female sex 
workers in the United States. AIDS and Behavior, 
19(9): 1701-19
Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, 
Briceno A, Semaan S et al. (2013) Effectiveness of 
structural-level needle/syringe programs to reduce 
HCV and HIV infection among people who inject 
drugs: A systematic review. AIDS and Behavior, 
17:2878-92.
www.hrb.ie172
Akbar T, Baldacchino A, Cecil J, Riglietta M, 
Sommer B and Humphris G (2011) Poly-drug use 
and related harms: A systematic review of harm 
reduction strategies implemented in recreational 
settings. Neuroscience and Biobehavioral Reviews, 
35(5):1186-202.
Aspinall EJ, Corson S, Doyle JS, Grebely J, 
Hutchinson SJ, Dore GJ et al. (2013) Treatment 
of hepatitis C virus infection among people who 
are actively injecting drugs: a systematic review 
and meta-analysis. Clinical Infectious Diseases 
57(Supplement 2):S80-9.
Bolier L, Voorham L, Monshouwer K, van Hasselt N 
and Bellis M (2011) Alcohol and drug prevention in 
nightlife settings: A review of experimental studies. 
Substance Use & Misuse 46(13): 1569-1591.
Camp Binford M, Kahana SY and Altice FL (2012) 
A systematic review of antiretroviral adherence 
interventions for HIV-infected people who use 
drugs (Provisional abstract). Current HIV/AIDS 
Reports, 9(4):287-312.
Clark AK, Wilder CM and Winstanley EL (2014) A 
systematic review of community opioid overdose 
prevention and naloxone distribution programs. 
Journal of Addiction Medicine, 8(3):153-63.
Gillies M, Palmateer N, Hutchinson S, Ahmed S, 
Taylor A and Goldberg D (2010) The provision of 
non-needle/syringe drug injecting paraphernalia 
in the primary prevention of HCV among IDU: a 
systematic review. BMC Public Health, 10:721.
Gowing L, Farrell MF, Bornemann R, Sullivan LE and 
Ali R (2011) Oral substitution treatment of injecting 
opioid users for prevention of HIV infection. 
Cochrane Database of Systematic Reviews, (8): 
CD004145.
Hagan H, Pouget ER and Des Jarlais DC (2011) 
A systematic review and meta-analysis of 
interventions to prevent hepatitis C virus infection 
in people who inject drugs. Journal of Infectious 
Diseases, 204(1):74-83.
Jones L, Bates G, McCoy E, Beynon C, McVeigh J 
and Bellis MA (2014) Effectiveness of interventions 
to increase hepatitis C testing uptake among high-
risk groups: a systematic review. The European 
Journal of Public Health 24: 781-788.
Jones L, Pickering L, Sumnall H, McVeigh J and 
Bellis MA (2008) A review of the effectiveness 
and cost-effectiveness of needle and syringe 
programmes for injecting drug users. Liverpool: 
Centre for Public Health.
Jones L, Pickering L, Sumnall H, McVeigh J and 
Bellis MA (2010) Optimal provision of needle and 
syringe programmes for injecting drug users: a 
systematic review. International Journal of Drug 
Policy, 21(5):335-42.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, 
Deren S, Bruneau J et al. (2012) Opiate substitution 
treatment and HIV transmission in people who 
inject drugs: systematic review and meta-analysis. 
BMJ, 345:e5945(2).
Malta M, Magnanini MMF, Strathdee SA and Bastos 
FI (2010) Adherence to antiretroviral therapy among 
HIV-infected drug users: A meta-analysis. AIDS and 
Behavior, 14(4):731-47.
Meader N, Li R, Des Jarlais DC and Pilling S (2010) 
Psychosocial interventions for reducing injection 
and sexual risk behaviour for preventing HIV in drug 
users. Cochrane Database of Systematic Reviews, 
(1): CD007192.
Meader N, Semaan S, Halton M, Bhatti H, Chan M, 
Llewellyn A et al. (2013) An international systematic 
review and meta-analysis of multisession 
psychosocial interventions compared with 
educational or minimal interventions on the HIV sex 
risk behaviors of people who use drugs. AIDS and 
Behavior, 17(6):1963-78.
Potier C, Laprévote V, Dubois-Arber F, Cottencin O 
and Rolland B (2014) Supervised injection services: 
What has been demonstrated? A systematic 
literature review. Drug and Alcohol Dependence, 
145:48-68.
Sacks-Davis R, Horyniak D, Grebely J and Hellard 
M (2012) Behavioural interventions for preventing 
hepatitis C infection in people who inject drugs: A 
global systematic review. International Journal of 
Drug Policy, 23(3):176-84.
Turner KM, Hutchinson S, Vickerman P, Hope V, 
Craine N, Palmateer N et al. (2011) The impact 
of needle and syringe provision and opiate 
substitution therapy on the incidence of hepatitis 
C virus in injecting drug users: Pooling of UK 
evidence. Addiction, 106(11):1978-88.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 173
Underhill K, Dumont D and Operario D (2014) 
HIV prevention for adults with criminal justice 
involvement: A systematic review of HIV risk-
reduction interventions in incarceration and 
community settings. American Journal of Public 
Health, 104(11):e27-e53.
Wang N, Sun X, Yin L, Liu H, Ruan Y, Shao Y et al. 
(2013) Meta-analysis of interventions for reducing 
number of sexual partners and drug and alcohol 
abuse among people living with HIV/AIDS. Journal 
of AIDS and Clinical Research, 4(5):213.
Werb D, Buxton J, Shoveller J, Richardson C, 
Rowell G and Wood E (2013) Interventions to 
prevent the initiation of injection drug use: A 
systematic review. Drug and Alcohol Dependence, 
133(2):669-76.
Zanini B, Covolo L, Donato F and Lanzini A (2010) 
Effectiveness and tolerability of combination 
treatment of chronic hepatitis C in illicit drug 
users: meta-analysis of prospective studies. 
Clinical Therapeutics, 32(13):2139-59.
10.2.3 Treatment review (n=62)
Álvarez Y, Pérez-Mañá C, Torrens M and Farré M 
(2013) Antipsychotic drugs in cocaine dependence: 
A systematic review and meta-analysis. Journal of 
Drug Abuse Treatment, 45(1):1-10.
Amato L, Davoli M, Minozzi S, Ferroni E, Ali R and 
Ferri M (2013b) Methadone at tapered doses for 
the management of opioid withdrawal. Cochrane 
Database of Systematic Reviews, 2013b (2): 
CD003409.
Amato L, Minozzi S, Davoli M and Vecchi S (2011a) 
Psychosocial and pharmacological treatments 
versus pharmacological treatments for opioid 
detoxification. Cochrane Database of Systematic 
Reviews, (9): CD005031.
Amato L, Minozzi S, Davoli M and Vecchi S (2011b) 
Psychosocial combined with agonist maintenance 
treatments versus agonist maintenance treatments 
alone for treatment of opioid dependence. 
Cochrane Database of Systematic Reviews, (10): 
CD004147.
Amato L, Minozzi S, Pani PP, Solimini R, Vecchi S, 
Zuccaro P and Davoli M (2011) Dopamine agonists 
for the treatment of cocaine dependence. 
Cochrane Database of Systematic Reviews, (12): 
CD003352.
Bender K, Tripodi SJ, Sarteschi C and Vaughn MG 
(2011) A meta-analysis of interventions to reduce 
adolescent cannabis use. Research on Social Work 
Practice, 21(2):153-64.
Benishek LA, Dugosh KL, Kirby KC, Matejkowski 
J, Clements NT, Seymour BL et al. (2014) Prize‐
based contingency management for the treatment 
of drug abusers: A meta‐analysis. Addiction, 
109(9):1426-36.
Blodgett JC, Maisel NC, Fuh IL, Wilbourne PL and 
Finney JW (2014) How effective is continuing care 
for drug use disorders? A meta-analytic review. 
Journal of Drug Abuse Treatment, 46:87-97.
Boyuan Z, Yang C, Ke C, Xueyong S and Sheng L 
(2014) Efficacy of Acupuncture for Psychological 
Symptoms Associated with Opioid Addiction: A 
Systematic Review and Meta-Analysis. Evidence-
Based Complementary and Alternative Medicine 
2014: 13.
Castells X, Casas M, Pérez-Mañá C, Roncero 
C, Vidal X and Capellà D (2010) Efficacy of 
Psychostimulant Drugs for Cocaine Dependence. 
Cochrane Database of Systematic Reviews, (2): 
CD007380.
Chiesa A and Serretti A (2014) Are mindfulness-
based interventions effective for drug use 
disorders? A systematic review of the evidence 
Substance Use & Misuse, 49(5):492-512.
Cooper K, Chatters R, Kaltenthaler E and Wong 
R (2015) Cannabis cessation therapy for regular 
cannabis users. Health Technology Assessment 
Database, 19(56)
Ferri M, Davoli M and Perucci CA (2011) Heroin 
maintenance for chronic heroin-dependent 
individuals. Cochrane Database of Systematic 
Reviews, (12): CD003410.
Ferri M, Minozzi S, Bo A and Amato L (2013b) Slow-
release oral morphine as maintenance therapy 
for opioid dependence. Cochrane Database of 
Systematic Reviews, (6): CD009879.
www.hrb.ie174
Filges T, Knudsen A-SD, Svendsen MM, Kowalski K, 
Benjaminsen L and Klint Jørgensen A-M (2015b) 
Cognitive-Behavioural Therapies for Young People 
in Outpatient Treatment for Non-opioid Drug 
Use: Campbell Systematic Reviews, 2015:3. The 
Campbell Collaboration.
Filges T, Rasmussen PS, Andersen D, Klint 
Jørgensen A-M (2015a) Multidimensional Family 
Therapy (MDFT) for Young People in Treatment 
for Non-opioid Drug Use: Campbell Systematic 
Reviews, 2015:3. The Campbell Collaboration.
Gowing L, Ali R and White JM (2009a) 
Buprenorphine for the management of opioid 
withdrawal. Cochrane Database of Systematic 
Reviews, (3):CD002025.
Gowing L, Ali R and White JM (2009b) Opioid 
antagonists with minimal sedation for opioid 
withdrawal. Cochrane Database of Systematic 
Reviews, (4):CD002021.
Gowing L, Farrell MF, Bornemann R, Sullivan LE and 
Ali R (2011) Oral substitution treatment of injecting 
opioid users for prevention of HIV infection. 
Cochrane Database of Systematic Reviews, 
(8):CD004145.
Gowing L, Farrell M, Ali R and White JM (2014) 
Alpha2-adrenergic agonists for the management 
of opioid withdrawal. Cochrane Database of 
Systematic Reviews, (3): CD002024.
Hayhurst K, Leitner M, Davies L, Flentje R, Millar 
T, Jones A et al. (2015) The effectiveness and 
cost-effectiveness of diversion and aftercare 
programmes for offenders using class A drugs: a 
systematic review and economic evaluation. Health 
Technology Assessment Database, 19(6).
Hedrich D, Alves P, Farrell M, Stöver H, Møller L 
and Mayet S (2012) The effectiveness of opioid 
maintenance treatment in prison settings: A 
systematic review. Addiction, 107(3):501-17.
Hunt GE, Siegfried N, Morley K, Sitharthan T and 
Cleary M (2013) Psychosocial interventions for 
people with both severe mental illness and drug 
misuse. Cochrane Database of Systematic Reviews, 
(10): CD001088.
Jegu J, Gallini A, Soler P, Montastruc JL and 
Lapeyre-Mestre M (2011) Slow-release oral 
morphine for opioid maintenance treatment: 
a systematic review. British Journal of Clinical 
Pharmacology, 71(6): 832-843.
Larney S (2010) Does opioid substitution treatment 
in prisons reduce injecting-related HIV risk 
behaviours? A systematic review. Addiction, 
105(2):216-23.
Larney S, Gowing L, Mattick RP, Farrell M, Hall W 
and Degenhardt LA (2014) A systematic review 
and meta‐analysis of naltrexone implants for the 
treatment of opioid dependence. Drug and Alcohol 
Review, 33(2):115-28.
Lee NK, Cameron J and Jenner L (2015) A 
systematic review of interventions for co‐occurring 
drug use and borderline personality disorders. Drug 
and Alcohol Review, 34(6): 663-72.
Lindstrøm M, Saidj M, Kowalski K, Filges T, 
Rasmussen PS, Klint Jørgensen A-M (2015) 
Family Behavior Therapy (FBT) for Young People 
in Treatment for Illicit Non-opioid Drug Use: a 
Systematic Review. Campbell Systematic Reviews 
2015: 9. The Campbell Collaboration.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, 
Deren S, Bruneau J et al. (2012) Opiate substitution 
treatment and HIV transmission in people who 
inject drugs: systematic review and meta-analysis. 
BMJ, 345:e5945(2).
Malivert M, Fatséas M, Denis C, Langlois E and 
Auriacombe M (2012) Effectiveness of therapeutic 
communities: A systematic review. European 
Addiction Research, 18(1):1-11.
Marshall K, Gowing L, Ali R and Le Foll B (2014) 
Pharmacotherapies for cannabis dependence. 
Cochrane Database of Systematic Reviews, (12): 
CD008940.
Mattick RP, Breen C, Kimber J and Davoli M 
(2009) Methadone maintenance therapy versus 
no opioid replacement therapy for opioid 
dependence. Cochrane Database of Systematic 
Reviews, (3):CD002209.
Mattick RP, Breen C, Kimber J and Davoli M 
(2014) Buprenorphine maintenance versus 
placebo or methadone maintenance for opioid 
dependence. Cochrane Database of Systematic 
Reviews, (2): CD002207.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 175
Milligan K, Niccols A, Sword W, Thabane L, 
Henderson J, Smith A et al. (2010) Maternal drug 
use and integrated treatment programs for women 
with drug abuse issues and their children: A meta-
analysis. Substance Abuse Treatment, Prevention, 
and Policy, 5:21.
Milligan K, Niccols A, Sword W, Thabane L, 
Henderson J and Smith A (2011) Length of stay and 
treatment completion for mothers with drug abuse 
issues in integrated treatment programmes. Drugs: 
Education, Prevention & Policy, 18(3):219-27.
Minozzi S, Amato L, Bellisario C and Davoli M (2014) 
Maintenance treatments for opiate-dependent 
adolescents. Cochrane Database of Systematic 
Reviews, (6): CD007210.
Minozzi S, Amato L, Bellisario C, Ferri M and Davoli 
M (2013) Maintenance agonist treatments for 
opiate-dependent pregnant women. Cochrane 
Database of Systematic Reviews, (12): CD006318.
Minozzi S, Amato L, Pani PP, Solimini R, Vecchi S, 
De Crescenzo F, Zuccaro P and Davoli M (2015) 
Dopamine agonists for the treatment of cocaine 
dependence. Cochrane Database of Systematic 
Reviews, (5): CD003352.
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer 
U and Verster A (2011) Oral naltrexone maintenance 
treatment for opioid dependence. Cochrane 
Database of Systematic Reviews, (4): CD001333.
Minozzi S, Cinquini M, Amato L, Davoli M, Farrell MF, 
Pani PP et al. (2015) Anticonvulsants for cocaine 
dependence. Cochrane Database of Systematic 
Reviews, (4): CD006754.
Mitchell O, MacKenzie D and Wilson D (2012) 
The Effectiveness of Incarceration-Based Drug 
Treatment on Criminal Behavior: A Systematic 
Review. Campbell Systematic Reviews 2012:18. The 
Campbell Collaboration.
National Collaborating Centre for Mental Health 
(2008) Drug misuse. Psychosocial interventions. 
National Clinical Practice Guideline Number 51. 
London: The British Psychological Society and The 
Royal College of Psychiatrists.
Pani PP, Trogu E, Vacca R, Amato L, Vecchi S 
and Davoli M (2010) Disulfiram for the treatment 
of cocaine dependence. Cochrane Database of 
Systematic Reviews, (1): CD007024.
Pani PP, Trogu E, Vecchi S and Amato L (2011) 
Antidepressants for cocaine dependence and 
problematic cocaine use. Cochrane Database of 
Systematic Reviews, (12): CD002950.
Pérez-Mañá C, Castells X, Torrens M, Capellà D and 
Farre M (2013) Efficacy of psychostimulant drugs 
for amphetamine abuse or dependence. Cochrane 
Database of Systematic Reviews, (9): CD009695.
Pérez-Mañá C, Castells X, Vidal X, Casas M and 
Capellà D (2011) Efficacy of indirect dopamine 
agonists for psychostimulant dependence: A 
systematic review and meta-analysis of randomized 
controlled trials. Journal of Drug Abuse Treatment, 
40(2):109-22.
Perry AE, Darwin Z, Godfrey C, McDougall C, Lunn 
J, Glanville JM et al. (2009) The effectiveness 
of interventions for drug-using offenders in the 
courts, secure establishments and the community: 
A systematic review. Substance Use & Misuse, 
44(3):374-400.
Perry AE, Neilson M, Martyn-St James M, Glanville 
JM, Woodhouse R, Godfrey C et al. (2015a) 
Interventions for drug-using offenders with co-
occurring mental illness. Cochrane Database of 
Systematic Reviews, (6): CD010901.
Perry AE, Neilson M, Martyn-St James M, Glanville 
JM, Woodhouse R, Godfrey C et al. (2015) 
Pharmacological interventions for drug-using 
offenders. Cochrane Database of Systematic 
Reviews, (6): CD010862.
Perry AE, Neilson M, Martyn-St James M, 
Glanville JM, Woodhouse R and Hewitt C (2015) 
Interventions for female drug-using offenders. 
Cochrane Database of Systematic Reviews, 
(6): CD010910.
Rapp RC, Van Den Noortgate W, Broekaert E 
and Vanderplasschen W (2014) The efficacy of 
case management with persons who have drug 
abuse problems: A three-level meta-analysis 
of outcomes. Journal of Consulting and Clinical 
Psychology, 82: 605-18.
Reif S, Braude L, Lyman DR, Dougherty RH, Daniels 
AS, Ghose SS, Salim O, Delphin-Rittmon ME (2014) 
Peer Recovery Support for Individuals With 
Substance Use Disorders: Assessing the Evidence. 
Psychiatric Services, 65: 853-861.
www.hrb.ie176
Reif S, George P, Braude L, Dougherty RH, Daniels 
AS, Ghose SS et al. Recovery housing: Assessing the 
evidence. Psychiatric Services, 65(3):295-300.
Roberts NP, Roberts PA, Jones N and Bisson 
JI (2015) Psychological interventions for post-
traumatic stress disorder and comorbid drug use 
disorder: A systematic review and meta-analysis. 
Clinical Psychology Review, 38:25-38.
Shonin E, Van Gordon W, Slade K and Griffiths 
MD (2013) Mindfulness and other Buddhist-
derived interventions in correctional settings: A 
systematic review. Aggression and Violent Behavior, 
18(3):365-72.
Smedslund G, Berg RC, Hammerstrom KT, Steiro 
A, Leiknes KA, Dahl HM et al. (2011) Motivational 
interviewing for drug abuse. Cochrane Database of 
Systematic Reviews, (11): CD008063.
Terplan M, Ramanadhan S, Locke A, Longinaker 
N and Lui S (2015) Psychosocial interventions for 
pregnant women in outpatient illicit drug treatment 
programs compared to other interventions. 
Cochrane Database of Systematic Reviews, (4): 
CD006037.
Torchalla I, Nosen L, Rostam H and Allen P (2012) 
Integrated treatment programs for individuals 
with concurrent drug use disorders and trauma 
experiences: A systematic review and meta-
analysis. Journal of Drug Abuse Treatment, 
42(1):65-77.
Turnbull C and Osborn DA (2012) Home visits during 
pregnancy and after birth for women with an 
alcohol or drug problem. Cochrane Database of 
Systematic Reviews, (1): CD004456.
Vanderplasschen W, Colpaert K, Autrique M, 
Rapp RC, Pearce S, Broekaert E et al. (2013) 
Therapeutic communities for addictions: a review 
of their effectiveness from a recovery-oriented 
perspective. The Scientific World Journal, doi: 
10.1155/2013/427817.
Wang D, Wang Y, Wang Y, Li R and Zhou C (2014) 
Impact of physical exercise on drug use disorders: 
a meta-analysis. Database of Abstracts of Reviews 
of Effects, (2):[e110728 p.].
Watson JM, Fayter D, Mdege N, Stirk L, Sowden AJ 
and Godfrey C (2013) Interventions for alcohol and 
drug problems in outpatient settings: A systematic 
review. Drug and Alcohol Review, 32:356-367.
Zgierska A, Rabago D, Chawla N, Kushner K, Koehler 
R and Marlatt A (2009) Mindfulness meditation for 
drug use disorders: a systematic review. Substance 
Abuse, 30(4):266-94.
10.3 References to 
excluded articles
Reasons are provided for all articles excluded at 
full-text screening, or quality assessment stages.
10.3.1 Review article did not meet 
methodological quality 
standards for this review 
(n=76)
Agabioa R, Preti A and Gessa GL (2013) Efficacy 
and tolerability of baclofen in drug use disorders: 
A systematic review. European Addiction Research, 
19(6):325-45.
Altena AM, Brilleslijper-Kater SN and Wolf JLM 
(2010) Effective interventions for homeless youth: A 
systematic review. American Journal of Preventive 
Medicine, 38(6):637-45.
Alvarez Y, Farré M, Fonseca F and Torrens M (2010) 
Anticonvulsant drugs in cocaine dependence: A 
systematic review and meta-analysis. Journal of 
Drug Abuse Treatment, 38(1):66-73.
Barnett E, Sussman S, Smith C, Rohrbach LA and 
Spruijt-Metz D (2012) Motivational interviewing 
for adolescent drug use: a review of the literature 
(Structured abstract). Addictive Behaviors, 
37(12):[1325-34 pp.].
Bogner J and Corrigan JD (2013) Interventions for 
drug misuse following TBI: A systematic review. 
Brain Impairment, 14(1):77-91.
Brogly SB, Saia KA, Walley AY, Du HM and Sebastiani 
P (2014) Prenatal buprenorphine versus methadone 
exposure and neonatal outcomes: systematic 
review and meta-analysis. Database of Abstracts of 
Reviews of Effects, (2):[673-86 pp.].
Brown RT (2010) Drug treatment court: 
Participants, processes, and drug abuse treatment 
completion. US: ProQuest Information & Learning.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 177
Canadian Agency for Drugs and Technologies 
in Health (2011) Suboxone for short-term 
detoxification: a review of the clinical evidence. 
Health Technology Assessment Database, (3).
Canadian Agency for Drugs and Technologies 
in Health (2012) Prevention strategies for drug 
misuse: a review of the clinical evidence. Health 
Technology Assessment Database, (3).
Canadian Agency for Drugs and Technologies in 
Health (2013) Suboxone versus methadone for the 
treatment of opioid dependence: a review of the 
clinical and cost-effectiveness. Health Technology 
Assessment Database, (3).
Carney T and Myers B (2012) Effectiveness of early 
interventions for drug-using adolescents: findings 
from a systematic review and meta-analysis. 
Substance Abuse Treatment, Prevention, and Policy, 
7(2):[25 p.].
Champion KE, Newton NC, Barrett EL and Teesson 
M (2013) A systematic review of school‐based 
alcohol and other drug prevention programs 
facilitated by computers or the Internet. Drug and 
Alcohol Review, 32(2):115-23.
Cunill R, Castells X, Tobias A and Capellà D (2015) 
Pharmacological treatment of attention deficit 
hyperactivity disorder with co-morbid drug 
dependence. Journal of Psychopharmacology, 
29(1):15-23.
Davis ML, Powers MB, Handelsman P, Medina 
JL, Zvolensky M and Smits JA (2014) Behavioral 
therapies for treatment-seeking cannabis users: 
a meta-analysis of randomized controlled trials. 
Database of Abstracts of Reviews of Effects, 
(2):[epub p.].
Deady M, Teesson M and Kay-Lambkin FJ (2014) 
Treatments for co-occurring depression and drug 
use in young people: a systematic review. Database 
of Abstracts of Reviews of Effects, (2):[3-17 pp.].
De Witte NA, Crunelle CL, Sabbe B, Moggi F and 
Dom G (2014) Treatment for outpatients with 
comorbid schizophrenia and substance use 
disorders: a review. Eur Addict Res 20: 105-14.
Dimova RB, Zeremski M, Jacobson IM, Hagan H, 
Des Jarlais DC and Talal AH (2013) Determinants of 
hepatitis C virus treatment completion and efficacy 
in drug users assessed by meta-analysis. Clinical 
Infectious Diseases, 56(6):[806-16 pp.].
Dolan J (2013) Treatment of dual diagnosis post 
traumatic stress disorder and drug use disorders: 
A meta-analysis. US: ProQuest Information 
& Learning.
Dunn KE, Sigmon SC, Strain EC, Heil SH and Higgins 
ST (2011) The association between outpatient 
buprenorphine detoxification duration and 
clinical treatment outcomes: a review (Provisional 
abstract). Drug and Alcohol Dependence, 119(1-
2):[1-9 pp.].
Espad JP, Gonzálvez MT, Orgilés M, Lloret D and 
Guillén-Riquelme A (2015) Meta-analysis of the 
effectiveness of school drug abuse prevention 
programs in Spain. Psicothema, 27(1):5-12.
Fareed A, Vayalapalli S, Casarella J and Drexler K 
(2012) Effect of buprenorphine dose on treatment 
outcome. Journal of Addictive Diseases, 31(1):8-18.
Farronato NS, Dürsteler-MacFarland KM, Wiesbeck 
GA and Petitjean SA (2013) A systematic review 
comparing cognitive-behavioral therapy and 
contingency management for cocaine dependence. 
Journal of Addictive Diseases, 32(3):274-87.
Fletcher K (2013) Couple therapy treatments for 
drug use disorders: A systematic review. Journal of 
Social Work Practice in the Addictions,13(4):327-52.
Fowler DN and Faulkner M (2011) Interventions 
targeting drug abuse among women survivors of 
intimate partner abuse: A meta-analysis. Journal of 
Drug Abuse Treatment, 41(4):386-98.
Gainsbury S and Blaszczynski A (2011) A systematic 
review of Internet-based therapy for the treatment 
of addictions. Clinical Psychology Review, 
31(3):490-8.
Hennessy EA and Fisher BW (2015) A meta-analysis 
exploring the relationship between 12-step 
attendance and adolescent drug use relapse. 
Journal of Groups in Addiction & Recovery, 
10(1):79-96.
Hides L, Samet S and Lubman DI (2010) Cognitive 
behaviour therapy (CBT) for the treatment of 
co-occurring depression and drug use: current 
evidence and directions for future research 
(Structured abstract). Drug and Alcohol Review, 
29(5):[508-17 pp.].
www.hrb.ie178
Hildebrand A, Behrendt S and Hoyer J (2015) 
Treatment outcome in drug use disorder patients 
with and without comorbid posttraumatic stress 
disorder: A systematic review. Psychotherapy 
Research, 25(5):565-82.
Hopfer S, Shin Y, Davis D, Elek E, Kam JA and Hecht 
ML (2010) A review of elementary school-based 
drug use prevention programs: Identifying program 
attributes. Journal of Drug Education, 40(1):11-36.
Islam MM, Topp L, Day CA, Dawson A and Conigrave 
KM (2012) The accessibility, acceptability, health 
impact and cost implications of primary healthcare 
outlets that target injecting drug users: A narrative 
synthesis of literature. International Journal of Drug 
Policy, 23(2):94-102.
Jensen CD, Cushing CC, Aylward BS, Craig JT, 
Sorell DM and Steele RG (2011) Effectiveness 
of motivational interviewing interventions 
for adolescent drug use behavior change: a 
meta-analytic review (Structured abstract). 
Journal of Consulting and Clinical Psychology, 
79(4):[433-40 pp.].
Katz D and Toner B (2013) A systematic review 
of gender differences in the effectiveness of 
mindfulness-based treatments for drug use 
disorders. Mindfulness, 4(4):318-31.
Koehler JA, Humphreys DK, Akoensi TD, Sánchez 
de Ribera O and Lösel F (2014) A systematic review 
and meta-analysis on the effects of European drug 
treatment programmes on reoffending. Psychology, 
Crime and Law, 20(6):584-602.
Kuerbis A and Sacco P (2013) A review of existing 
treatments for drug abuse among the elderly and 
recommendations for future directions (Provisional 
abstract). Drug Abuse, 7(2):[13-37 pp.].
Lobmaier PP, Kunøe N, Gossop M and Waal H 
(2011) Naltrexone depot formulations for opioid 
and alcohol dependence: A systematic review. CNS 
Neuroscience & Therapeutics, 17(6):629-36.
Lua PL and Talib NS (2012) The effectiveness of 
auricular acupuncture for drug addiction: a review 
of research evidence from clinical trials (Provisional 
abstract). ASEAN Journal of Psychiatry, 13(1):[55-68 
pp.].
Lundahl BW, Kunz C, Brownell C, Tollefson D and 
Burke BL (2010) A meta-analysis of motivational 
interviewing: Twenty-five years of empirical studies. 
Research on Social Work Practice, 20(2):137-60.
MacLean S, Cameron J, Harney A and Lee NK 
(2012) Psychosocial therapeutic interventions for 
volatile drug use: A systematic review. Addiction, 
107(2):278-88.
Martinez-Raga J, Knecht C, de Alvaro R, Szerman N 
and Ruiz P (2013) Addressing dual diagnosis patients 
suffering from attention-deficit hyperactivity 
disorders and comorbid drug use disorders: A 
review of treatment considerations. Addictive 
Disorders & Their Treatment, 12(4):213-30.
Matthys F, Stes S, van den Brink W, Joostens P, 
Möbius D, Tremmery S et al. (2014) Guideline for 
screening, diagnosis and treatment of ADHD in 
adults with drug use disorders. International 
Journal of Mental Health and Addiction, 
12(5):629-47.
McCarty D, Braude L, Lyman DR, Dougherty 
RH, Daniels AS, Ghose SS et al. (2014) Drug 
abuse intensive outpatient programs: assessing 
the evidence (Provisional abstract). Database 
of Abstracts of Reviews of Effects, 2014; 
(2):[718-26 pp.].
Meader N (2010) A comparison of methadone, 
buprenorphine and alpha₂ adrenergic agonists 
for opioid detoxification: A mixed treatment 
comparison meta-analysis. Drug and Alcohol 
Dependence, 108(1-2):110-4.
Meis LA, Griffin JM, Greer N, Jensen AC, 
MacDonald R, Carlyle M et al. (2013) Couple 
and family involvement in adult mental health 
treatment: A systematic review. Clinical Psychology 
Review, 33(2):275-86.
Naar-King S, Parsons JT and Johnson AM (2012) 
Motivational interviewing targeting risk reduction 
for people with HIV: a systematic review. Current 
HIV/AIDS reports 9: 335-43.
Ohinmaa A, Chatterley P, Nguyen T and Jacobs 
P (2010) Telehealth in drug abuse and addiction: 
review of the literature on smoking, alcohol, drug 
abuse and gambling. Health Technology Assessment 
Database, (3).
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 179
Pearson FS, Prendergast ML, Podus D, Vazan P, 
Greenwell L and Hamilton Z (2012) Meta-analyses 
of seven of the National Institute on Drug Abuse’s 
principles of drug addiction treatment. Journal of 
Drug Abuse Treatment, 43(1):1-11.
Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley 
KH and Papakostas GI (2011) Treatment of major 
depressive disorder and dysthymic disorder with 
antidepressants in patients with comorbid opiate 
use disorders enrolled in methadone maintenance 
therapy: A meta-analysis. Journal of Clinical 
Psychopharmacology, 31(5):582-6.
Pennay A, Cameron J, Reichert T, Strickland H, 
Lee NK, Hall K et al. (2011) A systematic review of 
interventions for co-occurring drug use disorder 
and borderline personality disorder. Journal of 
Drug Abuse Treatment, 41(4):363-73.
Porath-Waller AJ, Beasley E and Beirness DJ (2010) 
A meta-analytic review of school-based prevention 
for cannabis use (Structured abstract). Health 
Education and Behavior, 37(5):[709-23 pp.].
Prendergast ML, Pearson FS, Podus D, Hamilton 
ZK and Greenwell L (2013) The Andrews’ principles 
of risk, needs, and responsivity as applied in 
drug treatment programs: Meta-analysis of crime 
and drug use outcomes. Journal of Experimental 
Criminology, 9(3):275-300.
Rajasingham R, Mimiaga MJ, White JM, Pinkston 
MM, Baden RP and Mitty JA (2012) A systematic 
review of behavioral and treatment outcome 
studies among HIV-infected men who have sex with 
men who abuse crystal methamphetamine. AIDS 
Patient Care and STDs, 26(1):36-52.
Ramo DE, Liu H and Prochaska JJ (2012) Tobacco 
and marijuana use among adolescents and young 
adults: A systematic review of their co-use. Clinical 
Psychology Review, 32(2):105-21.
Rodriguez DM, Teesson M and Newton NC (2014) 
A systematic review of computerised serious 
educational games about alcohol and other 
drugs for adolescents. Drug and Alcohol Review, 
33(2):129-35.
Rongione D, Erford BT and Broglie C (2011) Alcohol 
and other drug abuse counseling outcomes for 
school-aged youth: A meta-analysis of studies from 
1990 to 2009. Counseling Outcome Research and 
Evaluation, 2(1):8-24.
Sabioni P, Ramos AC and Galduroz JCF (2013) 
The effectiveness of treatments for cocaine 
dependence in schizophrenic patients: a 
systematic review (Provisional abstract). Current 
Neuropharmacology, 11(5):[484-90 pp.].
Sandler I, Wolchik SA, Cruden G, Mahrer NE, Ahn S, 
Brincks A et al. (2014) Overview of meta-analyses 
of the prevention of mental health, drug use, 
and conduct problems. Annual Review of Clinical 
Psychology, 10:243-73.
Sharma M and Branscum P (2013) School-based 
drug abuse prevention programs in high school 
students (Provisional abstract). Database of 
Abstracts of Reviews of Effects, (2):[51-65 pp.].
Simoni JM, Nelson KM, Franks JC, Yard SS and 
Lehavot K (2011) Are peer interventions for 
HIV efficacious? A systematic review. AIDS and 
Behavior, 15(8):1589-95.
Speirs V, Johnson M and Jirojwong S (2013) 
A systematic review of interventions for 
homeless women. Journal of Clinical Nursing, 
22(7-8):1080-93.
Stein DM, Deberard S and Homan K (2013) 
Predicting success and failure in juvenile drug 
treatment court: A meta-analytic review. Journal 
of Drug Abuse Treatment, 44(2):159-68.
Tanner-Smith EE, Wilson SJ and Lipsey MW (2013) 
The comparative effectiveness of outpatient 
treatment for adolescent drug abuse: A meta-
analysis. Journal of Drug Abuse Treatment, 
44(2):145-58.
Tanner-Smith EE, Steinka-Fry KT, Hennessy EA, 
Lipsey MW and Winters KC (2015) Can brief alcohol 
interventions for youth also address concurrent 
illicit drug use? Results from a meta-analysis. 
Journal of Youth and Adolescence, 44(5):1011-23.
Teesson M, Newton NC and Barrett EL (2012) 
Australian school‐based prevention programs for 
alcohol and other drugs: A systematic review. Drug 
and Alcohol Review, 31(6):731-6.
Thomas CP, Fullerton CA, Kim M, Montejano L, 
Lyman DR, Dougherty RH et al. (2014) Medication-
assisted treatment with buprenorphine: Assessing 
the evidence. Psychiatric Services, 65(2):158-70.
www.hrb.ie180
Tolan P, Henry D, Schoeny M, Bass A, Lovegrove 
P and Nichols E (2013) Mentoring Interventions 
to Affect Juvenile Delinquency and Associated 
Problems: Campbell Systematic Reviews, 2013: 10. 
The Campbell Collaboration.
Tripodi SJ and Bender K (2011). Substance abuse 
treatment for juvenile offenders: A review of quasi-
experimental and experimental research. Journal 
of Criminal Justice, 39(3):246-52.
Tripodi SJ, Bledsoe SE, Kim JS and Bender K (2011) 
Effects of correctional-based programs for female 
inmates: A systematic review. Research on Social 
Work Practice, 21(1):15-31.
van Dam D, Vedel E, Ehring T and Emmelkamp PMG 
(2012) Psychological treatments for concurrent 
posttraumatic stress disorder and drug use 
disorder: A systematic review. Clinical Psychology 
Review, 32(3):202-14.
Werb D, Mills EJ, DeBeck K, Kerr T, Montaner JSG 
and Wood E (2011) The effectiveness of anti-illicit 
drug public-service announcements: A systematic 
review and meta-analysis. Journal of Epidemiology 
and Community Health, 65(10):834-40.
Wilder C, Lewis D and Winhusen T (2015) 
Medication assisted treatment discontinuation in 
pregnant and postpartum women with opioid use 
disorder. Drug and Alcohol Dependence, 149:225-
31.
Windsor LC, Jemal A and Alessi EJ (2015) Cognitive 
behavioral therapy: a meta-analysis of race and 
substance use outcomes. Cultural diversity & ethnic 
minority psychology 21: 300-13.
Wisdom JP, Manuel JI and Drake RE (2011) Drug 
use disorder among people with first-episode 
psychosis: A systematic review of course and 
treatment. Psychiatric Services, 62(9):1007-12.
Wong J (2015) Concurrent treatments of Drug Use 
Disorders with anxiety or trauma: A comprehensive 
meta-analysis. US: ProQuest Information & 
Learning.
Wright N, Bleakley A, Butt C, Chadwick O, 
Mahmood K, Patel K et al. (2011) Peer health 
promotion in prisons: A systematic review. 
International Journal of Prisoner Health, 7(4):37-51.
Zhornitsky S (2013) Psychiatric and neurological 
symptoms in schizophrenia and drug use disorder 
patients treated for 12-weeks with quetiapine. US: 
ProQuest Information & Learning.
Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson 
JP, Stip E, Rompré PP et al. (2010) Antipsychotic 
agents for the treatment of drug use disorders 
in patients with and without comorbid psychosis 
(Structured abstract). Journal of Clinical 
Psychopharmacology, 30(4):[417-24 pp.].
10.3.2 The methodology of the 
article was not appropriate 
for our review (n=55)
Argoff CE, Kahan M and Sellers EM (2014) 
Preventing and managing aberrant drug-
related behavior in primary care: systematic 
review of outcomes evidence. Journal of opioid 
management, 10: 119-34.
Bart G (2012) Maintenance medication for opiate 
addiction: The foundation of recovery. Journal of 
Addictive Diseases, 31(3):207-25.
Bentzley BS, Barth KS, Back SE and Book SW (2015) 
Discontinuation of buprenorphine maintenance 
therapy: Perspectives and outcomes. Journal of 
Drug Abuse Treatment, 52:48-57.
Bogenschutz MP and Johnson MW (2016) Classic 
hallucinogens in the treatment of addictions. 
Progress in Neuro-Psychopharmacology & 
Biological Psychiatry, 64: 250-8.
CADTH (2014) Administration of naloxone in a 
home or community setting: a review of the clinical 
effectiveness, cost-effectiveness, and guidelines. 
Rapid Reponse Report. Ottawa, Canadian Agency 
for Drugs and Technologies in Health.
CADTH (2014) Buprenorphine/naloxone (Suboxone) 
film versus buprenorphine/naloxone tablets for the 
treatment of opioid addiction: comparative safety. 
Rapid Reponse Report. Ottawa, Canadian Agency 
for Drugs and Technologies in Health.
CADTH (2014) Intranasal versus intravenous 
naloxone for opioid overdose in the pre-hospital 
setting: comparative clinical effectiveness. Rapid 
Reponse Report. Ottawa, Canadian Agency for 
Drugs and Technologies in Health.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 181
Carr A (2014) The evidence base for family therapy 
and systemic interventions for child‐focused 
problems. Journal of Family Therapy, 36(2):107-57.
Chandra G (2011) Evaluation of Internet as 
treatment support for methamphetamine abusers. 
US: ProQuest Information & Learning.
Darker CD, Sweeney BP, Barry JM, Farrell MF and 
Donnelly-Swift E (2015) Psychosocial interventions 
for benzodiazepine harmful use, abuse or 
dependence. Cochrane Database of Systematic 
Reviews, (5): CD009652).
Emmers E, Bekkering GE and Hannes K (2015) 
Prevention of alcohol and drug misuse in 
adolescents: An overview of systematic reviews. 
Nordic Studies on Alcohol and Drugs, 32(2):183-98.
Espada-Sánchez JP and Hernández-Serrano O 
(2015) Effects of the Saluda prevention program: A 
review of controlled evaluation studies. Electronic 
Journal of Research in Educational Psychology, 
13(1):171-88.
Fareed A, Casarella J, Amar R, Vayalapalli S and 
Drexler K (2010) Methadone maintenance dosing 
guideline for opioid dependence, a literature 
review. Journal of Addictive Diseases, 29(1):1-14.
Fareed A, Vayalapalli S, Casarella J, Amar R and 
Drexler K (2010) Heroin anticraving medications: A 
systematic review. The American Journal of Drug 
and Alcohol Abuse, 36(6):332-41.
Finfgeld-Connett D and Johnson ED (2011) Drug 
abuse treatment for women who are under 
correctional supervision in the community: A 
systematic review of qualitative findings. Issues in 
Mental Health Nursing, 32(10):640-8.
Finfgeld-Connett D and Johnson ED (2011) 
Therapeutic drug abuse treatment for incarcerated 
women. Clinical Nursing Research, 20(4):462-81.
Fullerton CA, Kim M, Thomas CP, Lyman DR, 
Montejano LB, Dougherty RH et al. (2014) 
Medication-assisted treatment with methadone: 
Assessing the evidence. Psychiatric Services, 
65(2):146-57.
Goodman JD, McKay JR and DePhilippis D (2013) 
Progress monitoring in mental health and addiction 
treatment: A means of improving care. Professional 
Psychology: Research and Practice, 44(4):231-46.
Hansen WB, Derzon J, Dusenbury L, Bishop 
D, Campbell K and Alford A (2010) Operating 
characteristics of prevention programs: 
Connections to drug use etiology. In: Scheier L, 
Scheier L, editor. Handbook of Drug Use Etiology: 
Theory, Methods, and Empirical Findings, p. 597-
616. Washington, DC, US: American Psychological 
Association.
Hayes, Inc (2010) Screening, brief intervention, 
and referral to treatment (SBIRT) for alcohol 
misuse (Structured abstract). Health Technology 
Assessment Database, (3).
Hayes, Inc (2012) Screening, Brief Intervention, 
and Referral to Treatment (SBIRT) using remote 
interventions for alcohol misuse (Structured 
abstract). Health Technology Assessment Database, 
(3).
Hellem TL, Lundberg KJ and Renshaw PF (2015) 
A review of treatment options for co-occurring 
methamphetamine use disorders and depression. 
Journal of Addictions Nursing, 26(1):14-23.
Hendershot CS, Witkiewitz K, George WH and 
Marlatt GA (2011) Relapse prevention for addictive 
behaviors. Substance Abuse Treatment, Prevention, 
and Policy, 6:17.
Hides L, Baker A, Kavanagh D and Proctor D (2011) 
Psychological interventions for co-occurring 
depression and drug misuse. Cochrane Database of 
Systematic Reviews, (12): CD009501.
Hines L (2013) Treatment views and 
recommendations of drug abusing women: A meta-
synthesis. Qualitative Social Work: Research and 
Practice, 12(4):473-89.
Holbrook AM and Nguyen VH (2015) Medication-
assisted treatment for pregnant women: A 
systematic review of the evidence and implications 
for social work practice. Journal of the Society for 
Social Work and Research, 6(1).
Hopson L, Wodarski J and Tang N (2015) The 
effectiveness of electronic approaches to 
substance abuse prevention for adolescents. 
Journal of evidence-informed social work 12: 310-
22.
Jhanjee S (2014) Evidence Based Psychosocial 
Interventions in Substance Use. Indian Journal of 
Psychological Medicine 36: 112-118.
www.hrb.ie182
Jones L, Atkinson A, Bates G, McCoy E, Porcellato 
L, Beynon C et al. (2014) Views and experiences 
of hepatitis C testing and diagnosis among people 
who inject drugs: Systematic review of qualitative 
research. International Journal of Drug Policy, 
25(2):204-11.
Kao TS, Gibbs MB, Clemen-Stone S and Duffy S 
(2013) A comparison of family interventions to 
address adolescent risky behaviors: A literature 
review. Western Journal of Nursing Research, 
35(5):611-37.
Kienast T, Stoffers J, Bermpohl F and Lieb K (2014) 
Borderline personality disorder and comorbid 
addiction. Deutsches Ärzteblatt International, 
111(16):280-6.
Krentzman AR (2013) Review of the application 
of positive psychology to drug use, addiction, 
and recovery research. Psychology of Addictive 
Behaviors, 27(1):151-65.
MacArthur GJ, van Velzen E, Palmateer N, Kimber 
J, Pharris A, Hope V et al. (2014) Interventions to 
prevent HIV and Hepatitis C in people who inject 
drugs: A review of reviews to assess evidence of 
effectiveness. International Journal of Drug Policy, 
25(1):34-52.
McCallum S, Mikocka-Walus A, Turnbull D, 
Gaughwin M and Andrews J (2013) The role of 
continuity of care (COC) in the treatment of 
comorbid mental health and drug use disorders 
(SUDS): A systematic review of the literature. 
Journal of Psychosomatic Research, 74(6):553.
McNeil R and Small W (2014) ‘Safer environment 
interventions’: A qualitative synthesis of the 
experiences and perceptions of people who inject 
drugs. Social Science & Medicine, 106:151-8.
Moggi F and Öjehagen A (2015) Evidence-supported 
psychosocial treatment for dual disorder patients. 
In: Dom G and Moggi F, editors. Co-occurring 
addictive and psychiatric disorders: A practice-
based handbook from a European perspective, 
p 261-277. New York, NY, US: Springer-Verlag 
Publishing.
Mulder I and Dom G (2012) Disulfiram as a 
treatment for cocaine dependency (Provisional 
abstract). Tijdschrift voor Psychiatrie, 
54(1):[51-8 pp.].
Notley C, Blyth A, Maskrey V, Craig J and Holland 
R (2013) The experience of long-term opiate 
maintenance treatment and reported barriers to 
recovery: A qualitative systematic review. European 
Addiction Research, 19(6):287-98.
Pan S, Gowing L, Li C and Zhao M (2012) 
Contingency management for drug use disorders. 
Cochrane Database of Systematic Reviews, 2012, 
(8); CD010029.
Raynor PA (2013) An exploration of the factors 
influencing parental self-efficacy for parents 
recovering from drug use disorders using the 
social ecological framework. Journal of Addictions 
Nursing, 24(2):91-9.
Reback CJ and Shoptaw S (2014) Development 
of an evidence-based, gay-specific 
cognitive behavioral therapy intervention for 
methamphetamine-abusing gay and bisexual men. 
Addictive Behaviors, 39(8):1286-91.
Rösner S, Willutzki R and Zgierska A (2015) 
Mindfulness-based interventions for drug use 
disorders. Cochrane Database of Systematic 
Reviews, (6): CD011723.
Ruff S, McComb JL, Coker CJ and Sprenkle DH 
(2010) Behavioral couples therapy for the treatment 
of drug abuse: A substantive and methodological 
review of O’Farrell, Fals-Stewart, and colleagues’ 
program of research. Family Process, 49(4):439-56.
Sacks S and Sacks JY (2010) Research on the 
effectiveness of the modified therapeutic 
community for persons with co-occurring drug use 
and mental disorders. Therapeutic Communities, 
31(2):176-211.
Schacht A, Dyachkova Y and Walton RJ (2013) 
Critical evaluation of mixed treatment comparison 
meta-analyses using examples assessing 
antidepressants and opioid detoxification 
treatments. International Journal of Methods in 
Psychiatric Research, 22(2):166-74.
Shinn AK and Greenfield SF (2010) Topiramate 
in the treatment of drug-related disorders: A 
critical review of the literature. Journal of Clinical 
Psychiatry, 71(5):634-48.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 183
Singh RD, Jimerson SR, Renshaw T, Saeki E, Hart 
SR, Earhart J et al. (2011) A summary and synthesis 
of contemporary empirical evidence regarding the 
effects of the Drug Abuse Resistance Education 
Program (D.A.R.E.). Contemporary School 
Psychology, 15:93-102.
Soyka M, Kranzler HR, van den Brink W, Krystal J, 
Möller HJ and Kasper S (2011) The World Federation 
of Societies of Biological Psychiatry (WFSBP) 
guidelines for the biological treatment of drug use 
and related disorders. Part 2: Opioid dependence. 
The World Journal of Biological Psychiatry, 12(3-
4):160-87.
Sussman S (2010) A review of Alcoholics 
Anonymous/Narcotics Anonymous programs for 
teens. Evaluation and the Health Professions, 
33(1):26-55.
Veilleux JC, Colvin PJ, Anderson J, York C and 
Heinz AJ (2010) A review of opioid dependence 
treatment: Pharmacological and psychosocial 
interventions to treat opioid addiction. Clinical 
Psychology Review, 30(2):155-66.
Walsh N, Verster A, Rodolph M and Akl EA 
(2014) WHO guidance on the prevention of viral 
hepatitis B and C among people who inject drugs. 
International Journal of Drug Policy, 25(3):363-71.
White HR, Jiao Y, Ray AE, Huh D, Atkins DC, Larimer 
ME et al. (2015) Are there secondary effects on 
marijuana use from brief alcohol interventions for 
college students? Journal of Studies on Alcohol and 
Drugs. 76(3):367-77.
Wignall ND and Brown ES (2014) Citicoline in 
addictive disorders: a review of the literature. The 
American Journal of Drug and Alcohol Abuse 40: 
262-8.
Young MM, Stevens A, Galipeau J, Pirie T, Garritty 
C, Singh K, Yazdi F, Golfam M, Pratt M, Turner L, 
Porath-Waller A, Arratoon C, Haley N, Leslie K, 
Reardon R, Sproule B, Grimshaw J and Moher D 
(2014) Effectiveness of brief interventions as part 
of the Screening, Brief Intervention and Referral 
to Treatment (SBIRT) model for reducing the 
nonmedical use of psychoactive substances: a 
systematic review. Systematic Reviews 3: 50.
Zschucke E, Heinz A and Ströhle A (2012) Exercise 
and physical activity in the therapy of drug use 
disorders. Scientific World Journal, (2):[article 
number 901741].
10.3.3 The scope of the review 
article was not appropriate 
for our review (n=50)
Baldwin SA, Christian S, Berkeljon A, Shadish WR 
and Bean R (2012) The effects of family therapies 
for adolescent delinquency and drug abuse: A 
meta‐analysis. Journal of Marital and Family 
Therapy, 38(1):281-304.
Bartlett A, Jhanji E, White S, Harty MA, Scammell 
J and Allen S (2015). Interventions with women 
offenders: A systematic review and meta-analysis 
of mental health gain. Journal of Forensic 
Psychiatry & Psychology, 26(2):133-65.
Bassuk EL, DeCandia CJ, Tsertsvadze A and 
Richard MK (2014) The effectiveness of housing 
interventions and housing and service interventions 
on ending family homelessness: A systematic 
review. American Journal of Orthopsychiatry, 
84(5):457-74.
Braga AA and Weisburd DL (2012) The effects 
of focused deterrence strategies on crime: 
A systematic review and meta-analysis of the 
empirical evidence. Journal of Research in Crime 
and Delinquency, 49(3):323-58.
Bröning S, Kumpfer K, Kruse K, Sack P-M, Schaunig-
Busch I, Ruths S, Moesgen D, Pflug E, Klein M and 
Thomasius R (2012) Selective prevention programs 
for children from substance-affected families: a 
comprehensive systematic review. Subst Abuse 
Treat Prev Policy 7: 23.
Burnhams NH, Musekiwa A, Parry C and London 
L (2013) A systematic review of evidence-based 
workplace prevention programmes that address 
drug abuse and HIV risk behaviours. African Journal 
of Drug and Alcohol Studies, 12(1):1-21.
Canadian Agency for Drugs and Technologies in 
Health (2011) Combination Benzodiazepine-Opioid 
use: a review of the evidence on safety (Structured 
abstract). Health Technology Assessment 
Database, (3).
Chinman M, George P, Dougherty RH, Daniels 
AS, Ghose SS, Swift A et al. (2014) Peer support 
services for individuals with serious mental 
illnesses: assessing the evidence. Psychiatric 
Services. Database of Abstracts of Reviews of 
Effects, (2):429-441.
www.hrb.ie184
Clark TT, McGovern P, Mgbeokwere D, Wooten N, 
Owusu H and McGraw KA (2014) Systematic review: 
The nature and extent of social work research 
on drug use disorders treatment interventions 
among African Americans. Journal of Social Work, 
14(5):451-472.
Coren E, Hossain R, Pardo Pardo J, Veras MMS, 
Chakraborty K, Harris H et al (2013) Interventions 
for promoting reintegration and reducing harmful 
behaviour and lifestyles in street-connected 
children and young people. Cochrane Database of 
Systematic Reviews, 2013 (6): CD009823.
Crippa JAS, Derenusson GN, Chagas MH, Atakan 
Z, Martín-Santos R, Zuardi AW et al. (2012) 
Pharmacological interventions in the treatment of 
the acute effects of cannabis: A systematic review 
of literature. Harm Reduction Journal, 9.
Des Jarlais DC, Feelemyer JP, Modi SN, Abdul-
Quader A and Hagan H (2013) High coverage 
needle/syringe programs for people who inject 
drugs in low and middle income countries: a 
systematic review (Provisional abstract). BMC Public 
Health, 13(2):53.
Everson‐Hock ES, Jones R, Guillaume L, Clapton 
J, Duenas A, Goyder E et al. (2011) Supporting 
the transition of looked‐after young people 
to independent living: A systematic review of 
interventions and adult outcomes. Child: Care, 
Health and Development, 37(6):767-79.
Feelemyer JP, Des Jarlais DC, Arasteh K, Phillips 
BW and Hagan H (2014) Changes in quality of life 
(WHOQOL-BREF) and addiction severity index 
(ASI) among participants in opioid substitution 
treatment (OST) in low and middle income 
countries: An international systematic review. Drug 
and Alcohol Dependence, 134:251-8.
Foxcroft D, Ireland D, Lister Sharp DJ, Lowe G 
and Breen R (2011) Primary prevention for alcohol 
misuse in young people. Cochrane Database of 
Systematic Reviews, 2011 (9): CD009308.
Foxcroft DR and Tsertsvadze A (2011) Universal 
family-based prevention programs for alcohol 
misuse in young people. Cochrane Database of 
Systematic Reviews, 2011 (9): CD009308.
Foxcroft DR and Tsertsvadze A (2011) Universal 
school-based prevention programs for alcohol 
misuse in young people. Cochrane Database of 
Systematic Reviews, 2011 (9): CD009308.
Foxcroft DR and Tsertsvadze A (2012) Universal 
alcohol misuse prevention programmes for children 
and adolescents: Cochrane systematic reviews. 
Perspectives in Public Health, 2012; 132(3):128-34.
Haesler E (2013) Buprenorphine for the 
management of opioid withdrawal. In: Merrick J, 
editors. Alternative medicine yearbook, 2011. Health 
and human development, p 275-8 Hauppauge, New 
York: Nova Biomedical Books.
Hennessy EA and Tanner-Smith EE (2015) 
Effectiveness of brief school-based interventions 
for adolescents: a meta-analysis of alcohol use 
prevention programs. Prev Sci 16: 463-74.
Hodge DR, Jackson KF and Vaughn MG (2012) 
Culturally sensitive interventions and drug use: A 
meta-analytic review of outcomes among minority 
youths. Social Work Research, 36(1):11-19.
Konghom S, Verachai V, Srisurapanont M, 
Suwanmajo S, Ranuwattananon A, Kimsongneun N 
et al. (2010) Treatment for inhalant dependence 
and abuse. Cochrane Database of Systematic 
Reviews, 2010, (12): CD007537.
Livingston JD, Milne T, Fang ML and Amari E (2012) 
The effectiveness of interventions for reducing 
stigma related to drug use disorders: A systematic 
review. Addiction, 107(1):39-50.
Manuel JK, Hagedorn HJ and Finney JW (2011) 
Implementing evidence-based psychosocial 
treatment in specialty drug use disorder care 
(Provisional abstract). Psychology of Addictive 
Behaviors, 25(2):225-37.
Marsh JC, Angell B, Andrews CM and Curry A 
(2012) Client-provider relationship and treatment 
outcome: A systematic review of drug abuse, child 
welfare, and mental health services research. 
Journal of the Society for Social Work and 
Research, 3(4): 233-267.
Marshall T, Goldberg RW, Braude L, Dougherty 
RH, Daniels AS, Ghose SS et al. (2014) Supported 
employment: Assessing the evidence. Psychiatric 
Services, 65(1):16-23.
Marshall Z, Dechman MK, Minichiello A, Alcock L 
and Harris GE (2015) Peering into the literature: 
A systematic review of the roles of people who 
inject drugs in harm reduction initiatives. Drug and 
Alcohol Dependence, 151:1-14.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 185
Melendez-Torres GJ and Bonell C (2014) Systematic 
review of cognitive behavioural interventions for 
HIV risk reduction in drug-using men who have 
sex with men. International Journal of STD & AIDS, 
25(9):627-35.
Milligan K, Niccols A, Sword W, Thabane L, 
Henderson J and Smith A (2011) Birth outcomes for 
infants born to women participating in integrated 
drug abuse treatment programs: A meta-
analytic review. Addiction Research and Theory, 
19(6):542-55.
Mitchell O, Wilson DB, Eggers A and MacKenzie DL 
(2012) Assessing the effectiveness of drug courts 
on recidivism: A meta-analytic review of traditional 
and non-traditional drug courts. Journal of 
Criminal Justice, 40(1):60-71.
Mutamba BB, Ginneken N, Paintain LS, 
Wandiembe S and Schellenberg D (2013) Roles and 
effectiveness of lay community health workers in 
the prevention of mental, neurological and drug 
use disorders in low and middle income countries: 
a systematic review (Provisional abstract). BMC 
Health Services Research,13(1):412.
Niccols A, Milligan K, Smith A, Sword W, Thabane 
L and Henderson J (2012) Integrated programs for 
mothers with drug abuse issues and their children: 
A systematic review of studies reporting on child 
outcomes. Child Abuse & Neglect, 36(4):308-22.
Niccols A, Milligan K, Sword W, Thabane L, 
Henderson J and Smith A (2012) Integrated 
programs for mothers with drug abuse issues: A 
systematic review of studies reporting on parenting 
outcomes. Harm Reduction Journal, 9.
North LW (2012) Working alliance and outcome 
in adolescents and adults in treatment for drug 
abuse. US: ProQuest Information & Learning.
Pani PP, Vacca R, Trogu E, Amato L and Davoli M 
(2010) Pharmacological treatment for depression 
during opioid agonist treatment for opioid 
dependence. Cochrane Database of Systematic 
Reviews, 2010, (9) CD008373.
Posadzki P, Choi J, Lee MS and Ernst E (2014) Yoga 
for addictions: a systematic review of randomised 
clinical trials (Provisional abstract). Focus on 
Alternative and Complementary Therapies, 
19(1):1-8.
Rahimi-Movaghar A, Amin-Esmaeili M, Hefazi M and 
Yousefi-Nooraie R (2013) Pharmacological therapies 
for maintenance treatments of opium dependence. 
Cochrane Database of Systematic Reviews, 2013, 
(1): CD007775.
Roozen HG, de Waart R and van der Kroft P (2010) 
Community reinforcement and family training: An 
effective option to engage treatment-resistant 
drug-abusing individuals in treatment. Addiction, 
105(10):1729-38.
Ruger JP and Lazar CM (2012) Economic evaluation 
of drug abuse treatment and HIV prevention 
programs in pregnant women: A systematic review. 
Addictive Behaviors, 37(1):1-10.
Schulte SJ, Meier PS and Stirling J (2011) Dual 
diagnosis clients’ treatment satisfaction—A 
systematic review. BMC Psychiatry, 11.
Shearer J, Tie H and Byford S (2015) Economic 
evaluations of contingency management in illicit 
drug misuse programmes: A systematic review. 
Drug and Alcohol Review, 34(3):289-98.
Starrels JL, Becker WC, Alford DP, Kapoor A, 
Williams AR and Turner BJ (2010). Systematic 
review: treatment agreements and urine drug 
testing to reduce opioid misuse in patients 
with chronic pain. Annals of Internal Medicine, 
152(11):712-20.
Stephen JH, Halpern CH, Barrios CJ, Balmuri 
U, Pisapia JM, Wolf JA et al. (2012) Deep 
brain stimulation compared with methadone 
maintenance for the treatment of heroin 
dependence: A threshold and cost‐effectiveness 
analysis. Addiction, 107(3):624-34.
Tait RJ and Christensen H (2010) Internet-based 
interventions for young people with problematic 
drug use: a systematic review (Structured 
abstract). Medical Journal of Australia, 192(11 
Supplement):[s15-s21]
van Boekel LC, Brouwers EPM, van Weeghel J 
and Garretsen HFL (2013) Stigma among health 
professionals towards patients with drug use 
disorders and its consequences for healthcare 
delivery: Systematic review. Drug and Alcohol 
Dependence, 131(1-2):23-35.
www.hrb.ie186
van der Stouwe T, Asscher JJ, Stams GJJM, Dekovic 
M and van der Laan PH (2014) The effectiveness 
of multisystemic therapy (MST): A meta-analysis. 
Clinical Psychology Review, 34(6):468-81.
van Ginneken N, Tharyan P, Lewin S, Rao Girish 
N, Meera SM, Pian J et al. (2013) Non-specialist 
health worker interventions for the care of mental, 
neurological and drug-abuse disorders in low- and 
middle-income countries. Cochrane Database of 
Systematic Reviews,2013, (11): CD009149.
Wang GY, Wouldes TA and Russell BB (2013) 
Methadone maintenance treatment and cognitive 
function: a systematic review (Provisional abstract). 
Current Drug Abuse Reviews, 6(3):220-30.
Weimer MB and Chou R (2014) Research gaps 
on methadone harms and comparative harms: 
Findings from a review of the evidence for an 
American Pain Society and College on Problems 
of Drug Dependence clinical practice guideline. 
The Journal of Pain, 15(4):366-76.
Zajac K, Kennedy CE, Fonner VA, Armstrong KS, 
O’Reilly KR and Sweat MD (2015) A systematic 
review of the effects of behavioral counseling 
on sexual risk behaviors and HIV/STI prevalence 
in low- and middle-income countries. AIDS and 
Behavior, 19:(7).
10.3.4 Foreign language article 
(n=3)
Beaudoin I and Bouchard S (2014) Efficacité de 
l’approche “logement d’abord” pour les personnes 
en situation d’itinérance vivant avec des troubles 
mentaux ou des troubles liés aux substances 
psychoactives. [Efficiency of the “housing first” 
approach for people who are homeless and living 
with mental illness or with disorders associated to 
psychoactive substances] Quebec: Institut national 
d’excellence en sante et en services sociaux 
(INESSS). ETMIS; 10(1).
Dalsbo T, Steiro A, Hammerstrøm K, Smedslund 
G. Heroinassistert substitusjonsbehandling for 
personer med kronisk heroinavhengighet. [Heroin 
maintenance for persons with chronic heroin 
dependence] Oslo: Norwegian Knowledge Centre 
for the Health Services (NOKC). Report from NOKC 
nr 17 - 2010.
Fiestas F and Ponce J (2012) Efficacy of the 
therapeutic community model in the treatment of 
drug use-related problems: a systematic review 
(Provisional abstract). Revista Peruana de Medicina 
Experimental y Salud Publica. 29(1):[12-20 pp.].
10.3.5 The review had been 
withdrawn (n=2)
Dalsbø TK, Hammerstrøm KT, Vist Gunn E, 
Gjermo H, Smedslund G, Steiro A et al. (2010) 
Psychosocial interventions for retention in 
drug abuse treatment. Cochrane Database of 
Systematic Reviews, 2010, (1): CD009269.
Mayet S, Farrell MF, Ferri M, Amato L and Davoli M 
(2014) Psychosocial treatment for opiate abuse and 
dependence. Cochrane Database of Systematic 
Reviews, 2014, (4): CD004330.
10.3.6 The review search was 
carried out in 2007 (n=2)
Lemstra M, Bennett N, Nannapaneni U, Neudorf 
C, Warren L, Kershaw T et al. (2010) A systematic 
review of school-based marijuana and alcohol 
prevention programs targeting adolescents aged 
10–15. Addiction Research & Theory, 18(1):84-96.
Turner W and Macdonald G (2011) Treatment foster 
care for improving outcomes in children and young 
people: A systematic review. Research on Social 
Work Practice 21(5): 501-527.
10.3.7 Updated review available 
(n=1)
Thomas RE, Lorenzetti DL and Spragins W (2011) 
Mentoring adolescents to prevent drug and alcohol 
use. Cochrane Database of Systematic Reviews, 
2011, (11): CD007381.
The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery 187
11
Appendices
11.1 Appendix 1 – 
Review protocol
Systematic review of evidence on 
the effectiveness of responses to 
problem drug use
A review of high-quality systematic reviews, with 
evidence presented across four strands:
Treatment
Which interventions are effective in treating drug 
misuse among people who misuse drugs?
Social reintegration
What interventions are effective in supporting 
people who use drugs to become better 
reintegrated into the community following/
alongside treatment?
3. Prevention
Which interventions are effective in preventing 
drug use among children and young people aged 25 
years and under?
4. Harm reduction
Which interventions are effective in reducing the 
harms related to drug use?
Across all strands of the review, drugs included 
were illegal drugs and new psychoactive 
substances. Drugs such as alcohol, tobacco, human 
enhancement drugs, and prescription medicines 
were not included in the review unless these 
outcomes were reported alongside illegal drug use 
as part of polydrug use behaviours.
Search strategy
The initial search for literature took place in August 
2015 in the following databases:
» Cochrane Library of Systematic Reviews
» Joanna Briggs Institute Database of Systematic 
Reviews
» DARE (Database of Abstracts of Reviews of 
Effects)
» Campbell Collaboration Library of Systematic 
Reviews
» EPPI-Centre Library
» PsycINFO
Database searching was supplemented by website 
searching, including the following websites:
» World Health Organization
» UNODC
» NDC
» EMCDDA
» Australian National Drug and Alcohol Research 
Centre
Within each article identified, reference lists were 
screened to identify any further articles to include 
in the review.
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A search strategy was developed to enable 
searching within the identified electronic 
databases. A single strategy was developed to 
identify evidence across all four strands of the 
review. During the screening stage of the review, 
articles identified for inclusion were categorised 
into the four review strands according to the 
inclusion criteria presented below.
Inclusion criteria
High-quality systematic reviews published since 
2010 were considered for inclusion. Where 
gaps in the evidence were identified, reviews 
published before 2010 and high-quality primary 
studies including RCTs, cohort studies, cross-
sectional studies and before and after studies 
were considered. Both quantitative and qualitative 
evidence were considered.
Studies were eligible for inclusion for each 
strand of the review if they met the criteria 
outlined below.
Treatment strand
Primary research question: Which interventions 
are effective in treating drug misuse among people 
who misuse drugs?
Population
In particular, the review sought to identify 
‘high-risk’ groups including individuals who are 
homeless or live in temporary accommodation, 
are members of the LGBT community, are members 
of the Travelling community, are in contact with 
the criminal justice system, are children of drug 
misusers, are looked after children, have mental 
health problems, are not in employment, education 
or training and who are involved in commercial 
sex work.
Interventions
Interventions that aimed to bring about cessation 
or reduction of drug use were eligible for 
inclusion. These included substitute prescribing, 
psychosocial interventions (for example, brief 
interventions and contingency management 
interventions), residential treatment programmes, 
recovery communities and mutual aid 
interventions (for example, peer support networks, 
12-step programmes).
Comparison
Interventions were compared with other 
interventions, treatment as usual and no 
intervention. Additionally, the review only included 
before and after studies.
Outcomes
Outcomes of interest were:
» Successful completion of treatment (according 
to the reviewed study, but including length 
of time of drug abstention, amount of 
drugs used per day, money spent per day, 
withdrawal symptoms)
» Retention in treatment (time participants spend 
in treatment, retention rate at a given time)
» Prevalence of drug use (opioids and cocaine)
» Relapse
» Criminal activity
Outcomes could be self-reported or verified e.g. 
through blood or urine analysis, police records, 
treatment records.
The review did not consider outcomes such as 
knowledge and attitudes towards drug use, or 
intentions towards future drug use.
Social reintegration strand
Primary research question: What interventions are 
effective in supporting people who use drugs to 
become better reintegrated into the community 
following/alongside treatment?
Population
Studies including individuals who are currently 
in drug treatment, or who have completed drug 
treatment.
In particular, the review sought to identify ‘high-
risk’ groups including individuals who were 
homeless or lived in temporary accommodation, 
were members of the LGBT community, were 
members of the Travelling community, were in 
contact with the criminal justice system, were 
children of drug misusers, were looked after 
children, have mental health problems, were not in 
employment, education or training and who were 
involved in commercial sex work.
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Interventions
Interventions that aim to bring about social 
reintegration, including vocational rehabilitation; 
housing, education and vocational training; 
employment strategies; and advocacy and 
stigma reduction.
Comparison
Interventions were compared with other 
interventions, normal conditions and no 
intervention. Additionally, the review only included 
before and after studies.
Outcomes
Outcomes of interest were:
» Housing status
» Employment status and quality of employment 
(including job satisfaction and numbers of hours 
worked)
» Education status (including statutory and 
vocational qualifications)
Prevention strand
Primary research question: Which interventions are 
effective in preventing drug use among children 
and young people aged 25 years and under?
Population
To be eligible for inclusion in this strand of the 
review, study participants must be children and 
young people aged 25 years and under.
In particular, the review sought to identify ‘high-
risk’ groups including individuals who are homeless 
or live in temporary accommodation, are members 
of the LGBT community, are members of the 
Travelling community, are in contact with the 
criminal justice system, are children of drug 
misusers, are looked after children, have mental 
health problems, are not in employment, education 
or training and who are involved in commercial 
sex work.
Studies involving young people receiving structured 
drug treatment were not be eligible for inclusion.
Interventions
Any intervention designed to prevent or reduce 
the use of drugs including indicated, selective, 
and universal interventions such as school-based 
and educational programmes, mass-media, and 
online interventions.
Comparison
Interventions were compared with other 
interventions, normal conditions (for example 
regular curriculum) and no intervention. 
Additionally, the review only includes before 
and after studies.
Outcomes
Outcomes of interest were:
» Age of drug use initiation
» Prevalence of drug use
» Frequency of drug use
» Cessation of drug use
Outcomes could be self-reported or verified, e.g. 
through blood or urine analysis, hospital records.
The review did not consider outcomes such as 
knowledge and attitudes towards drug use or 
intentions of future drug use.
Harm reduction strand
Primary research question: Which interventions are 
effective to reduce the harms related to drug use?
Population
The review included studies that focused on 
individuals who are current drug users.
In particular, the review sought to identify 
‘high-risk’ groups including individuals who are 
homeless or live in temporary accommodation, 
are members of the LGBT community, are members 
of the Travelling community, are in contact with 
the criminal justice system, are children of drug 
misusers, are looked after children, have mental 
health problems, are not in employment, education 
or training and who are involved in commercial 
sex work.
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Interventions
Interventions were activities or programmes 
that aimed to reduce the harms and risks that 
individuals are exposed to relating to their drug 
use. Examples of activities include needle and 
syringe programmes, supervised drug consumption 
facilities, blood-borne virus testing services, 
outreach services and peer support services.
Interventions with the primary aim of preventing 
drug use or use disorders were excluded from this 
strand of the review.
Comparison
Interventions were compared with other 
interventions, normal conditions (for example, 
harm reduction practice as normal in the case of 
studies into new innovations) and no intervention. 
Additionally, the review only included before and 
after studies.
Outcomes
Outcomes of interest included:
» Drug-related morbidity and mortality
» Prevalence and transmission of blood-borne 
viruses including hepatitis B, hepatitis C and HIV
» Uptake of testing and treatment for blood-
borne viruses, and uptake of hepatitis 
B vaccination
» Prevalence of high-risk behaviours associated 
with drug use; injection equipment sharing and 
risky injection behaviours, drug driving
» Injecting-related injuries
» Overdose
» Use of needle and syringe programmes 
and uptake of drug treatment and use of 
health services
» Disposal of used needles and equipment
» Risky sexual behaviours
Outcomes could be self-reported or verified, e.g. 
through blood or urine analysis, medical records.
Reference screening
References from the database searches were 
downloaded, deduplicated and screened on 
title and abstract against the criteria above. 
All references were screened by two reviewers 
independently, with any disagreements resolved 
through discussion between reviewers and 
consultation with a third reviewer if necessary.
Where abstracts met all the inclusion criteria, or 
if it was unclear from the study abstract whether 
it does, the full text was retrieved and re-
screened. Full-text screening was carried out by 
two reviewers independently and any differences 
resolved by discussion between reviewers and 
consultation with a third reviewer if necessary.
Studies that were excluded at the full paper 
stage were recorded along with the reason for 
their exclusion.
Data extraction and quality assessment
Quality assessment and data extraction for all 
included reviews was conducted in line with 
guidelines produced by the Joanna Briggs 
Institute.10 All reviews were quality assessed 
and data extracted by one reviewer, with all 
data checked in detail by a second reviewer. 
Details of all extracted data were entered into 
comprehensive evidence tables.
Data to be extracted included bibliographic details, 
population details, setting details, intervention 
details and outcomes.
10 http://joannabriggs.org/assets/docs/sumari/
ReviewersManual-Methodology-JBI_Umbrella%20
Reviews-2014.pdf
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11.2 Appendix 2 – Sample 
search strategy
For searching within Cochrane Library of 
Systematic Reviews, DARE and HTA libraries
#1 (Drug* or drug* or polydrug or “poly-drug” 
or “legal high*” or psychoactive* or “psycho-
active*” or psychotropic*):ti,ab
#2 (ketamine or speed or spice or cocaine 
or crack or mushroom* or solvent* or 
inhalant or “nitrous oxide” or “laughing 
gas” or benzodiazepine* or tranquiliser* or 
tranquilizer* or opioid* or hallucinogen* or 
“anabolic steroid*”):ti,ab
#3 (use* or abus* or misuse* or “mis-use*” 
or refus* or problem* or taking or take* or 
experiment*):ti,ab
#4 (#1 or #2) near/4 #3
#5 (Cannab* or marijuana or skunk or 
ecstasy or MDMA or LSD or “lysergic 
acid diethylamide” or amphetamine* or 
amfetamin* or mephedrone or mkat or 
“meow meow” or meth or methamphetamine 
or methamfetamin* or psychedelic* or pcp or 
phencyclidine or “anabolic steroid*” or ped 
or peds or pied or pieds or “performance 
enhancing” or “image enhancing” or heroin 
or poppers or “amyl nitrate” or “butyl 
nitrate” or “new psychoactive drug*” or 
“novel psychoactive drug*” or NPS):ti,ab
#6 MeSH descriptor: [Street Drugs] explode all 
trees
#7 MeSH descriptor: [Designer Drugs] explode all 
trees
#8 MeSH descriptor: [Marijuana Abuse] explode 
all trees
#9 MeSH descriptor: [Drug-Seeking Behavior] 
explode all trees
#10 MeSH descriptor: [Performance-Enhancing 
Drugs] explode all trees
#11 #6 or #7 or #8 or #9 or #10
#12 #4 or #5
#13 MeSH descriptor: [Drug-Related Disorders] 
explode all trees
#14 MeSH descriptor: [Amphetamine-Related 
Disorders] explode all trees
#15 MeSH descriptor: [Cocaine-Related 
Disorders] explode all trees
#16 MeSH descriptor: [Inhalant Abuse] explode all 
trees
#17 MeSH descriptor: [Marijuana Abuse] explode 
all trees
#18 MeSH descriptor: [Opioid-Related Disorders] 
explode all trees
#19 MeSH descriptor: [Phencyclidine Abuse] 
explode all trees
#20 MeSH descriptor: [Drug Abuse, Intravenous] 
explode all trees
#21 MeSH descriptor: [Marijuana Smoking] 
explode all trees
#22 {or #13-#21}
#23 #11 or #12 or #22 Publication Year from 2010 
to 2015
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11.3 Appendix 3 – Quality assessment tool
The Joanna Briggs Institute critical appraisal checklist was used to assess the methodological quality of 
systematic reviews identified for this review. The form is available at www.joannabriggs.org/assets/docs/
jbc/operations/criticalAppraisalForms/JBC_Form_CritAp_SRsRs.pdf.
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11.4 Appendix 4 – Quality assessment of included reviews
Each included review was assessed against the JBI Critical Appraisal Checklist for Systematic Reviews and 
Research Syntheses (Appendix 11.3). The results of this process are reported here. The questions 1–11 are 
provided in full in Appendix 11.3.
Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Rating
Abad et al., 2015 Y Y Y Y Y U Y Y NA Y N High
Abdul-Quader et al., 2013 Y Y Y Y Y U Y Y NA Y Y High
Akbar et al., 2011 Y Y Y N N N Y Y NA N Y Medium
Alvarez et al., 2013 Y Y Y Y Y Y Y Y Y Y N High
Amato et al., 2011a Y Y Y Y Y U Y Y Y Y Y High
Amato et al., 2011b Y Y Y Y Y U Y Y Y Y Y High
Amato et al., 2013 Y Y Y Y Y Y Y Y Y Y Y High
Aspinall et al., 2013 Y Y Y Y Y U Y Y Y Y Y High
Bender et al., 2011 Y Y Y Y Y Y Y Y N Y Y High
Benishek et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Blodgett et al., 2014 Y Y N N N Y Y Y Y Y N Medium
Boyuan et al., 2014 Y Y N Y Y Y Y Y N Y N High
Bolier et al., 2011 Y Y N Y N Y N Y NA Y Y Medium
Camp Binford et al., 2012 Y Y Y Y U U Y Y Y Y Y High
Carney et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Castells et al., 2010 Y Y Y Y Y Y Y Y Y Y Y High
Chiesa et al., 2014 Y Y Y N Y Y Y Y NA Y N High
Clark et al., 2014 Y Y N Y Y Y N N NA Y Y Medium
Cooper et al., 2014 Y Y Y Y Y Y Y Y NA Y Y High
Faggiano et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Ferri et al., 2011 Y Y Y Y Y Y Y Y Y Y Y High
Ferri et al., 2013a Y Y Y Y Y Y Y Y Y Y Y High
Ferri et al., 2013b Y Y Y Y Y Y Y Y Y Y Y High
Filges et al., 2015a Y Y Y Y Y Y Y Y Y Y Y High
Filges et al., 2015b Y Y Y Y Y Y Y Y Y Y Y High
Gillies et al., 2010 Y Y Y Y Y Y U Y NA Y Y High
Gowing et al., 2009a Y Y Y Y Y Y Y Y Y Y Y High
Gowing et al., 2009b Y Y Y Y Y Y Y Y Y Y Y High
Gowing et al., 2011 Y Y Y Y Y Y Y Y N Y Y High
Gowing et al., 2014 Y Y Y Y Y U Y Y Y Y Y High
Hagan et al., 2011 Y Y Y Y Y U Y Y Y Y Y High
Hayhurst et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Hedrich et al., 2012 Y Y N Y Y U Y Y NA Y N High
Hunt et al., 2013 Y Y Y Y Y U Y Y Y Y Y High
Jackson et al., 2012 Y Y N Y Y Y U Y NA Y Y High
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Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Rating
Jegu et al., 2011 Y Y Y Y Y Y U Y NA Y Y High
Jones et al., 2008 Y Y Y Y Y Y Y Y NA Y Y High
Jones et al., 2010 Y Y Y Y Y Y Y Y NA Y Y High
Jones et al., 2013 Y Y Y Y Y Y Y Y NA Y Y High
Larney et al., 2010 Y Y Y Y Y N N Y NA Y Y High
Larney et al., 2014 Y Y Y Y Y U Y Y Y Y Y High
Lee et al., 2015 Y Y Y N Y Y Y Y NA Y Y High
Lindstrom et al., 2015 Y Y Y Y Y Y Y Y Y Y Y High
MacArthur et al., 2012 Y Y Y Y Y U Y Y Y Y Y High
Malivert et al., 2012 Y Y N N N NA U Y NA Y Y Low
Malta et al., 2010 Y Y N Y N N Y Y Y Y Y Medium
Marshall et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Mattick et al., 2009 Y Y Y Y Y Y Y Y Y Y Y High
Mattick et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Meader et al., 2010 Y Y Y Y Y Y Y Y Y Y Y High
Meader et al., 2013 Y Y Y Y Y U Y Y Y Y Y High
Milligan et al., 2010 Y Y N Y Y Y Y Y Y Y N High
Milligan et al., 2011 Y Y N Y Y Y Y Y Y Y N High
Minozzi et al., 2011 Y Y Y Y Y Y Y Y Y Y Y High
Minozzi et al., 2013 Y Y N Y Y Y Y Y Y Y Y High
Minozzi et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Minozzi et al., 2015a Y Y Y Y Y Y Y Y Y Y Y High
Minozzi et al., 2015b Y Y Y Y Y Y Y Y Y Y Y High
Mitchell et al., 2012 Y Y Y Y Y Y Y Y Y Y Y High
National Collaborating Centre 
for Mental Health, 2008
Y Y Y Y Y U U Y NA Y Y High
Newton et al., 2013 Y Y Y Y Y Y Y Y Y Y Y High
Norberg et al., 2013 Y Y Y Y Y Y Y Y NA Y Y High
Pani et al., 2010 Y Y Y Y Y Y Y Y NA Y Y High
Pani et al., 2011 Y Y Y Y Y Y Y Y Y Y Y High
Patnode et al., 2014 Y Y Y Y Y Y Y Y NA Y Y High
Perez-Mana et al., 2011 Y Y Y Y Y Y Y Y Y Y N High
Perez-Mana et al., 2013 Y Y Y Y Y Y Y Y Y Y Y High
Perry et al., 2009 Y Y Y Y Y U Y Y Y Y Y High
Perry et al., 2015a Y Y Y Y Y Y Y Y Y Y Y High
Perry et al., 2015b Y Y Y Y Y Y Y Y Y Y Y High
Perry et al., 2015c Y Y Y Y Y Y Y Y Y Y Y High
Potier et al., 2014 Y Y N N Y N U Y NA Y Y Medium
Rapp et al., 2014 Y Y Y Y Y Y Y Y Y Y Y High
Reif et al., 2014a Y Y N N Y Y N Y NA Y Y High
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Citation Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Rating
Reif et al., 2014b Y Y U Y Y Y Y Y NA N Y Medium
Roberts et al., 2015 Y Y Y Y Y U Y Y Y Y Y High
Sacks-Davis et al., 2012 Y Y Y Y Y Y U Y Y Y Y High
Salvo et al., 2012 Y Y U Y Y U Y Y NA Y Y High
Shonin et al., 2013 N Y Y Y Y Y Y Y NA Y Y High
Smedslund et al., 2011 Y Y Y Y Y U Y Y Y Y Y High
Tait et al., 2013 Y Y Y Y Y Y Y Y Y Y Y High
Terplan et al., 2015 Y Y Y Y Y U Y Y Y Y Y High
Thomas et al., 2013 Y Y N N Y U U Y NA Y Y Medium
Torchalla et al., 2012 Y Y Y N Y U Y U Y Y Y High
Turnbull et al., 2012 Y Y Y Y Y U Y Y N Y Y High
Underhill et al., 2014 Y Y Y Y Y U Y Y NA Y Y High
VanBuskirk et al., 2014 Y Y Y Y Y N N Y Y Y N High
Vanderplasschen et al., 2013 Y Y N Y N N Y Y NA Y Y Medium
Vermeulen-Smith et al., 2015 Y Y Y Y N N N Y Y Y Y Medium
Wang et al., 2013 Y Y Y N Y U Y Y Y Y Y High
Wang et al., 2014 Y Y N N Y Y Y Y Y Y N High
Watson et al., 2013 Y Y N N Y Y Y Y NA Y N High
Werb et al., 2013 Y Y Y Y Y U Y Y NA Y Y High
Wood et al., 2014 Y Y Y Y Y Y Y Y NA Y Y High
Zanini et al., 2010 Y Y U Y Y Y Y Y Y Y Y High
Zgierska et al., 2009 Y Y Y Y Y Y U Y Y Y Y High
Y = Yes; N = No; U = Unclear, NA= Not applicable
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